<SEC-DOCUMENT>0001193125-15-179414.txt : 20150508
<SEC-HEADER>0001193125-15-179414.hdr.sgml : 20150508
<ACCEPTANCE-DATETIME>20150508152328
ACCESSION NUMBER:		0001193125-15-179414
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		14
CONFORMED PERIOD OF REPORT:	20150331
FILED AS OF DATE:		20150508
DATE AS OF CHANGE:		20150508

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			HERON THERAPEUTICS, INC. /DE/
		CENTRAL INDEX KEY:			0000818033
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				942875566
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33221
		FILM NUMBER:		15846321

	BUSINESS ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063
		BUSINESS PHONE:		6503662626

	MAIL ADDRESS:	
		STREET 1:		123 SAGINAW DRIVE
		STREET 2:		123 SAGINAW DRIVE
		CITY:			REDWOOD CITY
		STATE:			CA
		ZIP:			94063

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AP PHARMA INC /DE/
		DATE OF NAME CHANGE:	20010511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ADVANCED POLYMER SYSTEMS INC /DE/
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>d924919d10q.htm
<DESCRIPTION>10-Q
<TEXT>
<HTML><HEAD>
<TITLE>10-Q</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>UNITED STATES </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>SECURITIES AND EXCHANGE COMMISSION </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman" ALIGN="center"><B>WASHINGTON, DC 20549 </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q
</B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>(Mark One) </B></P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the quarterly period ended March&nbsp;31, 2015 </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OR </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:12pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B></B><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT><B></B><B></B></TD>
<TD ALIGN="left" VALIGN="top"><B>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d)&nbsp;OF THE SECURITIES EXCHANGE ACT OF 1934 </B></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>For the transition period from
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> to
<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U> </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Commission file number: 001-33221 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>(Exact name of registrant as specified in its charter) </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="50%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="48%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"><B>Delaware</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>94-2875566</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(State or other jurisdiction of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>incorporation or organization)</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>(I.R.S. Employer</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Identification No.)</B></P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>123 Saginaw Drive</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Redwood City, CA</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center"><B>94063</B></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="top" ALIGN="center"><B>(Address of principal executive offices)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="top" ALIGN="center"><B>(Zip Code)</B></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Registrant&#146;s telephone number, including area code: (650)&nbsp;366-2626 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant: (1)&nbsp;has filed all reports required to be filed by Section&nbsp;13 or 15(d) of the Securities Exchange Act
of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&nbsp;has been subject to such filing requirements for the past 90 days.&nbsp;&nbsp;&nbsp;&nbsp; Yes&nbsp;&nbsp;<FONT
STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp; No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check
mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule&nbsp;405 of Regulation&nbsp;S-T (&#167;232.405 of this chapter)
during the preceding 12&nbsp;months (or for such shorter period that the registrant was required to submit and post such files).&nbsp;&nbsp;&nbsp;&nbsp; Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;
No&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a large accelerated filer, an
accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of &#147;large accelerated filer,&#148; &#147;accelerated filer&#148; and &#147;smaller reporting company&#148; in Rule 12b-2 of the Exchange Act. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="16%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="60%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="20%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="1%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Large&nbsp;accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Accelerated&nbsp;filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="bottom">Non-accelerated filer</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;(Do not check if a smaller reporting company)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">Smaller&nbsp;reporting&nbsp;company</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"><FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT></TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange
Act).&nbsp;&nbsp;&nbsp;&nbsp;Yes&nbsp;&nbsp;<FONT STYLE="FONT-FAMILY:WINGDINGS">&#168;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;No&nbsp;&nbsp; <FONT STYLE="FONT-FAMILY:WINGDINGS">&#120;</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The number of shares of the registrant&#146;s common stock, par value $0.01 per share, outstanding as of April&nbsp;28, 2015 was 29,632,533. </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FORM 10-Q </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>FOR THE
QUARTERLY PERIOD ENDED MARCH 31, 2015 </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="2%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="7%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="87%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">PART I. FINANCIAL STATEMENTS</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;1.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_1">Condensed Consolidated Financial Statements &#151; Unaudited</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_2">Condensed Consolidated Balance Sheets as of March&nbsp;31, 2015 and December&nbsp;31, 2014</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">1</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_3">Condensed Consolidated Statements of Operations for the three months ended March&nbsp;31, 2015 and 2014</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">2</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_4">Condensed Consolidated Statements of Cash Flows for the three months ended March&nbsp;31, 2015 and 2014</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">3</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_5">Notes to Condensed Consolidated Financial Statements</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">4</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;2.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_6">Management&#146;s Discussion and Analysis of Financial Condition and Results of Operations</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">12</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;3.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_7">Quantitative and Qualitative Disclosures About Market Risk</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;4.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_8">Controls and Procedures</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">17</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="24" COLSPAN="5"></TD>
<TD HEIGHT="24" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5">PART II. OTHER INFORMATION</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;1.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_9">Legal Proceedings</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;1A.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_10">Risk Factors</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;2.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_11">Unregistered Sales of Equity Securities and Use of Proceeds</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;3.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_12">Defaults Upon Senior Securities</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;4.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_13">Mine Safety Disclosures</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;5.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_14">Other Information</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">18</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="top">ITEM&nbsp;6.</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"><A HREF="#toc924919_15">Exhibits</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">19</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8" COLSPAN="5"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" COLSPAN="5"><A HREF="#toc924919_16">SIGNATURES</A></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">20</TD></TR>
</TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>PART&nbsp;I.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>FINANCIAL STATEMENTS </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_1"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONDENSED CONSOLIDATED FINANCIAL STATEMENTS </B>&#151;<B> UNAUDITED </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON
THERAPEUTICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc924919_2"></A>Condensed Consolidated Balance Sheets </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">March&nbsp;31,<br>2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">December&nbsp;31,<br>2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(Unaudited)</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center">(Note 2)</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>ASSETS</U></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current assets:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">72,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other current assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">945</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,057</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">56,501</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,732</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Property and equipment, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,996</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,820</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other long-term assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total assets</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><U>LIABILITIES AND STOCKHOLDERS&#146; EQUITY</U></P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Current liabilities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,383</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,549</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,518</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,811</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and employee-related liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,656</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,731</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,320</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,931</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Convertible notes payable to related parties, net of discount</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,749</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,598</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total current liabilities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11,626</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">13,620</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stockholders&#146; equity:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">292</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Additional paid-in capital</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">383,512</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">378,007</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accumulated deficit</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(335,807</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(315,237</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48,001</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">63,062</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total liabilities and stockholders&#146; equity</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">59,627</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">76,682</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc924919_3"></A>Condensed Consolidated Statements of Operations </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in
thousands, except per share amounts) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three&nbsp;Months&nbsp;Ended<br>March&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating expenses:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,856</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,694</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">20,360</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">17,322</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Loss from operations</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(20,360</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,322</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Interest expense, net</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(210</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(216</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.70</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(0.74</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Shares used in computing basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,392</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,686</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc924919_4"></A>Condensed Consolidated Statements of Cash Flows </B></P>
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(in
thousands) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Three Months Ended<br>March&nbsp;31,</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2015</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">2014</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net loss</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(20,570</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">(17,538</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Adjustments to reconcile net loss to net cash used for operating activities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Depreciation and amortization</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">152</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amortization of debt discount</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">151</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Changes in operating assets and liabilities:</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Prepaid expenses and other assets</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">112</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,624</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accounts payable</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(166</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,238</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued clinical liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(293</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,029</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Accrued payroll and employee-related liabilities</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,075</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(1,254</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:5.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other accrued expenses</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(531</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">272</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for operating activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(19,669</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(15,713</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Investing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Purchases of property and equipment</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash used for investing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(328</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(57</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Financing activities:</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Proceeds from stock option exercises</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:7.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net cash provided by financing activities</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,878</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">958</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Net decrease in cash and cash equivalents</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(17,119</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(14,812</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at beginning of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,675</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">72,287</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents at end of period</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">55,556</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">57,475</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">See accompanying notes. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPUETICS, INC. </B></P>
 <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc924919_5"></A>Notes to Condensed Consolidated Financial Statements </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(Unaudited) </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Business </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc. (&#147;we,&#148; &#147;us&#148; and &#147;our&#148;) is a biotechnology company using its proprietary technology
and innovative efforts to develop products to address unmet medical needs. Our proprietary Biochronomer drug delivery technology is designed to improve the therapeutic profile of injectable pharmaceuticals.&nbsp;Our product development efforts focus
on identifying current therapies with the potential to be reformulated to expand or extend therapeutic effect or duration of action, minimize drawbacks or to apply new delivery methods. In addition, we continually evaluate potential development
programs, technologies or product candidates&nbsp;that may be complementary to or synergistic with our existing programs and product development goals. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Our Biochronomer technology, with which our lead investigational product candidate, SUSTOL (granisetron injection, extended release) (or &#147;APF530&#148;),
and certain of our other product candidates are formulated, consists of bioerodible polymers designed to release drugs over a defined period of time, depending on the medical need of a given therapeutic target. We have demonstrated that our
Biochronomer technology can deliver drugs over periods varying from days to weeks and that the technology is potentially applicable to a range of therapeutic areas, including the prevention of chemotherapy-induced nausea and vomiting
(&#147;CINV&#148;) and pain management, among others. Furthermore, we have completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymer is well tolerated. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">At present, our clinical and preclinical development programs include SUSTOL, in advanced development for the prevention of CINV following administration of
chemotherapeutic agents, as well as HTX-011 for the prevention of post-operative pain, HTX-019 for the prevention of CINV and HTX-003 for the management of chronic pain and opioid addiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">APF530, which we intend to market as SUSTOL subject to regulatory approval, is being developed for the prevention of both acute- and delayed-onset CINV
following the administration of moderately emetogenic chemotherapy (&#147;MEC&#148;) or highly emetogenic chemotherapy (&#147;HEC&#148;). Injectable 5-hydroxytryptamine type 3
(&#147;5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB>&#148;) receptor antagonists have been shown to be among the most effective and preferred treatments for CINV, however, an unmet need remains for patients suffering from CINV during
the delayed-onset phase, which typically occurs 1-5 days following administration of chemotherapy agents. For patients suffering from delayed-onset CINV, only one injectable 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3 </SUB>receptor
antagonist is approved for use following the administration of MEC agents, and none are approved for use following administration of HEC agents. SUSTOL contains the 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3 </SUB>receptor antagonist
granisetron, selected due to its broad use by physicians based on a well-established record of safety and efficacy, and because it is only currently approved for the prevention of CINV during the acute-onset phase. SUSTOL is formulated with our
proprietary Biochronomer drug delivery technology, and in clinical studies has been shown to maintain therapeutic drug levels of granisetron for up to five days with a single subcutaneous injection. In 2014, we initiated a Phase 3 clinical study
evaluating SUSTOL for the prevention of delayed-onset CINV following the administration of HEC agents (&#147;HEC study&#148;), which, if successful, would differentiate SUSTOL from the other currently approved 5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonists. We completed enrollment of our HEC study in April 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In May 2009, we filed
a New Drug Application (&#147;NDA&#148;) for SUSTOL with the U.S Food and Drug Administration (&#147;FDA&#148;) under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act. In March 2010, we received our first Complete Response Letter
(&#147;CRL&#148;), which stated that the May 2009 NDA requesting approval for SUSTOL could not be approved as it was initially submitted. The primary points raised in the initial CRL were related to the dosing system, certain identified deficiencies
in the chemistry, manufacturing, and control (&#147;CMC&#148;) review, and a request that we perform additional studies showing bioequivalence and metabolic rates, on human factors, and to perform a QT study. We met with the FDA
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
in 2011 to clarify the comments and requests and subsequently performed additional work and data analyses which we believed addressed the concerns raised in the 2010 CRL. In September 2012, we
resubmitted the NDA requesting approval for SUSTOL and, in March 2013, the FDA issued a second CRL. The FDA identified several additional issues precluding the approval of the SUSTOL NDA resubmission, including further issues relating to the CMC
review and deficiencies at certain of our contract manufacturers, and requested that we repeat human factors testing using commercially equivalent material, as well to provide data to allow reanalysis of our Phase 3 clinical results under the
revised American Society of Clinical Oncology guidelines for the prevention of CINV following the administration of MEC or HEC agents, published in 2011. We believe that we have substantially addressed the issues raised in the March 2013 CRL, which
will be reflected in our upcoming SUSTOL NDA resubmission. We intend to include the results of our Phase 3 HEC study in the resubmission of our NDA for SUSTOL, which we anticipate filing mid-year 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The lead product candidate in our pain management program is HTX-011. HTX-011, which utilizes our proprietary Biochronomer drug delivery technology, is a
long-acting formulation of the local anesthetic bupivacaine in combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The effective management of pain with a reduction in the use of opioids, which can lead to
post-operative complications, extended hospitalization and abuse, remains an important area of unmet medical need, and HTX-011 could potentially provide a differentiated therapeutic profile with advantages compared to currently available pain
management options. In a Phase 1 clinical trial, completed in March 2015, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam. Therapeutically relevant plasma bupivacaine levels were sustained for 2-3 days in the
absence of the large initial peak often observed with commercially available formulations of long-acting bupivacaine. The anesthetic effects of HTX-011 persisted through 96 hours, which closely correlated with plasma bupivacaine concentrations, and
HTX-011 was well-tolerated with no serious adverse events. We plan to move HTX-011 into Phase 2 clinical development in the second quarter of 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In
November 2014, we announced our development program for HTX-019. HTX-019 is a proprietary injectable formulation of aprepitant, a neurokinin-1 (&#147;NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148;) receptor antagonist for the
prevention of CINV. NK<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor antagonists are typically used in combination with 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonists. At present, the only
injectable NK<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor antagonist approved in the United States contains polysorbate 80, a surfactant, which may cause hypersensitivity reactions or other adverse reactions in some patients.
Our formulation for HTX-019 does not contain polysorbate 80, and may have a lower incidence of infusion-site reactions than reported with the commercially available injectable NK<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor
antagonist. We plan to discuss with the FDA our intent to develop HTX-019 utilizing the 505(b)(2) registration pathway. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In December 2014, we disclosed a
second investigational product in our pain management program. HTX-003, which utilizes our proprietary Biochronomer drug delivery technology, is a long-acting formulation of buprenorphine for the management of chronic pain and opioid addiction.
HTX-003 is designed to maintain therapeutic drug levels of buprenorphine for up to 30 days following a single subcutaneous injection with a low potential for patient abuse. We are presently evaluating our plans for further development of HTX-003.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidity </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We have incurred significant operating
losses and negative cash flows from operations, and we had an accumulated deficit of $335.8 million as of March&nbsp;31, 2015. Since 2011, we have completed a total of five rounds of equity and/or convertible debt financings, which provided us with
cash of approximately $194.3 million in the aggregate, net of issuance costs, to fund operations (see Notes 4 and 5). As of March&nbsp;31, 2015, we had cash and cash equivalents on hand of $55.6 million. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We believe that our current working capital is sufficient to fund operations through 2015, including pursuing regulatory approval for SUSTOL, completing Phase
1 and Phase 2 human clinical studies expected to commence in the second half of 2015 relative to our HTX-011 product candidate, and engaging in clinical and preclinical activities for our HTX-019 product candidate. In the event we were to pursue
clinical product development in other areas, potentially acquire other strategic assets, or begin to </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
make significant investments in preparing for commercialization of SUSTOL, we would need to raise additional capital. If we are unable to obtain sufficient financing on acceptable terms or
otherwise, we may be required to reduce or defer our activities. Our capital requirements going forward will depend on numerous factors, including but not limited to: the scope, rate of progress, results and costs of preclinical testing and clinical
trials, including completing our Phase 3 HEC study; an approval decision by the FDA with respect to SUSTOL; the timing of and costs associated with the commercial launch of SUSTOL, if approved; the degree of commercial success of SUSTOL; the number
and characteristics of product development programs we pursue and the pace of each program, including the timing of clinical trials; the time, cost and outcome involved in seeking other regulatory approvals; scientific progress in our research and
development programs; the magnitude and scope of our research and development programs; our ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our
product candidates; the cost and timing of establishing sales, marketing and distribution capabilities if we commercialize products independently; the cost of establishing clinical and commercial supplies of our product candidates and any products
that we may develop; and general market conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We may not be able to raise sufficient additional capital when we need it on favorable terms, or at
all. The sale of additional equity in the future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be required to curtail operations significantly or to obtain funds by entering into
financing, supply or collaboration agreements on unattractive terms. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Basis of Presentation </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally
accepted in the United States (&#147;GAAP&#148;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for
complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March&nbsp;31, 2015
are not necessarily indicative of the results that may be expected for other quarters or the year ending December&nbsp;31, 2015. The condensed balance sheet at December&nbsp;31, 2014 has been derived from the audited financial statements as of that
date, but does not include all of the information and disclosures required by GAAP. For more complete financial information, these unaudited condensed consolidated financial statements and the notes thereto should be read in conjunction with the
audited financial statements included in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2014 filed with the Securities and Exchange Commission (the &#147;SEC&#148;) on March&nbsp;13,&nbsp;2015. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Accounting Policies </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Principles of Consolidation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V., which was organized in the Netherlands in March 2015. Heron Therapeutics
B.V. has no operations and no material assets or liabilities and there have been no significant transactions related to Heron Therapeutics B.V. since its inception. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Use of Estimates </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The preparation of financial statements
in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies
that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Cash and Cash Equivalents </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Cash and cash equivalents consist of cash and highly liquid investments with original maturities from purchase date of three months or less. Our bank accounts
have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (&#147;Convertible Notes&#148;). </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Earnings Per Share
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Basic earnings per share (&#147;EPS&#148;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the
period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock
method. For purposes of this calculation, stock options, warrants and common stock underlying Convertible Notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Because we have incurred a net loss for all periods presented in the condensed consolidated statements of operations, outstanding stock options, warrants and
common stock underlying Convertible Notes are not included in the computation of net loss per share because their effect would be anti-dilutive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The
following table includes the number of outstanding stock options, warrants and common stock underlying Convertible Notes not included in the computation as of the dates shown below (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="84%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>As of March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock options outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,273</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warrants outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,843</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,825</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Common stock underlying convertible notes outstanding</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,777</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,385</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Comprehensive Income (Loss) </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our
comprehensive net loss for both periods presented was comprised solely of our net loss, and there were no other changes in equity from non-owner sources. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Recent Accounting Pronouncements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In January 2015, the
Financial Accounting Standards Board (&#147;FASB&#148;) issued Accounting Standards Update (&#147;ASU&#148;) No.&nbsp;2015-<I></I>01<I>, Income Statement&#151;Extraordinary and Unusual Items (Subtopic 225-20)</I> (&#147;ASU 2015-01&#148;). ASU
2015-01 eliminates the concept of extraordinary items from GAAP. FASB concluded that ASU 2015-01 will not result in a loss of information because although ASU 2015-01 will eliminate the requirements in Subtopic 225-20 for reporting entities to
consider whether an underlying event or transaction is extraordinary, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in
nature and infrequently occurring. The amendments in ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December&nbsp;15, 2015. A reporting entity may apply the amendments prospectively. A
reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We
adopted the provisions of ASU 2015-01 in the first quarter of 2015. The adoption of this ASU did not have a material impact on our results of operations or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In August 2014, FASB issued ASU No.&nbsp;2014-15, <I>Presentation of Financial Statements &#150; Going Concern
(Subtopic 205-40)</I> (&#147;ASU 2014-15&#148;). ASU 2014-15 requires management to assess an entity&#146;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in United States auditing
standards. Specifically, the amendments (1)&nbsp;provide a definition of the term substantial doubt, (2)&nbsp;require an evaluation every reporting period, including interim periods, (3)&nbsp;provide principles for considering the mitigating effect
of management&#146;s plans, (4)&nbsp;require certain disclosures when substantial doubt is alleviated as a result of consideration of management&#146;s plans, (5)&nbsp;require an express statement and other disclosures when substantial doubt is not
alleviated, and (6)&nbsp;require an assessment for a period of one year after the date that the financial statements are issued (or available to be issued). The amendments in ASU 2014-15 are effective for the annual period ending after
December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. We plan to adopt the provisions of ASU 2014-15 in 2016. We do not expect the adoption of this ASU to have a material impact on our results of
operations or financial condition. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2014, FASB issued ASU No.&nbsp;2014-12, <I>Compensation &#150; Stock Compensation (Topic 718)</I> (&#147;ASU
2014-12&#148;). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods
within those annual periods beginning after December&nbsp;15, 2015. Earlier adoption is permitted. The amendments in ASU 2014-12 may either be applied (a)&nbsp;prospectively to all awards granted or modified after the effective date or
(b)&nbsp;retrospectively to all awards with performance targets that are outstanding as of the beginning of the earlier annual period presented in the financial statements and to all new or modified awards thereafter. We plan to adopt the provisions
of ASU 2014-12 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Convertible Notes to Related Parties </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5&nbsp;million in Convertible Notes. We
received a total of $4.3 million, net of issuance costs, from the issuance of these Convertible Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Notes are secured by substantially
all of our assets, including placing our bank accounts under a control agreement. The Convertible Notes bear interest at 6%&nbsp;per annum, payable quarterly in cash or in additional principal amount of Convertible Notes, at the election of the
purchasers. The Convertible Notes mature on May&nbsp;2, 2021, however, the holders of the Convertible Notes may require prepayment of the Convertible Notes at any time, at each holder&#146;s option. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under
the Convertible Notes. There is no right to convert the Convertible Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the
Convertible Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2015, we were in compliance with all covenants under the Convertible Notes. Upon the occurrence of an event of default under the
Convertible Notes, the holders of the Convertible Notes have the right to require us to redeem all or a portion of their Convertible Notes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We filed a
registration statement with the SEC to register for resale 3.5&nbsp;million shares underlying the Convertible Notes. The registration statement was declared effective on July&nbsp;29,&nbsp;2011. The Note holders have agreed to waive their right to
require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Convertible Notes until they provide notice otherwise. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The Convertible Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250
shares for every $1,000 of principal and accrued interest due under the Convertible Notes, the total conversion benefit at issuance exceeded </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the loan proceeds. Therefore, a debt discount was recorded in an amount equal to the face value of the Convertible Notes on the issuance dates and we began amortizing the resultant debt discount
over the respective 10-year term of the Convertible Notes. During the three months ended March&nbsp;31, 2015, accrued interest of approximately $80,000 was paid-in-kind and rolled into the Convertible Note principal balance, which resulted in an
additional debt discount of approximately $80,000. For the three months ended March&nbsp;31, 2015 and 2014, interest expense relating to the stated rate was approximately $81,000 and $77,000, respectively, and interest expense relating to the
amortization of the debt discount was approximately $151,000 and $139,000, respectively. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2015, the carrying value of the Convertible
Notes was approximately $1,749,000, which is comprised of the $5,421,000 principal amount of the Convertible Notes outstanding, less debt discount of $3,672,000. If the $5,421,000 principal amount of Convertible Notes is converted, we would issue
6,776,998 shares of our common stock. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Stockholders&#146; Equity </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2011 Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June
2011, we sold 8.0&nbsp;million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at
an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July&nbsp;1,&nbsp;2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of
the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such
exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the warrants can amend or waive the foregoing limitation by
written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">On July&nbsp;29, 2011, we filed a registration
statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August&nbsp;4, 2011. We are obligated to maintain the
effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (&#147;Rule
144&#148;). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the
registration statement until it provides notice otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">During the three months ended March&nbsp;31, 2015, warrant holders exercised 66,667 warrants
under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 47,588&nbsp;shares of common stock and no net cash proceeds to us. During the three months ended March&nbsp;31, 2014, warrant holders exercised
144,040 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 108,409 shares of common stock and no net cash proceeds to us. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2012 Private Placement </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In July 2012, we sold
approximately 5.1&nbsp;million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1&nbsp;million in issuance costs). On August&nbsp;24, 2012, we filed
a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September&nbsp;6, 2012. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2013 Common Stock Offering </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In November 2013, we sold approximately 7.7&nbsp;million shares of our common stock at a public offering price of $8.00 per share. We received total net
proceeds of approximately $57.8 million (net of approximately $3.9&nbsp;million in issuance costs). The offering was made pursuant to an effective registration statement, which was previously filed with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>2014 Common Stock Offering </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">In June 2014, we sold
approximately 4.8&nbsp;million shares of our common stock at a public offering price of $11.75 per share. In addition, as a component of the offering, we sold 600,000 pre-funded warrants to purchase shares of our common stock at a public offering
price of $11.74 per share. The pre-funded warrants have an exercise price of $0.01 per share and expire on June&nbsp;30, 2021. We received total net proceeds of approximately $58.9 million (net of approximately $4.0 million in issuance costs) from
the sale of the common stock and the pre-funded warrants. The offering was made pursuant to an effective registration statement, which was previously filed with the SEC. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Stock Option Exercises </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">For the three months ended
March&nbsp;31, 2015, 351,698 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to us of approximately $2,878,000. For the three months ended March&nbsp;31, 2014, option holders exercised 275,352
stock options, a portion of which were exercised under the cashless exercise provision of our 2007 Amended and Restated Equity Incentive Plan, resulting in the net issuance of 215,350 shares of common stock and cash proceeds to us of approximately
$958,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stock-Based Compensation </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following
table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements for the three months ended March&nbsp;31,&nbsp;2015 and 2014 (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="82%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three&nbsp;Months&nbsp;Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Research and development</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">General and administrative</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,745</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,707</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense included in operating expenses</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,551</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">2,969</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Impact on basic and diluted net loss per share</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.09</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.13</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2015, there was $29,947,000 of total unrecognized compensation cost related to non-vested, stock-based
payment awards granted under all of our equity compensation plans and all non-plan option grants. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. We expect to recognize this compensation cost over a
weighted-average period of 2.4&nbsp;years. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing
model with the following weighted-average assumptions: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="85%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Risk-free interest rate</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Dividend yield</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">0.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Volatility</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">91.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">104.1</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expected life (years)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6.0</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">We estimated the fair value of each purchase right granted under our 1997 Employee Stock Purchase Plan at the
beginning of each new offering period using the Black-Scholes option pricing model. There were no new offering periods for the quarters ended March&nbsp;31, 2015 and 2014. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The following table summarizes the stock option activity for the three months ended March&nbsp;31,&nbsp;2015: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="62%"></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="8%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Weighted-</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Weighted-</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Remaining</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD COLSPAN="2" VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Average</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Contractual</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center"><B>Term</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(in&nbsp;thousands)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Price</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>(Years)</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at January&nbsp;1, 2015</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,918</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.69</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.92</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Granted</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">54</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Exercised</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(352</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Expired and forfeited</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">(327</TD>
<TD NOWRAP VALIGN="bottom">)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">10.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Balance at March&nbsp;31, 2015</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7,293</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">8.65</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8.31</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
</TABLE> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left"><B>6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>Income Taxes </B></TD></TR></TABLE>
 <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying
values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding our ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation
allowance has been established. We continue to maintain a full valuation allowance against our deferred tax assets as of March&nbsp;31, 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The impact
of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if
it has less than a 50% likelihood of being sustained. There have been no material changes in our unrecognized tax benefits since March&nbsp;31, 2015 and, as such, disclosures included in our 2014 Annual Report on Form&nbsp;10-K for the year ended
December&nbsp;31, 2014 continue to be relevant for the period ended March&nbsp;31, 2015. </P>

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_6"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MANAGEMENT&#146;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </B></TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>The following discussion and analysis of our financial condition and results of operations should be read together with our unaudited
condensed consolidated financial statements and related notes included in this quarterly report on Form 10-Q and the audited financial statements and notes thereto included in our Annual Report on Form 10-K for the year ended December&nbsp;31, 2014
filed with the Securities and Exchange Commission (the &#147;SEC&#148;), on March&nbsp;13,&nbsp;2015. </I></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>This Quarterly Report on
Form 10-Q contains forward-looking statements within the meaning of the federal securities laws. You can identify forward-looking statements by the use of the words &#147;believe,&#148; &#147;expect,&#148; &#147;anticipate,&#148; &#147;intend,&#148;
&#147;estimate,&#148; &#147;project,&#148; &#147;will,&#148; &#147;should,&#148; &#147;may,&#148; &#147;plan,&#148; &#147;intend,&#148; &#147;assume&#148; and other expressions which predict or indicate future events and trends and which do not
relate to historical matters. You should not rely on forward-looking statements, because they involve known and unknown risks, uncertainties and other factors, some of which are beyond our control. These risks, uncertainties and other factors may
cause our actual results, performance or achievements to be materially different from the anticipated future results, performance or achievements expressed or implied by the forward-looking statements. </I></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Factors that might cause these differences include the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the results of our study of SUSTOL in delayed-onset chemotherapy induced nausea and vomiting in highly emetogenic chemotherapy regimes, which closed enrollment in April 2015; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">estimates of the timing of our resubmission of the New Drug Application (&#147;NDA&#148;) for SUSTOL and potential regulatory approval for and commercial launch of SUSTOL; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the anticipated progress of our research and development programs for HTX-011, HTX-019 and HTX-003, and any other research and development programs we may pursue, including the initiation of new clinical trials and
preclinical testing; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether safety and efficacy results of our clinical trials provide data to warrant further development; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if approved, the market conditions at commercial launch of SUSTOL or other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully market, commercialize and achieve market acceptance for SUSTOL or other future product candidates, including our positioning relative to competing products; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and achieve regulatory approval for other future product candidates utilizing our proprietary Biochronomer drug delivery technology; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to establish key collaborations for our products and any other future product candidates; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully develop and commercialize any technology that we may in-license or products we may acquire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">unanticipated delays due to manufacturing difficulties, supply constraints, or changes in the regulatory environment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully establish and maintain key vendor relationships necessary for the manufacture of our products; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to successfully operate in other non-U.S. jurisdictions in which we may choose to do business, including compliance with applicable regulatory requirements and laws; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">uncertainties associated with obtaining and enforcing patents to protect our products, and our ability to successfully defend ourselves against unforeseen third party infringement claims; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our estimates regarding our capital requirements; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our ability to obtain additional financing and raise capital as necessary to fund operations or pursue business opportunities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These forward-looking statements were based on information, plans and estimates at the date of this Quarterly Report on Form&nbsp;10-Q, and we
assume no obligation to update any forward-looking statements to reflect changes in underlying assumptions or factors, new information, future events or other changes. In addition, please see the &#147;Risk Factors&#148; section of this Quarterly
Report on Form&nbsp;10-Q. These risk factors may be updated from time to time by our future filings under the Securities Exchange Act of 1934 (the &#147;Exchange Act&#148;). You should carefully review all information therein. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Overview </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Heron Therapeutics, Inc.
(&#147;we,&#148; &#147;us&#148; and &#147;our&#148;) is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. Our proprietary Biochronomer drug delivery technology is
designed to improve the therapeutic profile of injectable pharmaceuticals.&nbsp;Our product development efforts focus on identifying current therapies with the potential to be reformulated to expand or extend therapeutic effect or duration of
action, minimize drawbacks or to apply new delivery methods. In addition, we continually evaluate potential development programs, technologies or product candidates&nbsp;that may be complementary to or synergistic with our existing programs and
product development goals. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Biochronomer technology, with which our lead investigational product candidate, SUSTOL (granisetron
injection, extended release) (or &#147;APF530&#148;), and certain of our other product candidates are formulated, consists of bioerodible polymers designed to release drugs over a defined period of time, depending on the medical need of a given
therapeutic target. We have demonstrated that our Biochronomer technology can deliver drugs over periods varying from days to weeks and that the technology is potentially applicable to a range of therapeutic areas, including the prevention of
chemotherapy-induced nausea and vomiting (&#147;CINV&#148;) and pain management, among others. Furthermore, we have completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymer is well tolerated.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At present, our clinical and preclinical development programs include SUSTOL, in advanced development for the prevention of CINV
following administration of chemotherapeutic agents, as well as HTX-011 for the prevention of post-operative pain, HTX-019 for the prevention of CINV and HTX-003 for the management of chronic pain and opioid addiction. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">APF530, which we intend to market as SUSTOL subject to regulatory approval, is being developed for the prevention of both acute- and
delayed-onset CINV following the administration of moderately emetogenic chemotherapy (&#147;MEC&#148;) or highly emetogenic chemotherapy (&#147;HEC&#148;). Injectable 5-hydroxytryptamine type 3 (&#147;5-HT<SUB
STYLE="font-size:85%; vertical-align:bottom">3</SUB>&#148;) receptor antagonists have been shown to be among the most effective and preferred treatments for CINV, however, an unmet need remains for patients suffering from CINV during the
delayed-onset phase, which typically occurs 1-5 days following administration of chemotherapy agents. For patients suffering from delayed-onset CINV, only one injectable 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3 </SUB>receptor
antagonist is approved for use following the administration of MEC agents, and none are approved for use following administration of HEC agents. SUSTOL contains the 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3 </SUB>receptor antagonist
granisetron, selected due to its broad use by physicians based on a well-established record of safety and efficacy, and because it is only currently approved for the prevention of CINV during the acute-onset phase. SUSTOL is formulated with our
proprietary Biochronomer drug delivery technology, and in clinical studies has been shown to maintain therapeutic drug levels of granisetron for up to five days with a single subcutaneous injection. In
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
2014, we initiated a Phase 3 clinical study evaluating SUSTOL for the prevention of delayed-onset CINV following the administration of HEC agents (&#147;HEC study&#148;), which, if successful,
would differentiate SUSTOL from the other currently approved 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonists. We completed enrollment of our HEC study in April 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In May 2009, we filed a New Drug Application (&#147;NDA&#148;) for SUSTOL with the U.S Food and Drug Administration (&#147;FDA&#148;) under
Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act. In March 2010, we received our first Complete Response Letter (&#147;CRL&#148;), which stated that the May 2009 NDA requesting approval for SUSTOL could not be approved as it was
initially submitted. The primary points raised in the initial CRL were related to the dosing system, certain identified deficiencies in the chemistry, manufacturing, and control (&#147;CMC&#148;) review, and a request that we perform additional
studies showing bioequivalence and metabolic rates, on human factors, and to perform a QT study. We met with the FDA in 2011 to clarify the comments and requests and subsequently performed additional work and data analyses which we believed
addressed the concerns raised in the 2010 CRL. In September 2012, we resubmitted the NDA requesting approval for SUSTOL and, in March 2013, the FDA issued a second CRL. The FDA identified several additional issues precluding the approval of the
SUSTOL NDA resubmission, including further issues relating to the CMC review and deficiencies at certain of our contract manufacturers, and requested that we repeat human factors testing using commercially equivalent material, as well to provide
data to allow reanalysis of our Phase 3 clinical results under the revised American Society of Clinical Oncology guidelines for the prevention of CINV following the administration of MEC or HEC agents, published in 2011. We believe that we have
substantially addressed the issues raised in the March 2013 CRL, which will be reflected in our upcoming SUSTOL NDA resubmission. We intend to include the results of our Phase 3 HEC study in the resubmission of our NDA for SUSTOL, which we
anticipate filing mid-year 2015. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The lead product candidate in our pain management program is HTX-011. HTX-011, which utilizes our
proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The effective management of pain with
a reduction in the use of opioids, which can lead to post-operative complications, extended hospitalization and abuse, remains an important area of unmet medical need, and HTX-011 could potentially provide a differentiated therapeutic profile with
advantages compared to currently available pain management options. In a Phase 1 clinical trial, completed in March 2015, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam. Therapeutically relevant plasma
bupivacaine levels were sustained for 2-3 days in the absence of the large initial peak often observed with commercially available formulations of long-acting bupivacaine. The anesthetic effects of HTX-011 persisted through 96 hours, which closely
correlated with plasma bupivacaine concentrations, and HTX-011 was well-tolerated with no serious adverse events. We plan to move HTX-011 into Phase 2 clinical development in the second quarter of 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2014, we announced our development program for HTX-019. HTX-019 is a proprietary injectable formulation of aprepitant, a
neurokinin-1 (&#147;NK<SUB STYLE="font-size:85%; vertical-align:bottom">1</SUB>&#148;) receptor antagonist for the prevention of CINV. NK<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor antagonists are typically used in combination
with 5-HT<SUB STYLE="font-size:85%; vertical-align:bottom">3</SUB> receptor antagonists. At present, the only injectable NK<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor antagonist approved in the United States contains
polysorbate 80, a surfactant, which may cause hypersensitivity reactions or other adverse reactions in some patients. Our formulation for HTX-019 does not contain polysorbate 80, and may have a lower incidence of infusion-site reactions than
reported with the commercially available injectable NK<SUB STYLE="font-size:85%; vertical-align:bottom">1 </SUB>receptor antagonist. We plan to discuss with the FDA our intent to develop HTX-019 utilizing the 505(b)(2) registration pathway. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In December 2014, we disclosed a second investigational product in our pain management program. HTX-003, which utilizes our proprietary
Biochronomer drug delivery technology, is a long-acting formulation of buprenorphine for the management of chronic pain and opioid addiction. HTX-003 is designed to maintain therapeutic drug levels of buprenorphine for up to 30 days following a
single subcutaneous injection with a low potential for patient abuse. We are presently evaluating our plans for further development of HTX-003. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Critical Accounting Policies and Estimates </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have
been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities,
revenues and expenses, and related disclosure of contingent assets and liabilities. We evaluate our estimates on an ongoing basis, including those related to clinical trial accruals, income taxes and stock-based compensation. We base our estimates
on historical experience and on assumptions that we believe to be reasonable under the circumstances, the results of which form the basis of making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results may differ materially from these estimates under different assumptions or conditions. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There have been no
material changes to the critical accounting policies as previously disclosed in our Annual Report on Form&nbsp;10-K for the fiscal year ended December&nbsp;31, 2014 filed with the SEC on March&nbsp;13, 2015. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Recent Accounting Pronouncements </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See Note&nbsp;2 of Notes to Condensed Consolidated Financial Statements included in Item&nbsp;1 of this Quarterly Report on Form&nbsp;10-Q.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Results of Operations for the Three Months Ended March&nbsp;31, 2015 and 2014 </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Research and Development Expense </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Research and development expense consisted of the following (in thousands): </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="76%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="6" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Three Months Ended</B><br><B>March&nbsp;31,</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2015</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>2014</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">SUSTOL related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,956</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">7,244</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">HTX-011 related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,881</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">106</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">New product development related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">983</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Personnel and related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,121</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,828</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stock-based compensation expense</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">806</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,262</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Facility related costs</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">429</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">525</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Other</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">328</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">263</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Total research and development expense</P></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">14,504</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">11,628</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2015, research and development expense increased to $14.5 million
from $11.6 million for the same period in 2014. The increase was primarily a result of an increase in research and development expense for clinical and manufacturing costs associated with our Phase 1 clinical study for HTX-011, our lead product
candidate for our pain management program. In addition, the increase was due to an increase in SUSTOL related costs for the ongoing Phase 3 HEC study and other SUSTOL related activities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I><U>General and Administrative Expense </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For the three months ended March&nbsp;31, 2015, general and administrative expense of $5.9 million was comparable to general and administrative
expense of $5.7 million for the same period in 2014. For the three months ended March&nbsp;31, 2015, general and administrative expense consisted primarily of salaries and related expenses, professional fees, pre-commercialization costs and
insurance expense. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I><U>Interest Expense, net </U></I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Interest expense, net remained consistent at $0.2 million for each of the three months ended March&nbsp;31,&nbsp;2015 and 2014. Interest
expense, net primarily includes interest expense and amortization of debt discount related to our outstanding Senior Secured Convertible Notes (&#147;Convertible Notes&#148;). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Capital Resources and Liquidity </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of March&nbsp;31, 2015, we had approximately $55.6 million in cash and cash equivalents, compared to $72.7 million in cash and cash
equivalents as of December&nbsp;31,&nbsp;2014. The net decrease in cash and cash equivalents of approximately $17.1 million was primarily due to the use of cash to fund our continued development of SUSTOL and our other product candidates, personnel
costs and for other general corporate purposes (approximately $20.0 million), partially offset by cash proceeds of approximately $2.9 million from stock option exercises. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Historically, we have financed our operations, including technology and product research and development, primarily through sales of our
common stock and other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In November 2013, we closed a public offering of common stock whereby we received approximately $57.8
million of proceeds, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In June 2014, we closed a public offering of common stock and pre-funded warrants whereby we
received approximately $58.9 million of proceeds, net of issuance costs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We believe that our current working capital is sufficient to
fund operations through 2015, including pursuing regulatory approval for SUSTOL, completing Phase 1 and Phase 2 human clinical studies expected to commence in the second half of 2015 relative to our HTX-011 product candidate, and engaging in
clinical and preclinical activities for our HTX-019 product candidate. In the event we were to pursue clinical product development in other areas, potentially acquire other strategic assets, or begin to make significant investments in preparing for
commercialization of SUSTOL, we would need to raise additional capital. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. Our capital requirements going forward
will depend on numerous factors, including but not limited to: the scope, rate of progress, results and costs of preclinical testing and clinical trials, including completing our Phase 3 HEC study; an approval decision by the FDA with respect to
SUSTOL; the timing of and costs associated with the commercial launch of SUSTOL, if approved; the degree of commercial success of SUSTOL; the number and characteristics of product development programs we pursue and the pace of each program,
including the timing of clinical trials; the time, cost and outcome involved in seeking other regulatory approvals; scientific progress in our research and development programs; the magnitude and scope of our research and development programs; our
ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our product candidates; the cost and timing of establishing sales, marketing and distribution
capabilities if we commercialize products independently; the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; and general market conditions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not be able to raise sufficient additional capital when we need it on favorable terms, or at all. The sale of additional equity in the
future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be required to curtail operations significantly or to obtain funds by entering into financing, supply or collaboration agreements on
unattractive terms. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no current means of generating material cash flows from operations. There can be no assurance that our
product development efforts related to any of our product candidates will be successfully completed, that required regulatory approvals will be obtained, or that any products, if introduced, will be successfully marketed or achieve commercial
acceptance. Until we can generate significant continuing revenues, we expect to satisfy our future cash needs through public or private equity offerings, debt financings and corporate collaboration and licensing arrangements. We cannot be certain
that additional funding will be available to us on acceptable terms, or at all. Our ability to obtain new financing may be constrained by our failure to achieve significant business objectives, covenants applicable to the Convertible Notes, and
numerous other factors. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B><I>Contractual Obligations </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Below is a summary of fixed payments related to certain contractual obligations (in thousands), consisting solely of our operating lease
obligations. This table excludes amounts already recorded on our balance sheet as current liabilities as of March&nbsp;31, 2015. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="68%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="18" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Payment due by period</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Total</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Less&nbsp;than<BR>1&nbsp;year</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>1-3&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>3-5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>More&nbsp;than<BR>5&nbsp;years</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Operating lease obligations</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">1,341</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">818</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">523</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&#151;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE="border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of the Convertible Notes may require prepayment of the Convertible Notes at any time at each
holder&#146;s option (see Note 4 of Notes to Condensed Consolidated Financial Statements included in this Quarterly Report on Form 10-Q). As of March&nbsp;31, 2015, $5,421,000 aggregate principal amount of Convertible Notes were outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We also enter into agreements from time to time with clinical sites and clinical research organizations for the conduct of our clinical
trials. We make payments to these sites and organizations based in part upon the number of eligible patients enrolled and the length of their participation in the clinical trials. Under certain of these agreements, we may be subject to penalties in
the event that we prematurely terminate these agreements. At this time, due to the variability associated with clinical site and contract research organization agreements, we are unable to estimate with certainty the future costs we will incur. We
intend to use our current financial resources to fund our obligations under these commitments. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Off-Balance Sheet Arrangements </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have no off-balance sheet arrangements that have, or are reasonably likely to have, a current or future effect on our financial condition,
expenses, results of operations, liquidity, capital expenditures or capital resources. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_7"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The primary objective of our
investment activities is to preserve our capital to fund operations. Our exposure to market risk for changes in interest rates relates primarily to the increase or decrease in the amount of interest income we can earn. Our risk associated with
fluctuating interest income is limited to our investments in interest rate-sensitive financial instruments. As of March&nbsp;31, 2015, our cash equivalents consisted of investments in money market funds. Our debt obligations on our Convertible Notes
carry a fixed interest rate and, as a result, we are not exposed to interest rate risk on our convertible debt. We seek to ensure the safety and preservation of our invested principal by limiting default risk, market risk and reinvestment risk. We
do not have any material foreign currency obligations or other derivative financial instruments. </P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_8"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>CONTROLS AND PROCEDURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We maintain disclosure controls and procedures that are
designed to ensure that information required to be disclosed in our reports, filed under the Exchange Act, is recorded, processed, summarized and reported within the time periods specified in the SEC&#146;s rules and forms, and that such information
is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and
procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of
controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Over time, a control may
become inadequate because of changes in conditions or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not
be detected. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As required by the SEC Rule 13a-15(b), we carried out an evaluation under the supervision and with the participation of our
management, including our chief executive officer and chief financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures as of the end of the period covered by this report. Based on the foregoing, our
chief executive officer and chief financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">There has been no change in our internal control over financial reporting during the first quarter of 2015 that has materially affected, or is
reasonably likely to materially affect, our internal control over financial reporting. </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B>PART&nbsp;II.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER INFORMATION </B></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_9"></A>ITEM&nbsp;1.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>LEGAL PROCEEDINGS </B></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_10"></A>ITEM&nbsp;1A.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>RISK FACTORS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This report and other documents we file with the SEC contain
forward-looking statements that are based on current expectations, estimates, forecasts and projections about us, our future performance, our business, our beliefs and our management&#146;s assumptions. These statements are not guarantees of future
performance, and they involve certain risks, uncertainties and assumptions that are difficult to predict. You should carefully consider the risks and uncertainties facing our business. We have described in our Annual Report on Form 10-K for the
fiscal year ended December&nbsp;31, 2014, the primary risks related to our business, and we periodically update those risks for material developments.&nbsp;The risk factors from our Annual Report on Form 10-K are incorporated herein by reference.
Those risks are not the only ones facing us. Additional risks not currently known to us or that we currently believe are immaterial may in the future materially and adversely affect our business, operations, liquidity and stock price. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_11"></A>ITEM&nbsp;2.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_12"></A>ITEM&nbsp;3.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>DEFAULTS UPON SENIOR SECURITIES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_13"></A>ITEM&nbsp;4.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>MINE SAFETY DISCLOSURES </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Not applicable. </P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_14"></A>ITEM&nbsp;5.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>OTHER INFORMATION </B></TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">None. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="10%" VALIGN="top" ALIGN="left"><B><A NAME="toc924919_15"></A>ITEM&nbsp;6.</B></TD>
<TD ALIGN="left" VALIGN="top"><B>EXHIBITS </B></TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Executive Employment Agreement, dated May 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Dr. Barry Quart</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Executive Employment Agreement, dated May 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Robert Rosen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Management Retention Agreement, dated October 23, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Brian G. Drazba</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Executive Employment Agreement, dated November 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Paul Marshall</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Extension Definition</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Management contract or compensatory plan, contract or arrangement </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc924919_16"></A>SIGNATURES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May 8, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">(On behalf of the Registrant)</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD>
<TD HEIGHT="16" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Brian G. Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Vice President, Finance and Chief Financial Officer</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">(As Principal Financial and Accounting Officer)</TD></TR>
</TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HERON THERAPEUTICS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>INDEX TO EXHIBITS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD WIDTH="90%"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center"> <P STYLE="border-bottom:1.00pt solid #000000; width:26.20pt; font-size:8pt; font-family:Times New Roman" ALIGN="center">Exhibit<BR>Number</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" NOWRAP> <P STYLE="border-bottom:1.00pt solid #000000; width:37.25pt; font-size:8pt; font-family:Times New Roman">Description</P></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.1*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Executive Employment Agreement, dated May 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Dr. Barry Quart</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.2*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Executive Employment Agreement, dated May 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Robert Rosen</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.3*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Management Retention Agreement, dated October 23, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Brian G. Drazba</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;10.4*</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Amendment to Executive Employment Agreement, dated November 1, 2013, as amended on April 22, 2015, by and between Heron Therapeutics, Inc. and Paul Marshall</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;31.2</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>&nbsp;&nbsp;32.1</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">Certification Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.INS</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Instance Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.SCH</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Schema Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.CAL</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Calculation Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.DEF</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Extension Definition</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.LAB</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Label Linkbase Document</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="2"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top" NOWRAP>101.PRE</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top">XBRL Taxonomy Extension Presentation Linkbase Document</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">*</TD>
<TD ALIGN="left" VALIGN="top">Management contract or compensatory plan, contract or arrangement </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d924919dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO EXECUTIVE
EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Amendment to the Executive Employment Agreement (this &#147;<B><I>Amendment</I></B>&#148;) by and between
Heron Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;), and Dr. Barry Quart (the &#147;<B><I>Executive</I></B>&#148;) is effective as of April 22, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company are parties to the Executive Employment Agreement dated as of May 1, 2013 (the
&#147;<B><I>Original</I></B> <B><I>Agreement</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company desire to amend the Original
Agreement as described in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the parties agree
that the Original Agreement is amended as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Section 4.4.2 shall be amended and restated in its entirety to read as follows: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>4.4.2
Without Cause or With Good Reason.</B><B>&nbsp;</B>If the Executive&#146;s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason, the Executive shall receive the payments specified in Section&nbsp;4.4.1,
and, in addition, within ten days of the Executive&#146;s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as&nbsp;<B><I>Exhibit A</I></B>, within the applicable time period set forth therein, but in no
event later than 45 days following termination of the Executive&#146;s employment, the Executive shall receive the following: (i)&nbsp;a lump sum payment equal to the sum of the Executive&#146;s annual base salary then in effect and the
Executive&#146;s target performance bonus then in effect, less required deductions and withholdings; (ii)&nbsp;accelerated time-based vesting of shares subject to all stock awards issued by the Company, for the number of shares which would have
vested accordingly had the Executive continued employment with the Company for a period of 12 months after termination (for the avoidance of doubt, which shall include partial accelerated vesting of the Time-Based Shares, but not the
Performance-Based Shares); and (iii)&nbsp;reimbursement for or continuation of payment by the Company of its portion of the health insurance benefits provided to Executive immediately prior to termination pursuant to the terms of the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended (<B><I>&#147;COBRA&#148;</I></B>) or other applicable law for a period of up to 18 months from the date of termination.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Section 4.4.3 shall be amended and restated in its entirety to read as follows: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>4.4.3
Change in Control.</B>&nbsp;If the Executive&#146;s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason within three months before or within 18 months following a Change in Control, the Executive shall
receive the payments specified in Section&nbsp;4.4.1, and, in addition, within ten days of the Executive&#146;s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as&nbsp;<B><I>Exhibit A</I></B>, within the
applicable time period set forth therein, but in no event later than 45 days following termination of the Executive&#146;s employment, the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Executive shall receive the following: (i)&nbsp;a lump sum payment equal to 150% of the Executive&#146;s annual base salary then in effect, less required deductions and withholdings;
(ii)&nbsp;the greater of the Executive&#146;s target performance bonus then in effect, less required deductions and withholdings, or the Executive&#146;s performance bonus paid in the year preceding the year in which termination occurs, less
required deductions and withholdings; and (iii)&nbsp;provided that the Executive timely elects continued coverage under COBRA, the COBRA benefit for a period of up to 18 months. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Additionally, upon the close of a Change in Control transaction, the Executive will immediately vest in (i) 50% of any outstanding and unvested
time-based stock awards held by the Executive at such time, and (ii) 100% of any outstanding and unvested performance-based stock awards held by the Executive at such time. The remaining 50% of the Executive&#146;s outstanding and unvested
time-based stock awards will vest upon the earlier of (i) the Executive&#146;s termination by the Company without Cause or by the Executive with Good Reason following such Change in Control transaction, or (ii) the date that is six months following
the date of closing of the Change in Control transaction, subject to the Executive&#146;s voluntary continued employment through such date.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Except as modified by this Amendment, the Original Agreement shall remain in full force and effect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">By: /s/ Brian Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Brian Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: VP Finance &amp; CFO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Dr. Barry Quart</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>d924919dex102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.2 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO EXECUTIVE
EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Amendment to the Executive Employment Agreement (this &#147;<B><I>Amendment</I></B>&#148;) by and between
Heron Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;), and Robert Rosen (the &#147;<B><I>Executive</I></B>&#148;) is effective as of April 22, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company are parties to the Executive Employment Agreement dated as of May 1, 2013 (the
&#147;<B><I>Original</I></B> <B><I>Agreement</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company desire to amend the Original
Agreement as described in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the parties agree
that the Original Agreement is amended as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Section 4.4.2 shall be amended and restated in its entirety to read as follows: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>4.4.2
Without Cause or With Good Reason.</B><B>&nbsp;</B>If the Executive&#146;s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason, the Executive shall receive the payments specified in Section&nbsp;4.4.1,
and, in addition, within ten days of the Executive&#146;s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as&nbsp;<B><I>Exhibit A</I></B>, within the applicable time period set forth therein, but in no
event later than 45 days following termination of the Executive&#146;s employment, the Executive shall receive the following: (i)&nbsp;a lump sum payment equal to the sum of the Executive&#146;s annual base salary then in effect and the
Executive&#146;s target performance bonus then in effect, less required deductions and withholdings; (ii)&nbsp;accelerated time-based vesting of shares subject to all stock awards issued by the Company, for the number of shares which would have
vested accordingly had the Executive continued employment with the Company for a period of 12 months after termination (for the avoidance of doubt, which shall include partial accelerated vesting of the Time-Based Shares, but not the
Performance-Based Shares); and (iii)&nbsp;reimbursement for or continuation of payment by the Company of its portion of the health insurance benefits provided to Executive immediately prior to termination pursuant to the terms of the Consolidated
Omnibus Budget Reconciliation Act of 1985, as amended (<B><I>&#147;COBRA&#148;</I></B>) or other applicable law for a period of up to 18 months from the date of termination.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Section 4.4.3 shall be amended and restated in its entirety to read as follows: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>4.4.3
Change in Control.</B>&nbsp;If the Executive&#146;s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason within three months before or within 18 months following a Change in Control, the Executive shall
receive the payments specified in Section&nbsp;4.4.1, and, in addition, within ten days of the Executive&#146;s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as&nbsp;<B><I>Exhibit A</I></B>, within the
applicable time period set forth therein, but in no event later than 45 days following termination of the Executive&#146;s employment, the </P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">
Executive shall receive the following: (i)&nbsp;a lump sum payment equal to 150% of the Executive&#146;s annual base salary then in effect, less required deductions and withholdings;
(ii)&nbsp;the greater of the Executive&#146;s target performance bonus then in effect, less required deductions and withholdings, or the Executive&#146;s performance bonus paid in the year preceding the year in which termination occurs, less
required deductions and withholdings; and (iii)&nbsp;provided that the Executive timely elects continued coverage under COBRA, the COBRA benefit for a period of up to 18 months. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">Additionally, upon the close of a Change in Control transaction, the Executive will immediately vest in (i) 50% of any outstanding and unvested
time-based stock awards held by the Executive at such time, and (ii) 100% of any outstanding and unvested performance-based stock awards held by the Executive at such time. The remaining 50% of the Executive&#146;s outstanding and unvested
time-based stock awards will vest upon the earlier of (i) the Executive&#146;s termination by the Company without Cause or by the Executive with Good Reason following such Change in Control transaction, or (ii) the date that is six months following
the date of closing of the Change in Control transaction, subject to the Executive&#146;s voluntary continued employment through such date.&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Except as modified by this Amendment, the Original Agreement shall remain in full force and effect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">By: /s/ Barry Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Barry Quart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Robert Rosen</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Robert Rosen</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>4
<FILENAME>d924919dex103.htm
<DESCRIPTION>EX-10.3
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.3 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO MANAGEMENT
RETENTION AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Amendment to the Management Retention Agreement (this &#147;<B><I>Amendment</I></B>&#148;) by and between
Heron Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;), and Brian G. Drazba (the &#147;<B><I>Executive</I></B>&#148;) is effective as of April&nbsp;22, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company are parties to the Management Retention Agreement dated as of October&nbsp;23, 2013 (the
&#147;<B><I>Original Agreement</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company desire to amend the Original Agreement as
described in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the parties agree that the
Original Agreement is amended as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;2(b) shall be amended by replacing the first occurrence of the words &#147;twelve (12)&nbsp;month period&#148; contained therein with the words &#147;eighteen (18)&nbsp;month period&#148;.
</TD></TR></TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Section&nbsp;9(l) shall be amended by replacing the words &#147;twelve (12)&nbsp;month period&#148; contained therein with the words &#147;eighteen (18)&nbsp;month period&#148;. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Except as modified by this Amendment, the Original Agreement shall remain in full force and effect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above written. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">By: /s/ Barry Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Barry Quart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Brian G. Drazba</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>5
<FILENAME>d924919dex104.htm
<DESCRIPTION>EX-10.4
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.4</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.4 </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AMENDMENT </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>TO EXECUTIVE
EMPLOYMENT AGREEMENT </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">This Amendment to the Executive Employment Agreement (this &#147;<B><I>Amendment</I></B>&#148;) by and between
Heron Therapeutics, Inc. (the &#147;<B><I>Company</I></B>&#148;), and Paul Marshall (the &#147;<B><I>Executive</I></B>&#148;) is effective as of April 22, 2015. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company are parties to the Executive Employment Agreement dated as of November 1, 2013 (the
&#147;<B><I>Original</I></B> <B><I>Agreement</I></B>&#148;); and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">WHEREAS, the Executive and the Company desire to amend the Original
Agreement as described in this Amendment. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">NOW, THEREFORE, in consideration of the mutual covenants in this Amendment, the parties agree
that the Original Agreement is amended as set forth below: </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">Clause (iii) of Section 4.4.2 shall be amended and restated in its entirety to read as follows: </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;(iii)&nbsp;reimbursement for or continuation of payment by the Company of its portion of the health insurance benefits provided to
Executive immediately prior to termination pursuant to the terms of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (<B><I>&#147;COBRA&#148;</I></B>) or other applicable law for a period of up to 18 months from the date of
termination&#148; </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Section 4.4.3 shall be amended and restated in its entirety to read as follows: </TD></TR></TABLE> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:8%; font-size:10pt; font-family:Times New Roman">&#147;<B>4.4.3
Change in Control.</B>&nbsp;If the Executive&#146;s employment shall be terminated by the Company without Cause, or by the Executive for Good Reason within three months before or within 18 months following a Change in Control, the Executive shall
receive the payments specified in Section&nbsp;4.4.1, and, in addition, within ten days of the Executive&#146;s delivery to the Company of a fully effective Release and Waiver in the form attached hereto as&nbsp;<B><I>Exhibit A</I></B>, within the
applicable time period set forth therein, but in no event later than 45 days following termination of the Executive&#146;s employment, the Executive shall receive the following: (i)&nbsp;a lump sum payment equal to the Executive&#146;s annual base
salary then in effect, less required deductions and withholdings; (ii)&nbsp;the greater of the Executive&#146;s target performance bonus then in effect, less required deductions and withholdings, or the Executive&#146;s performance bonus paid in the
year preceding the year in which termination occurs, less required deductions and withholdings; (iii)&nbsp;accelerated vesting of 100% of any outstanding and unvested stock awards held by the Executive at such time (including both time-based and
performance-based stock awards) and (iv)&nbsp;provided that the Executive timely elects continued coverage under COBRA, the COBRA benefit for a period of up to 12 months.&#148; </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Except as modified by this Amendment, the Original Agreement shall remain in full force and effect. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><I></I></B>[<B><I></I></B><I>Remainder of page intentionally left blank.</I><B><I></I></B>]<B><I> </I></B></P>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:8%; font-size:10pt; font-family:Times New Roman">IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the date first above
written. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Heron Therapeutics, Inc.</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">By: /s/ Barry Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Name: Barry Quart</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Title: CEO</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Paul Marshall</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Paul Marshall</TD></TR>
</TABLE></DIV>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>d924919dex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 31.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Barry D.
Quart, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Heron Therapeutics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;8, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Barry D. Quart, Pharm.D.</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Chief Executive Officer</TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>d924919dex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<HTML><HEAD>
<TITLE>EX-31.2</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 31.2 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 302 CERTIFICATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">I, Brian G.
Drazba, certify that: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">1.</TD>
<TD ALIGN="left" VALIGN="top">I have reviewed this Quarterly Report on Form 10-Q of Heron Therapeutics, Inc.; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">2.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such
statements were made, not misleading with respect to the period covered by this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">3.</TD>
<TD ALIGN="left" VALIGN="top">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the
registrant as of, and for, the periods presented in this report; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">4.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control
over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its
consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of
financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">c)</TD>
<TD ALIGN="left" VALIGN="top">Evaluated the effectiveness of the registrant&#146;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of
the period covered by this report based on such evaluation; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">d)</TD>
<TD ALIGN="left" VALIGN="top">Disclosed in this report any change in the registrant&#146;s internal control over financial reporting that occurred during the registrant&#146;s most recent fiscal quarter (the registrant&#146;s fourth fiscal quarter
in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#146;s internal control over financial reporting; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="4%" VALIGN="top" ALIGN="left">5.</TD>
<TD ALIGN="left" VALIGN="top">The registrant&#146;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#146;s auditors and the audit committee of the
registrant&#146;s board of directors (or persons performing the equivalent functions): </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">a)</TD>
<TD ALIGN="left" VALIGN="top">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#146;s ability to record,
process, summarize and report financial information; and </TD></TR></TABLE>

<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="8%">&nbsp;</TD>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">b)</TD>
<TD ALIGN="left" VALIGN="top">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#146;s internal control over financial reporting. </TD></TR></TABLE>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="47%"></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="4%"></TD>
<TD VALIGN="bottom"></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="1%"></TD>
<TD WIDTH="46%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top">Date: May&nbsp;8, 2015</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">Brian G. Drazba</TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance and</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Chief Financial
Officer (As</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>d924919dex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-32.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>EXHIBIT 32.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>CERTIFICATION PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>18 U.S.C. SECTION 1350, </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>AS ADOPTED PURSUANT TO </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Each of the undersigned, in his capacity as Chief Executive Officer and Chief Financial Officer, respectively, of Heron Therapeutics, Inc. (the
&#147;Registrant&#148;), hereby certifies, for purposes of 18 U.S.C. Section&nbsp;1350, as adopted pursuant to Section&nbsp;906 of the Sarbanes-Oxley Act of 2002, to the best of his knowledge that: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Quarterly Report of the Registrant on Form 10-Q for the quarter ended March&nbsp;31,&nbsp;2015 (the &#147;Report&#148;), which accompanies this certification, fully complies with the requirements of
Section&nbsp;13(a) or 15(d) of the Securities Exchange Act of 1934; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the information contained in the Report fairly presents, in all material respects, the financial condition of the Registrant at the end of such quarter and the results of operations of the Registrant for such quarter.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Dated: May&nbsp;8, 2015 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><DIV ALIGN="right">
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="40%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt">


<TR>
<TD WIDTH="100%"></TD></TR>


<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Barry D. Quart</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Barry D. Quart, Pharm.D.</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Chief Executive
Officer</P></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="16"></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:1pt; border-bottom:1px solid #000000; font-size:10pt; font-family:Times New Roman">/s/ Brian G. Drazba</P></TD></TR>
<TR STYLE="font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">Brian G. Drazba</P> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:10pt; font-family:Times New Roman">Vice President, Finance and
Chief Financial Officer (As Principal Financial and Accounting Officer)</P></TD></TR>
</TABLE></DIV> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">This certification accompanies the Report to which it relates, is not deemed to be filed with the Securities and
Exchange Commission and is not to be incorporated by reference into any filing of Heron Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the
Report), irrespective of any general incorporation language contained in such filing. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR>
<TD WIDTH="5%" VALIGN="top" ALIGN="left">Note:</TD>
<TD ALIGN="left" VALIGN="top">A signed original of this written statement required by Section&nbsp;906 has been provided to Heron Therapeutics, Inc. and will be retained by Heron Therapeutics, Inc. and furnished to the Securities and Exchange
Commission or its staff upon request. </TD></TR></TABLE>
</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>9
<FILENAME>hrtx-20150331.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 02:02PM UTC 2015-05-08--><xbrli:xbrl xmlns="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:hrtx="http://herontx.com/20150331" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:schemaRef xlink:href="hrtx-20150331.xsd" xlink:type="simple"/>
  <dei:AmendmentFlag contextRef="d_2015-01-01_2015-03-31" id="c-13">false</dei:AmendmentFlag>
  <dei:CurrentFiscalYearEndDate contextRef="d_2015-01-01_2015-03-31" id="c-3">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:DocumentFiscalPeriodFocus contextRef="d_2015-01-01_2015-03-31" id="c-12">Q1</dei:DocumentFiscalPeriodFocus>
  <dei:DocumentFiscalYearFocus contextRef="d_2015-01-01_2015-03-31" id="c-11">2015</dei:DocumentFiscalYearFocus>
  <dei:DocumentPeriodEndDate contextRef="d_2015-01-01_2015-03-31" id="c-10">2015-03-31</dei:DocumentPeriodEndDate>
  <dei:DocumentType contextRef="d_2015-01-01_2015-03-31" id="c-9">10-Q</dei:DocumentType>
  <dei:EntityCentralIndexKey contextRef="d_2015-01-01_2015-03-31" id="c-2">0000818033</dei:EntityCentralIndexKey>
  <dei:EntityCommonStockSharesOutstanding contextRef="i_2015-04-28" decimals="INF" id="c-8" unitRef="xbrli-shares">29632533</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityCurrentReportingStatus contextRef="d_2015-01-01_2015-03-31" id="c-5">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityFilerCategory contextRef="d_2015-01-01_2015-03-31" id="c-4">Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityRegistrantName contextRef="d_2015-01-01_2015-03-31" id="c-1">HERON THERAPEUTICS, INC. /DE/</dei:EntityRegistrantName>
  <dei:EntityVoluntaryFilers contextRef="d_2015-01-01_2015-03-31" id="c-6">No</dei:EntityVoluntaryFilers>
  <dei:EntityWellKnownSeasonedIssuer contextRef="d_2015-01-01_2015-03-31" id="c-7">No</dei:EntityWellKnownSeasonedIssuer>
  <hrtx:AccruedClinicalLiabilities contextRef="i_2015-03-31" decimals="-3" id="c1207418" unitRef="iso4217-usd">3518000</hrtx:AccruedClinicalLiabilities>
  <hrtx:AccruedClinicalLiabilities contextRef="i_2014-12-31" decimals="-3" id="c1207419" unitRef="iso4217-usd">3811000</hrtx:AccruedClinicalLiabilities>
  <hrtx:BeneficialOwnershipAfterConversion contextRef="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207687" unitRef="xbrli-pure">0.0999</hrtx:BeneficialOwnershipAfterConversion>
  <hrtx:CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes contextRef="d_2011-07-28_2011-07-29" decimals="INF" id="c1207689" unitRef="xbrli-shares">3500000</hrtx:CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes>
  <hrtx:ConvertibleDebtIssuableInConnectionWithPrivatePlacement contextRef="i_2011-04-30" decimals="INF" id="c1207682" unitRef="iso4217-usd">4500000</hrtx:ConvertibleDebtIssuableInConnectionWithPrivatePlacement>
  <hrtx:ConvertibleNotesPayableRelatedPartiesCurrent contextRef="i_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207701" unitRef="iso4217-usd">1749000</hrtx:ConvertibleNotesPayableRelatedPartiesCurrent>
  <hrtx:ConvertibleNotesPayableRelatedPartiesCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207424" unitRef="iso4217-usd">1749000</hrtx:ConvertibleNotesPayableRelatedPartiesCurrent>
  <hrtx:ConvertibleNotesPayableRelatedPartiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207425" unitRef="iso4217-usd">1598000</hrtx:ConvertibleNotesPayableRelatedPartiesCurrent>
  <hrtx:DebtInstrumentConversionRatioMultipleOfPrincipal contextRef="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207686" unitRef="iso4217-usd">1000</hrtx:DebtInstrumentConversionRatioMultipleOfPrincipal>
  <hrtx:DebtInstrumentConversionRatioShares contextRef="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207685" unitRef="xbrli-shares">1250</hrtx:DebtInstrumentConversionRatioShares>
  <hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207507" unitRef="iso4217-usd-per-xbrli-shares">0.09</hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare>
  <hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1207508" unitRef="iso4217-usd-per-xbrli-shares">0.13</hrtx:ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare>
  <hrtx:IncreaseDecreaseInClinicalLiabilities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207471" unitRef="iso4217-usd">-293000</hrtx:IncreaseDecreaseInClinicalLiabilities>
  <hrtx:IncreaseDecreaseInClinicalLiabilities contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207472" unitRef="iso4217-usd">-1029000</hrtx:IncreaseDecreaseInClinicalLiabilities>
  <hrtx:LimitationOnExercisableWarrants contextRef="d_2011-06-01_2013-06-30_StatementClassOfStockAxis-PrivatePlacement2011Member" decimals="4" id="c1207714" unitRef="xbrli-pure">0.0999</hrtx:LimitationOnExercisableWarrants>
  <hrtx:NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes contextRef="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" id="c1207688">P61D</hrtx:NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes>
  <hrtx:StockIssuedDuringPeriodSharesStockOptionsExercisedNet contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207743" unitRef="xbrli-shares">351698</hrtx:StockIssuedDuringPeriodSharesStockOptionsExercisedNet>
  <hrtx:StockIssuedDuringPeriodSharesStockOptionsExercisedNet contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1207747" unitRef="xbrli-shares">215350</hrtx:StockIssuedDuringPeriodSharesStockOptionsExercisedNet>
  <us-gaap:AccountsPayableCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207416" unitRef="iso4217-usd">2383000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207417" unitRef="iso4217-usd">2549000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2015-03-31" decimals="-3" id="c1207431" unitRef="iso4217-usd">383512000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AdditionalPaidInCapital contextRef="i_2014-12-31" decimals="-3" id="c1207432" unitRef="iso4217-usd">378007000</us-gaap:AdditionalPaidInCapital>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c1207501" unitRef="iso4217-usd">806000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" decimals="-3" id="c1207502" unitRef="iso4217-usd">1262000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c1207503" unitRef="iso4217-usd">1745000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" decimals="-3" id="c1207504" unitRef="iso4217-usd">1707000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207505" unitRef="iso4217-usd">2551000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207506" unitRef="iso4217-usd">2969000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207699" unitRef="iso4217-usd">151000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AmortizationOfDebtDiscountPremium contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1207700" unitRef="iso4217-usd">139000</us-gaap:AmortizationOfDebtDiscountPremium>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-StockOptionMember" decimals="-3" id="c1207495" unitRef="xbrli-shares">7293000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-StockOptionMember" decimals="-3" id="c1207496" unitRef="xbrli-shares">7273000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="-3" id="c1207497" unitRef="xbrli-shares">3843000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" decimals="-3" id="c1207498" unitRef="xbrli-shares">3825000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2015-01-01_2015-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" decimals="-3" id="c1207499" unitRef="xbrli-shares">6777000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="d_2014-01-01_2014-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember" decimals="-3" id="c1207500" unitRef="xbrli-shares">6385000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
  <us-gaap:Assets contextRef="i_2015-03-31" decimals="-3" id="c1207412" unitRef="iso4217-usd">59627000</us-gaap:Assets>
  <us-gaap:Assets contextRef="i_2014-12-31" decimals="-3" id="c1207413" unitRef="iso4217-usd">76682000</us-gaap:Assets>
  <us-gaap:AssetsCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207406" unitRef="iso4217-usd">56501000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207407" unitRef="iso4217-usd">73732000</us-gaap:AssetsCurrent>
  <us-gaap:BasisOfAccounting contextRef="d_2015-01-01_2015-03-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;B&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;asis of Presentation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&amp;#x201c;GAAP&amp;#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for other quarters or the year ending December&amp;nbsp;31, 2015. The condensed balance sheet at December 31, 2014 has been derived from the audited financial statements as of that date, but does not include all of the information and disclosures required by GAAP. For more complete financial information, these unaudited condensed consolidated financial statements and the notes thereto should be read in conjunction with the audited financial statements included in&amp;nbsp;our Annual Report on Form&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;10-K for the fiscal year ended December&amp;nbsp;31, 2014 filed with the Securities and Exchange Commission (the &amp;#x201c;SEC&amp;#x201d;) on March&amp;nbsp;13,&amp;nbsp;2015&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BasisOfAccounting>
  <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="d_2015-01-01_2015-03-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;1.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Business&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Heron Therapeutics, Inc. (&amp;#x201c;we,&amp;#x201d; &amp;#x201c;us&amp;#x201d; and &amp;#x201c;our&amp;#x201d;)&amp;nbsp;is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. Our proprietary Biochronomer drug delivery technology is designed to improve the therapeutic profile of injectable pharmaceuticals.&amp;nbsp;Our product development efforts focus on identifying current therapies with the potential to be reformulated to expand or extend therapeutic effect or duration of action, minimize drawbacks or to apply new delivery methods. In addition, we continually evaluate potential development programs, technologies or product candidates&amp;nbsp;that may be complementary to or synergistic with our existing programs and product development goals.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Our Biochronomer technology, with which our lead investigational product candidate, SUSTOL (granisetron injection, extended release) (or &amp;#x201c;APF530&amp;#x201d;), and certain of our other product candidates are formulated, consists of bioerodible polymers designed to release drugs over a defined period of time, depending on the medical need of a given therapeutic target. We have demonstrated that our Biochronomer technology can deliver drugs over periods varying from days to weeks and that the technology is potentially applicable to a range of therapeutic areas, including the prevention of chemotherapy-induced nausea and vomiting (&amp;#x201c;CINV&amp;#x201d;) and pain management, among others. Furthermore, we have completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymer is well tolerated. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;At present, our clinical and preclinical development programs include SUSTOL, in advanced development for the prevention of CINV following administration of chemotherapeutic agents, as well as HTX-011 for the prevention of post-operative pain, HTX-019 for the prevention of CINV and HTX-003 for the management of chronic pain and opioid addiction. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;APF530, which we intend to market as SUSTOL&lt;div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;"&gt; &lt;/div&gt;subject to regulatory approval, is being developed for the prevention of both acute- and delayed-onset CINV following the administration of moderately emetogenic chemotherapy (&amp;#x201c;MEC&amp;#x201d;) or highly emetogenic chemotherapy (&amp;#x201c;HEC&amp;#x201d;). Injectable 5-hydroxytryptamine type 3 (&amp;#x201c;5-HT3&amp;#x201d;) receptor antagonists have been shown to be among the most effective and preferred treatments for CINV, however, an unmet need remains for patients suffering from CINV during the delayed-onset phase, which typically occurs 1-5 days following administration of chemotherapy agents. For patients suffering from delayed-onset CINV, only one injectable 5-HT3 receptor antagonist is approved for use following the administration of MEC agents, and none are approved for use following administration of HEC agents. SUSTOL contains the 5-HT3 receptor antagonist granisetron, selected due to its broad use by physicians based on a well-established record of safety and efficacy, and because it is only currently approved for the prevention of CINV during the acute-onset phase. SUSTOL is formulated with our proprietary Biochronomer drug delivery technology, and in clinical studies has been shown to maintain therapeutic drug levels of granisetron for up to five days with a single subcutaneous injection. In 2014, we initiated a Phase 3 clinical study evaluating SUSTOL for the prevention of delayed-onset CINV following the administration of HEC agents (&amp;#x201c;HEC study&amp;#x201d;), which, if successful, would differentiate SUSTOL from the other currently approved 5-HT3 receptor antagonists. We completed enrollment of our HEC study in April 2015. &lt;/div&gt;&lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In May 2009, we filed a New Drug Application (&amp;#x201c;NDA&amp;#x201d;) for SUSTOL with the U.S Food and Drug Administration (&amp;#x201c;FDA&amp;#x201d;) under Section&amp;nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act. In March 2010, we received our first Complete Response Letter (&amp;#x201c;CRL&amp;#x201d;), which stated that the May 2009 NDA requesting approval for SUSTOL could not be approved as it was initially submitted. The primary points raised in the initial CRL were related to the dosing system, certain identified deficiencies in the chemistry, manufacturing, and control (&amp;#x201c;CMC&amp;#x201d;) review, and a request that we perform additional studies showing bioequivalence and metabolic rates, on human factors, and to perform a QT study. We met with the FDA in 2011 to clarify the comments and requests and subsequently performed additional work and data analyses which we believed addressed the concerns raised in the 2010 CRL. In September 2012, we resubmitted the NDA requesting approval for SUSTOL and, in March 2013, the FDA issued a second CRL. The FDA identified several additional issues precluding the approval of the SUSTOL NDA resubmission, including further issues relating to the CMC review and deficiencies at certain of our contract manufacturers, and requested that we repeat human factors testing using commercially equivalent material, as well to provide data to allow reanalysis of our Phase 3 clinical results under the revised American Society of Clinical Oncology guidelines for the prevention of CINV following the administration of MEC or HEC agents, published in 2011. We believe that we have substantially addressed the issues raised in the March 2013 CRL, which will be reflected in our upcoming SUSTOL NDA resubmission. We intend to include the results of our Phase 3 HEC study in the resubmission of our NDA for SUSTOL, which we anticipate filing mid-year 2015. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The lead product candidate in our pain management program is HTX-011. HTX-011, which utilizes our proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The effective management of pain with a reduction in the use of opioids, which can lead to post-operative complications, extended hospitalization and abuse, remains an important area of unmet medical need, and HTX-011 could potentially provide a differentiated therapeutic profile with advantages compared to currently available pain management options. In a Phase 1 clinical trial, completed in March 2015, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam. Therapeutically relevant plasma bupivacaine levels were sustained for 2-3 days in the absence of the large initial peak often observed with commercially available formulations of long-acting bupivacaine. The anesthetic effects of HTX-011 persisted through 96 hours, which closely correlated with plasma bupivacaine concentrations, and HTX-011 was well-tolerated with no serious adverse events. We plan to move HTX-011 into Phase 2 clinical development in the second quarter of 2015. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In November 2014, we announced our development program for HTX-019. HTX-019 is a proprietary injectable formulation of aprepitant, a neurokinin-1 (&amp;#x201c;NK1&amp;#x201d;) receptor antagonist for the prevention of CINV. NK1 receptor antagonists are typically used in combination with 5-HT3 receptor antagonists. At present, the only injectable NK1 receptor antagonist approved in the United States contains polysorbate 80, a surfactant, which may cause hypersensitivity reactions or other adverse reactions in some patients. Our formulation for HTX-019 does not contain polysorbate 80, and may have a lower incidence of infusion-site reactions than reported with the commercially available injectable NK1 receptor antagonist. We&amp;nbsp;plan to discuss&amp;nbsp;with the FDA&amp;nbsp;our intent to develop&amp;nbsp;HTX-019 utilizing the 505(b)(2) registration pathway.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In December 2014, we disclosed a second investigational product in our pain management program. HTX-003, which utilizes our proprietary Biochronomer drug delivery technology, is a long-acting formulation of buprenorphine for the management of chronic pain and opioid addiction. HTX-003 is designed to maintain therapeutic drug levels of buprenorphine for up to 30 days following a single subcutaneous injection with a low potential for patient abuse. We are presently evaluating our plans for further development of HTX-003. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Liquidity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;We have incurred significant operating losses and negative cash flows from operations, and we had an accumulated deficit of $335.8 million as of March 31, 2015. Since 2011, we have completed a total of five rounds of equity and/or convertible debt financings, which provided us with cash of approximately $194.3 million in the aggregate, net of issuance costs, to fund operations (see Notes 4 and 5). As of March 31, 2015, we had cash and cash equivalents on hand of $55.6 million.&lt;/div&gt;&lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;We believe that our current working capital is sufficient to fund operations through 2015, including pursuing regulatory approval&amp;nbsp;for SUSTOL,&amp;nbsp;completing Phase 1 and Phase 2 human clinical studies expected to commence in the second&amp;nbsp;half of 2015 relative to our HTX-011&amp;nbsp;product candidate, and engaging in clinical and&amp;nbsp;preclinical activities for our HTX-019 product candidate. In the event we were to pursue clinical product development in other areas, potentially acquire other strategic assets, or begin to make significant investments in preparing for commercialization of SUSTOL, we would need to raise additional capital. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. Our capital requirements going forward will depend on numerous factors, including but not limited to: the scope, rate of progress, results and costs of preclinical testing and clinical trials, including completing our Phase 3 HEC study; an approval decision by the FDA with respect to SUSTOL; the timing of and costs associated with the commercial launch of SUSTOL, if approved; the degree of commercial success of SUSTOL; the number and characteristics of product development programs we pursue and the pace of each program, including the timing of clinical trials; the time, cost and outcome involved in seeking other regulatory approvals; scientific progress in our research and development programs; the magnitude and scope of our research and development programs; our ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our product candidates; the cost and timing of establishing sales, marketing and distribution capabilities if we commercialize products independently; the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; and general market conditions.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;We may not be able to raise sufficient additional capital when we need it on favorable terms, or at all. The sale of additional equity in the future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be required to curtail operations significantly or to obtain funds by entering into financing, supply or collaboration agreements on unattractive terms.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2015-03-31" decimals="-3" id="c1207606" unitRef="iso4217-usd">55556000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-12-31" decimals="-3" id="c1207491" unitRef="iso4217-usd">72675000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2013-12-31" decimals="-3" id="c1207492" unitRef="iso4217-usd">72287000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="i_2014-03-31" decimals="-3" id="c1207494" unitRef="iso4217-usd">57475000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207489" unitRef="iso4217-usd">-17119000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207490" unitRef="iso4217-usd">-14812000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2015-01-01_2015-03-31" id="c1264777">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Cash and cash equivalents consist of cash and highly liquid investments with original maturities from purchase date of three months or less. Our bank accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (&amp;#x201c;Convertible Notes&amp;#x201d;).&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2011-06-30_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207713" unitRef="iso4217-usd-per-xbrli-shares">3.60</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="i_2014-06-30_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" decimals="INF" id="c1207740" unitRef="iso4217-usd-per-xbrli-shares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="i_2011-06-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207712" unitRef="xbrli-shares">0.5</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
  <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="i_2014-06-30_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" decimals="INF" id="c1207738" unitRef="xbrli-shares">600000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
  <us-gaap:CommonStockValue contextRef="i_2015-03-31" decimals="-3" id="c1207429" unitRef="iso4217-usd">296000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue contextRef="i_2014-12-31" decimals="-3" id="c1207430" unitRef="iso4217-usd">292000</us-gaap:CommonStockValue>
  <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock contextRef="d_2015-01-01_2015-03-31" id="c1264779">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Comprehensive Income (Loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of our net loss, and there were no other changes in equity from non-owner sources. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
  <us-gaap:ConsolidationPolicyTextBlock contextRef="d_2015-01-01_2015-03-31" id="c1264775">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Principles of Consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V., which was organized in the Netherlands in March 2015. Heron Therapeutics B.V. has no operations and no material assets or liabilities and there have been no significant transactions related to Heron Therapeutics B.V. since its inception.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ConsolidationPolicyTextBlock>
  <us-gaap:DebtDisclosureTextBlock contextRef="d_2015-01-01_2015-03-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;4.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Convertible Notes to Related Parties&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5&amp;nbsp;million in Convertible Notes. We received a total of $4.3 million, net of issuance costs, from the issuance of these Convertible Notes. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Convertible Notes are secured by substantially all of our assets, including placing our bank accounts under a control agreement. The Convertible Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Convertible Notes, at the election of the purchasers. The Convertible Notes mature on May 2, 2021, however, the holders of the Convertible Notes may require prepayment of the Convertible Notes at any time, at each holder&amp;#x2019;s option.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Convertible Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes. There is no right to convert the Convertible Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Convertible Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of March 31, 2015, we were in compliance with all covenants under the Convertible Notes. Upon the occurrence of an event of default under the Convertible Notes, the holders of the Convertible Notes have the right to require us to redeem all or a portion of their Convertible Notes.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;We filed a registration statement with the SEC to register for resale 3.5 million shares underlying the Convertible Notes. The registration statement was declared effective on July&amp;nbsp;29,&amp;nbsp;2011. The Note holders have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Convertible Notes until they provide notice otherwise.&lt;/div&gt;&lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The Convertible Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a debt discount was recorded in an amount equal to the face value of the Convertible Notes on the issuance dates and we began amortizing the resultant debt discount over the respective 10-year term of the Convertible Notes. During the three months ended March 31, 2015, accrued interest of approximately $80,000 was paid-in-kind and rolled into the Convertible Note principal balance, which resulted in an additional debt discount of approximately $80,000. For the three months ended March 31, 2015 and 2014, interest expense relating to the stated rate was approximately $81,000 and $77,000, respectively, and interest expense relating to the amortization of the debt discount was approximately $151,000 and $139,000, respectively.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of March 31, 2015, the carrying value of the Convertible Notes was approximately $1,749,000, which is comprised of the $5,421,000 principal amount of the Convertible Notes outstanding, less debt discount of $3,672,000. If the $5,421,000 principal amount of Convertible Notes is converted, we would issue 6,776,998 shares of our common stock.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
  <us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments contextRef="d_2015-01-01_2015-03-31_DebtConversionByUniqueDescriptionAxis-InCaseOfDebtConversionMember_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207705" unitRef="xbrli-pure">6776998</us-gaap:DebtInstrumentConvertibleNumberOfEquityInstruments>
  <us-gaap:DebtInstrumentFaceAmount contextRef="i_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207702" unitRef="iso4217-usd">5421000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentFaceAmount contextRef="i_2015-03-31_DebtConversionByUniqueDescriptionAxis-InCaseOfDebtConversionMember_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207704" unitRef="iso4217-usd">5421000</us-gaap:DebtInstrumentFaceAmount>
  <us-gaap:DebtInstrumentIncreaseDecreaseOtherNet contextRef="d_2015-01-01_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207694" unitRef="iso4217-usd">80000</us-gaap:DebtInstrumentIncreaseDecreaseOtherNet>
  <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="i_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207684" unitRef="xbrli-pure">0.06</us-gaap:DebtInstrumentInterestRateStatedPercentage>
  <us-gaap:DebtInstrumentMaturityDate contextRef="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" id="c1207776">2021-05-02</us-gaap:DebtInstrumentMaturityDate>
  <us-gaap:DebtInstrumentUnamortizedDiscount contextRef="i_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207703" unitRef="iso4217-usd">3672000</us-gaap:DebtInstrumentUnamortizedDiscount>
  <us-gaap:DepreciationAndAmortization contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207460" unitRef="iso4217-usd">152000</us-gaap:DepreciationAndAmortization>
  <us-gaap:DepreciationAndAmortization contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207461" unitRef="iso4217-usd">114000</us-gaap:DepreciationAndAmortization>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1213399" unitRef="iso4217-usd-per-xbrli-shares">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1213400" unitRef="iso4217-usd-per-xbrli-shares">-0.74</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2015-01-01_2015-03-31" id="c1264778">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Earnings Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Basic earnings per share (&amp;#x201c;EPS&amp;#x201d;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying Convertible Notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Because we have incurred a net loss for all periods presented in the condensed consolidated statements of operations, outstanding stock options, warrants and common stock underlying Convertible Notes are not included in the computation of net loss per share because their effect would be anti-dilutive. &lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The following table includes the number of outstanding stock options, warrants and common stock underlying Convertible Notes not included in the computation as of the dates shown below (in thousands):&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div&gt; &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As of March 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock options outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff"&gt;7,293&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff"&gt;7,273&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Warrants outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;3,843&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;3,825&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Common stock underlying convertible notes outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff"&gt;6,777&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff"&gt;6,385&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt; &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207420" unitRef="iso4217-usd">1656000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207421" unitRef="iso4217-usd">2731000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="i_2015-03-31" decimals="INF" id="c1207751" unitRef="iso4217-usd">29947000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="d_2015-01-01_2015-03-31" id="c1207752">P2Y146D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213389" unitRef="iso4217-usd">5856000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213390" unitRef="iso4217-usd">5694000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2015-01-01_2015-03-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;6.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Income Taxes&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding our ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. We continue to maintain a full valuation allowance against our deferred tax assets as of March 31, 2015.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There have been no material changes in our unrecognized tax benefits since March 31, 2015 and, as such, disclosures included in our 2014 Annual Report on Form&amp;nbsp;10-K for the year ended December&amp;nbsp;31, 2014 continue to be relevant for the period ended March 31, 2015. &lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207469" unitRef="iso4217-usd">-166000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207470" unitRef="iso4217-usd">2238000</us-gaap:IncreaseDecreaseInAccountsPayable>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207473" unitRef="iso4217-usd">-1075000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207474" unitRef="iso4217-usd">-1254000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207475" unitRef="iso4217-usd">-531000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInOtherAccruedLiabilities contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207476" unitRef="iso4217-usd">272000</us-gaap:IncreaseDecreaseInOtherAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207467" unitRef="iso4217-usd">-112000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207468" unitRef="iso4217-usd">1624000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207697" unitRef="iso4217-usd">81000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:InterestExpenseDebtExcludingAmortization contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1207698" unitRef="iso4217-usd">77000</us-gaap:InterestExpenseDebtExcludingAmortization>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2015-03-31" decimals="-3" id="c1207437" unitRef="iso4217-usd">59627000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity contextRef="i_2014-12-31" decimals="-3" id="c1207438" unitRef="iso4217-usd">76682000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207426" unitRef="iso4217-usd">11626000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207427" unitRef="iso4217-usd">13620000</us-gaap:LiabilitiesCurrent>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207487" unitRef="iso4217-usd">2878000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207488" unitRef="iso4217-usd">958000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207482" unitRef="iso4217-usd">-328000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207483" unitRef="iso4217-usd">-57000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207477" unitRef="iso4217-usd">-19669000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207478" unitRef="iso4217-usd">-15713000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
  <us-gaap:NetIncomeLoss contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213397" unitRef="iso4217-usd">-20570000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213398" unitRef="iso4217-usd">-17538000</us-gaap:NetIncomeLoss>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2015-01-01_2015-03-31" id="c1264780">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In January 2015, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2015-&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;01&lt;div style="display: inline; font-style: italic;"&gt;, Income Statement&amp;#x2014;Extraordinary and Unusual Items (Subtopic 225-20)&lt;/div&gt; (&amp;#x201c;ASU 2015-01&amp;#x201d;). ASU 2015-01 eliminates the concept of extraordinary items from GAAP. FASB concluded that ASU 2015-01 will not result in a loss of information because although ASU 2015-01 will eliminate the requirements in Subtopic 225-20 for reporting entities to consider whether an underlying event or transaction is extraordinary, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring.&lt;div style="display: inline; font-style: italic;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The amendments in&lt;div style="display: inline; font-style: italic;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We adopted the provisions of ASU 2015-01 in the first quarter of 2015. The adoption of this ASU did not have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;&lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In August 2014, FASB issued ASU No. 2014-15, &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements &amp;#x2013; Going Concern (Subtopic 205-40)&lt;/div&gt; (&amp;#x201c;ASU 2014-15&amp;#x201d;). ASU 2014-15 requires management to assess an entity&amp;#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in United States auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;, including interim periods, (3)&amp;nbsp;provide principles for considering the mitigating effect of management&amp;#x2019;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#x2019;s plans, (5)&amp;nbsp;require an express statement and other disclosures when substantial doubt is not alleviated, and (6)&amp;nbsp;require an assessment for a period of one year after the date that the financial satements are issued (or available to be issued). The amendments in ASU 2014-15 are effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. We plan to adopt the provisions of ASU 2014-15 in 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In June 2014, FASB issued ASU No. 2014-12, &lt;div style="display: inline; font-style: italic;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718)&lt;/div&gt; (&amp;#x201c;ASU 2014-12&amp;#x201d;). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The amendments in ASU 2014-12 may either be applied (a)&amp;nbsp;prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earlier annual period presented in the financial statements and to all new or modified awards thereafter. We plan to adopt the provisions of ASU 2014-12 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:NonoperatingIncomeExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213395" unitRef="iso4217-usd">-210000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:NonoperatingIncomeExpense contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213396" unitRef="iso4217-usd">-216000</us-gaap:NonoperatingIncomeExpense>
  <us-gaap:OperatingExpenses contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213391" unitRef="iso4217-usd">20360000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213392" unitRef="iso4217-usd">17322000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213393" unitRef="iso4217-usd">-20360000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213394" unitRef="iso4217-usd">-17322000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207422" unitRef="iso4217-usd">2320000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207423" unitRef="iso4217-usd">2931000</us-gaap:OtherAccruedLiabilitiesCurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2015-03-31" decimals="-3" id="c1207410" unitRef="iso4217-usd">130000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent contextRef="i_2014-12-31" decimals="-3" id="c1207411" unitRef="iso4217-usd">130000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:PaidInKindInterest contextRef="d_2015-01-01_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember" decimals="INF" id="c1207693" unitRef="iso4217-usd">80000</us-gaap:PaidInKindInterest>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2011-06-01_2011-06-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207710" unitRef="iso4217-usd">1200000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2012-07-01_2012-07-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2012Member" decimals="INF" id="c1207729" unitRef="iso4217-usd">3100000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2013-11-01_2013-11-30_LegalEntityAxis-JefferiesLlcMember_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207734" unitRef="iso4217-usd">3900000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsOfStockIssuanceCosts contextRef="d_2014-06-01_2014-06-30_StatementEquityComponentsAxis-CommonStockAndPrefundedWarrantsMember" decimals="INF" id="c1207742" unitRef="iso4217-usd">4000000</us-gaap:PaymentsOfStockIssuanceCosts>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207480" unitRef="iso4217-usd">328000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207481" unitRef="iso4217-usd">57000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2015-03-31" decimals="-3" id="c1207404" unitRef="iso4217-usd">945000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="i_2014-12-31" decimals="-3" id="c1207405" unitRef="iso4217-usd">1057000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:ProceedsFromConvertibleDebt contextRef="d_2011-04-01_2011-04-30" decimals="INF" id="c1207683" unitRef="iso4217-usd">4300000</us-gaap:ProceedsFromConvertibleDebt>
  <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="d_2013-11-01_2013-11-30_LegalEntityAxis-JefferiesLlcMember_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207733" unitRef="iso4217-usd">57800000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet contextRef="d_2011-01-01_2015-03-31" decimals="-5" id="c1207603" unitRef="iso4217-usd">194300000</us-gaap:ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet>
  <us-gaap:ProceedsFromIssuanceOrSaleOfEquity contextRef="d_2014-06-01_2014-06-30_StatementEquityComponentsAxis-CommonStockAndPrefundedWarrantsMember" decimals="INF" id="c1207741" unitRef="iso4217-usd">58900000</us-gaap:ProceedsFromIssuanceOrSaleOfEquity>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207744" unitRef="iso4217-usd">2878000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromStockOptionsExercised contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1207748" unitRef="iso4217-usd">958000</us-gaap:ProceedsFromStockOptionsExercised>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2015-01-01_2015-03-31_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1214195" unitRef="iso4217-usd">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:ProceedsFromWarrantExercises contextRef="d_2014-01-01_2014-03-31_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1217902" unitRef="iso4217-usd">0</us-gaap:ProceedsFromWarrantExercises>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2015-03-31" decimals="-3" id="c1207408" unitRef="iso4217-usd">2996000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet contextRef="i_2014-12-31" decimals="-3" id="c1207409" unitRef="iso4217-usd">2820000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213387" unitRef="iso4217-usd">14504000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213388" unitRef="iso4217-usd">11628000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2015-03-31" decimals="-3" id="c1207600" unitRef="iso4217-usd">-335807000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="i_2014-12-31" decimals="-3" id="c1207434" unitRef="iso4217-usd">-315237000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:SaleOfStockPricePerShare contextRef="i_2012-07-31_SubsidiarySaleOfStockAxis-PrivatePlacement2012Member" decimals="INF" id="c1207727" unitRef="iso4217-usd-per-xbrli-shares">10.50</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare contextRef="i_2013-11-30_LegalEntityAxis-JefferiesLlcMember_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207732" unitRef="iso4217-usd-per-xbrli-shares">8</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:SaleOfStockPricePerShare contextRef="i_2014-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207737" unitRef="iso4217-usd-per-xbrli-shares">11.75</us-gaap:SaleOfStockPricePerShare>
  <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2015-01-01_2015-03-31" id="c-15">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As of March 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock options outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff"&gt;7,293&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff"&gt;7,273&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Warrants outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;3,843&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;3,825&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Common stock underlying convertible notes outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff"&gt;6,777&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff"&gt;6,385&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2015-01-01_2015-03-31" id="c-16">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;March 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;td&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;806&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;1,262&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;1,745&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;1,707&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock-based compensation expense included in operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;2,551&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;2,969&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Impact on basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;0.09&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;0.13&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2015-01-01_2015-03-31" id="c-18">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 55%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Balance at January 1, 2015&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;7,918&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.69&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;7.92&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;54&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;11.52&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;(352&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.18&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expired and forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;(327&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;10.67&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Balance at March 31, 2015&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;7,293&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.65&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.31&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2015-01-01_2015-03-31" id="c-17">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;20&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;20&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;1.6&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;2.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;91.7&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;104.1&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt; &lt;/tr&gt; &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;6.1&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 54pt; BACKGROUND-COLOR: #ffffff"&gt;6.0&lt;/td&gt; &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt; &lt;/tr&gt; &lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ShareBasedCompensation contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207462" unitRef="iso4217-usd">2551000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1207463" unitRef="iso4217-usd">2969000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2015-01-01_2015-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="0" id="c1207511" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="d_2014-01-01_2014-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="0" id="c1207512" unitRef="xbrli-pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2015-01-01_2015-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="3" id="c1207513" unitRef="xbrli-pure">0.917</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="d_2014-01-01_2014-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="3" id="c1207514" unitRef="xbrli-pure">1.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2015-01-01_2015-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="3" id="c1207509" unitRef="xbrli-pure">0.016</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="d_2014-01-01_2014-03-31_AwardTypeAxis-EmployeeStockOptionMember" decimals="3" id="c1207510" unitRef="xbrli-pure">0.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="d_2015-01-01_2015-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207721" unitRef="xbrli-shares">66667</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="d_2014-01-01_2014-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207723" unitRef="xbrli-shares">144040</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207526" unitRef="xbrli-shares">327000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207527" unitRef="iso4217-usd-per-xbrli-shares">10.67</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207520" unitRef="xbrli-shares">54000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2014-12-31" decimals="-3" id="c1207517" unitRef="xbrli-shares">7918000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="i_2015-03-31" decimals="-3" id="c1207529" unitRef="xbrli-shares">7293000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2014-12-31" decimals="INF" id="c1207518" unitRef="iso4217-usd-per-xbrli-shares">8.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="i_2015-03-31" decimals="INF" id="c1207530" unitRef="iso4217-usd-per-xbrli-shares">8.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207524" unitRef="iso4217-usd-per-xbrli-shares">8.18</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="d_2015-01-01_2015-03-31" decimals="INF" id="c1207521" unitRef="iso4217-usd-per-xbrli-shares">11.52</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:SharePrice contextRef="i_2014-06-30_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember" decimals="INF" id="c1207739" unitRef="iso4217-usd-per-xbrli-shares">11.74</us-gaap:SharePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2015-01-01_2015-03-31_AwardTypeAxis-EmployeeStockOptionMember" id="c1207515">P6Y36D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="d_2014-01-01_2014-03-31_AwardTypeAxis-EmployeeStockOptionMember" id="c1207516">P6Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2014-01-01_2014-12-31" id="c1207519">P7Y335D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2015-01-01_2015-03-31" id="c1207531">P8Y113D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2015-01-01_2015-03-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;3.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Accounting Policies&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Principles of Consolidation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V., which was organized in the Netherlands in March 2015. Heron Therapeutics B.V. has no operations and no material assets or liabilities and there have been no significant transactions related to Heron Therapeutics B.V. since its inception.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.&lt;/div&gt;&lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Cash and Cash Equivalents&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Cash and cash equivalents consist of cash and highly liquid investments with original maturities from purchase date of three months or less. Our bank accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (&amp;#x201c;Convertible Notes&amp;#x201d;).&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Earnings Per Share&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Basic earnings per share (&amp;#x201c;EPS&amp;#x201d;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying Convertible Notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Because we have incurred a net loss for all periods presented in the condensed consolidated statements of operations, outstanding stock options, warrants and common stock underlying Convertible Notes are not included in the computation of net loss per share because their effect would be anti-dilutive. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The following table includes the number of outstanding stock options, warrants and common stock underlying Convertible Notes not included in the computation as of the dates shown below (in thousands):&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt;   &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;         &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;As of March 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock options outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff"&gt;7,293&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff"&gt;7,273&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Warrants outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;3,843&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;3,825&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Common stock underlying convertible notes outstanding&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff"&gt;6,777&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff"&gt;6,385&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Comprehensive Income (Loss)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of our net loss, and there were no other changes in equity from non-owner sources. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Recent Accounting Pronouncements&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In January 2015, the Financial Accounting Standards Board (&amp;#x201c;FASB&amp;#x201d;) issued Accounting Standards Update (&amp;#x201c;ASU&amp;#x201d;) No. 2015-&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;01&lt;div style="display: inline; font-style: italic;"&gt;, Income Statement&amp;#x2014;Extraordinary and Unusual Items (Subtopic 225-20)&lt;/div&gt; (&amp;#x201c;ASU 2015-01&amp;#x201d;). ASU 2015-01 eliminates the concept of extraordinary items from GAAP. FASB concluded that ASU 2015-01 will not result in a loss of information because although ASU 2015-01 will eliminate the requirements in Subtopic 225-20 for reporting entities to consider whether an underlying event or transaction is extraordinary, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring.&lt;div style="display: inline; font-style: italic;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The amendments in&lt;div style="display: inline; font-style: italic;"&gt; &lt;/div&gt;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We adopted the provisions of ASU 2015-01 in the first quarter of 2015. The adoption of this ASU did not have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In August 2014, FASB issued ASU No. 2014-15, &lt;div style="display: inline; font-style: italic;"&gt;Presentation of Financial Statements &amp;#x2013; Going Concern (Subtopic 205-40)&lt;/div&gt; (&amp;#x201c;ASU 2014-15&amp;#x201d;). ASU 2014-15 requires management to assess an entity&amp;#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in United States auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;, including interim periods, (3)&amp;nbsp;provide principles for considering the mitigating effect of management&amp;#x2019;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&amp;#x2019;s plans, (5)&amp;nbsp;require an express statement and other disclosures when substantial doubt is not alleviated, and (6)&amp;nbsp;require an assessment for a period of one year after the date that the financial satements are issued (or available to be issued). The amendments in ASU 2014-15 are effective for the annual period ending after December&amp;nbsp;15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. We plan to adopt the provisions of ASU 2014-15 in 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In June 2014, FASB issued ASU No. 2014-12, &lt;div style="display: inline; font-style: italic;"&gt;Compensation &amp;#x2013; Stock Compensation (Topic 718)&lt;/div&gt; (&amp;#x201c;ASU 2014-12&amp;#x201d;). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The amendments in ASU 2014-12 may either be applied (a)&amp;nbsp;prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earlier annual period presented in the financial statements and to all new or modified awards thereafter. We plan to adopt the provisions of ASU 2014-12 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2011-06-01_2011-06-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207708" unitRef="xbrli-shares">8000000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2015-01-01_2015-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207722" unitRef="xbrli-shares">47588</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-01-01_2014-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207724" unitRef="xbrli-shares">108409</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2012-07-01_2012-07-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2012Member" decimals="INF" id="c1207726" unitRef="xbrli-shares">5100000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2013-11-01_2013-11-30_LegalEntityAxis-JefferiesLlcMember_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207731" unitRef="xbrli-shares">7700000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="d_2014-06-01_2014-06-30_StatementEquityComponentsAxis-CommonStockMember" decimals="INF" id="c1207736" unitRef="xbrli-shares">4800000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2014-01-01_2014-03-31" decimals="INF" id="c1207745" unitRef="xbrli-shares">275352</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1207523" unitRef="xbrli-shares">352000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2011-06-01_2011-06-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member" decimals="INF" id="c1207709" unitRef="iso4217-usd">22800000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="d_2012-07-01_2012-07-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2012Member" decimals="INF" id="c1207728" unitRef="iso4217-usd">50500000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockholdersEquity contextRef="i_2015-03-31" decimals="-3" id="c1207435" unitRef="iso4217-usd">48001000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity contextRef="i_2014-12-31" decimals="-3" id="c1207436" unitRef="iso4217-usd">63062000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2015-01-01_2015-03-31">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;5.&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;&amp;nbsp;Stockholders' Equity&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2011 Private Placement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In June 2011, we sold 8.0 million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July&amp;nbsp;1,&amp;nbsp;2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;On July 29, 2011, we filed a registration statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August 4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (&amp;#x201c;Rule 144&amp;#x201d;). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;During the three months ended March 31, 2015, warrant holders exercised 66,667 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 47,588&amp;nbsp;shares of common stock and no net cash proceeds to us. During the three months ended March 31, 2014, warrant holders exercised 144,040 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 108,409 shares of common stock and no net cash proceeds to us.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2012 Private Placement&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In July 2012, we sold approximately 5.1 million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1&amp;nbsp;million in issuance costs). On August 24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September 6, 2012. &lt;/div&gt;&lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2013 Common Stock Offering&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In November 2013, we sold approximately 7.7 million shares of our common stock at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9&amp;nbsp;million in issuance costs). The offering was made pursuant to an effective registration statement, which was previously filed with the SEC. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014 Common Stock Offering&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;In June 2014, we sold approximately 4.8 million shares of our common stock at a public offering price of $11.75 per share. In addition, as a component of the offering, we sold 600,000 pre-funded warrants to purchase shares of our common stock at a public offering price of $11.74 per share. The pre-funded warrants have an exercise price of $0.01 per share and expire on June 30, 2021. We received total net proceeds of approximately $58.9 million (net of approximately $4.0 million in issuance costs) from the sale of the common stock and the pre-funded warrants. The offering was made pursuant to an effective registration statement, which was previously filed with the SEC. &lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock Option Exercises&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;For the three months ended March 31, 2015, 351,698 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to us of approximately $2,878,000. For the three months ended March 31, 2014, option holders exercised 275,352 stock options, a portion of which were exercised under the cashless exercise provision of our 2007 Amended and Restated Equity Incentive Plan, resulting in the net issuance of 215,350 shares of common stock and cash proceeds to us of approximately $958,000.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Stock-Based Compensation&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements for the three months ended March&amp;nbsp;31,&amp;nbsp;2015 and 2014 (in thousands):&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt;   &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;         &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Three Months Ended&lt;/div&gt;&lt;/div&gt;&lt;/div&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;March 31&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2015&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;2014&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;      &lt;td&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Research and development&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;806&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;1,262&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;General and administrative&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;1,745&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff"&gt;1,707&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Stock-based compensation expense included in operating expenses&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;2,551&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;2,969&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Impact on basic and diluted net loss per share&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;0.09&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;0.13&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;  &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;As of March 31, 2015, there was $29,947,000 of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of our equity compensation plans and all non-plan option grants. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. We expect to recognize this compensation cost over a weighted-average period of 2.4&amp;nbsp;years.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;We estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-style: italic;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt;   &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;         &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;March 31,&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;20&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;15&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;20&lt;/div&gt;&lt;div style="display: inline; font-weight: bold;"&gt;14&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Risk-free interest rate&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;1.6&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;2.0&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Dividend yield&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff"&gt;0.0&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Volatility&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;91.7&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;104.1&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;%&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expected life (years)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;6.1&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 54pt; BACKGROUND-COLOR: #ffffff"&gt;6.0&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;      &lt;div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;We estimated the fair value of each purchase right granted under our 1997 Employee Stock Purchase Plan at the beginning of each new offering period using the Black-Scholes option pricing model. There were no new offering periods for the quarters ended March 31, 2015 and 2014.&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The following table summarizes the stock option activity for the three months ended March&amp;nbsp;31,&amp;nbsp;2015:&lt;/div&gt;&lt;/div&gt;  &lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;  &lt;div&gt;   &lt;table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"&gt;         &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Weighted-&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Remaining&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Average&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Contractual&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Shares&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Exercise&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Term&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(in thousands)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Price&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"&gt; &lt;div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;(Years)&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;&amp;nbsp;&lt;/div&gt;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 55%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Balance at January 1, 2015&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;7,918&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.69&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;7.92&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Granted&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;54&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;11.52&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Exercised&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;(352&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.18&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #ffffff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Expired and forfeited&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;(327&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;)&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"&gt;10.67&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;     &lt;tr style="BACKGROUND-COLOR: #cceeff"&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt; &lt;div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;Balance at March 31, 2015&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;7,293&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;$&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.65&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff"&gt;&amp;nbsp;&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"&gt;8.31&lt;/td&gt;      &lt;td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"&gt;&amp;nbsp;&lt;/td&gt;     &lt;/tr&gt;       &lt;/table&gt;  &lt;/div&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:UseOfEstimates contextRef="d_2015-01-01_2015-03-31" id="c1264776">&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style="display: inline; font-family: times new roman; font-size: 10pt"&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&lt;div style="display: inline; font-weight: bold;"&gt;Use of Estimates&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;&amp;nbsp;&lt;/div&gt;&lt;/div&gt;&lt;div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"&gt;&lt;div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"&gt;The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2015-01-01_2015-03-31" decimals="-3" id="c1213401" unitRef="xbrli-shares">29392000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="d_2014-01-01_2014-03-31" decimals="-3" id="c1213402" unitRef="xbrli-shares">23686000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <link:footnoteLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended"/>
  <xbrli:unit id="iso4217-usd">
    <xbrli:measure>iso4217:USD</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-pure">
    <xbrli:measure>xbrli:pure</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="xbrli-shares">
    <xbrli:measure>xbrli:shares</xbrli:measure>
  </xbrli:unit>
  <xbrli:unit id="iso4217-usd-per-xbrli-shares">
    <xbrli:divide>
      <xbrli:unitNumerator>
        <xbrli:measure>iso4217:USD</xbrli:measure>
      </xbrli:unitNumerator>
      <xbrli:unitDenominator>
        <xbrli:measure>xbrli:shares</xbrli:measure>
      </xbrli:unitDenominator>
    </xbrli:divide>
  </xbrli:unit>
  <xbrli:context id="d_2011-01-01_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-04-01_2011-04-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-04-01_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-04-01</xbrli:startDate>
      <xbrli:endDate>2011-04-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-06-01_2011-06-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>
      <xbrli:endDate>2011-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-06-01_2013-06-30_StatementClassOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-06-01</xbrli:startDate>
      <xbrli:endDate>2013-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2011-07-28_2011-07-29">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2011-07-28</xbrli:startDate>
      <xbrli:endDate>2011-07-29</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2012-07-01_2012-07-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2012-07-01</xbrli:startDate>
      <xbrli:endDate>2012-07-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2013-11-01_2013-11-30_LegalEntityAxis-JefferiesLlcMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hrtx:JefferiesLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2013-11-01</xbrli:startDate>
      <xbrli:endDate>2013-11-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-03-31_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-01-01_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-01-01</xbrli:startDate>
      <xbrli:endDate>2014-12-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-06-01_2014-06-30_StatementEquityComponentsAxis-CommonStockAndPrefundedWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">hrtx:CommonStockAndPrefundedWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2014-06-01_2014-06-30_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2014-06-01</xbrli:startDate>
      <xbrli:endDate>2014-06-30</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-StockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_AwardTypeAxis-EmployeeStockOptionMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_DebtConversionByUniqueDescriptionAxis-InCaseOfDebtConversionMember_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">hrtx:InCaseOfDebtConversionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_StatementEquityComponentsAxis-WarrantMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="d_2015-01-01_2015-03-31_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:startDate>2015-01-01</xbrli:startDate>
      <xbrli:endDate>2015-03-31</xbrli:endDate>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-04-30">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-04-30_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-04-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-06-30_StatementEquityComponentsAxis-CommonStockMember_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2011-06-30_SubsidiarySaleOfStockAxis-PrivatePlacement2011Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2011Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2011-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2012-07-31_SubsidiarySaleOfStockAxis-PrivatePlacement2012Member">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">hrtx:PrivatePlacement2012Member</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2012-07-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-11-30_LegalEntityAxis-JefferiesLlcMember_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="dei:LegalEntityAxis">hrtx:JefferiesLlcMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-11-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2013-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2013-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-06-30_ClassOfWarrantOrRightAxis-PreFundedWarrantsMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">hrtx:PreFundedWarrantsMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-06-30_StatementEquityComponentsAxis-CommonStockMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-06-30</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2014-12-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2014-12-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_DebtConversionByUniqueDescriptionAxis-InCaseOfDebtConversionMember_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:DebtConversionByUniqueDescriptionAxis">hrtx:InCaseOfDebtConversionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-03-31_LongtermDebtTypeAxis-ConvertibleDebtSecuritiesMember">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
      <xbrli:segment>
        <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtSecuritiesMember</xbrldi:explicitMember>
      </xbrli:segment>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-03-31</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
  <xbrli:context id="i_2015-04-28">
    <xbrli:entity>
      <xbrli:identifier scheme="http://www.sec.gov/CIK">0000818033</xbrli:identifier>
    </xbrli:entity>
    <xbrli:period>
      <xbrli:instant>2015-04-28</xbrli:instant>
    </xbrli:period>
  </xbrli:context>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>10
<FILENAME>hrtx-20150331.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 02:02PM UTC 2015-05-08--><xsd:schema xmlns:country="http://xbrl.sec.gov/country/2013-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2014-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2014-01-31" xmlns:hrtx="http://herontx.com/20150331" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2011-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2014-01-31" xmlns:us-roles="http://fasb.org/us-roles/2014-01-31" xmlns:us-types="http://fasb.org/us-types/2014-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://herontx.com/20150331">
  <xsd:import namespace="http://fasb.org/us-gaap/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-types-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2014-01-31" schemaLocation="http://xbrl.sec.gov/exch/2014/exch-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2014-01-31" schemaLocation="http://xbrl.sec.gov/currency/2014/currency-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/country/2013-01-31" schemaLocation="http://xbrl.sec.gov/country/2013/country-2013-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2014-01-31" schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2011-01-31" schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2011-01-31" schemaLocation="http://xbrl.sec.gov/naics/2011/naics-2011-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://fasb.org/us-roles/2014-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2014/elts/us-roles-2014-01-31.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20150331_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20150331_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20150331_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="hrtx-20150331_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://herontx.com/20150331/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-balance-sheets-current-period-unaudited" roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-operations-unaudited" roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-condensed-consolidated-statements-of-cash-flows-unaudited" roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business" roleURI="http://herontx.com/20150331/role/statement-note-1-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Disclosure - Note 1 - Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-basis-of-presentation" roleURI="http://herontx.com/20150331/role/statement-note-2-basis-of-presentation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Disclosure - Note 2 - Basis of Presentation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-accounting-policies" roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 3 - Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-convertible-notes-to-related-parties" roleURI="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 4 - Convertible Notes to Related Parties</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity" roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 5 - Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-income-taxes" roleURI="http://herontx.com/20150331/role/statement-note-6-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Document - Note 6 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://herontx.com/20150331/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-accounting-policies-tables" roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 3 - Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-tables" roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 5 - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-business-details-textual" roleURI="http://herontx.com/20150331/role/statement-note-1-business-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 1 - Business (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Statement - Note 3 - Accounting Policies - Equity Excluded From Calculation of Diluted Earnings Per Share (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-convertible-notes-to-related-parties-details-textual" roleURI="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 4 - Convertible Notes to Related Parties (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-details-textual" roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Statement - Note 5 - Stockholders' Equity - Allocation of the Recognized Cost (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-option-valuation-assumptions-details" roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-valuation-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Statement - Note 5 - Stockholders' Equity - Option Valuation Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-stockholders-equity-option-summary-details" roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-summary-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Statement - Note 5 - Stockholders' Equity - Option Summary (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="hrtx_AccruedClinicalLiabilities" name="AccruedClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="hrtx_BeneficialOwnershipAfterConversion" name="BeneficialOwnershipAfterConversion" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" name="CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_CommonStockAndPrefundedWarrantsMember" name="CommonStockAndPrefundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" name="ConvertibleDebtIssuableInConnectionWithPrivatePlacement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" name="ConvertibleNotesPayableRelatedPartiesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" name="DebtInstrumentConversionRatioMultipleOfPrincipal" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_DebtInstrumentConversionRatioShares" name="DebtInstrumentConversionRatioShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" name="ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_InCaseOfDebtConversionMember" name="InCaseOfDebtConversionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_IncreaseDecreaseInClinicalLiabilities" name="IncreaseDecreaseInClinicalLiabilities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_JefferiesLlcMember" name="JefferiesLlcMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_LimitationOnExercisableWarrants" name="LimitationOnExercisableWarrants" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" name="NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_PreFundedWarrantsMember" name="PreFundedWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_PrivatePlacement2011Member" name="PrivatePlacement2011Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_PrivatePlacement2012Member" name="PrivatePlacement2012Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" name="StockIssuedDuringPeriodSharesStockOptionsExercisedNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" name="statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-note-3-accounting-policies-tables" name="statement-statement-note-3-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" name="statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" name="statement-statement-note-5-stockholders-equity-option-summary-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" name="statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-note-5-stockholders-equity-tables" name="statement-statement-note-5-stockholders-equity-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="hrtx_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>11
<FILENAME>hrtx-20150331_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 02:03PM UTC 2015-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:type="arc"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:calculationArc order="8" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_AccruedClinicalLiabilities" xlink:label="hrtx_AccruedClinicalLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="hrtx_AccruedClinicalLiabilities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>12
<FILENAME>hrtx-20150331_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 02:02PM UTC 2015-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-6-income-taxes" xlink:href="hrtx-20150331.xsd#statement-note-6-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-6-income-taxes" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-2-basis-of-presentation" xlink:href="hrtx-20150331.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-document-and-entity-information" xlink:href="hrtx-20150331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-1-business" xlink:href="hrtx-20150331.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties" xlink:href="hrtx-20150331.xsd#statement-note-4-convertible-notes-to-related-parties" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_InCaseOfDebtConversionMember" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="hrtx_InCaseOfDebtConversionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-significant-accounting-policies-policies" xlink:href="hrtx-20150331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies-tables" xlink:href="hrtx-20150331.xsd#statement-note-3-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-3-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-tables" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-1-business-details-textual" xlink:href="hrtx-20150331.xsd#statement-note-1-business-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-1-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties-details-textual" xlink:href="hrtx-20150331.xsd#statement-note-4-convertible-notes-to-related-parties-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties-details-textual" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_BeneficialOwnershipAfterConversion" xlink:label="hrtx_BeneficialOwnershipAfterConversion" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DebtInstrumentConversionRatioShares" xlink:label="hrtx_DebtInstrumentConversionRatioShares" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_InCaseOfDebtConversionMember" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="hrtx_InCaseOfDebtConversionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_DebtInstrumentConversionRatioShares" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_BeneficialOwnershipAfterConversion" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaidInKindInterest" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonStockAndPrefundedWarrantsMember" xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_JefferiesLlcMember" xlink:label="hrtx_JefferiesLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PreFundedWarrantsMember" xlink:label="hrtx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2011Member" xlink:label="hrtx_PrivatePlacement2011Member" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2012Member" xlink:label="hrtx_PrivatePlacement2012Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hrtx_PrivatePlacement2012Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="hrtx_JefferiesLlcMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hrtx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-details-textual" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonStockAndPrefundedWarrantsMember" xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_JefferiesLlcMember" xlink:label="hrtx_JefferiesLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_LimitationOnExercisableWarrants" xlink:label="hrtx_LimitationOnExercisableWarrants" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PreFundedWarrantsMember" xlink:label="hrtx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2011Member" xlink:label="hrtx_PrivatePlacement2011Member" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2012Member" xlink:label="hrtx_PrivatePlacement2012Member" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="hrtx_PrivatePlacement2012Member" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_EntityDomain" xlink:to="hrtx_JefferiesLlcMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="hrtx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_LimitationOnExercisableWarrants" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_AccruedClinicalLiabilities" xlink:label="hrtx_AccruedClinicalLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="hrtx_AccruedClinicalLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:href="hrtx-20150331.xsd#statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_StockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-summary-details" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-option-summary-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-summary-details" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies" xlink:href="hrtx-20150331.xsd#statement-note-3-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://herontx.com/20150331/role/statement-note-3-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>13
<FILENAME>hrtx-20150331_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no" ?>
<!--Generated by ThunderDome XBRL - 02:02PM UTC 2015-05-08-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DocumentAndEntityInformation" xlink:label="hrtx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="hrtx_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DocumentAndEntityInformation" xlink:to="hrtx_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoteToFinancialStatementDetailsTextual" xlink:label="hrtx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="hrtx_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NoteToFinancialStatementDetailsTextual" xlink:to="hrtx_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-significant-accounting-policies-policies" xlink:label="hrtx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementsignificantaccountingpoliciespolicies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-significant-accounting-policies-policies" xlink:to="hrtx_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-3-accounting-policies-tables" xlink:label="hrtx_statement-statement-note-3-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-note-3-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote3accountingpoliciestables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-note-3-accounting-policies-tables" xlink:to="hrtx_statement-statement-note-3-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-tables" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-tables" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-note-5-stockholders-equity-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5stockholdersequitytables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-tables" xlink:to="hrtx_statement-statement-note-5-stockholders-equity-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:label="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote3accountingpoliciesequityexcludedfromcalculationofdilutedearningspersharedetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:to="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5stockholdersequityallocationoftherecognizedcostdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:to="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5stockholdersequityoptionvaluationassumptionsdetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:to="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" xlink:type="locator"/>
    <link:label xlink:label="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">statementnote5stockholdersequityoptionsummarydetails</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" xlink:to="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatements" xlink:label="hrtx_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="hrtx_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NotesToFinancialStatements" xlink:to="hrtx_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="hrtx_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="hrtx_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfStockDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConsolidationPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:type="locator"/>
    <link:label xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impact on basic and diluted net loss per share (in dollars per share)</link:label>
    <link:label xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Impact on basic and diluted net loss per common share in dollars per shar</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:to="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccounting-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccounting" xlink:to="us-gaap_BasisOfAccounting-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromConvertibleDebt</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromConvertibleDebt-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Convertible Debt</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromConvertibleDebt" xlink:to="us-gaap_ProceedsFromConvertibleDebt-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt and Capital Securities, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LongtermDebtTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SaleOfStockPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SaleOfStockPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaidInKindInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaidInKindInterest</link:label>
    <link:label xlink:label="us-gaap_PaidInKindInterest-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Paid-in-Kind Interest</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaidInKindInterest" xlink:to="us-gaap_PaidInKindInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other long-term assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used for operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentIncreaseDecreaseOtherNet</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Other, Net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionNameDomain" xlink:to="us-gaap_DebtConversionNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion Description [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentMaturityDate</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentMaturityDate-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Maturity Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDate" xlink:to="us-gaap_DebtInstrumentMaturityDate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used for operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Convertible, Number of Equity Instruments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AmortizationOfDebtDiscountPremium</link:label>
    <link:label xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of Debt Discount (Premium)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfDebtDiscountPremium" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2011Member" xlink:label="hrtx_PrivatePlacement2011Member" xlink:type="locator"/>
    <link:label xlink:label="hrtx_PrivatePlacement2011Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2011 [Member]</link:label>
    <link:label xlink:label="hrtx_PrivatePlacement2011Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private placement 2011 [member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacement2011Member" xlink:to="hrtx_PrivatePlacement2011Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInAccountsPayable</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders&#x2019; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Debt Securities [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertibleDebtSecuritiesMember" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodValueNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and employee-related liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOfCommonStock</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentFaceAmount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentFaceAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2012Member" xlink:label="hrtx_PrivatePlacement2012Member" xlink:type="locator"/>
    <link:label xlink:label="hrtx_PrivatePlacement2012Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement 2012 [Member]</link:label>
    <link:label xlink:label="hrtx_PrivatePlacement2012Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private placement 2012 [member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PrivatePlacement2012Member" xlink:to="hrtx_PrivatePlacement2012Member-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired and forfeited (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfStockIssuanceCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_LimitationOnExercisableWarrants" xlink:label="hrtx_LimitationOnExercisableWarrants" xlink:type="locator"/>
    <link:label xlink:label="hrtx_LimitationOnExercisableWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_LimitationOnExercisableWarrants</link:label>
    <link:label xlink:label="hrtx_LimitationOnExercisableWarrants-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Limitation on Exercisable Warrants</link:label>
    <link:label xlink:label="hrtx_LimitationOnExercisableWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">There is no right to exercise the Warrants to the extent that the holder would beneficially own in excess of the stated percentage of The Company's outstanding shares of common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_LimitationOnExercisableWarrants" xlink:to="hrtx_LimitationOnExercisableWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2015 (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2015 (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired and forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_JefferiesLlcMember" xlink:label="hrtx_JefferiesLlcMember" xlink:type="locator"/>
    <link:label xlink:label="hrtx_JefferiesLlcMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Jefferies, LLC [Member]</link:label>
    <link:label xlink:label="hrtx_JefferiesLlcMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Jefferies, LLC [member</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_JefferiesLlcMember" xlink:to="hrtx_JefferiesLlcMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromWarrantExercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other accrued expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_InCaseOfDebtConversionMember" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:type="locator"/>
    <link:label xlink:label="hrtx_InCaseOfDebtConversionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Case of Debt Conversion [Member]</link:label>
    <link:label xlink:label="hrtx_InCaseOfDebtConversionMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">When the debt principal is converted into the underlying securities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_InCaseOfDebtConversionMember" xlink:to="hrtx_InCaseOfDebtConversionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingExpenses</link:label>
    <link:label xlink:label="us-gaap_OperatingExpenses-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance or Sale of Equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued payroll and employee-related liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of period</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PreFundedWarrantsMember" xlink:label="hrtx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="hrtx_PreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-funded Warrants[Member]</link:label>
    <link:label xlink:label="hrtx_PreFundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-funded warrants offered as a component of the 2014 Common Stock offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_PreFundedWarrantsMember" xlink:to="hrtx_PreFundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</link:label>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net decrease in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:type="locator"/>
    <link:label xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_IncreaseDecreaseInClinicalLiabilities</link:label>
    <link:label xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical liabilities</link:label>
    <link:label xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The increase (decrease) during the reporting period in the aggregate amount of obligations related to clinical liabilities.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:to="hrtx_IncreaseDecreaseInClinicalLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_AccruedClinicalLiabilities" xlink:label="hrtx_AccruedClinicalLiabilities" xlink:type="locator"/>
    <link:label xlink:label="hrtx_AccruedClinicalLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued clinical liabilities</link:label>
    <link:label xlink:label="hrtx_AccruedClinicalLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of clinical obligations incurred and payable.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_AccruedClinicalLiabilities" xlink:to="hrtx_AccruedClinicalLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonStockAndPrefundedWarrantsMember" xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock and Prefunded Warrants [Member]</link:label>
    <link:label xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information relating to the proceeds from the issuance of common stock and pre-funded warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:to="hrtx_CommonStockAndPrefundedWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:type="locator"/>
    <link:label xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet</link:label>
    <link:label xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</link:label>
    <link:label xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of share options (or share units) exercised during the current period, net of shares retained for cashless exercises.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible notes payable to related parties, net of discount</link:label>
    <link:label xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Notes Payable, Related Parties, Current</link:label>
    <link:label xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentInterestRateStatedPercentage</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest expense, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used for investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScenarioUnspecifiedDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario, Unspecified [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementScenarioAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected life (years)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders&#x2019; equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationAndAmortization</link:label>
    <link:label xlink:label="us-gaap_DepreciationAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapital-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</link:label>
    <link:label xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:type="locator"/>
    <link:label xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement</link:label>
    <link:label xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible Debt Issuable in Connection with Private Placement</link:label>
    <link:label xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible debt issuable in connection with private placement.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_InterestExpenseDebtExcludingAmortization</link:label>
    <link:label xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt, Excluding Amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseDebtExcludingAmortization" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basic and diluted net loss per share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares excluded (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharePrice</link:label>
    <link:label xlink:label="us-gaap_SharePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:type="locator"/>
    <link:label xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal</link:label>
    <link:label xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Ratio Multiple of Principal</link:label>
    <link:label xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The multiple of principal used in calculating the number of shares converted from the notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_BeneficialOwnershipAfterConversion" xlink:label="hrtx_BeneficialOwnershipAfterConversion" xlink:type="locator"/>
    <link:label xlink:label="hrtx_BeneficialOwnershipAfterConversion-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_BeneficialOwnershipAfterConversion</link:label>
    <link:label xlink:label="hrtx_BeneficialOwnershipAfterConversion-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Beneficial Ownership after Conversion</link:label>
    <link:label xlink:label="hrtx_BeneficialOwnershipAfterConversion-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage amount the holder would beneficially own of the company's outstanding common stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_BeneficialOwnershipAfterConversion" xlink:to="hrtx_BeneficialOwnershipAfterConversion-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DebtInstrumentConversionRatioShares" xlink:label="hrtx_DebtInstrumentConversionRatioShares" xlink:type="locator"/>
    <link:label xlink:label="hrtx_DebtInstrumentConversionRatioShares-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_DebtInstrumentConversionRatioShares</link:label>
    <link:label xlink:label="hrtx_DebtInstrumentConversionRatioShares-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument Conversion Ratio Shares</link:label>
    <link:label xlink:label="hrtx_DebtInstrumentConversionRatioShares-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of shares per $1,000 of principal of note.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_DebtInstrumentConversionRatioShares" xlink:to="hrtx_DebtInstrumentConversionRatioShares-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:type="locator"/>
    <link:label xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes</link:label>
    <link:label xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notice Period Associated with Beneficial Ownership Percentage Limitation Convertible Notes</link:label>
    <link:label xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notice period associated with beneficial ownership percentage limitation, convertible notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares used in computing basic and diluted net loss per share (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:type="locator"/>
    <link:label xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</link:label>
    <link:label xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares Registered for Resale in Connection with Convertible Notes</link:label>
    <link:label xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common shares registered for resale in connection with convertible notes.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#x2019; equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DebtInstrumentUnamortizedDiscount</link:label>
    <link:label xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentUnamortizedDiscount" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Balance at January 1, 2015</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>14
<FILENAME>hrtx-20150331_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?><!--Generated by ThunderDome XBRL - 02:02PM UTC 2015-05-08--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-6-income-taxes" xlink:href="hrtx-20150331.xsd#statement-note-6-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-6-income-taxes" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-2-basis-of-presentation" xlink:href="hrtx-20150331.xsd#statement-note-2-basis-of-presentation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-2-basis-of-presentation" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BasisOfAccounting" xlink:label="us-gaap_BasisOfAccounting" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BasisOfAccounting" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-document-and-entity-information" xlink:href="hrtx-20150331.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DocumentAndEntityInformation" xlink:label="hrtx_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_DocumentAndEntityInformation" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-1-business" xlink:href="hrtx-20150331.xsd#statement-note-1-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-1-business" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:label="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties" xlink:href="hrtx-20150331.xsd#statement-note-4-convertible-notes-to-related-parties" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_InCaseOfDebtConversionMember" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="hrtx_InCaseOfDebtConversionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-significant-accounting-policies-policies" xlink:href="hrtx-20150331.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-significant-accounting-policies-policies" xlink:label="hrtx_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies-tables" xlink:href="hrtx-20150331.xsd#statement-note-3-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-3-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-3-accounting-policies-tables" xlink:label="hrtx_statement-statement-note-3-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-note-3-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-tables" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-tables" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-tables" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-tables" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-1-business-details-textual" xlink:href="hrtx-20150331.xsd#statement-note-1-business-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-1-business-details-textual" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoteToFinancialStatementDetailsTextual" xlink:label="hrtx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" xlink:label="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-n2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties-details-textual" xlink:href="hrtx-20150331.xsd#statement-note-4-convertible-notes-to-related-parties-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties-details-textual" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_BeneficialOwnershipAfterConversion" xlink:label="hrtx_BeneficialOwnershipAfterConversion-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" xlink:label="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" xlink:label="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal" xlink:label="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_DebtInstrumentConversionRatioShares" xlink:label="hrtx_DebtInstrumentConversionRatioShares-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_InCaseOfDebtConversionMember" xlink:label="hrtx_InCaseOfDebtConversionMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoteToFinancialStatementDetailsTextual" xlink:label="hrtx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes" xlink:label="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:label="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtConversionNameDomain" xlink:label="us-gaap_DebtConversionNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments" xlink:label="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentIncreaseDecreaseOtherNet" xlink:label="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentMaturityDate" xlink:label="us-gaap_DebtInstrumentMaturityDate-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscount" xlink:label="us-gaap_DebtInstrumentUnamortizedDiscount-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_InterestExpenseDebtExcludingAmortization" xlink:label="us-gaap_InterestExpenseDebtExcludingAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaidInKindInterest" xlink:label="us-gaap_PaidInKindInterest-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromConvertibleDebt" xlink:label="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LongtermDebtTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="hrtx_InCaseOfDebtConversionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtConversionByUniqueDescriptionAxis" xlink:to="us-gaap_DebtConversionNameDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDate-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromConvertibleDebt-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_DebtInstrumentConversionRatioShares-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_BeneficialOwnershipAfterConversion-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaidInKindInterest-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_InterestExpenseDebtExcludingAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentUnamortizedDiscount-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonStockAndPrefundedWarrantsMember" xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_JefferiesLlcMember" xlink:label="hrtx_JefferiesLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PreFundedWarrantsMember" xlink:label="hrtx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2011Member" xlink:label="hrtx_PrivatePlacement2011Member" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2012Member" xlink:label="hrtx_PrivatePlacement2012Member" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="hrtx_PrivatePlacement2012Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="hrtx_JefferiesLlcMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="hrtx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-details-textual" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-details-textual" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_CommonStockAndPrefundedWarrantsMember" xlink:label="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_JefferiesLlcMember" xlink:label="hrtx_JefferiesLlcMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_LimitationOnExercisableWarrants" xlink:label="hrtx_LimitationOnExercisableWarrants-2" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NoteToFinancialStatementDetailsTextual" xlink:label="hrtx_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PreFundedWarrantsMember" xlink:label="hrtx_PreFundedWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2011Member" xlink:label="hrtx_PrivatePlacement2011Member" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_PrivatePlacement2012Member" xlink:label="hrtx_PrivatePlacement2012Member" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" xlink:label="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromIssuanceOrSaleOfEquity" xlink:label="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="hrtx_PrivatePlacement2011Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="hrtx_PrivatePlacement2012Member" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="hrtx_JefferiesLlcMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="hrtx_PreFundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="hrtx_CommonStockAndPrefundedWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_LimitationOnExercisableWarrants-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharePrice-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOrSaleOfEquity-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_IncreaseDecreaseInClinicalLiabilities" xlink:label="hrtx_IncreaseDecreaseInClinicalLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AmortizationOfDebtDiscountPremium" xlink:label="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfDebtDiscountPremium-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="hrtx_IncreaseDecreaseInClinicalLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment-n7" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-4" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-option-valuation-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:href="hrtx-20150331.xsd#statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_AccruedClinicalLiabilities" xlink:label="hrtx_AccruedClinicalLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:label="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="hrtx_AccruedClinicalLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:href="hrtx-20150331.xsd#statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:label="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ConvertibleDebtSecuritiesMember" xlink:label="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_StockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_ConvertibleDebtSecuritiesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:label="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:type="locator"/>
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-summary-details" xlink:href="hrtx-20150331.xsd#statement-note-5-stockholders-equity-option-summary-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-summary-details" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" xlink:label="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n7" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-1" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n7" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_statement-statement-note-5-stockholders-equity-option-summary-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-n7" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod-n7" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://herontx.com/20150331/role/statement-note-3-accounting-policies" xlink:href="hrtx-20150331.xsd#statement-note-3-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://herontx.com/20150331/role/statement-note-3-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="hrtx-20150331.xsd#hrtx_NotesToFinancialStatementsAbstract" xlink:label="hrtx_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" xlink:type="locator"/>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2014/elts/us-gaap-2014-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="hrtx_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementScenarioAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>15
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0`!@`(````(0#67\;=M@$``#,/```3``@"6T-O;G1E;G1?5'EP97-=
M+GAM;""B!`(HH``"````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````#,E\M.PS`41/=(_$/D+6I<
MES=JRH+'$BH!'V#LVR:J8UNV*>W?<Y,^A%!I55&)NXF5V)XY\6*2Z=_.:I--
M(<3*V8*)O,LRL,KIRHX+]O;ZV+EB64S2:FF<A8+-(;+;P?%1_W7N(6:XV\:"
ME2GY&\ZC*J&6,7<>+,Z,7*AEPMLPYEZJB1P#[W6[%UPYF\"F3FHTV*!_#R/Y
M85+V,,/'"Y(`)K+L;K&P\2J8]-Y42B8DY5.K?[ATE@XY[FS7Q++R\00Q&-_H
MT,S\;K#<]XQ'$RH-V5"&]"1KQ.`SPS]=F+P[-\FWBVR@=*-1I4`[]5'C">31
M!Y`ZE@"I-GD[YK6L[(I[BW^[./)V$`<&:=ZO%=Z3HT>$XY0(QQD1CG,B'!=$
M."Z)<%P1X;@FPB&Z5$"H)*J@$JF"2J8**J$JJ*2JH!*K@DJN"BK!*J@D:^^_
MDC5A)0#>7O^>J:W,CG_2F.8&XH&_(PO17<ZE#*!?4L#R='"`[]H[.)0TZJ[$
M%G'@0UCK;O/':C,,SD<L>0'V!UBUN&9WQZ,0A%3!NL=MZD-K1RR(^QO^*&30
M5%`->H,W;ROOX`L``/__`P!02P,$%``&``@````A`+55,"/U````3`(```L`
M"`)?<F5L<R\N<F5L<R"B!`(HH``"````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````````````````````````````````````",DL].PS`,
MQN](O$/D^^IN2`BAI;M,2+LA5![`).X?M8VC)$#W]H0#@DICV]'VY\\_6][N
MYFE4'QQB+T[#NBA!L3-B>]=J>*V?5@^@8B)G:13'&HX<85?=WFQ?>*24FV+7
M^ZBRBXL:NI3\(V(T'4\4"_'L<J61,%'*86C1DQFH9=R4Y3V&OQY0+3S5P6H(
M!WL'JC[Z//FRMS1-;W@OYGUBETZ,0)X3.\MVY4-F"ZG/VZB:0LM)@Q7SG-,1
MR?LB8P.>)MI<3_3_MCAQ(DN)T$C@\SS?BG-`Z^N!+I]HJ?B]SCSBIX3A363X
M8<'%#U1?````__\#`%!+`P04``8`"````"$`^'8)1)(!``#0#0``&@`(`7AL
M+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS(*($`2B@``$`````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````O)?+3L,P$$7W2/Q#Y#UUQGVCIEV`D+J%\@%6
MXB91$SNRS:-_CU4@H5(96%BSB61;&5^=>\>)5YOWMDE>E76UT1F#4<H2I7-3
MU+K,V//NX6;!$N>E+F1CM,K843FV65]?K1Y5(WUXR55UYY)01;N,5=YWMYR[
MO%*M="/3*1U6]L:VTH>A+7DG\X,L%1=I.N/V9PVV/JN9;(N,V6T1]M\=N[#S
MW[7-?E_GZM[D+ZW2_L(6_,W8@ZN4\J&HM*7R&>NG'#^M+$9!,>.7Q<"86`V,
M43G4<`"E0PT'92,@IE4^!%H-H3D-^>D)F$'SF!KZI`XZ^JFO\,XQ,2"(U8!`
MY5##`90.-1R<S8S:JAEFE0A?!=)#6*28G*B=W;?0[UV%MCBU4ZA10(X&92,F
M,7.3RR:_JV2M!Z?Z*2PNTY@B_A&7*28&J-4`*D=$_6:[2EI5/'D;_A[=X-+9
M-`J'^IP!_)Q9$B<'EAB=J,WTCQQ/,#'4:%`R0(T&4#8BZK^$\\<F7+KZ"\OG
M^-L;?G8/6W\```#__P,`4$L#!!0`!@`(````(0!,@S7TI`(``%L'```/````
M>&PO=V]R:V)O;VLN>&ULE%7;4MLP$'WO3/_!H_?B2RY<AH2!0J>\4*:D\*@1
MUB;6($NN)3?A[UD[C;-)1(<^V:O+\=FS9]?G%ZM21W^@=LJ:"4N/$A:!R:U4
M9C%AOV;?OIRPR'EAI-#6P(2]@F,7T\^?SI>V?GFV]B5"`.,FK/"^.HMCEQ=0
M"G=D*S"X,[=U*3R&]2)V50U"N@+`ESK.DF0<ET(9MD8XJS^"8>=SE<.US9L2
MC%^#U*"%1_JN4)5CT_.YTO"XSB@2574G2N2]TBS2POD;J3S("1MA:)>PLU`W
MU56C-.Z>#I(!BZ=]DO=U)&$N&NUGF-X&'?7*AEDV;D^V4CPJ6+KMI3:,5D_*
M2+MLCZ*TKWTT0`++;NM)25_@?I(D_=IW4(O";Q81/B;XG8+XG>X9F2Z]C2+\
MTDA^8[SRK_S6K-57%DO8JGZ+F:4LJL\4OM2W,FV)4Y2OUD@P#B3'-V>UD@+%
MXE=""Y,#0<DH3/9!F`>/:"6%&1`RG=X?(/,7!0GT.0T)S'"?S)WUP%-^U3AE
MP#ER+<O(O5'P7H:Y.^6XG?/[&AQ:KG,:!:$Y=$Z@.70?'_#+/+<-%L4L^#VJ
MFBMLHBW]C/(_#O(8M@7!+O7J60-O41WWEO^D8F;HGKZT)T&8$7_P-G\IK);8
M'_SF=X,^H4S&!.(T"#%&6^6V!#X3J]TLCLG=--F__*`61F'O"N,#<E`..'#Z
M--(#B[ZO*#)ZICBG%.?`HQU.4(\]G`&V[9;/@4L[G*V]^#5XH;3C,UCY1A`^
M*:TR!GNM]X^\L$P4AY8Y#=OV7;O0KDEIL3$($0H+A#E20CN%#_LWC'.I<2CW
M79SN%/X_#,Q_5#M\=@H?=G&8#^)0@=J!W5<>@W8,=VQQ]N9"Y_A3:!_=5!V.
MQC@3VQ.;_^+T#0``__\#`%!+`P04``8`"````"$`;&:01Z($``#6$0``&```
M`'AL+W=O<FMS:&5E=',O<VAE970T+GAM;)Q876_J.!!]7VG_0Y1W"'9(`HAP
M5:BZ>Z6]TFJU'\\A&(B:Q"@)I?WW.\XDN1XG?+0\M&".Q\=GQF=BEM_>L]1Z
M$T69R#RTV7AB6R*/Y2[)#Z']S]\OHYEME564[Z)4YB*T/T1I?UO]^LOR(HO7
M\BA$94&$O`SM8U6=%HY3QD>11>58GD0.W^QED445?"P.3GDJ1+2K)V6IPR<3
MW\FB)+<QPJ)X)(;<[Y-8/,OXG(F\PB"%2*,*^)?'Y%2VT;+XD7!95+R>3Z-8
M9B<(L4W2I/JH@]I6%B^^'W)91-L4]OW.IE'<QJX_],)G25S(4NZK,81SD&A_
MSW-G[D"DU7*7P`Z4[%8A]J']Q!8;/K6=U;(6Z-]$7$KMO54>Y>6W(MG]D>0"
MU(8\J0QLI7Q5T.\[-023G=[LESH#?Q;63NRC<UK])2^_B^1PK"#='NQ(;6RQ
M^W@690R*0I@Q]U2D6*9``/Y:6:)*`Q2)WNO_EV17'4/;]<=>,'$9P*VM**N7
M1(6TK?A<5C+[#T&L"85!>!/$!?;-]_S1(`X2JO?W'%71:EG(BP5%`TN6ITB5
M(%M`X'9C2*/;ZK6=PA95D"<5);1]VX)-E)">MY4W6SIOH&C<0-9]"*.(38M0
MB0!V'478MTYQ6/.6B0(K)BH'BMH:!R!V1XT;Z_81TY_D"1,0Z'$F"AS:@;:P
M-Z<KKQ'B=F0WV@!9>/J9A14XM&%7W8X]SU@8(;,Z4R,^@4J$%\5L"(8%GCO3
M,80>U+"NBRHB%\[8[4RI250?WZ"P1HBFCS9`"$#EZ01N+ZS`5!_?*,4U0J:U
M/LP#LS68;0B`374`(0;I?YR8`AO$C%I=(P2)<<]C^L)UO6\(8N[/=02AIGJ3
M<?+O)TU-,BBZM&[6"&FU&V!(`.YU@O.O$%23C*J:&@01HE65-D`48E##ND2W
MRZI&&]J8YZ[!-.*P@<(BB!'S^?7:8LHPM0S>H8?VJMN":RI31PQMI`>+^WKQ
M8'D1".<W3($I7WV<'KHPH==3#S$-/3YW!^@1")OPZ^7%##=_S+7J633+KF\4
M6(-I99P$W@!1M/H6P[T;>?Z4^[.^_;N!21`QS>*>.W!(FS`(X0&I5'I(#/._
M4X7HX'J:_9Y\B&FEF?O4Q)HZI"`O8*0:*,5/M0>&W@X^VO5/OR<@8C0/:6;5
M(W1Q9<B/'P.T;Z+/SX<1?*)ANL6/7$[Z<J,.@=3MO2L!RL[H`G>R-V#_YC,-
MT^W]"CL"N<7.:`%WV/6]/S#Z]III7M](I8T0:?BGW+]&4U\(S*>*!M.<J5DP
MD#@"F7L$0=D9YO^8>_%^$PC,1XP&<Y,EAD'(39;*CK7B?Y`EFKA^"`+S*8,C
MIC6)@#'B])A;`S2=T8Y+!?U2.^!HXX2JV54;#%(-N#_4#@P,GZDG\N$C"_?<
MKVC:;PN!V5_KR*&-UP(/7@/]GV*"*=T,*HK7:+QF9J(XB(U(T]**Y5E=D3D\
M57>CW?7]B:M;D#&^AFM]?0=VNB_@5GV*#N)'5!R2O+12L8>0DW$`[:#`>SE^
MJ.2IOMQN907WZ?KM$7X_$7`EG(P!O)>R:C^H"V?WB\SJ?P```/__`P!02P,$
M%``&``@````A`-V+O<]N"```.2H``!D```!X;"]W;W)K<VAE971S+W-H965T
M,3<N>&ULG)I;;^)*%H7?1YK_@/S>X!NW*$FK[;JU-".-1N><>7;`25`#1MCI
M=/_[J7*5[5U[^P1(/X3D8]7&JZX+M^^__CKL)S_+<[VKC@]!-`V#27G<5-O=
M\>4A^/,/\6453.JF.&Z+?74L'X+?91U\??SG/^[?J_./^K4LFXFN<*P?@M>F
M.=W-9O7FM3P4];0ZE4?]SG-U/A2-_O/\,JM/Y[+8MHT.^UD<AHO9H=@=`UOA
M[GQ-C>KY>;<I6;5Y.Y3'QA8YE_NBT==?O^Y.=5?ML+FFW*$X_W@[?=E4AY,N
M\;3;[YK?;=%@<MC<?7\Y5N?B::]]_XK28M/5;O\@Y0^[S;FJJ^=FJLO-[(52
MS^O9>J8K/=YO=]J!Z?;)N7Q^"+Y%=RH-@]GC?=M!?^W*]QK\/JE?JW=YWFW_
MM3N6NK?U.)D1>*JJ'T;Z?6N0;CPCK44[`O\Y3[;E<_&V;_Y;O:MR]_+:Z.&>
M:T?&V-WV-ROKC>Y1768:STVE3;77%Z!_3@X[,S5TCQ2_VM?WW;9Y?0B2Q72^
M#)-(RR=/9=V(G2D93#9O=5,=_F=%D2MEB\2NB'YU1:+Y-$K#Q0TU$E=#OW8U
MXILO)'5%]&M?Y&H7VF_;%?JU:QQ-TWB^7-W2%PM71;]V56[WL71%]&M?Y&H?
M>FFW/O1KUWAQM8^9G1_M=&-%4SS>GZOWB5[#>@;4I\+L"-&=KMS-,SLK^IGW
M=Q-/SSA3Y)NI\A#HOM%SJM:KY>=CG"[O9S_U#-\X348UD:_(.X69SJ8LZP`H
M&\_]1KS3=(T$!A(#98'^":YVU9>=Z9[INT=/?=@]X\NOZP4C-KW074IF@?=!
M_<>T#G.J2(<KL9U`)7&Z]LOP$<T\]#5B3(-&0(YI8K^.&M,DO<;K/;WH8>^9
MR;706^''O6@:/03Z4X;1F:=]_;9/,JM)VYF6S*/%&G5:#@5Q-$]P;S`K2/JQ
MXA@(#"0&"@#/MMZFH.V/[1HQMHOF>&8U*[NP5LM5&*+!S:%B/:<"9@7`+P8"
M`XF!`L#SJW=6Z-<,<ZK9Q[Y-(^Q[@8;9:KIAUA$$VX:">*F'&4U69@7`-@8"
M`XF!`L"SK;>[VVV;1M@VWBFMQMJ.U^MT28U;R>"+8<`Q$!A(#!0`GE%]7&&C
MEY>Q:82-HE6:68U>1F"IHZTM[S3=ILHPX!@(#"0&"@#/J8G/Z#1,+FY8IA%R
MND`3-;.:8;QR#!@&'`.!@<1``>#96G_&EFF$;:'S(K,:.U/3Y7R%!CB'[T?A
M*@W1Z#(H,+L6F>G<*H:>$QA(#!0`7C=$>BAO']ZV%>X(M,]D3C1<9DX(<\2M
MZ]C:]7<\3EH)0B0A"A+?L8DZ8$)_O"5'-AAY1^]B.-KMT>M$T*EM-A#F--9I
M9/9MO'-S4D80(@E1D/A&32H!1J\[@R*;97S#.&LXT6`O)X3UQ$3?<(K.;]Z_
MW6UB@A!)B(+$-VN"!S)[>9N*;%SQS:(KS9P(F@4IQP92HN&$"$(D(0H2WY\)
M&LC?Y0,GLO'$]X<3A1/9F;G0_]#9FWN"*$W#%&WES"F&+N*$"$(D(0H2W[X)
M',#^A45KXXEO&[G*S*T#O9D/UYP3P@CAA`A")"$*$M^7R1?7^[)IQ/>%SI<L
MZB)+N^[\O33_Z$W6O]DM24Z(($02HB#QW9J,`=R:'>F*16J3B>\:'9I9!.)+
MNR1S0I@C:_L5:8K6`2<-!"&2$`6);]8DC]O-VKSBF5VBY99%(-0XLY@PHN&$
M"$(D(0H2WY^)%+?[LT'$\[?`$2H":<7YPX01#7?$[F/S:.2$%:21)$1!XAF.
M/Q65VE:7HI(3@;V($$8(=\09#N=CCDDK28B"Q'=\4U2*KXE*3@2=DJA$--P1
MZS09'5K22!*B(/&-ZOD(Y_+'QTMLU&A(EW@..Q$T:IL-A!$-)T00(@E1D/B^
M4"JZX&LD#2UQJH]Q]LD)881P1^S6&Y$T*$@+28B"Q'<YDHTN'ROQ2#9:XF3O
M1,.8Y80P0C@A@A!)B(+$]X?"SW7'IOD/"3Q+R4[K1-`?CD6,:#@APA&[0)?F
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MK*=K.ZIV-H=APK\,WRI\WS?EH60L#^$;0TX$?9,\1#2<$$&()$1!XOOZ5`A*
M1D+0@OC#P21WS0;'C!!.B"!$.F)/E'`:HF^X"K;PW:(`=.6!,A*$5FCORQ(2
MA`AAA'!"!"'2$;OQ+D9RO8)M/+_ZH3<O&'V\"[5J%(A6J&\S)QK&,">$$<()
M$81(1X:<@%*U>82OOR]N;=HG\NPC4H?R_%+FY7Y?3S;5FWG:SBSRGO9/`GZ+
MS6,DB&?17=X^3H<XB^[T$TE:/^O?T`_NG8J7\M_%^65WK"?[\EE_5*A333`Y
MVT?_[!]-=6H?V'JJ&OW(7OOKJWY$L]2/2NF[#,'DN:J:[@_S`?U#GX__!P``
M__\#`%!+`P04``8`"````"$`$^"EV>X"```-"```&0```'AL+W=O<FMS:&5E
M=',O<VAE970Q."YX;6R,5=N.VC`0?:_4?[#\OKD#`1%6"ZMM5VJEJNKEV21.
M8FT21[99=O^^8YN$)+24%R"9,\=GS@SC]?U;7:%7*B3C38)]Q\.(-BG/6%,D
M^.>/I[L8(ZE(DY&*-S3![U3B^\W'#^LC%R^RI%0A8&AD@DNEVI7KRK2D-9$.
M;VD#D9R+FBAX%(4K6T%)9I+JR@T\;^[6A#78,JS$+1P\SUE*'WEZJ&FC+(F@
M%5&@7Y:LE1U;G=Y"5Q/Q<FCO4EZW0+%G%5/OAA2C.ET]%PT79%]!W6]^1-*.
MVSQ<T-<L%5SR7#E`YUJAES4OW:4+3)MUQJ`";3L2-$_P@[_:Q=C=K(T_OQ@]
MRL%O)$M^_"18]H4U%,R&-ND&[#E_T=#G3+^"9/<B^\DTX)M`&<W)H5+?^?$S
M946IH-LS*$C7M<K>'ZE,P5"@<8*99DIY!0+@$]5,3P880M[,]Y%EJDQP.'=F
M"R_T`8[V5*HGIBDQ2@]2\?JW!?DG*DL2G$A"4'^*![>2N%:0J>^1*+)9"WY$
M,#-PI&R)GD!_!<1=859&7^J_*H42-<F#9C%<4(2$[KQN@CA8NZ]@:7K";"UF
MCE&/\<>(78?0G0!YO48H?*HQA!;^W?Q.DDX:2XH6X_.VEY")YMTE(HI[DI%&
M\&ZH\;HV#4XPD/=6!''8\QI+MQ836S-GLZE7H_!RONRS1ZJBL2K=W?\[IY.F
MZJ*>WZJSF*51YSG>^7@3WHW#_KFVD3H8_:%GMZG325-ULXDZBPG-OT?/YV[P
M8J0`IG&HX'K7-'AZ\KDRZXO%A,:7V)N/=>UL-#)1/YB?IVTD:C$6=9LM.FDJ
M;G+\UF(&M@Q>C!3H6VNP%*[;HL'3DZ>V6(P=9G\13?H%FUM3=&'O_#^UJNQ:
MMFNKIJ*@.UI5$J7\H%>N#W;V;^UML(7;P.Q.MP_`-FY)0;\24;!&HHKFD.HY
M"Y@,8?>Y?5"\-5MCSQ7L8?.SA&N7PA1Y#H!SSE7WH/=4?Y%O_@```/__`P!0
M2P,$%``&``@````A`"@W2:[@`@``YP<``!D```!X;"]W;W)K<VAE971S+W-H
M965T,3DN>&ULE%5=;YLP%'V?M/]@^;U\A4(2A51-NFZ3-FF:]O'L&`-6,4:V
MT[3_?M<XD$!6*>4!L'U\?.ZYE\OJ[D74Z)DIS663X=`+,&(-E3EOR@S__O5X
M,\=(&]+DI)8-R_`KT_AN_?'#ZB#5DZX8,P@8&IWARIAVZ?N:5DP0[<F6-;!2
M2"6(@:$J?=TJ1O)NDZC]*`@27Q#>8,>P5-=PR*+@E#U(NA>L,8Y$L9H8T*\K
MWNJ>3=!KZ`113_OVADK1`L6.U]R\=J08";K\6C92D5T-<;^$,:$]=S>XH!><
M*JEE83R@\YW0RY@7_L('IO4JYQ"!M1TI5F3X/EQN4^RO5YT_?S@[Z+-WI"MY
M^*QX_HTW#,R&--D$[*1\LM"ON9V"S?[%[L<N`3\4REE!]K7Y*0]?&"\K`]F^
MA8!L7,O\]8%I"H8"C1?=6B8J:Q``=R2XK0PPA+QTSP//397A6>+=IL$L!#C:
M,6T>N:7$B.ZUD>*O`X5'*D<2'4G@>20)8R^,@^0='+,C!SQ[CNA:(;X+JO/H
M@1BR7BEY0%!W(%NWQ%9QN`1B:\X,+':A#':]Y1;89$GN+4N&$XQ@NX8,/Z^C
M>;KRGR$M](C97&+",6+;(VPV0=Z@$4P[U_C_Q/52+-A*L8FTVC9N`KA/VB;G
M7B+B^0`9*0&'KE=BP1D&\M/!\Q.O$^<PLT'M]FQB='+\GI,M>'QRF$S3X3#)
MK,M6Z"6?;J(AYD[;=H0(O."T/E(&'\'UGECP5-EB?.[&88[*@O'B]HW%D2*H
MP^L56?!$43HY=.,PO2)O$:;!^15/-([@\&.)@\7Y-:!'HM/WB+;@J>C)U[1Q
M&*BGL_*;6`UMU_*,,(M3\$Z?:ZRN:0BF2K9E=:T1E7O;-".HGV%VZ.?WD:WH
MR?P&^GS7%?UA`?IL2TKVG:B2-QK5K`#*P$LAR\IU:C<PLNU:U4X:Z+#=:P4_
M5`;?=^`!N)#2]`/;/89?]/H?````__\#`%!+`P04``8`"````"$`0,KM-TD#
M```."@``&0```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6R45EUOFS`4?9^T
M_X#\7L`D)"$*J9I4W2IMTC3MX]D!$ZP"1K;3M/]^USA0,%E%7R#&QR?GGGOM
MZ\WM2UDXSU1(QJL88=='#JT2GK+J&*/?OQYN5LB1BE0I*7A%8_1*);K=?OZT
M.7/Q)'-*E0,,E8Q1KE2]]CR9Y+0DTN4UK6`FXZ(D"H;BZ,E:4)(VB\K""WQ_
MX96$5<@PK,44#IYE+*'W/#F5M%*&1-""*-`O<U;+EJU,IM"51#R=ZIN$ES50
M'%C!U&M#BIPR63\>*R[(H8"X7_"<)"UW,QC1ERP17/),N4#G&:'CF",O\H!I
MNTD91*!M=P3-8G2'UWN,D;?=-`;]8?0L>[\=F?/S%\'2;ZRBX#;D26?@P/F3
MACZF^A,L]D:K'YH,_!!.2C-R*M1/?OY*V3%7D.X0(M*!K=/7>RH3<!1HW"#4
M3`DO0``\G9+IT@!'R$OS/K-4Y3&:+=QPZ<\PP)T#E>J!:4KD)">I>/G7@)J(
M.I+@0@+O"PD.W7D0+E<?89E=6.#=LBPFLW@FKL:F>Z+(=B/XV8':`^6R)KJ2
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MB<&T)8TMR_9F>JP#PWZ:[DF#MI58Q^#N`FI="99C5RZ0*W+T&=I+T;0M#QUX
M;)!5%+L+Z%(UOKNPREOW<<W2$V7:LNDW)15'NJ=%(9V$GW3+Q7!\=%^[Z\!=
MT-1_-P'=N"9'^IV((ZND4]`,EOKN$C:R,/W<#!2OFVYVX`KZ</,SAWL7A?/>
M=P&<<:[:@;XQ=#>Y[3\```#__P,`4$L#!!0`!@`(````(0#[8J5ME`8``*<;
M```3````>&PO=&AE;64O=&AE;64Q+GAM;.Q93V_;-A2_#]AW('1O;2>V&P=U
MBMBQFZU-&\1NAQYIF9984Z)`TDE]&]KC@`'#NF&7`;OM,&PKT`*[=)\F6X>M
M`_H5]DA*LAC+2](&&];5AT0B?WS_W^,C=?7:@XBA0R(DY7';JUVN>HC$/A_3
M.&A[=X;]2QL>D@K'8\QX3-K>G$COVM;[[UW%FRHD$4&P/I:;N.V%2B6;E8KT
M81C+RSPA,<Q-N(BP@E<15,8"'P'=B%76JM5F)<(T]E",(R![>S*A/D%#3=+;
MRHCW&+S&2NH!GXF!)DV<%08[GM8T0LYEEPETB%G;`SYC?C0D#Y2'&)8*)MI>
MU?R\RM;5"MY,%S&U8FUA7=_\TG7I@O%TS?`4P2AG6NO76U=V<OH&P-0RKM?K
M=7NUG)X!8-\'3:TL19KU_D:MD]$L@.SC,NUNM5&MN_@"_?4EF5N=3J?12F6Q
M1`W(/M:7\!O59GU[S<$;D,4WEO#USG:WVW3P!F3QS25\_TJK67?Q!A0R&D^7
MT-JA_7Y*/8=,.-LMA6\`?*.:PA<HB(8\NC2+"8_5JEB+\'TN^@#00(85C9&:
M)V2"?8CB+HY&@F+-`&\27)BQ0[Y<&M*\D/0%353;^S#!D!$+>J^>?__J^5/T
MZOF3XX?/CA_^=/SHT?'#'RTM9^$NCH/BPI???O;GUQ^C/YY^\_+Q%^5X6<3_
M^L,GO_S\>3D0,F@AT8LOG_SV[,F+KS[]_;O')?!M@4=%^)!&1*);Y`@=\`AT
M,X9Q)2<C<;X5PQ!39P4.@78)Z9X*'>"M.69EN`YQC7=70/$H`UZ?W7=D'81B
MIF@)YQMAY`#W.&<=+DH-<$/S*EAX.(N#<N9B5L0=8'Q8QKN+8\>UO5D"53,+
M2L?VW9`X8NXS'"L<D)@HI.?XE)`2[>Y1ZMAUC_J"2SY1Z!Y%'4Q+33*D(R>0
M%HMV:01^F9?I#*YV;+-W%W4X*]-ZAQRZ2$@(S$J$'Q+FF/$ZGBD<E9$<XH@5
M#7X3J[!,R,%<^$5<3RKP=$`81[TQD;)LS6T!^A:<?@-#O2IU^QZ;1RY2*#HM
MHWD3<UY$[O!I-\114H8=T#@L8C^04PA1C/:Y*H/O<3=#]#OX`<<KW7V7$L?=
MIQ>".S1P1%H$B)Z9B1)?7B?<B=_!G$TP,54&2KI3J2,:_UW99A3JMN7PKFRW
MO6W8Q,J29_=$L5Z%^P^6Z!T\B_<)9,7R%O6N0K^KT-Y;7Z%7Y?+%U^5%*88J
MK1L2VVN;SCM:V7A/*&,#-6?DIC2]MX0-:-R'0;W.'#I)?A!+0GC4F0P,'%P@
ML%F#!%<?414.0IQ`WU[S-)%`IJ0#B1(NX;QHADMI:SST_LJ>-AOZ'&(KA\1J
MCX_M\+H>SHX;.1DC56#.M!FC=4W@K,S6KZ1$0;?785;30IV96\V(9HJBPRU7
M69O8G,O!Y+EJ,)A;$SH;!/T06+D)QW[-&LX[F)&QMKOU4>86XX6+=)$,\9BD
M/M)Z+_NH9IR4Q<J2(EH/&PSZ['B*U0K<6IKL&W`[BY.*[.HKV&7>>Q,O91&\
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MJ=\7T#B8V@'1`E>\,`U!!7?4YK\@A_J_S3E+PZ0UG"35`0V0H+`?J5`0L@]E
MR43?*<1JZ=YE2;*4D(FH@K@RL6*/R"%A0UT#FWIO]U`(H6ZJ25H&#.YD_+GO
M:0:-`MWD%//-J63YWFMSX)_N?&PR@U)N'38-36;_7,2\/5CLJG:]69[MO45%
M],2BS:IG60',"EM!*TW[UQ3AG%NMK5A+&J\U,N'`B\L:PV#>$"5PD83T']C_
MJ/"9_>"A-]0A/X#:BN#[A28&80-1?<DV'D@72#LX@L;)#MI@TJ2L:=/625LM
MVZPON-/-^9XPMI;L+/X^I['SYLQEY^3B11H[M;!C:SNVTM3@V9,I"D.3["!C
M'&.^E!4_9O'1?7#T#GPVF#$E33#!IRJ!H8<>F#R`Y+<<S=*MOP```/__`P!0
M2P,$%``&``@````A`+'<1(B^"P``XFD```T```!X;"]S='EL97,N>&ULW%U[
M;^/&$?^_0+\#P6N+!J@MB:(LR;$<G&2S/>#B!#D'*=`4!251-F,^5)*ZLU/T
MNW=F^9H57TN+TCJ-D+-(<6=^\]B9V0?)JV^>74?Y;`6A[7LS=7#>5Q7+6_EK
MVWN8J3_>&V<350DCTUN;CN]9,_7%"M5OKG__NZLP>G&L3X^6%2E`P@MGZF,4
M;2][O7#U:+EF>.YO+0]^V?B!:T9P&#STPFU@F>L0&[E.3^OW+WJN:7MJ3.'2
M78D0<<W@:;<]6_GNUHSLI>W8T0NCI2KNZO+#@^<'YM(!J,\#W5REM-E!@;QK
MKP(_]#?1.9#K^9N-O;****>]:0\H75]Y.]=PHU!9^3LOFJE:=DJ)?_FPGJD7
MJA*+O/#7`.)/_][YT==_B/^\^\N[=_U_??7U/WZPUO_\^<_%WW[^2NVE;`A-
ML$$]S?-^+5GX.:;<2R2XOMKX'A%$`S6AMBZ?//^+9^!OX`P@'EYV?17^JGPV
M'3@S0'@KW_$#)0(K@WSLC&>Z5GS%PG3L96#C91O3M9V7^+2&)YAC)->Y-I@)
M3_9B#J?ELT0TJ4P3A,')-,0S5"871#+Q9+U,YB\E,G&\1LV\#M$?QXM)42]7
M9[R*?E'0X2&\,EL1/L'#<J8:!L200;^/:J4&.Q*SZ:(/_$[&[&)T,LF&QM`8
M=RH9YXM%NR'#H=&E*AL8&N_'-R=39_?,JJ1+PO"I>@!VN&ZU:$/7K>G?8P,_
MI_"3$R>TXUB,4>6"/NMZ>6R\MUTK5.ZL+\H/OFMZJ%B:U-C57$[F'*][\ISY
MNR>/Z(_&@NDI!`7:CI,5A<,1EDUPYOH*ZM/("CP##I3D^_W+%HHF#TIIU'PO
MOJ[AZH?`?!EHK'00:Q#ZCKU&%`\+5JHEJ7)Q<6LL;AE?@DP41051PUB,CT#T
M=CY==(]T,9UV350SX-,QT?<C_'1,U(#_%IWI-`F6>E<@,WI*9./0JG\^GDZG
MD\'%9#*9ZL.!KC,E+Q./MKVU]6SA:*LS-141C`#!=#B97F@`I*]/&*N3(A@"
M@/%H-!D-IIH._[/H?'P$7>MTI,JV*D$@R:H$@22KLNJ^UT'D3WH*3'1([JL$
M@22K$@22K#KN.`*/I5N5()!D58)`DE79G%2'?14F$"7W58)`DE4)`DE6[:SX
M3"+P5+I5"0))5B4(3FW5=%BUN+TUV`Q%L3+KK#Y.>&$1WYX7&S7".'7I!VM8
MZ4F7+P8ZC!'C<]=7CK6)8$0:V`^/^#?RM_#OTH\B6!>YOEK;YH/OF0Y\[:4M
MTK\U+6'E"!:)9FKT:*^>@!DW,1'K)F9Q+`Y9U--Q-*&/]?Y8'VD7\8"M(]:N
MM;9W;E&ZC'>I7X(:4;?-@A,=>AF3Q!WRR;$>6B$QGV`+9FIF:<$&X!.I2PBV
MZ$+&?*)85$;20DQ&TD!01M)"5$;H.F6=*]7DVM_!HN6^@0UCTN_'<W*B?.H)
M$N`E'E,.@K0IZK.Q28E&&]NTE17B2Z%OS#7\L.JX1-*&%D4Y&QJ42-G00E1&
MWF]2ZW+$LZD+#,\E2/;TS5W^.AC`*&Z8XMD+@DE\PK6">+5`.-R5B]M(OD3J
MQC8=B;ZG79FB@_+*,G62LJ$"6%F.\PES\M\W61D`,VO75\\;LMT`]H#@>CSN
M9L"O,'V=?(U3?GP`O*H:P6Z"BD:*N=TZ+W<[=VD%!ML8PEBPLP;PR8_FK%;)
MC]\[]H/G6FQN4(W)?!_XD;6*V,85MG)0A6=8@6>0$!+!<PA_O8(_Z$E8'X?P
MA[FG4GN`7J3R!^<2YM^E/^`6G<2IP034J>OP=(D`9AA2!&`$&0AP2U&B`W!/
M&0A@Y)8B``?-$0"<&J\XI!\,2#0#'\A9`O]CL808DTK)L3RBE%7A%_C72&EP
MX?<@-9-X"XZ>JQD.:@`<Q+(JQ,H*,<3LT--R%<!!C0H,R+K=I+Q!5<R7IA`2
M=`%#KA$(`W4:Z<XK2<P%GCF`>HW,.ZQ#B%-@*)(-`>!(@4`,,9"4?P<4@Z0,
M3+U!4@JF$+@<?,(^02W!94A)&`"/E%Z1UPD#+F.<4`T$@JP(2;Q!DQ4B*099
M,3(WA28K1!((LB(DM82L$$DQR(J1Q!2R0B2!`!J1$B&I)62%2(I!5HS,33&4
M%2()!%D1DEAB>.00V:/3IO$D*ID_O<!EU*JI1S!0.OS?M]7SIG$B=5`U:`):
M:?-X]!2/',$6;"Q%AM)X$Y>9SITJCWY@_PJ#3+R9:P63J5:@XLU_D;VB9[X$
MYO;>>H:A:+ST]+PY2,`&3#E_F,17E=,R;^2&<QF-<^%[QN#GDQN-THB!#>9E
M@T!/3C#\!MRR<XAMO11[KFR309*4CH&Z#23,IF#XZFCVRRZ,[,U+N_B!(ZW_
M<T2-P848"+\F:P+PE:OQ^&Q3F5_:]A+"?'!,[\`=`"U=HVLXAZB&N.EP?RS&
M6\:`F(-I.^E';/8T/:JT&JT*#NY'QP#8Z,0D2],^W8"E/$\?K$*V>83W-@5O
M6$'+Q+=6U!54+?"7(ZU9F.=H[P^HWYPC'0'@JQVI'LO;=Z1Z_(<YTI$CTF\\
M=G>=1VBP+@[A6@^A*M,NKE#5A81YLC#6*KL<%3`@>8N`#Z^J&J/6J<JH@XL#
M`%I35O)AZ#3E2B>(WHR!VL=*7&41*_IE6*>A@.,A&>VKW9)2#<JG7J$^>^OU
M92EH&A7H"(*K!9K"/*]4X:#?V".J--H`KGVE)0R9)M82O^BDA,?]#G4YZM3:
MYDJW(CAYVF[ET)P4X/7B&A;*,7%0/<KXO:CRNI#6E2N7*I?-F*83O,)%JXB'
M""GYF)5A@TM4XFL,8C3""JN,MW`E<QJ.4N6T`E09\AO4P<<@(7QUX9(]"*Z8
M4:GJY"(M[0UO!UZ6=^)[P@NE"45:Y8--2?Y5@>553EF%L,$G*[VP58_HFOG!
M7;0*T``R6ET2DV^OSA"V,N`)`T5Q))5UQ.9%\5/.LQ:!M@IH)ZF=J)%?J\93
M`&VEN8:1"I_F^:3ZJOY;DF1?C[<AWO)P*Z,O#8#,#YL`:3!'MQ%:8N35)X3@
M5;-31T5T6-\$&RW9)&MR]V5=1A!2D"`<K!8V$O8NL&U6L+&*W*;*WZ2:;<-2
M\'F6\/SM_A^5,^7]"BN1;/(7)[27.]N!Y]V@WG"+W`KV!OCN/#Z9;&JJHY4-
MTC4,.H06=/FVM+),KN&V24(+<EE;6L`^]H$A2$MHP1V\K6G!5M:$%FYJS7'I
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M@?#.$R%*C];J25G`HR4R0GQ_P#0J0NCV>>N8GAGYP8N"^X\S<KS11X+D_NK[
MF8YX"AH<B@#Z&[RM!%Z$HH!>8@WQ/HQ3IFW(9'V!5P_>C-B&#+2.T?#^AX/.
M-F2@=4R&#ZI8/XF0^>!M=YF%^%B*J5N$Q$?;>[+6O.?P&M8`I`BE.VL7!6;F
M?WR7T@05<X</),EH\"$B?C)Y^O24I/Z\@^>/I$K$/=HD&&`-+0+\NUU$U(BM
M"!$<FX@0N;<C>'14VHDY$@A+B(0/]P1D)/8BBB"-G\S`P]["==T]'ZV0*+_#
M`JK_]7/^<!JF]PC?Y\,>6Y.-!T!1:VMC[ISH/OMQIN;?OV4/90-G2J[ZWO[L
M1XS$3,V_?\2GW4$OAF$KA)N/(3Q!#?XJN\">J?^YG8^G-[>&=C;ISR=G^M`:
MG4U'\YNSD;Z8W]P8T[[67_P75(8O/[J$M^<<\'(A]A(DN,=BH%^&#KR"*$B$
M3<!_RL_-5'(0PV>/N`+8L&Z="M$+LY<S7?\/``#__P,`4$L#!!0`!@`(````
M(0"EL.Q-P38```ND```4````>&PO<VAA<F5D4W1R:6YG<RYX;6S,G=UN&]FU
MY^\'F'<H&`Y&!B19G[:5=/I`ENVTDVY;L>3T"8*Y*)$EB3')8EBD905S$0SF
M#69N!I@!C',]3^%YDSS)_/YK[5VU6452<J=S,#@G:)FLVGOMM=?'?WWLS6_^
MY=-HF'TLIM6@'/_ZP>[VSH.L&/?*_F!\]>L'[\]?;3U[D%6S?-S/A^6X^/6#
MVZ)Z\"_?_L?_\$U5S3+>'5>_?G`]FTU^^?AQU;LN1GFU74Z*,=]<EM-1/N.?
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M:6?`XUZOX'N^[3,H?[5GC)2%B=\5DW(Z0RBRLUD^FU?MQ_]8=#X*(_RA',['
MLWQZZ_-T'GM3ML<*+_Y8#(=;'\;ES3@[*_(*Z>MGKZMJOIK6<C0J>7A6]CYL
M9F?7^;2HLK?SF8FO2-\8C+/*/G[4GK,6L?/;28>CNSM;OU_YPFDQ'902R^6[
M40^<;MTK!+K#B/:38>"ES_Y^MTW/,0K2-R5Y-<ROVM^>E$C6N(*#_%65PT'?
M=OYY/LS'O0)>H9A5MA'%+$S]?IS/^P-$Y%&V\?[L1?:PP[;7X^S\NIQ7V(=J
M$P4>%E65E;/K8GHSJ(JLFA2]P>6@JX0OBEZMA`<=8H/,Y54%5;_L?)U7UQD3
M9CW]4?QE/OB8#XOQK,/0TVDQR0?]K/B$0:J0!;UDQ&6]A2G:,YR7,Y1L_3.G
M4\S<%$.D047$1,S?S,;%K#W<6_$CPWQ>;<V*Z2CS=;6?\DF7?Q?W93C(+P;#
MP6Q0=-F"1LMR5MDDO\TOAATAYOOI'`'H#0?C@8Q(,EB;EO@L0TW+X=#7.)H,
MR]NBV)H60Q.>->_[BO,P8^1_>Q9$$<<S&T!L-BYG;%`@/9N569QEDO-$@7#!
MV*R\S/I80*VS/=CBGJVAS<S#=3GLX_/^[[_]_;_^G[__MW^S#9S==D7-+4HE
MB]*>\+B/:N!]X*2D;`O;TLLG`R2G\V0/]S5WIO6+RT%OL()ZFV<Y:>TQ?;G)
M,FV/OF*`%19!UKV0)*/&E]E;1#S7(K$-7VL,BD^]8C++,"5NBC-,3OXU-B)U
MU!T;$2C#J$?IZFS>NZ+"3?;<5O2+C\6P-!UML_(WQ9A5NI#G_1':(>\^&WSL
MJ)`S77K/U\G4[1&_+[&"E]-RE(5G86#[F==C;$$!A@KT+[4<;Y#Y(8.U7WZ>
M5X.>[7A_,)S+ATL[]&0&<>[CS-OUT=Y\FGS:L>#!3<[E&R3"Y6@RM\5=W'>.
M%1[U7@)V(A/^:EC>W$O`FDW/>^S/"CO8__.\FKD(FQWIE>,>"*=A$9^*7>8^
M;-T@R;A3[.J:L5\4X-C>P%3"V)^/A(K^:A^T-\D,S19LE-&%K?@@?S'L>/OY
MXV0L*=^+XF*6O0CF+MO`FXT&\U%G`T^N\_$5MI/-:R33W8B1F-B(CHJL\9#+
M'9$$\FZ^M5?V&CM?F5"MX>WI'%V%669X)DN]:WO<+C6#)3.UWWHU&`-ZI+_K
MJ)F6O:+H!S4VNPI[90I1V&+:`]UTM+(F!^H_#@@]LHO;['+);&V*]&*_Z!$B
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M1=]@VUABN4U<,UV8Y?F@[%VSK'*$`^A/YU<,.602XJZ$`(CO%]7@2K$4LPY&
M$M4B`Z#J?Y$=&OA2)A/!&8S_7/1F`I39A-!IE/>,8_FP@M&!"%$<5V`A2%S8
MI>*<#%ZC#83ME[?B3\35/B'8+KL9S*Z-A@E<Y3ED!>(NBFQ:*,@/T(F/L)QB
M(>8:`9!\ID0S*93JR_[<48OHEXZ7X\U,?GTT^&L!;_*;B[SW`;JFFB:?3(:W
M.(2;AF&P^[H4DU^/,S;!8-YF=E.PT5`WGN=#WBB(.N:`I:PA.@$98N'5-!\A
M637[M53F#%N,'1WW+0ZKOGR>7:.PH_Q6BY:O&!H&4]`,A;Q3W8)1E';`[1NW
M$$=XH`_@:)S+9#4.GQ)S56J_VFJ@W5L0FYK26U:K/;FY'H"?-->0]`VR8';\
MRK2038I3U2LAZGY_=O[V^VR#M8.CBID4S47(=L&W#>$#WLO:$5BR.M3K^/35
MX?Z.-&S35M$C,,CETBYM>H_:.O.ABM,B:V1D4SN$Q4!_>!$E1='[%E],RN$M
MFK$H_H$(4Q?>0%E0;2%TJ8=;3(TS&XR*33['@_?-G(Y-6%.%-$G+KM`W^ZY6
M)`S`53';SGXLLNL<1>L79"@,7DH!M>EB[HI-D(1$H4QI=,JJ["/R(7H,:?;S
M6S,D-T6!:$M+;'C3[,92H?^UN"+#DGV,BI1;FI"Q:5>F]:E>P>(<,1Z,>T.R
M`<RG,2=3`#7*P/;"(27^;(ORR2V!$/:`Y9$\`(`;*1_+$4K$JS*P)Z_?_$$;
M[=*J31[EX_S*))[-AT%X+!&``KZ:3_47R(@=0`&-B:X@0KWZ:UI<@ZQD3I&X
M$5*IM5_/&9,U?1KTW$17,VB70Q+/;100"0L?D)-<M1-!9C*8=D,NBN%"QJRC
M2<<S,40.:M,VM(ZQ10O?U/].E;+66N<L61C3'7$:J_-1B9D^VU_'+9+S);P7
M._EJ"(@6A],(IK,Y9KHS>$U\!ZO#NOCO=^?_NK6SN[MBBDE9S;8"N(3/A+L8
M5'_E:,4K1I56;X_M[->/-7OM@H.!P*9I2-NX<C(H2=G(ZIKA[K+:#`7"8*8)
MD1@02$G:2\1H^@%'R7*<DVU[5\TOY,OTZ+2XDE<A,2H=P`?F0_A>87[%P\!T
MV+^<Y1>()XZ%P&O+B,;3YK=%?PO59O[6ADA;NILR*LD_X#WD2'`W)5L"&U(]
M,EWYX>6)J0H[?SVXNK[CZ>_\:?FMVFD?;EW?]J?EI]O9]'8RRW&#Z#HYSFS?
M)CC<^NY\WZ9`2HG7F8C$=G[%KLB*FJ9<%%BUZEJ)6%B'AW(=U<)&2(9@#&QU
M#31QORS(5K,E&(X0B(F/XLMFQC"(]%16/@`;`1HV1/4`X#8/3O`ODM"LFC/R
M5#MB)LX8BV_7!YI\D>T3!0]1+EBAP!+\*DF^8/9WMPY)0&`B[ZDIR(5I"29H
M#46+%/@"R[%FA<L)<C(NL\8.AR5S+H!!V#"9"8G+90>A:'08T1]K-CG"-2-U
M)1!AJ=<8O+;@C>V"YEU-<^+;-[,*1]Z3+>[/S8D(_5Y,2]""ED(`-+F^)5DQ
MR-E<CX6Q2KD9U*W4!,.<<FH!1Y5?%C&O>DFV+.\!1V1*+HJ>7`H`6VPS/@<L
M"<<7UB[Z,;N)AVK+CFNO*ZQ)SG:$+@R-$$;068,MC$2-Z!?\]2JL[31CUFKC
M'WT0@LI:4IV2[!O<@?`:.]C`0]E_0S,)UTU+YA-IXZ74S@3;*,TSA2"X<VP=
M]BD?%R3G@R3BJPW14O<Z,&<*(@9K:^_R[%3:@TU8(+8&N=*X("-2T"Y[NXIP
MIQ0W\F>&2/\4@VX=`YIYQR1?LA)*555U.<="WY3S(9(VD%D0^A#\CG0IW2;"
M'"HN$8R5`@W.`)\UJ*(8*^EM@4R`GS5Q\LW4"`=#JQYVG-/K<?8#()[ZYI%Q
M6$&4N/N&Z.*%8K)C!UR&FX2%WKPX-N,KKH:%V#YJ(>^WSS`^E)8D^_YVDIU$
MBS3`JS#`G/H.0\@.E^,OGP]W#C<N'FWL/3+\RF"O"OF;H0VX::.Y?)Z4%>X'
MUW/<`Z8:_4J9(B,[M@+9+$0,Q02G7@ZFF/L3BT_@_+NBFDB#LN^+&<E,H^?D
MW??)!JIR+/FJH6CD3L;"L8>4>SV"<>V%OH01I/G9['&I3$:CWN@.^G^C_YCX
MRL8C[.!+)MI64(_F@P/Q[),2K:H`M00BEMP45\-;&81BA#":L="`,NG[?FE!
M?'5;D0<GG@AQ2`A@*67A=I3"IT@N/(D\Z"TY;ASF%$L%P)E?$G6:GW(FRZXB
M4LZ@']RC8YT&Q8U_#_!V5CBC`#5`?!DAPT':43@3K8<<L?11T4VL??5@$$+"
M3N87%/=ZK)GL"UAT')"P""JG?*+'6&D]?O;[<U<[TP$&:()Q1$O+0Q1V]4J/
M1#(1O"^7NHAY:`T7:/>@@ZVHM);QC'T)L\"S&$6SCIMR^L'(4#V`/_+AK9)^
M-9Z[(&V!T;-WE/[@+^,P6=QBBA-9W$X)JO;29/<,`%.,+A!%/MX+\EL+APUS
M#[EC38;!J3^X)NP3P[/'Q@_5GZ71%>Z*M=O,Y_%+3W)(1BIA'!:;K'N@5Y49
M(AIHXJA:\!5G,DXP`DZFD5ZI,T,$Q=<N/2;"!]J`)K\&B5R`3WXX84LD7,[E
M5%J)?:)`!\MFHHEP)&)+X.5R$C;6-H`W$4L*JD"Z19DBO^$Z[-DOS"AQ-O[>
M<B110#4^)H)/&;H.IV"&)4JM-"09XZ7RAEE<*N3D/?SO>"<$8SY$M]WLB7%:
MLF2%.O@4S$`;0(F"@B,8XB26/-_2V6(9NZLY"LVG;,ARAV9XH<&*FJ$+H03$
M,-R-)]O,)O,84P;5,;T*,LT..Q\-5DM5\-!*=PF_>++/F(V5"GN[8+H:@93<
M(=X>`@T(3;&0Y,H"$F-F6>OYA+U(/'=;IHRR)GJ*4:@ST]G;8O^"&XS/87I-
M1.->:9K&BM=4RD+A9P:`>Q`N16Q,V(BRZ:U:65#7PXXS/8?GEG9"2BS#6*>9
M9):T0HL:DX"2!Y5S$SH,`>UV_"/20;9W2!80R=+[7X_I&#KW4CY*HS7(3"N4
M1$FCKR4O+=5'N."1?.O%?$*/0@^0)_\CI'%!5<!>J;V]N$/JY'*8CU`5!:8C
M"I;D+UC/<A%=$I6[_VOBL80W;*6Q*\!$XK.Y8041I*T4L-9V6_R-`7#ADB+9
M'LAG+&8!6(4EC[0,GJ\S>]=E957P4!4S(Y1?,/PF(NI!'H.2>2;US:(5N.2:
MN9OE=BL44Q,.!]+L5;0>Y.Q21&C^HD;1/&2I;%^WTBI$M^R_R&=J\X8)6/R8
M#X:>[&:W9!1#8BH4?X"*KQ6^N$':;>#RS&V;,:40Y.'M6E\/8[9DEZS!M7LW
M\5RI>)%``*+$>OD!`9&\1)JU[Y9K2`7('7T0#=OPN%:S([@#,M/P=3+,JQ&5
MBD3V0C!AL*>:8WR8SW,<>UO['D4$:<CQXFH,8E]$**[_JH%.^(`/?$/:)2MY
M;BIG;>QE]8WMSVM6)BIB%MTZ88+Z).2Y\"9JXW)LKT0A`%$HO<N$,XH=\ZOK
M[.@)*04B_%IBJ8(KJT(T:9XQTK:$'?B^'D#%:P4,(,[&B00PE?3;JI-^OL1Q
MB6^?#A15D:.#&JHX"C,1#&(()K$<R4A%E3@4)K8,`K/7"$R:V`M,#YCB+W-:
M7L`P\'ZI740`WS!^Q#D>R^54E>:6,91A2P='F,PH2IB<I*-H%8]D*?,%,Y@D
M+9)M$RWY!.]/>XMRG#GUDOE4\CH8;^T:KGWSN]U5::05]DLN=COC/>Q")S$"
M76#S)HV#_3"=0L06;>>ZJ.X8+8AI68FQI0R2%:Z8NPDVPL:\)])@^C,%,[(<
M(4NB_'!53B_DT9X1+H$*YU,A;>.1&U#5=#QK<4W2#7$A56VM"[>L6CJ`\12&
M\*@UBE3S%114E/3JG)@7_M*M2?:5X`7Z%#$%&K'9+1(1<9%D`$2.#%N`J>HI
MO'%UQP4!Y,KQ%G0*5$0:@2YC_BFK'55*+%VA\G<S6?KRY7-4&'5US2L*8;4_
M!&U_^2Q9-H0R$SH,4OWE<Q#CS)VY85](:6)>LKL*QMS#`CBN;_+;#KQ`C5X@
M=XMJ)#ID0!*(OZKHQ<X8AFCYB:!N0<5V]J-=^F<##PPI*9%R.KD6RI!0:'M2
M!Z8RS5W9=K<0I.LQ#/).L5!\GP15EP)/4>WO=#*OZ[-4;FE-.IMJE2TI9(8S
MPQ-F<64E6+A*+QC]4).51-C>8(X=X,>8*36,V#03I)W]CFQ\3R/Z@+KO;;N$
M@(TWU4%EU$%*H`>+Z'`%)U'*0\&1.297)Q::*(<R+E0NQ1U8V\REM3JU6L/<
M\Q!>79,U1<OHFVSW"\H`/]S?/]Q^!F@>#@4V<5!\Z!@CMK.3Q(2RPF)V!*]3
M+\M1([6V\J(E#G&A-.[JGTHE>-+U,:*#^<"W>6=F7VU(=1=+[6>1<^]QP1.Z
M\U<K%R-91/N)#,Q,;OCA[M'!]GY-=#"H^=45.LH3=5NG`AYK1>Z!,ID$=;^$
MMLA36<F-JBCP?#+!!\;:PT?;V?$2+H254QX42=H$^Z/.EA`W*C&B+Z#WX>'A
M]I-(8$<2V/"%X$UB%>"B93*TVZ'M4SJCBH4EA\Q@M5<0,8O<>AK13\`O<XVT
MI"SUY;-TV=,"FU\^8V]I#C`A.[64+9"2=?C?>R$R7TCB*DNECC-+TL-6L]@2
MDK`7CCJ^?+[.A\!_QQP0HI`&J>4%+3E@&0QV.Q9SX2W&5SG=1C2_)/EN"-,+
M3?53OL2[]DR;FX&/T.%6C&=`6R;,X)5DV6`K]!BWT*<8U,=74]V6<>9EBEEX
M,,0I#1OR'K*.V?`'O!A_!>KVCC>29H!NM4YI[:/\`[GT1,?=&WCRBT=8'5&$
M%JY=:IQA#'[@9]@Z6X%G-%7O8FQ+9*49HB!'K/Q23\NTS<>Q.%]>6($@$;!:
M)R7-V`R27_XP]7(D/&`*]>&;0LCM7\BCV^J=`@6!,$*`D8RZ[72S1PXUHG"'
M]WSE5V16;<DW.36;&V4@O#U"I(SG!`$"R'72T5,+>N5B/C-\,J07QU!\^4OS
M4_1T3R`3\VDQ!UN*@:C8N)CH,2V6:9"(IC*%.3!ML`>B2%@TQMO-Q(G>2.Q<
M7_8M=6-5AU^9X9TP,:5@%D.#GXPL]2O)H%)_9N0@1YJD[?-]_95]3X>(5@=I
M#9V($QDH%A2"(XW3"`@A%7#=#&84$&H=G@TL^CYJOX`)QH_DO5`.T5PI!3!=
M>4^;GFB2721*@3.]P##7KE1%C,<T*$G4@DKI;9$YH<E+$P#^KJ69BA]29NJ9
M9LFU(CK7:XZPGS+F1E,YG[$&V9R/Y5#Q(KJ#.2>`"+T>;'2G(E_]*JN4:*=Q
MS(-BDPF]JBV4TU_6WAT)YFW1.<IQT-25/$-N<J:EW7,$/9;;D0OKQ$+6O&?$
M%E6#HL:&D%XD?5`Z]#0EQ#S,Z-VJK@<3AR*1;G44U;T=L*J671?H5B$A3*@&
MAR!I(HV]6<R,A477?&]VJ29=KU<<F$$]1M8PH0^T\V!?=A`-E>"C]KYN*W*8
M/6J$4&UT86I50%SU#8$YSVUZR4]DEZ:H%^@J$C,%N$S5Q'!285>Z:S+JU%]9
MSQGSJ+)I@8M2X'Y&S=[R[KXRY(^.+8NQECEVO1W+2Z$%RFUR8F23!'ZTA#?T
M&TEIK&^!6A3<NLP_LN<VAHRO^1`RO21D/*DA?FM]R6@!<,G-(*67<^I%$E:S
MT=;4GWC?]%C'6N^0]QE6-E3(`XXJ8M/)N90T*%_B"L`T^!>0H6-8X:W$[0'D
M<!(8O>"%?'B,(YN.G6%W+<E1>R3:`K2K]M:"2M!Q@$ES)P)UN+<9<9I@`19%
MK.OLDP!?MJ=&XV6MP&U\7C_$"2:=$A)IZ[J%TV;A]ECWF>^<O</U*I<XMEX\
M5D1Q1T9?LJ=C9_9751^Y"SS"R:`<\:A-TV:#:\-BN('4P-.^H6)S/OIW6!,E
M3H)VD&`511YF\[T*8'6I<S%MH6KQ;XZ/3^MZLP)K*J41VT,1L3_9;`^;I4UU
M,$YGSFSJ^6+OZ59M4J<B3>F.B11Z"#B5.&3\G1MR&9&SK7\%H=LJV(@AQ5%D
M'8WE_`4Y"G?.\`_TP'M2@S8!(1Q'-:C[1>""V&D=$7$)#JNB8$W]"VRM(21)
M[;'H898F(`:X,G&>G!;98,N47930\"C!M-H)P:^$>OH,_D[I_:T>:6\K4B;:
MIS$YA*I2N5D(,,<4#&27+2)U3C:;&U9,F?IM'2KRI%6R]+980(R`SZ<)4@>8
M"T2HWXKQ#!>*?W'F`5N/$28&-34*K(SCFJD,"E^'`9K,X6](-IJKTO16CF%:
MK3>F1[Y\;N++<YYI)/LBG!^EB5*-=QQ7B1F5\,9!5C>[P"ZTG'1S;-2(BK)L
MZT)T:\13)P9*"#G6Z:U_4'2\J4M-I:S%XJE4@!(A-(&M#(;_!*V6"HFG;!;R
MRU]3&OW42*>^!H/BUE,M?OX9,&A^MU:YM=R)@L2^>Y+L>*RN='1O0GY.=O\5
MPMLV:%\^H[*_,SD569?DNG@G[CA;$W>OWO`#'E('2TT5#2;S*1Z5]6AU+S]Q
M9$<MPR=D_D,9<$-C8VO.8NMB*(0P^SX!K&+?-F'+C?X^1E_&(YB\4S4V,''[
MY;,D.EOR^%KSOY_8_R7OMJ<Z;:PN6G:"$7"SCFUI/WH.$[`7_ZACB((NGFHX
M>&%`Z;M5)UBT*VK!N^$8J?SOC2H\JC23SL)(48CJO)D]W_[#=DQ3JN[!A0VT
M4O^5%P,ZX7P2PDLR#4S!1TU=BRSG\N%,[:F5)'!"E/%)[`,(X;9P17)"S:1*
MDX74E;7)J>:2;#*`@9-TIB[R"B0JH!3%6D4*_3S*=L`4_6%GBSH"]QXE9TM?
M8OQ%8$?(M)T8=5RSVW2>76JVX`[:C'DEO+UUM3%?%9Q7E?@?D6SI!>%]F]06
M3]@X'QF1H5D]]V,M)@$C%P`(\31\1(]+G)\-EOK/$>`P;NB"9([=/'GWR+)5
MA42`]-X*VXU.4EXPG<2X8?Q#<+>P67^>]Z\$]XR<9J51KB%DY:%TBS@5-,[R
M3\'>&!!><J12*&,F`QB]'II2-PK6(H<^!.=#AE_!B;.](PSUJ3C[XR7YDA47
M#-0/=O*+"(&0A&3*OI/PAP;NH>66Q2PH<"1LYK6<#D@ZL09D(=I8(Y?@W`Y&
MJDO&I'0!(DA_`""^1Q?YF-ZJ:"<:X$&9I8>2$!0H1R`1M7ZT&HQ++O1:BC85
M7Y[1E<X$9O5Y'XM7IX7?F-38>8[VIT*8'::^S*<ZBU@U!\+;)E/8O4?.(3P'
M0HH'F?$F+T_/#+B28T4&>^JX@""@8)^,HJ$5*0CE<S\%S1?Z]TU!TSP/;G'V
M9DHE7[DII4FT+7@L_&1EUX&0#FAN"8E(#`(X,HEAY"04WXMK!OIJ"Y`.D=Y#
ML<VI73^5#=7*"LL-V"GMGXU>R=.JZ=<LAF`9S*\S`&K/%L83E]2G7\U!L'[,
ME29`3K^%QO?YE+8/M`^.S:X3YN/R"/)T+P(VWB)L&)5/,<W8V90Z>\0$;V@!
M4E>&E.>,O(4NS"+8*"[.7A?R#RKH-I(W0BU737&\%`QA%(T`]N/A>&V#1>VL
M%G3N?056XM(^@4H[TOH\M)H3+"_6>U3Y#C(F.5$(X7)BG7TJ0R74+(\`D[@/
MKC8>DJQ!(H4_'V^Q[_"GQ2B3R%J2ZS4U2G<1.+#`,N^_9GO8YL%63%-TN'>.
M4"6]<Y9]"!08#D[4\.=?\EW+%<#Q:%/VE#2''6RAR$/GH2X(DK)72'#UJ'-<
M_MA>C26WMOW:;']PEJI'NKGM!W^,BI-PH_W,2;!7;7U"<VJ;/#:;O'X04$P\
M+_>:;DC<Z\;W5"N[UPH@(<VC[)X]JL+F(R\.@Q00=;@I$Q+"`-@G707ZA&,Z
M-)>8%0V.-T5N,A(>@WH#C5N-P93:)QH"4B-=JE"1TRU;@K%X`UP2'P<XLD!?
M+<!22FN9ZFJEH"VK('6BI`S07?5):2".+K[OU2Q6A(6Q>I,PK/X95FCX-RQQ
M!77MC7M'2`S^.6Y0TZF.::M9Q[Q_^_G7X^RWM)`KH^!U0O'W58WPDG'.8%.?
M`DR5/2]5A['S`,=GSX.CM$[EI8^_GQB4T//'9^_M\3<E]YX1FFVUR;&3\=I[
M9O-TU=__]C]>?@*$@Q:@"C*UD^_'<PJXW&#&,Y1JS^87,[(NO6QO[W!K;Z<C
M76%JGW+'.H?`<&?OXP<9S;FX*5-0DR^U:G&;#-M%HV$R-ZDVYK.M$-#&:\$`
MN9-@[PR8I@-;L0I%"5#1D(]C!L9.0G^<D/?MY$-9!#K-.J/4-)H*+!3(4(06
M"RSL=N`NOXM(>!B-NXO.3S[*9(T>@,1C>@$4N4X"'ZG@`B.\11V-E0MRNZYM
M:0*`3"W/EDN4BCC;C#ERO_.P>Y`-S^=RKX`DG9P32[0R1D5;C'F8?Q(9WCNH
M.>*'?C@?U6))P=JWYS'-[$ZF41;FL:F5<UOJ6KATSZ\ZDS:VY37=)2VM:8;5
MNI.<1^6Z'K.@T5X([<$&]IP88?%QJPK;A1HYS8_3.EV2J9HOY4&$88UBLWJ+
M:>,EIT]=#^Y)D!/:J698,1'\,;Q=^BJY1L6(*]YG$](1Q':#(Z!6,I!F=I>`
MDN4!'N@<`O-^N.($Z6(`/U.CJHMW>IBX:!&U*/&<EJ83#Z:"^K+A4G"S"1.E
MOW$2;]_1C!(97K1Y5'4U+YONH^V'=D/'C]KMD7;D)P[JKAVR]#JW*RCWY@@N
MK\-`]1Z3/E"63*8_AHR0UF`QR7_#*134RT@=<7P]SH[G5W/(8O_IQ#3K8\W[
MG$2`A&!6#[80D;:DGJ;*RNR-C:]-;44B[;]GO[%J^XE,X)137XUAV3G<.EAK
M6S6O16/1>.D#5FPM`.UDA/H?N&T$XV/&B8-X_Y-_-<5/N(!<<\H3/YIGW@+`
M9T84@8T@`L%"Z("22KM!D"K,)S";!ZV%(:E=U`9(*78W,>SU8MW"$J$:1*C`
MW!U=3GZO('`_%!52O=K8?11E%CKM.@>K`;IL>)W)4F*,I\,7I)7Q5IN93LL%
MUA@3B#BHI2F4P`+CYAK-=N5J[V=:(6]9%0;?Y^J8H$E0![.\>B.C!!,ML-0B
MI0CHW4!-8W(3GOQ!.IK"A>V+&B>Q8!L'#<V1OXW-5QI0QTR;@R:^5GD/6,>)
M&8NB;3]=#<2C2$X=':R8^I`5I?SZ-&&,JBEK&2YP\'0_DJ2K#5ENGC>>+,[B
M0FH9);&NQI?27OH>+9GMUEF<-)A3FZU&H;F(*Q0AY2*"ONHFDJ9IW<-0_XH^
MLW-&2VPW4AH,E&E4U]%H=GJR!8E<6E3+T8XNN@Z2XNX[GOAR;4WI:])'.4?\
M#:6Z:-49G9A=3F@[6V.Z%WK2S42N-K2V#I:%'7MB[_6]2N<U(_==T3W`;$L&
MB`7PR2+D?YI]_>V<?;W+NNYUK"OQTJ2^<4U6U*.QA8\WS@VC/MU]M@Z@PIF]
MMA'=BY8B)FFU-6P>JD*NV6]]@4?J`3`-YK(6Y1NU_VRG?>$I2L!4?22DD5M3
M*VO`KCA>,6#(($0\;K<JX#)-:]-9T=O@I1+9W#.D:#2HQGY/^5H`00MBK)/K
MI"G7HR")Y`"`5'ME[`V4.IY8KTM[AG<*0!COBSD!7FSD;C\;Q!3Q3JX>-,K@
M2CW!%I28NS7LTMF@:U+%!@6:2>`ACD>SATL15!C1LK(I@WU;XXYC.))(6]MA
M:K$$`!61':EBXP0,JT,R6B<:$_,40RW7_@#L=$75PNI\X:DM^!%!P3$8:Z2L
M-NY27"6A;B;NXJK_CVS`&[(:=/QN+4D_PYEWH0!TZO?$MIUR?8DBF0O%->N:
M00Z2:N!)DE81`>SZG7.]QBG@VNUN`.X7)W<(I,%0F_W6]4I)]?0T)O6/8T.,
MZZ:P`;?#V3YZ@D!BY8WT#P^V#[]\COW?2$V'2#/<4Q(.5FE/NKUYM6["7MES
M74-X>3TS9"[1!$+=F=J,/D>".T]9KP(-QG#>DO4)$E&X0?*4&03"Y=;5]NUQ
MH^RD2A;ZK[Y=+&M8:`PW>^TJAEN6+A$7**"[4&RPNA2>_$+FR/PS?8WQTN$0
M6$`8K+6J#=K&GTG35@!N.'6NP)FKY=_*P'4"SB0%3^Z*9S>CA%2T%#P6<G2Q
MU7)V6>E'N6UJK*1_%%7N(4GUG3D:)=P/'*U-=[D*&",NP\BP/(-+OI?+]@B>
MT%Q'-8PV"TBWKD^?Q:"FQX2=T&?Y"H2$V)B:(R`7M3SPL=E'[28Y.*N\6"93
M'K)N^]W=W#O<B4_+53GP?KB[N;-CO44)_W&C5*RL>&CH2%NK*VA<.L2H#F>,
MZ]"'-R*M1[GMFGVR](O(-5O9>4</:#`[WJIG<AU_L_"?V]XDH`&B:YESVF5]
M\7YFO]FN<'/)!>V).A^@N$6U>8F7[DD&-K,]1]M'1[^(&I'ZEI1C`GQ,X_NS
M6@AT<!=E4F7'DCET-/O?!MP:.JQ#P+I3$\JIR..K55V[H>BK<Y[CDMHOV*.D
M;%2W"JCMFR_DIAO_BE9@`9_L^ID?YY2.VEL(%6301^M(U+%Q(:;7/:5B9M0R
ML5)*,!W-`H)8YIQE0'H<A:3UBZK3VIU_KPA4^^&II7C:3<&NCF^*D42*.:U8
MZ\;Q+-N=&FB`6)/5,A;U<6Y^!&M($Z3;/\P0IQ/(&$&?LX<*54<,.[S"T\?+
M9:;I:3>"9`]MG$,B@D8<;9P_AMF38J&.:DG=WSZ,)U^BVAD7O52GE[N4F.E:
M-2<H"$GCN##VOI$)EO;;^?"6YI\C[P#:=0,H<UG;,X\BY`W[(O<F%UZ%!-BQ
M@HUU_[4(K6?39;11+U:0:1@\X8C>3ZQ\,%=W<0)!D:CSLG4F*T<6]<2B7IV\
MZ.S;^3*>2O4L-2)QI$#=5TFS,239)9=N"+Q8W*`R!J=NF78+,\K<0;!KIRV$
MBX>AG,XH?*E!FP!@\&EQ['CDXI]L>UUS_/19LC(W1.:4:_IE$%$0I`!>#4O(
M!\':9<S!@"/`\E1(V@4V/UZ0+;X`?:A*\*K<-O_O3IIT%QX;F=*`'$HIN#ES
MB*L(UJ@CXLLYRH#DN@W>^]#H[%_E`#0J^H3IP`RUB+([1<,#.C@BF:8)S](4
M0$,NB/=29(<&>@CFUG2JEQ<:/HHE/:%PH^T+&=A.DS0G\3BB+#<J/G$3A'ZP
M8(OS%[A1_J<+KXQM@4MM>F+*"CZ&GL_H!7SE#<N;7T58W)Y5]'B?P;U6:91Z
M)J!V^4I/Z`HJ/["FW?!M-CO(N@2EM>(V+QQ2:.D/GSX57^RH4=@B)17UU9VS
M(&"2@CI3IF4L+GO)W+N'R>2[^T?=V3M6XWBI9]1L/4K'UE=QAT@OHV/SZ4&8
MW,^J@XOD8;T^&@3SX>'F`1!4@L,7REHN@%^1T)85:&WZ&#:M.ZG%%,9^N+_Y
MY.F>QK4##1KGCJFZTQB]!C4+M>FPT=;U93F[[,GFTZ=/-H^.GD7'QJ1M]-GA
MLSFD0T)-2Q8%/_^?LI=6T_ZF]3-3RYZQ\ZEV:?\]XLW#)-Y<-EA[0D1_-SL-
M\>&I6KH$[-M/O9:S]929!Z%4NOO9L^V=MJ=?PA##!JJ%1XLK^_1P;R\Y=KRA
MK_FTI5"[VV1NPLEDC&]MS.TX+_G35T+S`J[F7.M0B'W3UGLS'!>4R8*'^^98
M0F@HDD['V"G;`;(T\42*C!6[R-=]TO53F`3D%5.O!>QO/T%\@3[VHF./,+:.
MORDDX#@2#;)V9#D,8%TKL@*8&#LN&D',KF,8,B3GD%Z/H[!+2#A,3T6,)7L8
MR8V@-/=PYZF.^+'$Y':"!J]95&)12.JO14"3E-:0XE>`;ZQ-_UK!#ML#G4FR
MZDND*WJ<2#>=];I`3^67/AQB2`MCPM<B>Q&@+GZK$(%U\Y96:K_^%"<*SKH=
M;<6OC?)(1+3:]XZR%D8)L5!L3OI)(=8*'K)Z6["7,3PLPIN$O>[;#0E(C24W
M[(2:LE#J3J0"&S(\EJ+O1&SURA6H66%!G*Y!KX2'WVT3O+!)W<.L#LAT67O8
M&45:9*#M:*7C/O`,X:9)@<3%Y+EV63FQVA87B$;HBIK0]=BQC&]=^C,0O)+Q
M;EE^A@@DD5^)>O)/R52:*5@49U](T/2@!Y&GKI@KU$R.<'F($@JY![Y`+T]C
M&DHN=--5!1:5_.20HXX5$ENG7(F?S"-WH`O&@Q#>P8A67!)7;0$?GC<5&$0*
M4\&I3I`GD8"]F;V;ZZS6P4&T!$E6DBYJ?;I[M+\/`@(UJ=."E:M=)[[FI9!S
M5:"DVTWEUJ3,+SY6L4/B?$TGB'+8JH)P[YK`&,/CACVQS7?LH_W(@X5.B]Q0
MB-]:S^("'*194!0=B)T[L+9FVR[7)[7^_]PAI.\G21++KF,(HOZL#OV^#M"'
M;:W#XVCQ^MF3)YM/GCQM'(\S10K1L<%.G9UDQRGKD3ALW?J]#,?K0;GYVHNS
M:0=/-P^?/?OR>86AE,R25--;YO-J`('OGE=?%<V@@)'*F&EI%H_<;NX<*(H)
MO<;_/JO?W7FV>;!S%#44?BS8ICM6WX9H&-"]>P(Y#+>>-GAK0&X1=QUN[]:P
MJ]F9-LXU9%0[I`08[8*F$F04KUN0VT%>VD!P<>J'AX)B$?.M@(7[V[L+%8M:
MHB(NQ*_$!AHWO+[4G^I9D%R07^"$T)(CI9_H$<YTG-8.#%">US9TW"(?[A,`
M-;\[FKTEU:+`O;WGP/+TUC;L*P'+DAU]NOVT9NK=.XIOZF%2?<ID8X'[R;XN
MEH4\"7/7YCZ]&_/O;Q^MW]QS[$A-G!ROG4$"&*F\!-2E)I9BW>4>.QHHO3_1
M+:^T9Z,5+B&6!I:Y(LFY;',.[KTY,6:2]5FZ,0<)0W[ZQNSN;C\]3&,1Y"*F
M'MWE6@R.&_6DM-866=A0]H1\A8?DQ9;.XN.B:X.8!DO_&)T'*9W:2]C?F<[3
MMDO#KIWMG=UF",NHI+$4`=X^:1>5N'Z*@#[;/JH5987U.4B"7NQ9R_@T+8N6
M"\>FB]D=NZX/ERS<34K<&MC_[RW=EC'@(+DANY<AZNP<7'R%#=0*[I%"W"<O
M]60A7[+`"X^3=2]Q7ZZD5F&-'OVST!W(+ST4Y/G!X%$648&>;OF4O<UG3Y]Y
M5NB^E*.P7J%<`I7VGAYN[A_NM6E:J+B$6Y0%9^,RXDDYDX=V7(LPT`]KF`KZ
MY6JY[O^I[ITV/104>`?\M8C!$T=<&:LC`,K]DK49M[RL)FF#K3VZPO:;4BCS
M+&R%YEB"LI;P\^C0N=GV1B8\6UXBP'W5G5+MY\XAKGV2A_.I(^Z\TB7*MM=+
MSF,JQFS2LAXZI<_&FG2K=R<5JZ0Y0.VJ'"F!!36=-!;0[^._&>77ZHB-JX3<
MSK/[T7.S0GCM@[O.^IS;/0P_4)A9]4/R#]O,<J9>6-UE@=C(#>]N@!T8H]!K
M#-(*WW94]W7=ILR0N'GM>CS1)H'169S&O+:).5Z5,D;.9:P>$LD?`>KE1I`O
M!P7SL2HH7)BDP]\+2[`K?9+#UCJ5HRA/F==[[*RC]#OV5*U+'ACJ0<V@3Z)V
M6X,7D<2YW6!X!Z7Q3()?[\%BA`7#)3N]Y@=368"=`;;O+^DZFV.NS!EI4PB&
M<:8U1Q`OQ;NI%/I%1TJXZ!=M6F=-/9,BYNYM'WSYK)I/]WJ;'[$Z-1&28;L_
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M4//=?4MD3Y(26?-V=^07NK]232>X6$W/E1&AI]`$?^&&$52IMNGN&`CR:<'1
M4<;X0P(Z?7I1S/@Q32YWJ\]>UL6:D+YLYEHLP]*+Y(?KH4)&T$^-HK=X%#DB
M:8T9+,_9IY,J)^R^A\68]T$AZ".A'8!5D4O3>1OUBM@=/*K;T(=H!PMDJI+3
M.GX3'IL2O!X<B>>PQ2"#D)P[`5L!38FGZ0[3#V,$BE:RDQB5$7'/S>D8G'5Y
M8TU9]5U/6'\FL]_6-&_:0TOMZ!`KJ%/H:P;*KU@A'D1KLJM)M;7IGBX!-TL-
M6SSJ1:"A]'<\(I-("=<;A--!GB!-OJ(]?,Z!J]$<2BX6A`8UUA[:SR+P9>@S
M\4PT<:`NEAH./NA\,9]9]YSVCC&:7UVP<HR=;8J7C(*N_)<;;*%SDM\TW^E@
MX%V4UT=:%XFDV$A^6GMB=3FC).>6]%\X;8-K_;88GLI_\[*F+/H<"^SC_3NZ
MGT:_<)$>@];F+,`PT1T:>@@-8&31N;I,/ZT$02I5<?^E7[8NS"6]K6]RT,`&
MT9?>:M6ZQ4IZE+G'6W)]52IXQIW`XJB%`:,M\Y@=>;KKHJF->$-5Q_PFA[#C
M,]F?CB]T;6AOUOD%<UP:>4'],C0UF\W,WKC-_A3^N^:GS]N7&'W-NR?QJFS[
M0W$K"HYEJ+YFD)?Q[I;38IJ9^_V:MT_4>]*ZG.!KWM>/[*6<7CAE_U4#R9>M
MN'TLVSB7&>UZ>#G`"K>G+]M^#T3.3<M4W="V8RRA17%*!R2E-ZY2<P6P+GSQ
M@I]OC%VA7<9RD,',^1IQ,)>\JIEEY3I26AO0&TXAV9Z&>%\DQ@-6F]DQ3D`7
M$%)E9)'OFB@24:">3!I6=S??370Z?3K;:>AB/R;/B0VQ4#LDOQ#1/]1'-8^3
MZ[-^^FR+:VM-1I'4`?#=X]L6[(**G@L0J#%UXX6.SO.+GMHXVA+Y`?3W9R^R
MAQV;<;B;K4L^8.NVLW#)XGY;WM[%X_FUW&R@&/5O"@"6"`EGG2E/0YNE)T9?
M)X=`ON<WN;?P`"/.O--S*?!PDD_X,9AA(L*;_,SEK$W*&KN"$SV)W6O:P`Z6
M-NZMTL.MT)6E.PA=<5[IMI"3<#E4$,07\2*FCF6J=Z+#AI"T"YG5/_U@%:".
ME?;H`JP69E>L4%G$T1GP1Z]59JN&PN`#\OS7%HR_B5E8]8[QYKZ'HNJUWBEU
M.VN%;KU(TN+-'2*A/Z0M!QR,0EXMW;^[V_ZRPP"3/;4NP52^Y*93LRQ6[2'L
ML@-21-[+&^`6Q;@]=G=N+][Y$95WUIM%M.V!`8E<M<DOH2(=5GO1L?FO8Q9$
MB0IP-C^ZBNIL!G%50N8X:1[M4M6(A`V?80!E\#>QK:1$H"\<>-O,3OSL_+HA
M5DE5]E\6ZV.KI,W>?VV7`-M9(E^]Y<#?R>B[L^_P(&72&A)>L\DD3>4X[*ED
M]'L2Q,4+:NN&H_-N0V2+>!C6Z!LVJ[X1+NA]L\S.>CHC_>!7]=UF+]B2]@9T
MGJY%`IZQD6?X=^TC34P`K25)C]8`@>Z$ZS_0<ZYK!,0YU,*[<]MD/*_/'&5O
M=8V2;J(/)Y@:1K=?>N/G?8+SQJDN_)3!TB&;=63?Z_B0@X&$U_[;+>V9PDFA
M]L>GH4/]=^I0CXQK/]1BD%U5Y*><<+-^WNG19O:64(W>RR7.J?/^^W'N2LF^
MO`@'"]J3OA$Z7`VK[NO?]P[7FEK*T:OMI5G:X/P[R1^Z#.HW.\@@'?:@O;+T
MR\Z;*1A+X5%VW%1B%,FFS[5`FWM4X%I,9EE>Q&5LZ?XL6O(%&%:/T4ECI03\
M$PAM,^TK,/(;V1W[\4)#L3!B@3Y!9.D(J:%9@J#_W2<D5'+,KB`Y('FYWS8A
M>R&'M7OPQ`[[M;_O.&H%];LU"KJO[_%M%R*04L[M4$R4&=MK^*C0SY[HF.QU
M;QOH7/=RD%]+-C4#6:K+XIGVBD^&E$YDC"/B$P-5%6*2VLTDX`ZPJE,W:(V=
MZ6R_U1[^;H;&$5:YS9]!-Q#BK0"-NPZS4>V.6MY!?'>M?N3+8Y&XKMIPM!]?
MP_GXCCPD&*'9'78J;$]':I82N_?5HGO',.U%G(5?"3%10PN-7D3=;6K[:6R'
MCE&[7,8-1ZE^JZ;O*1>E;V;??W]2T]Q^?=&VIL%>.G#[K?2[E4,O/*18\906
M7[+4B'K82#(!*\*J563!A,`=E[HV80GD@"EASRU#$J=LOP%1L9DI/K**J#72
M=8=>QY%7BYJII.]UF\(W:Y$&E^,OY%R4D$[R+N9-8K9A998A-0B])*$3FQ+:
M)'U=3X+U6/0Y6DA)K.E4Z,3'1%DD<3DB(5EYP7GL83FQ,".$3BN%Y3=`VVD^
MM/>.^]P7J5\P`G>26;OKU;MX&TS<\L12PM;&_5O;4RMIT%GJ^L?;W'X2/.S^
M<@<;OFZ_=<^EG5D;SVV=&U@I(_0JK\M$)27"5FG3MK]:GA.YXZV[A>991!\T
MX')\I6/"GT;>[1\N_3[46=?1F#YR-T'1SW!:8G4J:/&A^PRZI'"[?H)5+ZR;
M['%5S;[]?P(```#__P,`4$L#!!0`!@`(````(0`-E?$$20,``/()```8````
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&ULG%;+;MLP$+P7Z#\(O-MZ67[!<A`I
M2%N@!8JBCS,M4181211(.D[^ODO2EDTZ29U>$DL[',[.KG>]NGEJ&^^1<$%9
MEZ)P'""/=`4K:;=-T:^?]Z,Y\H3$78D;UI$4/1.!;M8?/ZSVC#^(FA#I`4,G
M4E1+V2]]7Q0U:;$8LYYT$*D8;[&$1[[U1<\)+O6AMO&C()CZ+:8=,@Q+?@T'
MJRI:D#M6[%K224/"28,EZ!<U[<61K2VNH6LQ?]CUHX*U/5!L:$/ELR9%7ELL
MOVP[QO&F@;R?P@DNCMSZX8*^I05G@E5R#'2^$7J9\\)?^,"T7I44,E"V>YQ4
M*;H-EWD8(G^]T@;]IF0OSCY[HF;[3YR67VE'P&VHDZK`AK$'!?U2JE=PV+\X
M?:\K\)U[):GPKI$_V/XSH=M:0KD3R$@EMBR?[X@HP%&@&4>)8BI8`P+@K]=2
MU1K@"'[2__>TE'6*XNDXF05Q"'!O0X2\IXH2><5.2-;^,2"=T4`2'4AB4'^(
M1]>2^$:0SN\.2[Q><;;WH&G@2M%CU8+A$HB/B1D90ZJO90HI*I);Q:*Y(`D!
MY7E<3Z8K_Q$<+0Z0S$"FR!L@H8W(CPA5"%`W2(2\78DQ5/!E[X^*U"%'T<R^
M+[N$1#8BOT1,Y@/$T@C6G6M\6YL"IVAV9L5D,=!J0S,#B74K*8?SLQ?6Q9/W
M7*S`*8*LAAHD@7.Q@<QU#<-)$DSL>&[%PVGTBA_0U=?[H<".+*<W,@.9:%G)
M/'&:*[?"T\5)M.45--_UHA38$>6T1V8@1E04Q%/'R_P\'L[BZ'3>D@6-<+TL
M!79DQ7:),@,QLD8OZ;(`;PA3V^ML-KS=U`KL"#N5P32U@<2ZB*,H=.URPJ<:
M6VXMWB-*@1U1B>.6@9B&![=@*-N`W`*$LR1^I>5#F$GG=JE1^N\YI4\Y$D^9
M&]\.F(4Q+A@[@RR_B)^,MZR##?D_"LU<MJ:&HR#3S"DZ?!46\>+4ZCH%M9Q5
M)0Z`>#H_Y6@DFM5K5E-+^);DI&F$5["=6JLAI#Z\-2L_4RM?+^TA`!NWQUOR
M#?,M[837D`J.@ETP';C9V>9!LEZOA@V3L&OUQQI^6Q&8L\$8P!5C\OB@EM'P
M:VW]%P``__\#`%!+`P04``8`"````"$`>X8VL8,$``";$```&````'AL+W=O
M<FMS:&5E=',O<VAE970R+GAM;)Q878^C-A1]K]3_@'B?@&T^HR2KA=&T*[52
M576WSX0X"1K`$3"3F7_?ZX\$VTQF0^=A$KC'Q\?W7A]P5E_>FMIYI5U?L7;M
MHH7O.K0MV:YJ#VOW^S]/#XGK]$/1[HJ:M73MOM/>_;+Y]9?5F77/_9'2P0&&
MME^[QV$X+3VO+X^T*?H%.]$6(GO6-<4`E]W!ZT\=+79B4%-[V/<CKRFJUI4,
MR^X>#K;?5R5]9.5+0]M!DG2T+@;0WQ^K4W]A:\I[Z)JB>WXY/92L.0'%MJJK
MX5V0NDY3+K\=6M85VQK6_8:"HKQPBXL)?5.5'>O9?E@`G2>%3M><>JD'3)O5
MKH(5\+0['=VOW:]HF6/L>IN52-"/BIY[[;O3']GYMZ[:_5&U%+(-=>(5V#+V
MS*'?=OP6#/8FHY]$!?[JG!W=%R_U\#<[_TZKPW&`<H>P(KZPY>[]D?8E9!1H
M%CCD3"6K00#\=YJ*MP9DI'@3G^=J-QS7+HD68>P3!'!G2_OAJ>*4KE.^]`-K
M_I4@I*@D"58D\*E($)Y-0A0)?(XD.`E1&/U<BB>7);+T6`S%9M6QLP.M!\+[
M4\$;&2V!F:<GN)D>R`L?\Y4/$D,!W4--7S>8K+Q7*$.I()F$1*XS0DQ$_@$B
MO$(\D'?5"&FS-1)HA(]+>-'(!UD:@RN]6$8F(9$H%5]7KMTP!$!B=`&?3\S!
M:S?65QY9$TL(&2?6;A@3!W,FYN"U"VL84QY;$TM((DH6PI\E+-?C,8[B&P6!
M!M'SP9OFYP7A@RQYB25/0HB0EP;CY*)<N8P&(HK\<%R;D3)H.5W;Y[7B8$M3
M:FF2$#EK&(4^,N.Y'H])3/`U;LB"?KA?%@>;LHA_I96]*R%2%DY3NY!&.,'C
M:$,4?\AIF__S7'&P)<K*128ALG[(EIS?BAJ2TCF2.-B2-*9?YDE"5/G2"(]=
M(YM*C\=1E(SC#5D(_.;^5`FTZ0%D8I"<$?;-:`)JE+AC3FZ9].=U0M)8=1\@
MMO,IC&H?DECB<C,>!N.F,(5QP[R[@9"T5T.8M<<SA9'"2(@LA\C->(+&#C2%
M68Y]GT,A:<.&0&MC90HC!:)HXJ!&',?DEL!9SHZFUDZL1LX4YE)2;<O+1C?C
MZ4UA_\O;^1N5O1.MTF4*HS(7:SVE!!K^'J;C>+.TLPP>31V>C,TL+4)AE#`4
M8:OFN0D@D99;4]HLDT?2H^'_]7D=C#ZMI$F,;A+:'7/R66:.IFX>C*VJ)M<-
M&T\>,8I"NCU.;QGG+$-'4T</1F(E2[=LL*X068A<L<B"DCCQ_7&S&#G#LUQ=
MH,W'36`99Z8P<NH'0L)$FUOHSRT("K&VETUYLWP?3WT_L'U?8:2\`!)CU3PW
M`!'QHS&WIC3+^>\S6#CHV39AO^5E"J/>43]X8AN`CQ[9\BPH3SD-[0XTIW7=
M.R5[X><\#.^/U[OR#)JA92:.H-;]G)]-^?/9NP;@:'@J#O3/HCM4;>_4=`^4
M_B(&[^KDX5)>#.PD#A];-L"A4'P]PH\`%$X9_@+`>\:&RP6?X/JSPN8_````
M__\#`%!+`P04``8`"````"$`09S59Z(#```7#```&````'AL+W=O<FMS:&5E
M=',O<VAE970Q+GAM;)26VXZC.!"&[U?:=T#<!S#DK)!1AU;OCK0CC>:TUPZ8
M!#5@UG8ZW6\_538PX(RVR4T2R,=?OZM<IG8?7JO2>6%"%KR.7>(%KL/JE&=%
M?8K=[]^>9FO7D8K6&2UYS6+WC4GWP_[//W97+I[EF3'E@$(M8_>L5+/U?9F>
M646EQQM6PS\Y%Q55<"E.OFP$HYE^J"K],`B6?D6+VC4*6S%%@^=YD;)'GEXJ
M5BLC(EA)%?B7YZ*1G5J53I&KJ'B^-+.45PU('(NR4&]:U'6J=/OQ5'-!CR6L
M^Y7,:=IIZXL;^:I(!9<\5Q[(^<;H[9HW_L8'I?TN*V`%F'9'L#QV'\@V(0O7
MW^]T@GX4["H'OQUYYM>_1)']4]0,L@UU4O3XE94L52R#RKD.5N3(^3,^^A%N
M!1!$:@"#R/^Z,`\A1O'[,,/?7<@G7;;/PLE83B^E^L*O?[/B=%80:0%IP&QL
ML[=')E,H`\3R0NT]Y25(P*=3%;B?((WTU;@K,G6.W6CI+59!1`!WCDRJIP(E
M72>]2,6K?PU$T&`O$K8B\'UM10)O'BY6ZWM4HE8%OEL5$GID'BS?=^*;5>F$
M/5)%]SO!KPYL5_`M&XJ;GVQ!]_=9@94@^X!P["ZA;K$KH30O^V#GOT#RTY8X
M&`(^>X*,B:0CL'[@H3<"J9EN!&$T@CE&9P=S8Q@WM.+>$E%/C(Q`%J8;03AV
M0;M?[[Q7-<X,`9\]L1@324?8&9G?8P3AL9'E.,S!$)$NVYJL@^C7^K73I`-L
M'[#-IR<$X;&/E>7#$.@CW\]F))Q%L$5RW$PSLAFS2<?:EF`+3K>$\-C2>ASF
M8(AAC6PC'6$;6=UC!.&Q$6+WCT&&3HC=0!UB6\&WW.1.1MBR8C7,P2`C*_:.
MZ1#;RN8>*PA;5NP>,LC_6ND0VPJ!M\PP+7C\1W#OG8,.G[),66U[T,H@UA]"
M27MGKELLW"RC<#%HLM$A0_`8G%PM35MV[/9NF5&2K-9+>N8F2W@Z3K=CSM+A
MJ4?LEB*&6>A<S,-@8]4T:0&=OG%J8`EW>$':2HW5O`=B&'/TA0&Q*IGT_]^D
MY:XCF-R>P:'=WRTSK%)H-WC/W-BYZR3&(<?*3&CW>,L8.T==*\LQ#G0H,ZB3
M&;O,%%$Q<6()*TOII/R"8Q0!E?YN/Q>V`UO_!TQ8#3VQ3U2<BEHZ)<OAT<!;
M03!A9C1SH7BC9Y0C5S!;Z9]G&,`9O/,##^"<<]5=8+KZD7[_$P``__\#`%!+
M`P04``8`"````"$`>3V(])$%```J%P``&0```'AL+W=O<FMS:&5E=',O<VAE
M970Q-BYX;6R<6%MO\D80?:_4_V#Y/8!OW`1\BK&W_:16JJI>GAVS@!6,D>V$
M?/^^LYX%9F=I@.2!P/&98<[LY2P[^_91[IQW63=%M9^[7F_@.G*?5ZMBOYF[
M?_\EGL:NT[39?I7MJKV<NS]DXWY;_/S3[%C5K\U6RM:!#/MF[F[;]C#M]YM\
M*\NLZ54'N8<GZZHNLQ8^UIM^<ZAEMNJ"REW?'PR&_3(K]BYFF-;WY*C6ZR*7
M296_E7+?8I):[K(6ZF^VQ:$Y92OS>]*56?WZ=GC*J_(`*5Z*7='^Z)*Z3IE/
MOV_V59V][$#WAQ=F^2EW]\%*7Q9Y7375NNU!NCX6:FN>]"=]R+28K0I0H-KN
MU'(]=Y^]J?!#M[^8=0WZIY#'AKQWFFUU_*4N5K\5>PG=AG%2(_!25:^*^GVE
M(`CN6]&B&X$_:F<EU]G;KOVS.OXJB\VVA>&.0)$2-EW]2&230T<A3<^/5*:\
MVD$!\.J4A9H:T)'LH_M_+%;M=NX&PUXT&@0>T)T7V;2B4"E=)W]KVJK\%TF>
M3H5)?)TD@.KU\Z@7^M%H_$B64&>![SUE\1\N9:B3P/]+$G\<>='PMJ`^-J?K
M=9*UV6)65T<')C#(;PZ96@[>%#*?FHPM.;?]_[H.[59)GE66N0OQT-`&ILK[
MPO>#6?\=AC?7G!@Y\$HXH<E97N-$)B>QO\LS&>F)H>:$*D^<TJKI!KK/XF%T
MJ?CK,^ND49&5QE/6&`'(300-S5*6US@CDY-<X9B,U&:$8Y,B;(I_:9PA&J8R
M%:U&/(#%^;EX%31WX4N(5E9"C)S@W*`E`N-N/H310/V952<\).6`(("A`I84
M5?%Y]8K,JY^8I<3((=4C$&+UP;7J>4C*`4$`HWK8"&CU]XV!"F(J`M;0&#E8
M='"MY4MD7'0F'$@Y(`A@J(#U_K@*%<15L`4<(^=2XY(#"0*H<^Q9$RNEST<C
MZ[D@"0U)HZ](4D&FI"'?_)!"%'$@00`5>=$5208AF-B:2$I#DSH0L2W^]H)7
M0:8F/_#9DD$.$<6!!`$M:A3:1:<\1!@AT61,=1JR)E^1I8*X+#Y6R"&R.)!P
M(.6`((!1M`<[[>.#T47QLIEWQII$ZM:(;K\?L<TBL2)2"Q$4,94H4WUX6GEH
MQ8:1!!>CZNPZUB2J!,,N2&)Q4@L1%#%K5VY):O_</3ST5K-F9O2Q)ETJ7%I(
MHA$<CRCTKRQR*TA0Q!2AK)&(N,]$/#144PP[D<2:1,40'^X&*=$<%#,<C8:3
M"3L0I%8:01%3C')*(N;&B*"O&B)\OCMYQ'R[DI<6DEA(:B&"(F;-RA?OKQE=
MU*@Y8!V+U>\;V)]HXQ&)\!@2!AX+2:R0U$($14P)R@>)A#OG$+JG*86?ISQB
ML;K]B`R#3LN@-V!K*+%"4@L1%#&E*/M[7`J:IB$E9/MD[!%GU5(0T3LKM2B]
M.'A$:N40%#&5*`LD2FZL!31,4P$_4'G<9I<:T8,QZ4V4-U_^@O2)K:?$RI%:
MB*"(J4D9(M&D)EH(4_N&-K114QNK*_:(U^K1.2'DUTK(7#ZQPE(+$10QY/C,
MQC^7T;&9?8?<OC6)+'T+232"TTZ=C-A,3:T001%3PI?\V[_BWR'W;TVB4BS_
MUIQ/I/`00=.:4F""\,EU^X3KJR@V*M815Y.H%`R[((GFZ,W@ZBG72B,H8HIA
MMGYC:EVS<[:OQCXW[Z6%)!I!$=?/)E:0H(@I@MGY?;X"MXG6B(26&,O6=1@=
M$>3@S4,P','-K;52>!IUEWGV7A2#5Y-X75;*>B.7<K=KG+QZ4]>./MC8&3U?
MB3[[ZOZ#X8DWA4LI=?MT?@`WE8=L(W_/ZDVQ;YR=7$/*06\$>V*-=YWXH:T.
MW27=2]7"'67W=@MWTA*NM08](*^KJCU]4%]PON5>_`<``/__`P!02P,$%``&
M``@````A`()C:<X``P``.P@``!D```!X;"]W;W)K<VAE971S+W-H965T,30N
M>&ULE%5=;YLP%'V?M/]@^;U\?R112-66=*NT2=.TCV<'3+`*&-E.T_[[7>-`
M(71;DP<,-\?'Y]QK7Z^OG^L*/5$A&6\2[%H.1K3)>,Z:?8)__KB_6F`D%6ER
M4O&&)OB%2GR]^?AA?>3B49:4*@0,C4QPJ52[LFV9E;0FTN(M;>"?@HN:*/@4
M>UNV@I*\FU17MN<XD5T3UF##L!+OX>!%P3*:\NQ0TT89$D$KHD"_+%DK>[8Z
M>P]=3<3CH;W*>-T"Q8Y53+UTI!C5V>IAWW!!=A7X?G8#DO7<W<>,OF:9X)(7
MR@(ZVPB=>U[:2QN8-NN<@0.==B1HD>`;=[4-L;U9=_GYQ>A1CMZ1+/GQDV#Y
M%]902#:421=@Q_FCAC[D.@23[=GL^ZX`WP3*:4$.E?K.CY\IVY<*JAV"(>UK
ME;^D5&:04*"QO$Y&QBL0`$]4,[TS("'DN1N/+%=E@OW("F/'=P&.=E2J>Z8I
M,<H.4O'ZMP&Y6M1`XIU(8#R1N)$5>&&\N(3%/['`V+/X5NPZ2S]^OY3@1`)C
M3^)=[`>6ZY("XRN)MPC=,/I_5FR3X:Y@*5%DLQ;\B.`00`YE2_21<E?`W%?*
MY'6HW=]*!^G6)#>:)<$11E`5"=OM:>.YWMI^@CV2G3"W!@//$<:?8NYZC*ZC
M)D[/`]M1P`8+@P^H\MC'VSNMEZO!6FZ_S*T)3+2=*7L#$4XAZ1P2+*:0[1SB
MN<&`F1B"#3<VI`OCPT'\MS$]*<&PRBC'9S)O#6;15>G*]\.%$SN.,XCH\GXW
M!;FAY\]!J0'Y0QJWH\#$"^S[R[WH2>=>HJG,6X,).B_N,O#!R,R*P;RJ3,\#
MVU%@(AO.P^6R]:1SV?&9;(,Q)0CA%\U5CR&Q%\7A#)*.(6$<O`&!'J_%F(5B
MSUM,BFB\FB9N>D)-Q9[>T:J2*.,'W:!=2.T0'>Z.&Z]K_\,?T+M;LJ=?B=BS
M1J**%C#5L72'%*;[FP_%VZ[C[+B"KMV]EG!)4SCIC@7@@G/5?^C[9;CV-W\`
M``#__P,`4$L#!!0`!@`(````(0!99+[*!`0``$0/```8````>&PO=V]R:W-H
M965T<R]S:&5E=#4N>&ULG%?;CJ,X$'U?:?\!\3XA=JY$(:/N:?7L2#O2:+0[
M\TR#DU@-&&&GT_WW6V43@@U)R+Y$H2C7\:G+,5Y_?L\S[XU5DHLB\LEH['NL
M2$3*BUWD__O/\Z>E[TD5%VF<B8)%_@>3_N?-GW^LCZ)ZE7O&E`<1"AGY>Z7*
M51#(9,_R6(Y$R0IXLQ55'BMXK':!+"L6IWI1G@5T/)X'><P+WT1854-BB.V6
M)^Q))(><%<H$J5@6*]B_W/-2GJ+ER9!P>5R]'LI/B<A+"/'",ZX^=%#?RY/5
MMUTAJO@E`][O9!HGI]CZH1,^YTDEI-BJ$80+S$:[G,,@#"#29IUR8(!I]RJV
MC?P'LGJDH1]LUCI!OS@[RM9_3^[%\6O%T[]YP2#;4">LP(L0K^CZ+443+`XZ
MJY]U!7Y47LJV\2%3/\7Q+\9W>P7EG@$C)+9*/YZ83""C$&9$9Q@I$1EL`'Z]
MG&-K0$;B]\BG`,Q3M8_\R7PT6XPG!-R]%R;5,\>0OI<<I!+Y;^-$]*9,++VU
MIUC%FW4ECA[4&[QE&6/WD!4$[M\+;`)]']`Y\N>^!S`2$OBV6<S7P1MP3FJ7
M1^,"OXT+:3P"P&R``6PX,#HC,"8%=_)H#&T8V@\SN0<&G2-_T=K\8M&$-<#&
M9:)SVJ8SO0<'G2'A$*O)TF+I`-4^T&5GG[#QL5()U1^>2G36V$TN:XOIDS8G
M*'0[+O8KG>CFO-$GN-#&J"WM@BW'_6P@_6W4ZQV)SC92;>FR01EM=;IF,YN-
M%D#_.@8NM#%JB\7F0IN'-NIU)'2VD6I+EPV!QG#I$#(;W62C%]H@)Y/%Y\(\
M$7!JXUXGI+T=,`P`IAY*CB3H"LU1"V\4B-1JH*?2C.G)9%&:]#<<SF&;$N).
MQ^$(>O8&.R,&L+Z9)1U+LSN/[7)Z`?<NS2"-:)S!:A/MJ!$>*_^/$BYT"E:;
MK%3.+E!R).-&_KHZ01JA`):6R!%'%TR5E@/F5Z]T.#4JT2K3^2BS@1WAN,&I
MJQ:DD8L.)T<=AFL2Z4K%R635Z7Q\69RHHQ[7.6EO.X$G4W>**<ZWH[-D$0X8
M8[W2@<%@8+(XG4]*FY,C'S<X=36#UB;S%=<^"*FC$#="=V5!!P`>[=-\>>$T
MIW?)@O9VDE;+0D]M>F2!S"8#9@A%V-&%DZE=F_#"F4[OT@7M[7"J=:$K=;17
M%P:HMU[HH/3(0GCA8*=WR8+V=L`NR@)<0KHC1)=#1J@K"SH8(%ME<@]W<V<Q
M%X.<53OVA669]!)QP/L(A4_]QMK<E1YT+5S[=/5@[E!!\P;N,&6\8]_C:L<+
MZ65L"S''NNDJ<PLR#TJ4L$^XR0@%MQ?]=P^W50;?^V/\KMD*H4X/J*3-_7?S
M'P```/__`P!02P,$%``&``@````A`$]C.4[&`@``NP<``!@```!X;"]W;W)K
M<VAE971S+W-H965T-BYX;6R45=MNHS`0?5]I_\'R>S&06T$A5;I5=RMMI=5J
M+\^.,6`5,+*=IOW['=N$AC9;T9<0AN-S9LX,P_KJJ:G1(U=:R#;#41!BQ%LF
M<]&6&?[]Z_;B$B-M:)O36K8\P\]<XZO-YT_K@U0/NN+<(&!H=88K8[J4$,TJ
MWE`=R(ZW\*20JJ$&;E5)=*<XS=VAIB9Q&"Y)0T6+/4.JIG#(HA",WTBV;WAK
M/(GB-360OZY$IX]L#9M"UU#UL.\NF&PZH-B)6IAG1XI1P]*[LI6*[FJH^RF:
M4W;D=C=OZ!O!E-2R,`'0$9_HVYH3DA!@VJQS`158VY'B18:W47H=A9ALULZ@
M/X(?],E_I"MY^*I$_EVT'-R&/MD.[*1\L-"[W(;@,'ES^M9UX(=".2_HOC8_
MY>$;%V5EH-T+J,@6EN;/-UPS<!1H@GAAF9BL(0'X18VPHP&.T"=W/8C<5!F.
MDV`>+U:7$>#1CFMS*RPG1FROC6S^>E34<WF6N&>!:\\R6P:+53B;0$)\1J[`
M&VKH9JWD`<'4@*3NJ)W!*`7B\Q5!*1:[M>`,+S&"7#6TX7&3S-;D$9QC/>3:
M0^!W@$0#@H#F(`QBTX4MV`I;:VTFUSYP*A.?EYE]1,:",[PZ27ZU&FB]L(?,
MW+B<EC/_B(X%@^'`-;B4S%\)]9C0V?R?XF!VIGMHP4YT,+&/P.OPDL9B2&/4
M+>CY="4+'BOUD9'2\KP2N#]=R8+'2GW$O3FC"NPN/AET^PK/%JM@!2:\/_3V
MX%BCCYQ.7_(R)R/5Y(PJQ-Y7M(?&BGUDI'AYWC_8@Z-"WY=RZ+'6,3022UZ)
M^57I-TG#5<F_\+K6B,F]78,Q#.T0'5;T-K9OS>OX/-WZU4V&)[`Z.UKR>ZI*
MT6I4\P(X0]<JY9>OOS&R@]1A?TH#.]/]K>`CR6%!A`'TM9#2'&]`F0R?W<T_
M````__\#`%!+`P04``8`"````"$`_#@/D-0+``!U00``&````'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;*R<6V_C.!*%WQ?8_V#X?>)(MG,QDAZT+5ZQ"RP6
M>WEV.TIB=&P%MOOV[Z<HDJ:*1]L=9>>EDWPLEEV'%'5$27WW^_?=R^AK?3AN
MF_W]N+BX'(_J_:9YV.Z?[L?__I?\[68\.I[6^X?U2[.O[\<_ZN/X]P]__<O=
MM^;P^?A<UZ<19=@?[\?/I]/K8C(Y;I[KW?IXT;S6>VIY;`Z[]8G^/#Q-CJ^'
M>OW0=MJ]3,K+RZO);KW=CWV&Q>$M.9K'Q^VFKIK-EUV]/_DDA_IE?:+O?WS>
MOAYCMMWF+>EVZ\/G+Z^_;9K=*Z7XM'W9GGZT2<>CW69AGO;-8?WIA>K^7LS6
MFYB[_0/2[[:;0W-L'D\7E&[BORC6?#NYG5"F#W</6ZK`R3XZU(_WXX_%PLYG
MX\F'NU:@_VSK;\?.[Z/C<_--';8/?]ON:U*;QLF-P*>F^>Q"S8-#U'D"O64[
M`O\XC![JQ_67E],_FV^ZWCX]GVBXYU21*VSQ\*.JCQM2E-)<E'.7:=.\T!>@
M?T>[K9L:I,CZ^_VXI`_>/IR>[\?3JXOY]>6TH/#1I_IXDEN7<CS:?#F>FMU_
M?5`14ODDTY!D=DY27%\4L\LKE^,G_:BU_7#Z&3Z\+"[*FWDQ_U7/J]"3IG'H
M^;9/O`W]Z.?`3RQH:-HOZWYYRV=.O-+MP%7KT_K#W:'Y-J*C@;0\OJ[=L54L
M7+(X9%ZH\R#^KS&DP7-9/KHT]V,2@H;G2!/OZX?B\O)N\I4FRR;$+'MB>,0J
M1KB9X=)6.1`YD#E0.=`Y,#FP'3`A6<[:T#3\,[1Q:9PVL:IE!$FL,A,B1L0N
M50Y$#F0.5`YT#DP.;`<P(>B08D+T'\]Q+KCH^_%U9RY<7_/ZECZDO#UKL@)2
M`1%`)!`%1`,Q0&R7L,II$1E0N8NF`XFR=0Z#(JO=!TWI6.L$Y1/@''2>`4`$
M$`E$`=%`#!#;)4P.6AL'R.&B6SEB$4M/J/9(5D`J(`*(!**`:"`&B.T25BBM
M9`,*==&\4$^R09[RF;`Z!T4U*B`"B`2B@&@@!HCM$E8[';D#:G?1O'9/IOZL
M[);Q%9`*B``B@2@@&H@!8KN$%>IL9W[N*^<7-"D&GOU<(JZ!)Z1!]R"?9>-_
M#CJ//Q`!1`)10#00`\1V"9.%[`B3Y>>KO8OFM7O2/<B!5$`$$`E$`=%`#!#;
M):Q0YW<&5-J&\U(#RH[S>3;.*>H\T(@$(HE((=*(#"++$)?!^9_N<?#S`2^\
M7:*S7*QF&5#WD$=4(1*()"*%2",RB"Q#O&9G=;HU.]_[KF._\*:)R>%1=O1?
MY;/B'!5UK$*NCHX"D42D$&E$!I%EB"OD/%%7H5_,"F^AF`P>3<OS1%DY:T2K
M10=5B`0BB4@ATH@,(LL0K]D9GP$U>Y]$^>((+HNS=>HN_)G]7:6HV+%")!!)
M1`J11F0068:X#,X6#9#!NR@F0]=8M9=R*[</X(8^>;\*D4`D$2E$&I%!9!GB
M-3L[U*WY_0N"-U9,CN"UN!VXR1>$<U2:%8!$`4@B4H@T(H/(,L05<CZJJ]`O
M%@1ONY@,P8FEXV55`*H0"402D4*D$1E$EB%>LS-)`VKVGHK5'&P6O]R[S8?^
M')6&'I`H`$E$"I%&9!!9AK@,SD(-D,$[+B9#,&&=BX("4(5(()*(%"*-R""R
M#+&:R]P<N@5A>N,V+H=>'K2IN'$,B%N$(MLQ6Z6H\[1`)!!)1`J11F0068:X
M1,.,8XG&,:".X5DAJA`)1!*10J01&426(5[SGV8<2S2.`66S(MM`6J6H-"O`
M2PJ,DH@4(HW((+(,<86&&<<2C6-`;%8$XYC6CPJC!"*)2"'2B`PBRQ"O>9AQ
M+-$X!I0-?;XMF*+2T`?'F901&"41*40:D4%D&>(R.(_W]O.$6TJSO8.`V-`'
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MM)FY1,-\ICN'9J>5@)R5[2P/^8Y<C.J<:1")B,KV8)K>S+)"9`Q(E[DJHI19
M(S(1Q<QE-H8V!K29N42]MO2JO5KYQ81"&TK;<TY`=Y[OJ)5O8H4HNGB.1W:%
M2$3DA_WJ.K\5+&-`=T*%KY0RZQB5D(DH9)[>@%HA3<^$&F91IVA1`Z(?L?@5
MH@J10"01*40:D4%D&>(S9)A%G:)%#<@=IYUID>]BI:BH3(5(()*(%"*-R""R
M#'$9AEG4*5K4@.A8C`6N$%6(!"*)2"'2B`PBRQ"OV1G,W'V\ZV;'U%O5K@,)
MR"U-G5F1;W"EJ"A:A4@@DH@4(HW((+(,<86<"^PJ](LUTYM&)H-'='#$`E=3
M0!4B@4@B4H@T(H/(,L1K=@9O0,W!#Z85;SGUB"\(9;Z)E:*B,A4B@4@B4H@T
M(H/(,L1E&.8YI^@Y`V(+@H_JH`JC!"*)2"'2B`PBRQ"K>3;,<[;AW',&Q(_Z
M,M^I2E'GH4<D$$E$"I%&9!!9AK@,PWSE#'UE0"1#^\ACMJN?6E/Y/D=G8@B,
MDH@4(HW((+(,\?*=/WK[`C`+=JJS``3DSK9I[2_S3:L4E63PN:AC1`*C)"*%
M2",RB"Q#7(;<#+Y_HW^&1C&@[$#)+AE6*2KJ42$2B"0BA4@C,H@L0URB8=YQ
MAMXQH$R&;+-@E:*2##X7.V``2>RH$&E$!I%EB,N0>\?_8Z:@KYQYE$F47=2L
M4E22Z-PQ(H%1$I%"I!$91)8A+E%N-7]NI&;H)P.BJ[M8S0I1A4@@DH@4(HW(
M(+(,\9J'F<<9FL>`LJ'/MR=25%2F0B00240*D49D$%F&N`S#_.0,_61`V>DD
MWW=(44F&8$2[IQ-`$CLJ1!J10609XC+D?M(M$N^ZV)JAU0PHFRCY)7B*2@J!
M(148)1$I1!J106098@K-<_?I%)J3,1KXU&V;A]O2@#)]\HO1%'76!Y%`)!$I
M1!J10609XOH,LZ5.N6R[,R"2(1:X0E0A$H@D(H5((S*(+$.\YF%>=(Y>-"`^
M]-/\8C1%164J1`*11*00:40&D66(RY![T9^?/N?H-P/B:^@TOS!+44D&GZMK
MR3%*(E*(-"*#R#+$9<C]YGM7"#2B]/JC.UJR:9)?LJ2HI,^Y8T0"HR0BA4@C
M,HC<FYKAJ](G>GW\FY?^!;Y=?7BJ5_7+RW&T:;ZXMRKG5W09>L;^E<_EO*1W
M/ELS!2U3:FFOYJ!E%M\3S5MF5POGA.@+0<LUM;3;\]!R0RTWO7UNJ:7=GL_[
MS"_I&[1[:=#BWF%M%[:\949]Z&*_[[M1'[H.[FLA=>C2L*^%U*$KHKX64H<N
M$OI:YM32WAW-O]N4^OA#"UJH#VW=]F2;DM:T9=G70EK3QEY?"VE->UU]+:0U
M[0CUM)2D#CWPU-="ZM"#/GTMI`X]#M/70I72G:.^%JK4W[,'#2@;W;GHZ5-0
M'W^_.>]3D#KTL&I?'U+'WY6"/J0./>78UX?4H6<!>UI*FE5TW["GA;KT]BBH
M![UMT=.C(*7IG82^%E*:GL7O:R%M_$8S5$-*TT/<V(=>\_[8GXLZ],0OW3#W
M<3<L/?SC;/&1%B?\X*4[,OHXC6+O%*<Q[!U"&L'>Z4WCUSM\Y=5B24]?X#>B
M)VD6J]X6>J!FX1YQP3[T,`FU]&6CYU](J;X6>L1BX9ZBP&STB`1E:ULFYQ&D
ME]Y?UT_UW]>'I^W^.'JI'VGYOFP?ECGXU^;]'Z?FM7UHYE-SHM?=VU^?Z;\W
MJ.FENDOWGMICTYSB'_31D_-_F/#A#P```/__`P!02P,$%``&``@````A`/<)
MV>K5`@``V@<``!D```!X;"]W;W)K<VAE971S+W-H965T,34N>&ULE%5=;YLP
M%'V?M/]@^;T0(`E)%%(U5-TJ;=(T[>/9`0-6`2/;:=I_OVL[(9AT5?J28-_C
M<\\]OES6MR]-C9ZID(RW"0Z\"4:TS7C.VC+!OW\]W"PPDHJT.:EY2Q/\2B6^
MW7S^M#YP\20K2A4"AE8FN%*J6_F^S"K:$.GQCK80*;AHB(*E*'W9"4IR<ZBI
M_7`RF?L-82VV#"MQ#0<O"I;1>Y[M&]HJ2R)H313HEQ7KY(FMR:ZA:XAXVG<W
M&6\ZH-BQFJE70XI1DZT>RY8+LJNA[I=@2K(3MUE<T#<L$USR0GE`YUNAES4O
M_:4/3)MUSJ`";3L2M$CP7;!*%]C?K(T_?Q@]R,$SDA4_?!$L_\9:"F;#->D+
MV''^I*&/N=Z"P_[%Z0=S`3\$RFE!]K7ZR0]?*2LK!;<]@X)T7:O\]9[*#`P%
M&B^<:::,UR``?E'#=&>`(>3%_!]8KJH$1W-O%D^B`.!H1Z5Z8)H2HVPO%6_^
M6E!PI+(DX9$D`O7'>'@MB6\%F?KNB2*;M>`'!#T#*65'=`<&*R`^%69E]*7^
MKU(H49/<:1;#!45(N)WG31@LUOXS6)H=,5N+F6/48P(7D9X0^B9`7J\1"A]K
MC.`*WS;_)$D?&DF:NOFV;T!<1'J)F)[+<C2"=T.-[VO3X`0#>6]%&"S=U%N+
MB4P':(_3P8:3>?J1S!H\RAQ.1IDM9FJN,0Z7D1M.W7!\#CNJH*VO]T.#QZI&
MS;&UF($?@PTG,W38]9DU>)QY[(?%6#^BQ?1<L.G]U`V'L]XN1U7\$54:/%85
M]KPF[=9B!GX,-IS,^A,T>,/?[TP-'F<>^V$QUH]Y',>N,!C#FN(8CA9C/^R,
MM3.HH:*D*:UKB3*^U_,S@*[K=^UHW\)H-X/0[P,P6CM2TN]$E*R5J*8%')UX
M,;2$L,/9+A3OS`C8<05#U3Q6\`VE\#I-/``7G*O30@^=_JN\^0<``/__`P!0
M2P,$%``&``@````A`,^X.)U4`P``U`H``!@```!X;"]W;W)K<VAE971S+W-H
M965T."YX;6R45MN.VC`0?:_4?XC\O@03((`(*[:K;5=JI:KJY=DD#K$VB2/;
M++M_W[&=A-Q8X`7(,#YGSLQX,NO[MRQU7JF0C.<!PJ,Q<F@>\HCE^P#]^?UT
MMT".5"2/2,IS&J!W*M']YO.G]9&+%YE0JAQ`R&6`$J6*E>O*,*$9D2->T!S^
MB;G(B()'L7=E(2B)S*$L=2?C\=S-",N115B):S!X'+.0/O+PD-%<61!!4Z(@
M?IFP0E9H67@-7$;$RZ&X"WE6`,2.I4R]&U#D9.'J>9]S078IZ'[#4Q)6V.:A
M!Y^Q4'#)8S4".-<&VM>\=)<N(&W6$0,%.NV.H'&`MGCU@!?(W:Q-@OXR>I2-
MWXY,^/&K8-%WEE/(-M1)5V#'^8MV?8ZT"0Z[O=-/I@(_A1/1F!Q2]8L?OU&V
M3Q24>P:*M+!5]/Y(90@9!9C19*:10IY"`/#I9$RW!F2$O`5H`L0L4DF`O/EH
MYH\]#.[.CDKUQ#0D<L*#5#S[9YVP"<IBF=`>B2*;M>!'!^H-WK(@NGOP"H"K
MF"Q"'>6Y("$Z#;+5*`&:(P?X)63V=8,];^V^0C;"TN?!^L#GR:?V<"&:.B0(
MHQG2<'HJ9NVLF76Z="@/UM"DF0S3>+?0:.<`^8W@?;^&M<36Q3/9;LJ9WL*C
MG:$4@'7*DC?M,)5.\-5PFM5.K61"9UR?3.ULV.MLEA;;0TU54.LFKNX;W]=]
M>Z:=JWKI<VV*TM*L&/;FPVJ@`$W6CUM#.[>I2DM?C1ZQO5O@C?R+<O3!-D=I
M:<LY]4JK.,LV[<=RM'.;JK3TY6"833T]_O**\IB3;9;*U%:T&"X0!J\F\\>2
MC'>'30.`:4!49R[HEEN"T`L4Y3PP]])>5%R:VH*69P3=-";TQ>T4J3(-".I,
M!C-[)XMKJE2/B?JBXM+4$C4=GQ&EKW6CWR^DL!P"S126IDEOVN&!P>#AY>CB
M33('.[TP-!JF^(RFFV8#[@^'RC10J*'Q@&=7:.J/!U@PROYN#.]I]Q5E=PC[
MHLZHV-,O-$VE$_*#W@\F\(:MK?7NLC7%Z-JGJZW=:=SZ']@I"K*G/XC8LUPZ
M*8T!<VR&G;!;B7U0O(!ZP&;!%6P3YF<"VR.%M^Q8:X\Y5]4#]*%;[Z.;_P``
M`/__`P!02P,$%``&``@````A`,2`O,*J`@``W@8``!D```!X;"]W;W)K<VAE
M971S+W-H965T,3`N>&ULE%7+;MLP$+P7Z#\0O$>TY%<L6`Z<!FD#M$!1]'&F
M*4HB(HH"2<?)WW=)RHH4!XEST8,:SNSL+E?KJT=9HP>NC5!-AN-H@A%OF,I%
M4V;XS^_;BTN,C*5-3FO5\`P_<8.O-I\_K0]*WYN*<XN`H3$9KJQM4T(,J[BD
M)E(M;^!+H;2D%EYU24RK.<W])EF39#)9$$E%@P-#JL_A4$4A&+]1;"]Y8P.)
MYC6U$+^I1&N.;)*=0R>IOM^W%TS)%BAVHA;VR9-B)%EZ5S9*TUT-OA_C&65'
M;O]R0B\%T\JHPD9`1T*@IYY79$6`:;/.!3AP:4>:%QG>QNGU)2:;M<_/7\$/
M9O",3*4.7[7(OXN&0[*A3*X`.Z7N'?0N=TNPF9SLOO4%^*E1S@NZK^TO=?C&
M15E9J/8<##E?:?YTPPV#A`)-E,P=$U,U!`!7)(7K#$@(??3W@\AME>%I$L6S
MR0+0:,>-O16.$2.V-U;)?P$3=TR!(^DXX'[D6$3SY60:OT]"0CS>W@VU=+/6
MZH"@94#2M-0U8)P"\>M^P(C#;ATXPPN,(%8#-7C8Q*MD31X@<:S#7`<,7)\Q
M/8*`:*\,:N<K.[!3=IEUH5R'A:',<R`CF>E'9!PXP\M!\,ME'WT0#I"I[Y:A
MG=E'=!P8,@Y<SUE:35\H=2#HU0%HUH-&+J&+SD^F`WOU/IO=2C@#0U=0ZR%O
M:/MIM(0-;[>*VSC6Z%:&)8M7\]?M0`6&LF]+.?!8JEOQQV>4)C>-!]WN[2Q7
M[LB^8\=M'&MT*V,[BQ=VPCP)!TYR7?(OO*X-8FKO9D4"1ZA?[<?8-G&]]7)]
MEF[]>"/]!Q@O+2WY#ZI+T1A4\P(H)[XT.@RH\&)5"Y'#E%$6)HM_K.`_PN$4
M32(P7BAECR\@3/H_T^8_````__\#`%!+`P04``8`"````"$`['UC>@0+``#1
M,```&0```'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6RLFUMOX[H1Q]\+]#L8
M?C^V*4N^"$D.8MWE"XKBM'WV.DIB;&P%MO?V[3L4.2(YHTWBM"^;Y*?AG^1P
M2`XI[<V?/P\OO>_5Z;ROC[=],1CU>]5Q5S_LCT^W_7_]E?XQZ_?.E^WQ8?M2
M'ZO;_J_JW/_S[N]_N_E1G[Z>GZOJT@.%X_FV_WRYO(;#X7GW7!VVYT']6AWA
MR6-].FPO\.?I:7A^/57;AZ;0X67HC4:3X6&[/_:50GCZB$;]^+C?57&]^W:H
MCA<E<JI>MA=H__EY_WI&M</N(W*'[>GKM]<_=O7A%22^[%_VEU^-:+]WV(7%
MT[$^;;^\0+]_"G^[0^WF#R9_V.].];E^O`Q`;J@:ROL\'\Z'H'1W\["''DBW
M]T[5XVW_7H2;L>@/[VX:!_U[7_TX6[_WSL_UC^RT?UCMCQ5X&\9)CL"7NOXJ
M38L'B:#PD)5.FQ'XQZGW4#UNO[U<_EG_R*O]T_,%ACN`'LF.A0^_XNJ\`X^"
MS,`+I-*N?H$&P+^]PUZ&!GAD^_.V[T'%^X?+\VU_/!D$T]%8@'GO2W6^I'LI
MV>_MOITO]>$_RJCI42OB:Q'XJ47$8!8$_F0V_;@(6#8M@9\H(@;>+!#!Y(JF
M3+0*_-0JWM7=@;G1M`1^8DNN[\Y<B\!/%/$&PA]=TQD!X="T1/[RZ>Z(,:K`
M+UK%'_A>,)U]8)"'*F":^(NWE^W=S:G^T8-)#2%Q?MW*)4*$`D8>(T_%21N+
MOPM%B$&I<B]E;OLP7!!E9Y@_W^^\T>QF^!UB?J=M%MQ&N!816L@`E[(Q!0D%
M*049!3D%!04E!4L*5A2L*=A88`BN;?T+,_+_X5\I(_V+GED@L!Q.G(D66"2F
M(*$@I2"C(*>@H*"D8$G!BH(U!1L+.,Z$R'><V;T\8DQ*Z]O^U(G)B>NDA;+Q
MYJUC(T9B1A)&4D8R1G)&"D9*1I:,K!A9,[*QB>-"F.)7N%!:P\H`:M:\GA,?
M*B.]+\EI&S$2:V(O$&(R<H62U@A#-F4D8R1GI&"DU*39.AUWP#9UA3ND=>,.
M;.!"$;OOC,2*^.-F6?2]T=PG_6X-4#9E)&,D9Z1@I%1$-<_I-PR$TV^U[`_D
M1G]YWN^^+FJ5+G3,,-D/M>A+$=<=BMCN8"36Q)Z70E"7M$:M2QC)&,D9*1@I
M->&A``WZWUTB15R7:**RMF9V,!(KXLWTQBD"$B#M\]8;3"-C)&]+J>V8^KAH
MGZ-J:6LXX2+/&7:6T!$6,.@8%]+:=8(FGEEF&8D921A)&<D8R1DI&"EMXG04
M\KPK.BJMW8YJ`D'6+I@!6>8B;3-MG1&WQ)02$Y(<)<IH+-W\_6XV(CM9JC7,
M3I:UJCB^>4O>J*?0]4R:>H0W\=Q@+.V*'-_)]-9QWJ<6E4;%=:I&'N@;KQ+W
M1&BDSC0J>Y0-@J.0\72BK<9JJHFI3Z9:BC+C=G0R1$8Y1QFC7"!"Y=&4^`UE
M&F77<3)YM*>7=)P'D_'C2[%0^2?LU#C8"XT\V/M:KPDZFA$6-#V)-1K#0%L%
MB;\3;>6/U*(5!,0@164K(A&9RO(/55:0RN83DH.4J-Q4YCI7)I/4N2(P6]U?
M]2N$V[L'')63.@Y6R#-Q$0F&8HX2CE*.,HYRC@J.2@>YOI!I(?6%-Y%W"M?$
MFDHN'5<HY(,;K9`9NS,@DGFD7"_-\,<:O1=K6MYK8FTT&)'A3U'9CC566?ZA
MR@IMY6-E@G2C="IS_2OS3.I?`3<QVKT8:E?,:Y6YRBI;QWJ"["@+>7`'Q_I^
M._LCCF)$[KPF^TABK'`E23G*.,HY*C@J$35-=9TGDU7;>6\G&?)ZC&R^&@7-
M75N3HD8<Q8C4^'K$EXEY;/JOJ@K,XIJAE4$YHF[=PCQ&W1*1NANT;PV$S%)M
M7WQN*U6Y+@0/5KEHA&_[CHN4E85B;>7/50Y`]LC$/$;=E.MF'.6FH,QA6$)J
M'J-NZ8BXX2*35=M%[X2+SFUM7VAD)VMB0K;M"%8KMF@QE&@KG9V)`9E5*:JX
M<X_<D&5H91;(G*/"K8NF9UC@=S6Y3I2)\!5.U'FS[42%G-Q,T.TY$MK*;)4Q
M1XE&ODH]R<1,L8"]%(H)<R&K*<>"IO+BS9I*+/"[FEP7@J.O<:$T)^FM1DX<
M3DGW(Z&M3&S$'"4:Z3B<BP$)YQ3+@%J[H71XD5668T%3?^%6)D;^@.2`)1;Z
M76V.)V4,7>')QMSUI$9N,$Y)HR*T,O$0<Y1HY$^;-7!"NY9B$3,7,D1&..>H
M0&%U4"`+18D%&EG7/?24\/:"!VFI#C0ST)X@OEAH*SMSX"CF*$%D[C521"8+
MR3C*.2H0&:T2D=%:<K32*'#2SBFY2UH;*]Q6-HZ6ZV5Z7'C'R_Q8X"GDN)2A
MF%LEB(P;4D3&#1E'.4<%(J-5(C):2XY6&A&7D@Q@;:R,2^T^NBZ5F?C'-QE/
MFI-YK9#C4H9B7="R2A`9-Z2(C!LRCG*-B!M(9!7&"MU0<JTE1RM3T$Q.,25K
MP=I8H?S&T7*]3,\>[P1N>[!`[86\*2"G"(YBCA)$MI>95H96QO&Y1L3+)-@*
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MIK(E(E/9BJ.UJSP=S$D$;+`,O^:$ET=7C8<Z)CD30:'`'0^R&$=-/3!J)L>-
M.4HTTLES0`8UQ1(F&C)$1C<WZ,W14,W650DQ"(C32M0QM2T1F=I6'*TU"LR^
MMG&LW`D!D^N:"2'-29:C4."<`V<D*8C@6X6FH(FDF*-$(S@'6KZ;D:TOU58!
MS$1K"I*YDW'YW""K()\HJJGXRFI`9V6),O9$8=U;H97I\5HC6#MP5=@X5L[(
MC.FY\E-;1Z/B#IA&9,:073325O:,T<A^,85:$,UF*.9DRTS1"IQDK&9TP'B-
MN4%6039@V@KGTFA`;\-*U+'F$B)K+G&TULB>2XZ5.V+TJ/NY$6M/P!@D"_B&
MD^\Y<[*-1]K*WG,T@O<4J)5HI%^`3;TYV4]3E#%E,D0FE'.#WAP9U?!V*DW(
MNERBC*ELB<A4MN)HK5&K/";>D-^]-@M.HZR&27W'JKXC/%2GIRJJ7E[.O5W]
M37ZC"F%]=]-B_0&M)\)[4`+OT2?PH/DN@/`%?'+;9;_P0O@^C.LLQO");@>_
M]\-[M<V1"NX%/('K%BX%YY)0GCKX$SA2A/+`P)]`QA[*?)P_@60;U+J>0)X,
M:EU/(-\$M>9S/])J2!5!K>L)9'F@UO4$[MW#`F[2>=O@%40H[]CY$[A;`;6N
M`8`K`GC2-01P:H:V=0T"''BA3->3>!HF38#2?DY#^$"%MPO>8D%?ND9@`7V1
M[S=X&7@+%$:=3^!E4"C?^/`R\`X$GG2II5!&ON_@9>"M4"A?>_`G\'((6MU5
MS\(/%UTE(C^,NG@,W>_J?0P5=.G',/1=.J4?PJ=0T-)AZWCXH/QU^U2MMZ>G
M_?'<>ZD>83*/FA?E)_5)NOKCHE^8?ZDO\"DY;(GPU3#\UX$*OOP;R5>=CW5]
MP3]D!>U_1KC[+P```/__`P!02P,$%``&``@````A`([BK(Q@!```60\``!D`
M``!X;"]W;W)K<VAE971S+W-H965T,3(N>&ULK)==KZ,V$(;O*_4_(.XW!/*-
MDJR2$+[42M5JVUYSB).@`SC"SOGX]QUCFP.>;+5'[4T2'H8WS.OQV%Y_?:M*
MZX4TK*#UQG9'8]LB=4Y/17W9V']^#[\L;8OQK#YE):W)QGXGS/ZZ_?67]2MM
MGMF5$&Z!0LTV]I7SF^\X++^2*F,C>B,UW#G3ILHX7#87A]T:DIW:AZK2\<;C
MN5-E16U+!;_Y&0UZ/A<Y"6A^KTC-I4A#RHS#^[-K<6-:K<I_1J[*FN?[[4M.
MJQM(/!5EP=];4=NJ<C^YU+3)GDK(^\V=9KG6;B^0?%7D#67TS$<@Y\@7Q3FO
MG)4#2MOUJ8`,A.U60\X;>^?ZJ3NVG>VZ->BO@KRRWF^+7>EKU!2GWXJ:@-LP
M3F($GBA]%J')22!XV$%/A^T(_-%8)W+.[B7_1E]C4ERN'(9[!AF)Q/S3>T!8
M#HZ"S,B;":6<EO`"\&E5A2@-<"1[V]@>_'%QXM>-/9F/9HOQQ(5PZXDP'A9"
MTK;R.^.T^EL&N4I*BD!D*P+?2L1U1]YRYL[FGU!9*17X_KR*(_-J;0HRGFW7
M#7VUH/;@S=DM$Y7L^C`0EC9(IM-9]B/'P"JALA,R&WMN6V`&@V%^V7KCV=IY
M@:')5<P>Q[C#B(..$.,@9`,3'$T0FB`R06R"Q`1I#SA@2^<-#/K_X8V0$=[H
MK/8:],PRC-`1^I'`!$<3A":(3!";(#%!V@,#(R:&$8]GCZX%$;VQ%X-:F`\3
MW,L8;]69<D`D0.2(2(A(A$B,2()(VB>#U*>?2EU$PTP"M=X\6!BYRR#5;D29
M'Q`)%.E/*->=#(6.79`NDQ"1")$8D0215)&V(P[L@!;V8$J,%L#YM<B?]U1V
MPP<5,H&V()N%$&E=TN^]EZ1O"2*!(OVZ<MVI84D7I*5#1")$8D021%)%L"4P
M1O_=$B$RM$01N2BU58)(((FW5`W7-3KNL;O?N8$T(D3B[BG9QDV/D^Z^5DW[
M&H-R@<$:>/.@+&#0=5V(Z*$)BG@?;0*1`)$C(B$B$2(Q(@DB:9\,$A7[Q?XR
M^N^)BNAAHHJ`D5WC<,WA/*B@1>=&@,A1$5D2"V]E](Q0W?]HO!'2B!%)#-6%
MH9KV50>^P&;E$[Z(Z*$ODGBP,>GY8BPF!Q4D-UWMO@&1HR)>.U4FRZF10:CN
M3SIO(Z01(Y(8JIXQ`=.^ZL`7L=4:&"/V7=Y<;$)_L#?5DZ1]<FB20AYT[9Y+
MQK)ST`_VR@>CHT:R@.:+A2$3ZH!>!6GTH1QCE&BDE"=+TRP=T"I+M^2^7FY8
M*])<R(&4);-R>A=[=E>,9H>[`\6N;1<&WXN#AAA<DWL^;'L>\(D/FP+,=U-_
M!R^*;^RG/BQCF!^F_N$1#Z8^++PX/ICYL/I@GDY]6(,P#^8^]'G,X[D/G1JX
MTV4,!YM;=B&_9\VEJ)E5DC.8.&X7[T8>C>0%IS<P%XXWE,.1IOUYA2,L@:W*
M>`0%>J:4ZPOQ!]VA>/L/````__\#`%!+`P04``8`"````"$`L:E6*J02```^
M:0``&````'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;*R=VW+;NI*&[Z=JWL'E
M^RV+.MJJ.+MBDB!XK*FI/3/7CJTDJF5;+DM96>OM=X,`!'3_C&VZYB:./S0:
MY(\&B`8A^=,__WI\./MS^W+8[9^NSY/)]/QL^W2WO]\]?;\^_Y]_J7]<GI\=
MCK=/][</^Z?M]?G?V\/Y/S__YW]\^K5_^>/P8[L]GI&'I\/U^8_C\7ES<7&X
M^[%]O#U,]L_;)RKYMG]YO#W2KR_?+P[/+]O;^[[2X\/%;#I=73S>[I[.K8?-
MRWM\[+]]V]UML_W=S\?MT]$Z>=D^W![I^@\_=L\'[^WQ[CWN'F]?_OCY_(^[
M_>,SN?BZ>]@=_^Z=GI\]WFW*[T_[E]NO#W3??R6+VSOON_\%W#_N[E[VA_VW
MXX3<7=@+Q7N^NKBZ($^?/]WOZ`Z,[&<OVV_7YU^23;=.SB\^?^H%^M_=]M<A
M^O_9X<?^5_&RNV]V3UM2F_K)],#7_?X/8UK>&T25+Z"VZGO@OU[.[K??;G\^
M'/][_TMO=]]_'*F[EW1'YL8V]W]GV\,=*4IN)K.E\72W?Z`+H'_/'G<F-$B1
MV[^NSV?4\.[^^./Z?+Z:+-?3>4+F9U^WAZ/:&9?G9W<_#\?]X_]9H_Z.3D[F
MS@G]=$YFZ\GL<IDL5\;+*S47KB;]=#67D\5LN;[LFW^E(KGMKYM^^NN>3];)
M]&J^?KW%E:M(/UW%=;C?5QI<NWKT<^0]TE#K+Y5^CKO'*U>1?OI[7+U/UH3B
MJ&_3_&?4;28^()(0$>_MS,3'@?F/:S693Y+%]*TP2'P<F/^XFF^T>F$#N1\7
MV>WQ]O.GE_VO,YILZ`8.S[=FZDHVQIT?$;9O3V/D=T.$QH;Q\L6XN3ZG**'H
M/]"X_O-SLIA_NOB3QN*=L[D9L.$6J;<P`\^XS23()5`2%!)H"4H)*@EJ"1H)
M6@FZ"%R0M"=]*2[^/_0U;HR^7ID;#X+@,R&FM_!5,@ER"90$A01:@E*"2H):
M@D:"5H(N`DQ,&BA,S.%IV\>DL;X^IQGH%)/K-=?HQIK,KDZZID`R(#D0!:0`
MHH&40"H@-9`&2`NDBPE3D$;X"`6--4T,Y.TD8;)8"`VMT9P;+;E1>C(Z12.0
M'(@"4@#10$H@%9`:2`.D!=+%A,E*#]$1LAKK7E8OQHTE<[M.,#-?"B0#D@-1
M0`H@&D@)I`)2`VF`M$"ZF##!Z$DQ0C!CS06S9$7/ZR@R5R+H3D9>YPQ(#D0!
M*8!H("60"D@-I`'2`NEBPC2DF6V$AL:::VC)O%\Q]X_;%$@&)`>B@!1`-)`2
M2`6D!M(`:8%T,6&"F2Q.KG7FEV:E[Q;=[U[N&$]<3$MH!,<!*1XWZ<GH%)!`
M<B`*2`%$`RF!5$!J(`V0%D@7$Z8OK;R9OJ\_GHTUU]"2>!8$D@')@2@@!1`-
MI`12`:F!-$!:(%U,F&`FWV"*F=7WQR*R=\7E=$C$Y*68)(/5*2@1Y8@4H@*1
M1E0BJA#5B!I$+:*.(2ZW6:3'$\#K`6J2.Q&A#L4ABBA#E"-2B`I$&E&)J$)4
M(VH0M8@ZAKA^9ET>ZV?"=;:<C)\_3;HLI;5(1.N5C-:358A60+ES'W630E0@
MTHA*1!6B&E&#J$74,<35-HOX6.TWHM6N^6FQ[I6Y,0MW4CF2(464(<H1*40%
M(HVH1%0AJA$UB%I$'4-</[-:'Z&?7=R3OZ"?17R5N9S*D#Q9^8J9V4@AX:FB
M1SDBA:A`I!&5B"I$-:(&48NH8XA+:M;S(R2URW\FJ47QHM/LOYHH#6)EB')$
M"E&!2",J$56(:D0-HA91QQ#7SZSE8_T^/H':K(!):Q&?0)>)C-:3E0_-+`&4
M(U*("D0:48FH0E0C:A"UB#J&N-HF$8C5?F,"M7D#D]2E$K/3.$X30!FB')%"
M5"#2B$I$%:(:48.H1=0QQ/4S"_T1^MF\@.EGD9A`Y49E<K(*(0DH1RN%J$"D
M$96(*D0UH@91BZACB$MJ4H$1DMK,@4D:)Q,V:T\`98AR1`I1@4@C*A%5B&I$
M#:(64<<0TV\F$Z;7AW1OSI,BA\0L*5Y5I,'J%)*(<D0*48%((RH158AJ1`VB
M%E''$)=T7%(TPZ3(H56T>XDH0Y0C4H@*1!I1B:A"5"-J$+6(.H:X?B;]>/^0
MGMEL)1[2#HE94FRSI\$JA*3U%2\ST4HA*A!I1"6B"E&-J$'4(NH8XI*.RWQF
MF/DX%&<^B#)$.2*%J$"D$96(*D0UH@91BZACB.MGTH\X)#^\S)S91(9%JT5B
M`I7O>US%J`,R1#DBA:A`I!&5B"I$-:(&48NH8XBK/2XI,KO-8NO#H4BL%%&&
M*$>D$!6(-*(2486H1M0@:A%U#'']3/H11^L;SW2;K;"0M$A,H/)MT.QD%290
M0#E:*40%(HVH1%0AJA$UB%I$'4-<TG&9SPPS'X=82+K,)SSF,[3*$2E$!2*-
MJ$14(:H1-8A:1!U#7#^3?L0A^?$)U"8R+%HM$A.H?%4T.UF%:`64HY5"5"#2
MB$I$%:(:48.H1=0QQ-4>EQ31:0V80%T&%/;N4F=%QQ*"?F"5HY5"5"#2B$I$
M%:(:48.H1=0QQ/2CG3,>K:]/H+TY3XH<XF<XEO)-4;`Z28HH1Z00%8@THA)1
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MB3D*?_RQN_OC9D\]1Q//0(28V[$GGN<V=XA7=@Y%,J2(,H]H.1T")`%UK'M:
MHWHI5*CH48%((RH151X-!(C,'<S:=[PZF%+,'8J'#Z#,6=%JT1PBGTT3L;.0
M!P.O@D+/!2(=*CK/0O(R&'C/%7/#@\@LQN,@&@@6"H13M-BU.XL6A^(5`J!L
M#BA'I!`5B#2B$E'%$+_G<0OU.2[4/8HG1WBA[HU"Z&<!16-F)=YMYLZ*1K[I
MX<NIV`%0WDLX[EUX%-K2`;W25NG;6O5M);.5>*M5>3=]8TS&A5RO?VB$]5[X
M,MXAL]=_FEG@!;`W"NNCS"$*=A_XN4=V&";KA1B&RKN)IFJ/@F?MW03/I4?>
M\U1DOI5WTWOFPLE5>9^6TQSR_EE[@2MUA\P&WTFU1'9GZBN&.\D<,AT=591!
MZ:SHKOII9RD[1'G/451Z%!K3[VJL%(U=K<2"N?*>!Z)2+MEE5/YK__R[IV(T
MT2UP*>\0O4+QX94BRA#EB!2B`I%&5"*J&.*!)M?:?:#1I\E&K1!H&2.7X`Z9
M7HA"1KY]]!5#]V<.O15KMD6Z,1-KT\E4=+_RGN-8<U<9&M/O:JQT5J?&$G$;
M%6N,ZRO7XA^,-5RC+RR*LI<4488H1Z00%8@THA)1A:A&U"!J$74,<5W-^CE>
ME/1Q^Y$#F@N[$H_7*P[QC'PE%E%IL/*#/4.4(U*("D0:48FH0E0C:A"UB#J&
MN-HRCWA]";C`A,&A:*\B190ARA$I1`4BC:A$5"&J$36(6D0=0UP_L_J/H_4-
M_5RR$%8<-PN+1$B*I4H:K$)(GBIZE*.50E0@THA*1!6B&E&#J$74,<0E-=G"
M"$E=<A%+:A%M('AET@6@#%&.2"$J$&E$):(*48VH0=0BZACB^LD,1SZ8WK4U
ML,#$QR&:NH.LUBI"F;?B*TJ1QN3!ROM2B`I$&E&)J/*HOU2FSE(F+J\/V-Z<
M9R@.T0]_Z2FBS".[C)G)O;-0[)THCT(@%XBT1\-^RU#L_58>]=?+M1C*149O
MDRPQ'7&(6O97D2+*'**^,BL]V"0)Q=Z)0B<%(ATJ]G[%T[T,Q=YOQ9QPB61&
M\4:X8.:P="C>+DA6(F%,O558P6:(<H?<YD`R$:-*^2I\[(EW8(6W"FUI1"5O
M2^X,^`J_:XF+*%.1-T3$G&-I$=L52&1BF'JKD*1EB'*'Z)G>)QC\;+GR%:C!
M*+L!"=WUA):TKQA0^6I+E:_PNY:XA#+;>$-"S"J6#K$X7(MY*?56(38R1+E#
M+@ZODHD(9^7K_"X\^NWGPEN%QC2BDC>63!<3L3U1^4J_:XTK*?.+-Y3$)&)I
M$0_&M;BHU%N%>,@0Y0[1:L@$XTK>FO)5XH>":SXXUMXJH-([MEM48J*H?(7>
M+9=G7$*PQ(3`(7H+Z.?7%%&&*$>D$!6(-*(2486H1M0@:A%U#'']QB4$2TP(
M'.()P5I,P&FP\BIGB')$"E&!2",J$56(:D0-HA91QQ"7=%Q"L,2$P*$X1T64
M(<H1*40%(HVH1%0AJA$UB%I$'4-</YH71R142V,NEKP6B9`4>V6IJQBIG"'*
M$2E$!2*-J$14(:H1-8A:1!U#3%)S3'.$I+TYE]2A2*P4488H1Z00%8@THA)1
MA:A&U"!J$74,<?UDYO'Z0Y@^EB%#TJ$H\TP198ARC\(K7.512&P+1!I1Z5'P
M57D4?-6(&H=,WA%6F6N1J;3!RL_Q'?/%)1V7J=#N,DAJ$9,44.8J1E:Y1T$&
MY5&0H4"D$94>!5^51\%7C:AQ2$@J]M':8!4DC>^12VI6^>_?B5K9I"#>;W8H
M$BM%E"'*/0HR*(^"#`4B[9"00416&:R\#!7ZJA$UH6(<N&)YV08K[[YCOKC*
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MI6_,G2V:R`VTRKL)C=4>A<8:1"WWO)Y<B0CH?!T\L[$:E]WUYF(I;1,^LPL4
M%E.78C).7<7H!$>&*'?([<<L1:<J7R/:CO$H[+WH@*(+PMZPE^V:2I+)4HA6
M>3^AM=JCT%J#J'6(=GG"@+"MV=OG`\(D=R-6.<9<=(!%9E,DZ@"Q*$A7KF*(
MI`Q1[I`Y^1KY$H\^Y:S,GD%D)<9.@>YU0%%%[!I[J?X0WD2.RLJ[B0<*W%[C
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M9E2'3J8/7-OLBDIZL62=.6E`'S0;J#.G/W9@]["@SHQ*^G<`LF1&=>RD`B54
MA[Y28:"=&6E-7Q8P5$):V^D4O)'6]G,,4$):TR>/![PE5(>^^VJHA.K0]S0-
ME9#6=LC)=A+2FKY(9Z@.:4U?$3-0,B.MZ=720`E5&:R14`WZPLB!&@DI35^%
M.%1"2M/7]@V5D-)V"P/NAI2F[U7#.O07+[X,^Z(*`_8WIIN'N!E0`_S+8O.%
M!C,V?&/&V1"G7ASL1.K#P2ZD'AP<8-1_0]U'^?_&9/=X192Z;TQBCB64&6],
MWHLEE-22MZ$2RD?)VU`)Y77D;>A>*"4C;T,EE$V1MZ$2.C*Q,><B\-KH],C&
M'(_`$MK#)&_#)3,J&>I@VIVB:QOJ8MI8HCI#)3=+ZC1:6N(5W"RIVV@).%1"
M'4<O1(9*:!31OCZ6T*=V-N:#.5A"G[K9F`_68`D==MJ8XT=8<D.ZW0SJ1H>%
M-N8T#-:A,T.;W)Z9$4./CLI0R5`=.C6T,<=BT!L='MJ8TS%80F>(J+<')XSY
M8G-#N2C6H4\);LP'P;"$/BQ(Z@Q&_)SBFA[/0W4H1@>]T:?^-N:#753GXB0"
M_?6:Y]OOV_;VY?ONZ7#VL/U&#^MI_UFW%_OW;^PO1W>Z_^O^2'^WAI:\]*=`
MZ.\4;>F[Z*?F"UZ_[?='_XMIX/27CS[_6P````#__P,`4$L#!!0`!@`(````
M(0`7KBN_*`L``-\Z```9````>&PO=V]R:W-H965T<R]S:&5E=#$Q+GAM;*R;
M6V_KN!6%WPOT/QA^G]B2G#@QD@QL2;P(+5`4O3S[.$IBG-@*;)_;OY]-412Y
MN31)G/9EYN3CYI:X>-$B+=W^_G/W,OI>'X[;9G\W3BZFXU&]WS0/V_W3W?C?
M_Q*_78]'Q]-Z_[!^:?;UW?A7?1S_?O_7O]S^:`Y?C\]U?1I1AOWQ;OQ\.KTN
M)I/CYKG>K8\7S6N]IY+'YK!;G^C/P]/D^'JHUP]MI=W+))U.KR:[]78_MAD6
MAX_D:!X?MYNZ:#;?=O7^9),<ZI?UB>[_^+Q]/;ILN\U'TNW6AZ_?7G_;-+M7
M2O%E^[(]_6J3CD>[S4(_[9O#^LL+M?MG,EMO7.[V#TB_VVX.S;%Y/%U0NHF]
M46SSS>1F0IGN;Q^VU`(C^^A0/]Z-E\FBFLW'D_O;5J#_;.L?Q^#?H^-S\T,>
MM@]_V^YK4IOZR?3`EZ;Y:D+U@T%4>0*U1=L#_SB,'NK'];>7TS^;'ZK>/CV?
MJ+LOJ46F88N'7T5]W)"BE.8BO329-LT+W0#]=[3;FJ%!BJQ_WHU3NO#VX?1\
M-\ZN+B[GTRRA\-&7^G@26Y-R/-I\.YZ:W7]M4-*ELDFR+LFL3Y+,+Y+9],KD
M>*,>E;87I_]W%T^3B_3Z,KE\K^955Y.&<5?S8U>\Z>K1_\^\8D)=T]ZL^<='
MKCFQ2K<=5ZQ/Z_O;0_-C1+.!M#R^KLW<2A8FF>LR*U3?B7_6A]1Y)LO2I+D;
MDQ#4/4<:>-_ODYOY[>0[#99-%[,:B.$1N8LP(\.D+6)0QD#$0,9`Q4#'H`K`
MA&3IM:%A^/_0QJ0QVKA6K1SP8J61$"["52EB4,9`Q$#&0,5`QZ`*`!."IA03
M8G@^N[%@HN_&<S86KGD#5S8FO>E%R8$40$H@`H@$HH!H(%5(6--I%3FCZ2::
M9A)E"^;!3=1V&Y319/-!TXP'Y7U0/P2`E$`$$`E$`=%`JI`P.6AQ/$,.$]W*
MX1JQLB2S*[:9XCF0`D@)1`"10!00#:0*"6LH+66LH69=3"\O*/[,E=$DXAI8
M0AJ$_3^+^K\/<M(50$H@`H@$HH!H(%5(F"PTJYDL;Z\$)CJ:#N3(>$M7-BB:
M#I<\*.^#>CF`E$`$$`E$`=%`JI`P.8QQ#9^>;\MAHOE0L"2<#D`*("40`40"
M44`TD"HDK*%D45A#/ST=3"*N@271=+B*^K\/ZOL?2`E$`)%`%!`-I`H)D\4X
M)J;+VP.@#8<)D?"VKKJH:$9$;BKW4;TDB$I$`I%$I!!I1!5#7!ECJCX^-1+K
MP>C)Z5JSZA#)X%".J$!4(A*()"*%2".J&.)M-OXI;/.G9TEBG1B3PZ)HGD2^
M*N\J!BM*@:A$)!!)1`J11E0QQ!4R/BM4Z)WY8FT9\U/I-#++*U-,:THT7R+7
ME?LH-YP*1"4B@4@B4H@THHHAKHRQ7&<H8QT:Y7.M626=:0N\%:("48E(()*(
M%"*-J&*(M]FXK[#-9KYDU^9LX%R794X9HN=*A_B$22+WD?LH)V2!J$0D$$E$
M"I%&5#'$)3).+)3HG0ECC1L;%J&7:W?5>0*H0%0B$H@D(H5((ZH8XFTV=BML
M\^>746O<F!R=EV/N.XD>P7G21_E1`:C$*(%((E*(-***(:Z0\6FA0N^,"FOK
MF`RAT^M&!:`B`50B$H@D(H5((ZH8XFTV)NR,-EO/QMK<V[A@XY5$3Y,\Z:-\
MUP,J,4H@DH@4(HVH8HC)D)[G.-MP[K<[%%B$'%&!J$0D$$E$"I%&5#'$VWR>
METS12W:('BRN4W-$A4.T//J3F20ZF2E]E,LE$$E$"I%&5#G4WBJ78<A>)I<7
M<WKVG9ZWFZ^KAFZ;&C^P&F1T)FM/:E.TEAUBZMBH`!4NBM;!0)WHW*+T45Z=
M+E?[PT-[$Q*C%"*-J')H0)W86IJGQOGJ]([3W?XJ[5`X=@`5751ZW1Y^I],D
M.L$H?8#++#"S1*1\17.L3IDCR;4/<)DKEH8/HO-\9HH^TZ$TF$M=E$<%1I6(
M!"*)2"'2B"J&>)MCGSDP06BD]S,$O225MO:2KPQ1%^<NR@_T`E'ID!TI\_0F
M6F"$"_"'X](AGUDAT@ZYS/,H<^4"VLQ<(F,)/_YT3:V##)^N'3*K>+`\Q.<X
M+LIO4@I$I4-I.YFRZUG4$.$"_/9'.N0S*T3:(9<YC?JP<@%M9BZ1,8"A1*TM
MO6IW*^\,*&L=F5H6F3$;J!6?\:1=1=_M!:+2(=OM5_-YE$:X@'!`06;EHOS%
MM$-=YNP:U.K2#`PH8QU#M=Z1R#I-DLCKD<8_BJQH=<6=?A*?@?@HMQX6B$I$
M`I%$I!!I1!5#?!P9-WF&,M9\LL$#?C2G7]):9?SH+Q"5B`0BB4@ATH@JAEB;
MS=D,:_.GMW1M)FYH.Q1M]./S'Q_5CPI$)2*!2")2B#2BBB&NT'D>US36GG>$
M\R5R!JLNRES5KS)I?`3BH[PR-CU5=*C$*(%((E*(-***(:Y,;'O?7DDR]+<=
MHDNXUN2("D0E(H%((E*(-***(=YF8S`_OD9DG1_UC\-5AXRL0=?'YQP^RBE3
M("H1"402D4*D$54,<1G.,ZL9FM4.D0SM.RG\EY;<E_KFVQS!6"DQ2B"2B!0B
MC:ABB#?_/-^:H6_MD+E$,`KB(P\?Y66PN:BB0R5&"402D4*D$54,<1EB;VH>
M'I\[)L[0MW8HFBB1X<Q]E-.C0%0B$H@D(H5((ZH8XA(9'W;&>M'9MG"]L"B2
M(7J@Y%D?Y64`5&*40"01*40:4<40ER$VG?_#2.D-J6OI*NO<)U]2(TN<^RA7
ML4!4(A*()"*%2".J&.(2G><^,W2?':*'EVM@CJA`5"(2B"0BA4@CJAAB;9[%
M[O-M!]&&<XO9H6AVQ)M;'^64*1"5B`0BB4@ATH@JAK@,QM1]?)&860\8;CPZ
M%#U.HNUF[J.\##97^#C!*(%((E*(-***(2Y#["<_O1>9H=7L4#10XAVJC_(*
MV5Q4T:$2HP0BB4@ATH@JAKA"L?LT"EU2%Y[YZML,;6F'(GWBO9J/<F(4B$I$
M`I%$I!!I1!5#7)_S;.D,;6F'@M[.$16(2D0"D42D$&E$%4.\S>=YT1EZT0[Q
MKL_BS:B/\EW?>=%P:@`26%$B4H@THHHA+D/L1=]YE*#?G%G$U]`LWICY*"]#
M7]&A$J,$(HE((=*(*H:X#,;TA8^2SZX0UCRR9TSO)X,M2Q9O6>@KEOB\"U&)
M2""2B!0BC<A\2N-OPNIC/XVQ7UCLZL-3G=<O+\?1IOEF/GNYG-$VM,?VFYS5
M+*6/<EHS!249E;0>'4IF5-+NS:#DDDK:GZJ@Y(I*VJ\0H&1.)>VQ;UR241W:
M=="`@Q*J0T9\J.2:2JX'2VZHI#TJCK/-IG0'[6$3E)A/EMJ9'Y4LT^O%TAY0
M125T3+PPYZ\#]Y;2'=`IY4!)1G<PF&V9)8OEGZA#]V:7\/@.,NI3:Y"AA/J4
M#CR&[H#ZU!HDJ$-]2MMCK+-,LL62#NFQA%Z*6YBWS89*Z#KT3M90"5V'7D4:
M*J%Q0"_L#)70.*`7589*J!?H=8ZA$NH%>L-AH"2E7J!?D+!D.5\L!VO0Y0>O
M3A<?O#9=>BC/,IDNEO3>(EYY127F/=>A$NI_>AMTJ(3Z?S`;?8&W'+X*51C*
M1(D&X\TP&HA?SA;+P7XR"\9`_(JZ?+#'J<,'\Z3)8D4_PF.;Z86*13Y80N]5
M+,R;#EB'WBF@DJ%L]!H$-7RHA'YI7Y@?TS$;_5).V=J223^%Z//"U_53_??U
MX6F[/XY>ZD=:AZ?M.Q,'^X&B_>/4O+;O3GQI3O1A8?O/9_J0M*9/5*;FJX_'
MICFY/^C2D_[3U/L_````__\#`%!+`P04``8`"````"$`BL69OFH"``#`!@``
M$``(`61O8U!R;W!S+V%P<"YX;6P@H@0!**```0``````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M``````````````````"<5=UOVC`0?Y^T_R'*>PG0KIJ0246A4R=M*QJT>[2,
M<P$+8V>^`T'_^EV(^-J22NO;^3Y_]VEQMUW9:`,!C7?]N--JQQ$X[3/CYOWX
M>?KEZG,<(2F7*>L=].,=8'R7?OP@QL$7$,@`1NS"83]>$!6])$&]@)7"%HL=
M2W(?5HKX&>:)SW.C8>3U>@6.DFZ[?9O`EL!ED%T51X=QY;&WH?<ZS;PN\>'+
M=%<PX%0,BL(:K8BS3+\;'3SZG**'K08KDG.A8'03T.M@:)>V17+^%!.M+`S9
M<9HKBR"2$T,\@BJ+-E8F8"HVU-N`)A\B-*]<MFX<S11"":<?;U0PRA'#*M6J
MQYZV!5)(?_FPQ`4`H4A8H6+NR7/=<]K<I%W&RLI,76J6S`H)"RXQ3@U9P*=\
MK`+50>91.&'>HZ@05X`.790#E\D'1UPO^=55W3;^'/DQAZ'G1CN$3#*%WII,
M$3_NE55.<S6/BF5=JB@-)A-BR]5[3#JU87YX`MF1]VLT#O"B[D<H>YTNHT6#
MTN=R'`!YBO<SU>ST6@ZT]FNNCYO+,>>L>6.:U6_*TO`ZDIE9D&5(E.3ES_I4
M]Y`^R0EYO5QXF_$:RX??:VY%<X1;[I+V*Y!3M6U`,C%S9WA3>49KT#>[KLV5
MX\R:36K!OVUR:I,<`2EC44[YB*Q5<Y1Z8%RI9I/&1KPQ0/7),,CF,/4F`\M7
MZ3AXIVUH[K=\*OX["IM<)'-Q*OXZ#M^,6^)S,?4C7KS#];MDBLE"!<CX+ASD
M)X9XY,,7;.EDN%!N#ME!YU]!>:M?J@\I[=RTVM=M/FUG/)&<OI[T#P```/__
M`P!02P,$%``&``@````A`#N#Q/R5````J0```!````!X;"]C86QC0VAA:6XN
M>&UL/(Y!"@(Q$`3O@G\8YNYF%121)`L*OD`?$+*C"223)1-$?V^\>&DH&JI;
M3^^<X$558F&#VV%$(/9ECOPT>+]=-T<$:8YGEPJ3P0\)3G:]TMXE?PDN,G0#
MB\'0VG)22GR@[&0H"W%O'J5FUSK6IY*EDILE$+6<U&X<#RIW`5KMH1H\[Q%B
M_X"0?JFL5O\1^P4``/__`P!02P,$%``&``@````A`)MKK9DS`0``0`(``!$`
M"`%D;V-0<F]P<R]C;W)E+GAM;""B!`$HH``!````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M````````````````````````````````````````````````````````````
M`````````````````)R144O#,!2%WP7_0\E[FW9C8X8V`Y4].1"<.'R+R=T6
M;-*0&^WV[\VZKD[T2<A+..=^.?>DG.]-G7R"1]W8BA193A*PLE':;BORO%JD
M,Y)@$%:)NK%0D0,@F?/KJU(Z)AL/C[YQX(,&3"+)(I.N(KL0'*,4Y0Z,P"PZ
M;!0WC3<BQ*O?4B?DN]@"'>7YE!H(0HD@Z!&8NH%(>J22`])]^+H#*$FA!@,V
M("VR@GY[`WB#?PYTRH73Z'!P<:<^[B5;R9,XN/>H!V/;MED[[F+$_`5=+Q^>
MNE53;8]=22#\V$\M,"QCE1L-ZO;`]V^^3A!W)?VME4IVZ9CT(`*H)+['3NG.
MRLOX[GZU('R4%Y,TCV>V*F[8:,HFX]>2GEW]/!^`I@_P;^(9P+O</_^<?P$`
M`/__`P!02P$"+0`4``8`"````"$`UE_&W;8!```S#P``$P``````````````
M````````6T-O;G1E;G1?5'EP97-=+GAM;%!+`0(M`!0`!@`(````(0"U53`C
M]0```$P"```+`````````````````.\#``!?<F5L<R\N<F5L<U!+`0(M`!0`
M!@`(````(0#X=@E$D@$``-`-```:`````````````````!4'``!X;"]?<F5L
M<R]W;W)K8F]O:RYX;6PN<F5L<U!+`0(M`!0`!@`(````(0!,@S7TI`(``%L'
M```/`````````````````.<)``!X;"]W;W)K8F]O:RYX;6Q02P$"+0`4``8`
M"````"$`;&:01Z($``#6$0``&`````````````````"X#```>&PO=V]R:W-H
M965T<R]S:&5E=#0N>&UL4$L!`BT`%``&``@````A`-V+O<]N"```.2H``!D`
M````````````````D!$``'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M+0`4``8`"````"$`$^"EV>X"```-"```&0`````````````````U&@``>&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+`0(M`!0`!@`(````(0`H-TFNX`(`
M`.<'```9`````````````````%H=``!X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L!`BT`%``&``@````A`$#*[3=)`P``#@H``!D`````````````````
M<2```'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"+0`4``8`"````"$`
M^V*E;90&``"G&P``$P````````````````#Q(P``>&PO=&AE;64O=&AE;64Q
M+GAM;%!+`0(M`!0`!@`(````(0"QW$2(O@L``.)I```-````````````````
M`+8J``!X;"]S='EL97,N>&UL4$L!`BT`%``&``@````A`*6P[$W!-@``"Z0`
M`!0`````````````````GS8``'AL+W-H87)E9%-T<FEN9W,N>&UL4$L!`BT`
M%``&``@````A``V5\01)`P``\@D``!@`````````````````DFT``'AL+W=O
M<FMS:&5E=',O<VAE970S+GAM;%!+`0(M`!0`!@`(````(0![AC:Q@P0``)L0
M```8`````````````````!%Q``!X;"]W;W)K<VAE971S+W-H965T,BYX;6Q0
M2P$"+0`4``8`"````"$`09S59Z(#```7#```&`````````````````#*=0``
M>&PO=V]R:W-H965T<R]S:&5E=#$N>&UL4$L!`BT`%``&``@````A`'D]B/21
M!0``*A<``!D`````````````````HGD``'AL+W=O<FMS:&5E=',O<VAE970Q
M-BYX;6Q02P$"+0`4``8`"````"$`@F-IS@`#```["```&0``````````````
M``!J?P``>&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+`0(M`!0`!@`(````
M(0!99+[*!`0``$0/```8`````````````````*&"``!X;"]W;W)K<VAE971S
M+W-H965T-2YX;6Q02P$"+0`4``8`"````"$`3V,Y3L8"``"[!P``&```````
M``````````#;A@``>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L!`BT`%``&
M``@````A`/PX#Y#4"P``=4$``!@`````````````````UXD``'AL+W=O<FMS
M:&5E=',O<VAE970W+GAM;%!+`0(M`!0`!@`(````(0#W"=GJU0(``-H'```9
M`````````````````.&5``!X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L!
M`BT`%``&``@````A`,^X.)U4`P``U`H``!@`````````````````[9@``'AL
M+W=O<FMS:&5E=',O<VAE970X+GAM;%!+`0(M`!0`!@`(````(0#$@+S"J@(`
M`-X&```9`````````````````'><``!X;"]W;W)K<VAE971S+W-H965T,3`N
M>&UL4$L!`BT`%``&``@````A`.Q]8WH$"P``T3```!D`````````````````
M6)\``'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6Q02P$"+0`4``8`"````"$`
MCN*LC&`$``!9#P``&0````````````````"3J@``>&PO=V]R:W-H965T<R]S
M:&5E=#$R+GAM;%!+`0(M`!0`!@`(````(0"QJ58JI!(``#YI```8````````
M`````````"JO``!X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"+0`4``8`
M"````"$`%ZXKOR@+``#?.@``&0`````````````````$P@``>&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;%!+`0(M`!0`!@`(````(0"*Q9F^:@(``,`&```0
M`````````````````&/-``!D;V-0<F]P<R]A<'`N>&UL4$L!`BT`%``&``@`
M```A`#N#Q/R5````J0```!```````````````````]$``'AL+V-A;&-#:&%I
M;BYX;6Q02P$"+0`4``8`"````"$`FVNMF3,!``!``@``$0``````````````
M``#&T0``9&]C4')O<',O8V]R92YX;6Q02P4&`````!X`'@#[!P``,-0`````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	word-wrap: break-word;
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Stockholders' Equity</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">2011 Private Placement</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In June 2011, we sold 8.0 million shares of our common stock for net proceeds of $22.8 million (net of approximately $1.2 million in issuance costs). For each share purchased, the investors received one warrant to purchase 0.5 shares of common stock at an exercise price of $3.60 per share. The warrants were immediately exercisable and expire on July&nbsp;1,&nbsp;2016. The warrants may be exercised for cash only, or, if a registration statement is not then effective and available for the resale of the shares of common stock issuable upon exercise of the warrants, by surrender of such warrant, or a portion of such warrant, by way of cashless exercise. There is no right to exercise the warrants to the extent that, after giving effect to such exercise the holder would beneficially own in excess of 9.99% of our outstanding shares of common stock or such other limit as may be designated by any particular purchaser. Each holder of the warrants can amend or waive the foregoing limitation by written notice to us, with such waiver taking effect only upon the expiration of a 61-day notice period.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">On July 29, 2011, we filed a registration statement with the SEC to register for resale the shares and the shares of common stock issuable upon the exercise of the warrants. The registration statement was declared effective on August 4, 2011. We are obligated to maintain the effectiveness of the registration statement until the investors are able to sell shares and the shares of common stock underlying the warrants without limitation or restriction under Rule 144 of the Securities Act of 1933, as amended (&#x201c;Rule 144&#x201d;). There is currently only one investor who is an affiliate of ours and is therefore not able to sell without limitation under Rule 144, and that investor has agreed to waive its right to require us to maintain the effectiveness of the registration statement until it provides notice otherwise. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">During the three months ended March 31, 2015, warrant holders exercised 66,667 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 47,588&nbsp;shares of common stock and no net cash proceeds to us. During the three months ended March 31, 2014, warrant holders exercised 144,040 warrants under the cashless exercise provision in the warrant agreement, which resulted in the net issuance of 108,409 shares of common stock and no net cash proceeds to us.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">2012 Private Placement</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In July 2012, we sold approximately 5.1 million shares of our common stock at a purchase price of $10.50 per share, resulting in net proceeds of approximately $50.5 million (net of approximately $3.1&nbsp;million in issuance costs). On August 24, 2012, we filed a registration statement with the SEC to register these shares for resale. The registration statement was declared effective on September 6, 2012. </div></div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;"></div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">2013 Common Stock Offering</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In November 2013, we sold approximately 7.7 million shares of our common stock at a public offering price of $8.00 per share. We received total net proceeds of approximately $57.8 million (net of approximately $3.9&nbsp;million in issuance costs). The offering was made pursuant to an effective registration statement, which was previously filed with the SEC. </div></div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">2014 Common Stock Offering</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In June 2014, we sold approximately 4.8 million shares of our common stock at a public offering price of $11.75 per share. In addition, as a component of the offering, we sold 600,000 pre-funded warrants to purchase shares of our common stock at a public offering price of $11.74 per share. The pre-funded warrants have an exercise price of $0.01 per share and expire on June 30, 2021. We received total net proceeds of approximately $58.9 million (net of approximately $4.0 million in issuance costs) from the sale of the common stock and the pre-funded warrants. The offering was made pursuant to an effective registration statement, which was previously filed with the SEC. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;"><div style="display: inline; font-weight: bold;">Stock Option Exercises</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">For the three months ended March 31, 2015, 351,698 shares of common stock were issued pursuant to the exercise of stock options, resulting in proceeds to us of approximately $2,878,000. For the three months ended March 31, 2014, option holders exercised 275,352 stock options, a portion of which were exercised under the cashless exercise provision of our 2007 Amended and Restated Equity Incentive Plan, resulting in the net issuance of 215,350 shares of common stock and cash proceeds to us of approximately $958,000.</div></div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Stock-Based Compensation</div></div></div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes stock-based compensation expense related to stock-based payment awards granted pursuant to all of our equity compensation arrangements for the three months ended March&nbsp;31,&nbsp;2015 and 2014 (in thousands):</div></div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">         <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">806</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,262</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General and administrative</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">1,745</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">1,707</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-based compensation expense included in operating expenses</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,551</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,969</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Impact on basic and diluted net loss per share</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0.09</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0.13</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>       </table>  </div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2015, there was $29,947,000 of total unrecognized compensation cost related to non-vested, stock-based payment awards granted under all of our equity compensation plans and all non-plan option grants. Total unrecognized compensation cost will be adjusted for future changes in estimated forfeitures. We expect to recognize this compensation cost over a weighted-average period of 2.4&nbsp;years.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We estimated the fair value of each option grant on the grant date using the Black-Scholes option pricing model with the following weighted-average assumptions:</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-style: italic;">&nbsp;</div></div></div>  <div>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">         <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31,</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">15</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">14</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1.6</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2.0</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff">0.0</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff">0.0</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Volatility</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">91.7</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">104.1</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">6.1</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 54pt; BACKGROUND-COLOR: #ffffff">6.0</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>     </tr>       </table>  </div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We estimated the fair value of each purchase right granted under our 1997 Employee Stock Purchase Plan at the beginning of each new offering period using the Black-Scholes option pricing model. There were no new offering periods for the quarters ended March 31, 2015 and 2014.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table summarizes the stock option activity for the three months ended March&nbsp;31,&nbsp;2015:</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">         <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Remaining</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contractual</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Shares</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Term</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(in thousands)</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(Years)</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 55%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance at January 1, 2015</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7,918</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.69</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7.92</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">54</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">11.52</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercised</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">(352</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">)</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.18</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expired and forfeited</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">(327</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">)</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">10.67</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance at March 31, 2015</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7,293</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.65</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.31</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>       </table>  </div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(d),(e))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 4<br><br> -Subparagraph (SAB TOPIC 4.C)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.29-31)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 310<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SAB TOPIC 4.E)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section C<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 4<br><br> -Section E<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Article 4<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Preferred Stock<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6521494<br><br><br><br>Reference 10: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br>Reference 11: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 12: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 13: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 14: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 15: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 11<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21564-112644<br><br><br><br>Reference 16: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21488-112644<br><br><br><br>Reference 17: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21484-112644<br><br><br><br>Reference 18: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph d<br><br> -Article 4<br><br><br><br>Reference 19: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 30<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>18
<FILENAME>Financial_Report.xls
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xls
M[[N_34E-12U697)S:6]N.B`Q+C`-"E@M1&]C=6UE;G0M5'EP93H@5V]R:V)O
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M<B!E9&ET;W(@9&]E<VXG="!S=7!P;W)T(%=E8B!!<F-H:79E(&9I;&5S+B`@
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M;V9T+6-O;3IO9F9I8V4Z97AC96PB('AM;&YS/3-$(FAT='`Z+R]W=W<N=S,N
M;W)G+U12+U)%0RUH=&UL-#`B/@T*/&AE860^#0H\;65T82!N86UE/3-$(D5X
M8V5L(%=O<FMB;V]K($9R86UE<V5T(CX-"@T*/&UE=&$@;F%M93TS1%!R;V=)
M9"!C;VYT96YT/3-$17AC96PN4VAE970^#0H\;&EN:R!R96P],T1&:6QE+4QI
M<W0@:')E9CTS1")7;W)K<VAE971S+V9I;&5L:7-T+GAM;"(^#0H-"CPA+2U;
M:68@9W1E(&US;R`Y73X\>&UL/@T*(#QX.D5X8V5L5V]R:V)O;VL^#0H@(#QX
M.D5X8V5L5V]R:W-H965T<SX-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@
M(#QX.DYA;64^1&]C=6UE;G1?06YD7T5N=&ET>5]);F9O<FUA=&EO/"]X.DYA
M;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T
M<R]3:&5E=#`Q+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@
M(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O
M;G-O;&ED871E9%]"86QA;F-E/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T
M4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`R+FAT;6PB+SX-"B`@
M(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*
M("`@(#QX.DYA;64^0V]N9&5N<V5D7T-O;G-O;&ED871E9%]3=&%T96UE/"]X
M.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H
M965T<R]3:&5E=#`S+FAT;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@(#QX.D5X8V5L5V]R:W-H965T/@T*("`@(#QX.DYA;64^0V]N9&5N<V5D
M7T-O;G-O;&ED871E9%]3=&%T96UE,3PO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-"YH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DYO=&5?,5]"=7-I;F5S<SPO>#I.86UE/@T*("`@
M(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P
M-2YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E
M;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?,E]"87-I<U]O9E]0<F5S
M96YT871I;VX\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,#8N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7S-?06-C;W5N=&EN9U]0;VQI8VEE<SPO>#I.86UE/@T*("`@(#QX
M.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970P-RYH
M=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O
M<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-%]#;VYV97)T:6)L95].;W1E
M<U]T;U]293PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F
M/3-$(E=O<FMS:&5E=',O4VAE970P."YH=&UL(B\^#0H@("`\+W@Z17AC96Q7
M;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE
M/DYO=&5?-5]3=&]C:VAO;&1E<G-?17%U:71Y/"]X.DYA;64^#0H@("`@/'@Z
M5V]R:W-H965T4V]U<F-E($A2968],T0B5V]R:W-H965T<R]3:&5E=#`Y+FAT
M;6PB+SX-"B`@(#PO>#I%>&-E;%=O<FMS:&5E=#X-"B`@(#QX.D5X8V5L5V]R
M:W-H965T/@T*("`@(#QX.DYA;64^3F]T95\V7TEN8V]M95]487AE<SPO>#I.
M86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E
M=',O4VAE970Q,"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@
M("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/E-I9VYI9FEC86YT
M7T%C8V]U;G1I;F=?4&]L:6-I93PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E
M=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,2YH=&UL(B\^#0H@
M("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-
M"B`@("`\>#I.86UE/DYO=&5?,U]!8V-O=6YT:6YG7U!O;&EC:65S7U1A8CPO
M>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS
M:&5E=',O4VAE970Q,BYH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^
M#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-5]3
M=&]C:VAO;&1E<G-?17%U:71Y7U1A8CPO>#I.86UE/@T*("`@(#QX.E=O<FMS
M:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q,RYH=&UL(B\^
M#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS:&5E
M=#X-"B`@("`\>#I.86UE/DYO=&5?,5]"=7-I;F5S<U]$971A:6QS7U1E>'1U
M83PO>#I.86UE/@T*("`@(#QX.E=O<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O
M<FMS:&5E=',O4VAE970Q-"YH=&UL(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE
M970^#0H@("`\>#I%>&-E;%=O<FMS:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?
M,U]!8V-O=6YT:6YG7U!O;&EC:65S7T5Q=3PO>#I.86UE/@T*("`@(#QX.E=O
M<FMS:&5E=%-O=7)C92!(4F5F/3-$(E=O<FMS:&5E=',O4VAE970Q-2YH=&UL
M(B\^#0H@("`\+W@Z17AC96Q7;W)K<VAE970^#0H@("`\>#I%>&-E;%=O<FMS
M:&5E=#X-"B`@("`\>#I.86UE/DYO=&5?-%]#;VYV97)T:6)L95].;W1E<U]T
M;U]293$\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS
M1")7;W)K<VAE971S+U-H965T,38N:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R
M:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.
M;W1E7S5?4W1O8VMH;VQD97)S7T5Q=6ET>5]$970\+W@Z3F%M93X-"B`@("`\
M>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T,3<N
M:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC96Q7
M;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S5?4W1O8VMH;VQD97)S7T5Q
M=6ET>5]!;&P\+W@Z3F%M93X-"B`@("`\>#I7;W)K<VAE9713;W5R8V4@2%)E
M9CTS1")7;W)K<VAE971S+U-H965T,3@N:'1M;"(O/@T*("`@/"]X.D5X8V5L
M5V]R:W-H965T/@T*("`@/'@Z17AC96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M
M93Y.;W1E7S5?4W1O8VMH;VQD97)S7T5Q=6ET>5]/<'0\+W@Z3F%M93X-"B`@
M("`\>#I7;W)K<VAE9713;W5R8V4@2%)E9CTS1")7;W)K<VAE971S+U-H965T
M,3DN:'1M;"(O/@T*("`@/"]X.D5X8V5L5V]R:W-H965T/@T*("`@/'@Z17AC
M96Q7;W)K<VAE970^#0H@("`@/'@Z3F%M93Y.;W1E7S5?4W1O8VMH;VQD97)S
M7T5Q=6ET>5]/<'0Q/"]X.DYA;64^#0H@("`@/'@Z5V]R:W-H965T4V]U<F-E
M($A2968],T0B5V]R:W-H965T<R]3:&5E=#(P+FAT;6PB+SX-"B`@(#PO>#I%
M>&-E;%=O<FMS:&5E=#X-"B`@/"]X.D5X8V5L5V]R:W-H965T<SX-"B`@/'@Z
M4W1Y;&5S:&5E="!(4F5F/3-$(E=O<FMS:&5E=',O<F5P;W)T+F-S<R(O/@T*
M("`\>#I!8W1I=F53:&5E=#XP/"]X.D%C=&EV95-H965T/@T*("`\>#I0<F]T
M96-T4W1R=6-T=7)E/D9A;'-E/"]X.E!R;W1E8W13=')U8W1U<F4^#0H@(#QX
M.E!R;W1E8W17:6YD;W=S/D9A;'-E/"]X.E!R;W1E8W17:6YD;W=S/@T*(#PO
M>#I%>&-E;%=O<FMB;V]K/@T*/"]X;6P^/"%;96YD:69=+2T^#0H\+VAE860^
M#0H@(#QB;V1Y/@T*("`@/'`^5&AI<R!P86=E('-H;W5L9"!B92!O<&5N960@
M=VET:"!-:6-R;W-O9G0@17AC96P@6%`@;W(@;F5W97(N/"]P/@T*("`\+V)O
M9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96)E93@S,F)?9C,V
M9E\T-6)A7V$R9#1?,S1C,S5F-C(S930W#0I#;VYT96YT+4QO8V%T:6]N.B!F
M:6QE.B\O+T,Z+V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T
M-R]7;W)K<VAE971S+U-H965T,#$N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%
M;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT
M+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^
M#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT
M/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$
M=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V
M92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*
M("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$4T14%%/@T*("`@
M("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R
M;W=S<&%N/3-$,CX\<W1R;VYG/D1O8W5M96YT($%N9"!%;G1I='D@26YF;W)M
M871I;VX\8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$
M=&@@8V]L<W!A;CTS1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@
M,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y!<'(N(#(X
M+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M;G1I='D@4F5G:7-T<F%N="!.86UE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#Y(15)/3B!42$5205!%551)0U,L($E.0RX@+T1%+SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M($-E;G1R86P@26YD97@@2V5Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#XP,#`P.#$X,#,S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#=7)R96YT($9I<V-A;"!996%R($5N9"!$871E
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XM+3$R+3,Q/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I
M='D@1FEL97(@0V%T96=O<GD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/D%C8V5L97)A=&5D($9I;&5R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;G1I='D@0W5R<F5N="!297!O<G1I
M;F<@4W1A='5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y997,\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D5N=&ET>2!6;VQU;G1A<GD@1FEL97)S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#Y.;SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@
M8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P
M;"!V86QI9VX],T1T;W`^16YT:71Y(%=E;&PM:VYO=VX@4V5A<V]N960@27-S
M=65R/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#Y.;SQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^16YT:71Y
M($-O;6UO;B!3=&]C:RP@4VAA<F5S($]U='-T86YD:6YG("AI;B!S:&%R97,I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR.2PV,S(L-3,S/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$
M;V-U;65N="!4>7!E/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#XQ
M,"U1/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E
M>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y$;V-U;65N="!097)I;V0@16YD($1A=&4\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/DUA<B`S,2P-"@D),C`Q-3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&]C=6UE;G0@1FES
M8V%L(%EE87(@1F]C=7,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/C(P,34\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D1O8W5M96YT($9I<V-A;"!097)I;V0@1F]C=7,\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/E$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!;65N9&UE;G0@1FQA9SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^9F%L<V4\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
M/"]H=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5B964X,S)B7V8S-F9?-#5B
M85]A,F0T7S,T8S,U9C8R,V4T-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO
M+R]#.B]E8F5E.#,R8E]F,S9F7S0U8F%?83)D-%\S-&,S-68V,C-E-#<O5V]R
M:W-H965T<R]3:&5E=#`R+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I
M;F<Z('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL
M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%4%5!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#$^/'-T<F]N9SY#;VYD96YS960@0V]N<V]L:61A=&5D($)A;&%N8V4@
M4VAE971S("A#=7)R96YT(%!E<FEO9"!5;F%U9&ET960I("A54T0@)"D\8G(^
M26X@5&AO=7-A;F1S+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R
M;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T
M<F]N9SY#=7)R96YT(&%S<V5T<SH\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@8V%S:"!E<75I=F%L96YT<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`U-2PU-38\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<R+#8W
M-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')E<&%I9"!E>'!E;G-E<R!A;F0@;W1H97(@8W5R<F5N="!A<W-E=',\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/CDT-3QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L,#4W/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T
M86P@8W5R<F5N="!A<W-E=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C4V+#4P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C<S+#<S,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4')O<&5R='D@86YD(&5Q=6EP;65N="P@;F5T
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#DY-CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.#(P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y/
M=&AE<B!L;VYG+71E<FT@87-S971S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$;G5M<#XQ,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XQ,S`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y4;W1A;"!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4Y+#8R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<V+#8X,CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#=7)R96YT
M(&QI86)I;&ET:65S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y!8V-O=6YT<R!P87EA8FQE/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR+#,X,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-30Y/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-R=65D(&-L:6YI8V%L(&QI
M86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#4Q
M.#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C,L.#$Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y!8V-R=65D('!A>7)O;&P@86YD(&5M<&QO>65E+7)E;&%T960@
M;&EA8FEL:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L
M-C4V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,BPW,S$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D]T:&5R(&%C8W)U960@97AP96YS97,\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L,S(P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPY,S$\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@
M("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE(&YO
M=&5S('!A>6%B;&4@=&\@<F5L871E9"!P87)T:65S+"!N970@;V8@9&ES8V]U
M;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S0Y/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,2PU.3@\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;W4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y4;W1A;"!C=7)R96YT(&QI86)I;&ET:65S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XQ,2PV,C8\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ,RPV,C`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^4W1O8VMH;VQD
M97)SXH"9(&5Q=6ET>3H\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]M;6]N('-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XR.38\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XR.3(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D%D9&ET:6]N86P@<&%I9"UI;B!C87!I=&%L
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS.#,L-3$R/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,S<X+#`P
M-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^06-C=6UU;&%T960@9&5F:6-I=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;3XH,S,U+#@P-RD\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M/B@S,34L,C,W*3QS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E=3X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E1O=&%L('-T;V-K:&]L9&5R
M<^*`F2!E<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C0X
M+#`P,3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C8S+#`V,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E1O=&%L(&QI86)I;&ET:65S(&%N9"!S=&]C:VAO;&1E
M<G/B@)D@97%U:71Y/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD
M(#4Y+#8R-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-S8L-C@R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P13-/04,^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N
M9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($]P97)A=&EO;G,@
M*%5N875D:71E9"D@*%531"`D*3QB<CY);B!4:&]U<V%N9',L(&5X8V5P="!0
M97(@4VAA<F4@9&%T82P@=6YL97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T
M<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$
M,CXS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^
M/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E
M<F%T:6YG(&5X<&5N<V5S.CPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y297-E87)C:"!A;F0@9&5V96QO<&UE;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,30L-3`T/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2PV,C@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D=E
M;F5R86P@86YD(&%D;6EN:7-T<F%T:79E/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XU+#@U-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C4L-CDT/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F]U/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^5&]T86P@;W!E<F%T:6YG(&5X<&5N
M<V5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR,"PS-C`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-RPS
M,C(\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y,;W-S(&9R;VT@;W!E<F%T:6]N<SPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH,C`L,S8P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#$W+#,R,BD\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DEN=&5R97-T(&5X<&5N<V4L
M(&YE=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,C$P*3QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#(Q-BD\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y.970@;&]S<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@R
M,"PU-S`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q-RPU,S@I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y"87-I8R!A;F0@9&EL=71E9"!N970@;&]S<R!P
M97(@<VAA<F4@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@
M(#QT9"!C;&%S<STS1&YU;3XD("@P+C<I/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;3XD("@P+C<T*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S('5S960@
M:6X@8V]M<'5T:6YG(&)A<VEC(&%N9"!D:6QU=&5D(&YE="!L;W-S('!E<B!S
M:&%R92`H:6X@<VAA<F5S*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^,CDL,SDR/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,C,L-C@V/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M;#X-"@T*+2TM+2TM
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M:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\345402!H='1P+65Q=6EV
M/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H=&UL.R!C:&%R<V5T
M/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S8W)I<'0@<W)C/3-$
M4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M;65N="`J+SPO<V-R
M:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE(&-L87-S/3-$<F5P
M;W)T(&ED/3-$240P14)8044^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^0V]N
M9&5N<V5D($-O;G-O;&ED871E9"!3=&%T96UE;G1S(&]F($-A<V@@1FQO=W,@
M*%5N875D:71E9"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3W!E<F%T:6YG(&%C=&EV:71I97,Z
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!L;W-S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#(P+#4W
M,"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;3XD("@Q-RPU,S@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY!9&IU<W1M96YT<R!T;R!R
M96-O;F-I;&4@;F5T(&QO<W,@=&\@;F5T(&-A<V@@=7-E9"!F;W(@;W!E<F%T
M:6YG(&%C=&EV:71I97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/D1E<')E8VEA=&EO;B!A;F0@86UO<G1I>F%T:6]N/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ-3(L,#`P/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3$T+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VLM8F%S960@8V]M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C(L-34Q+#`P,#QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(L.38Y+#`P,#QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^06UO<G1I
M>F%T:6]N(&]F($1E8G0@1&ES8V]U;G0@*%!R96UI=6TI/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XQ-3$L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3,Y+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY#
M:&%N9V5S(&EN(&]P97)A=&EN9R!A<W-E=',@86YD(&QI86)I;&ET:65S.CPO
M<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y0<F5P
M86ED(&5X<&5N<V5S(&%N9"!O=&AE<B!A<W-E=',\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1N=6UP/C$Q,BPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#8R-"PP,#`I/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y!8V-O=6YT<R!P
M87EA8FQE/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-C8L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(L,C,X+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^06-C<G5E9"!C;&EN:6-A;"!L:6%B:6QI=&EE<SPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,CDS+#`P,"D\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q+#`R.2PP,#`I
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y!8V-R=65D('!A>7)O;&P@86YD(&5M<&QO>65E+7)E;&%T960@;&EA8FEL
M:71I97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$L,#<U+#`P
M,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@Q+#(U-"PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y/=&AE<B!A8V-R=65D(&5X<&5N<V5S/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M/B@U,S$L,#`P*3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C(W,BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M974^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y.970@
M8V%S:"!U<V5D(&9O<B!O<&5R871I;F<@86-T:79I=&EE<SPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;3XH,3DL-C8Y+#`P,"D\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B@Q-2PW,3,L,#`P*3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M/'-T<F]N9SY);G9E<W1I;F<@86-T:79I=&EE<SH\+W-T<F]N9SX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4'5R8VAA<V5S(&]F('!R;W!E
M<G1Y(&%N9"!E<75I<&UE;G0\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6T^*#,R."PP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1&YU;3XH-3<L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O=3X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE="!C87-H('5S960@9F]R(&EN=F5S
M=&EN9R!A8W1I=FET:65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M/B@S,C@L,#`P*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6T^*#4W+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^1FEN86YC:6YG(&%C=&EV:71I
M97,Z/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R;V-E961S(&9R;VT@<W1O8VL@;W!T:6]N(&5X97)C:7-E<SPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,BPX-S@L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.34X+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E=3X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE
M="!C87-H('!R;W9I9&5D(&)Y(&9I;F%N8VEN9R!A8W1I=FET:65S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XR+#@W."PP,#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY-3@L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F]U/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M3F5T(&1E8W)E87-E(&EN(&-A<V@@86YD(&-A<V@@97%U:79A;&5N=',\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^*#$W+#$Q.2PP,#`I/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;3XH,30L.#$R
M+#`P,"D\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@870@8F5G:6YN:6YG
M(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-S(L
M-C<U+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<R+#(X-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@86YD(&-A<V@@97%U:79A;&5N=',@
M870@96YD(&]F('!E<FEO9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^)"`U-2PU-38L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`U-RPT-S4L,#`P/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-"CPO:'1M
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M<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@("`\3454
M02!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G=&5X="]H
M=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT+VIA=F%S
M8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H:7,@0V]M
M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@/'1A8FQE
M(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y%/@T*("`@("`@/'1R/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\
M<W1R;VYG/DYO=&4@,2`M($)U<VEN97-S/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T97,@=&\@1FEN86YC:6%L
M(%-T871E;65N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0G5S:6YE<W,@1&5S8W)I<'1I;VX@86YD($)A<VES(&]F(%!R
M97-E;G1A=&EO;B!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\=&0@8VQA
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M8G-P.R9N8G-P.R9N8G-P.T)U<VEN97-S/"]D:78^/"]D:78^/"]D:78^("`\
M9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P
M=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^("`\
M9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P
M=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/DAE
M<F]N(%1H97)A<&5U=&EC<RP@26YC+B`H)B-X,C`Q8SMW92PF(W@R,#%D.R`F
M(W@R,#%C.W5S)B-X,C`Q9#L@86YD("8C>#(P,6,[;W5R)B-X,C`Q9#LI)FYB
M<W`[:7,@82!B:6]T96-H;F]L;V=Y(&-O;7!A;GD@=7-I;F<@:71S('!R;W!R
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M/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE.
M.B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV
M/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE.
M.B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^
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M*&]R("8C>#(P,6,[05!&-3,P)B-X,C`Q9#LI+"!A;F0@8V5R=&%I;B!O9B!O
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M/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-
M05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^
M/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-
M05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S
M-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M=F5N=&EO;B!O9B!#24Y6(&%N9"!(5%@M,#`S(&9O<B!T:&4@;6%N86=E;65N
M="!O9B!C:')O;FEC('!A:6X@86YD(&]P:6]I9"!A9&1I8W1I;VXN(#PO9&EV
M/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@
M34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
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M='1O;3HN,S-E;3LG/B`\+V1I=CYS=6)J96-T('1O(')E9W5L871O<GD@87!P
M<F]V86PL(&ES(&)E:6YG(&1E=F5L;W!E9"!F;W(@=&AE('!R979E;G1I;VX@
M;V8@8F]T:"!A8W5T92T@86YD(&1E;&%Y960M;VYS970@0TE.5B!F;VQL;W=I
M;F<@=&AE(&%D;6EN:7-T<F%T:6]N(&]F(&UO9&5R871E;'D@96UE=&]G96YI
M8R!C:&5M;W1H97)A<'D@*"8C>#(P,6,[345#)B-X,C`Q9#LI(&]R(&AI9VAL
M>2!E;65T;V=E;FEC(&-H96UO=&AE<F%P>2`H)B-X,C`Q8SM(14,F(W@R,#%D
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M;F=L92!S=6)C=71A;F5O=7,@:6YJ96-T:6]N+B!);B`R,#$T+"!W92!I;FET
M:6%T960@82!0:&%S92`S(&-L:6YI8V%L('-T=61Y(&5V86QU871I;F<@4U53
M5$],(&9O<B!T:&4@<')E=F5N=&EO;B!O9B!D96QA>65D+6]N<V5T($-)3E8@
M9F]L;&]W:6YG('1H92!A9&UI;FES=')A=&EO;B!O9B!(14,@86=E;G1S("@F
M(W@R,#%C.TA%0R!S='5D>28C>#(P,60[*2P@=VAI8V@L(&EF('-U8V-E<W-F
M=6PL('=O=6QD(&1I9F9E<F5N=&EA=&4@4U535$],(&9R;VT@=&AE(&]T:&5R
M(&-U<G)E;G1L>2!A<'!R;W9E9"`U+4A4,R!R96-E<'1O<B!A;G1A9V]N:7-T
M<RX@5V4@8V]M<&QE=&5D(&5N<F]L;&UE;G0@;V8@;W5R($A%0R!S='5D>2!I
M;B!!<')I;"`R,#$U+B`\+V1I=CX\+V1I=CX@("`@("`\9&EV('-T>6QE/3-$
M)R!-05)'24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>"<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;B<^)FYB<W`[/"]D:78^/"]D:78^
M("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ
M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G
M/DEN($UA>2`R,#`Y+"!W92!F:6QE9"!A($YE=R!$<G5G($%P<&QI8V%T:6]N
M("@F(W@R,#%C.TY$028C>#(P,60[*2!F;W(@4U535$],('=I=&@@=&AE(%4N
M4R!&;V]D(&%N9"!$<G5G($%D;6EN:7-T<F%T:6]N("@F(W@R,#%C.T9$028C
M>#(P,60[*2!U;F1E<B!396-T:6]N)FYB<W`[-3`U*&(I*#(I(&]F('1H92!&
M961E<F%L($9O;V0L($1R=6<L(&%N9"!#;W-M971I8R!!8W0N($EN($UA<F-H
M(#(P,3`L('=E(')E8V5I=F5D(&]U<B!F:7)S="!#;VUP;&5T92!297-P;VYS
M92!,971T97(@*"8C>#(P,6,[0U),)B-X,C`Q9#LI+"!W:&EC:"!S=&%T960@
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M8VAE;6ES=')Y+"!M86YU9F%C='5R:6YG+"!A;F0@8V]N=')O;"`H)B-X,C`Q
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M=&AE(&-O;F-E<FYS(')A:7-E9"!I;B!T:&4@,C`Q,"!#4DPN($EN(%-E<'1E
M;6)E<B`R,#$R+"!W92!R97-U8FUI='1E9"!T:&4@3D1!(')E<75E<W1I;F<@
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M86=E;G1S+"!P=6)L:7-H960@:6X@,C`Q,2X@5V4@8F5L:65V92!T:&%T('=E
M(&AA=F4@<W5B<W1A;G1I86QL>2!A9&1R97-S960@=&AE(&ES<W5E<R!R86ES
M960@:6X@=&AE($UA<F-H(#(P,3,@0U),+"!W:&EC:"!W:6QL(&)E(')E9FQE
M8W1E9"!I;B!O=7(@=7!C;VUI;F<@4U535$],($Y$02!R97-U8FUI<W-I;VXN
M(%=E(&EN=&5N9"!T;R!I;F-L=61E('1H92!R97-U;'1S(&]F(&]U<B!0:&%S
M92`S($A%0R!S='5D>2!I;B!T:&4@<F5S=6)M:7-S:6]N(&]F(&]U<B!.1$$@
M9F]R(%-54U1/3"P@=VAI8V@@=V4@86YT:6-I<&%T92!F:6QI;F<@;6ED+7EE
M87(@,C`Q-2X@/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,
M24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9B<^)FYB<W`[/"]D:78^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;B<^/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J
M=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M
M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68G/E1H92!L96%D('!R;V1U8W0@8V%N9&ED871E(&EN
M(&]U<B!P86EN(&UA;F%G96UE;G0@<')O9W)A;2!I<R!(5%@M,#$Q+B!(5%@M
M,#$Q+"!W:&EC:"!U=&EL:7IE<R!O=7(@<')O<')I971A<GD@0FEO8VAR;VYO
M;65R(&1R=6<@9&5L:79E<GD@=&5C:&YO;&]G>2P@:7,@82!L;VYG+6%C=&EN
M9R!F;W)M=6QA=&EO;B!O9B!T:&4@;&]C86P@86YE<W1H971I8R!B=7!I=F%C
M86EN92!I;B!C;VUB:6YA=&EO;B!W:71H('1H92!A;G1I+6EN9FQA;6UA=&]R
M>2!M96QO>&EC86T@9F]R('1H92!P<F5V96YT:6]N(&]F('!O<W0M;W!E<F%T
M:79E('!A:6XN(%1H92!E9F9E8W1I=F4@;6%N86=E;65N="!O9B!P86EN('=I
M=&@@82!R961U8W1I;VX@:6X@=&AE('5S92!O9B!O<&EO:61S+"!W:&EC:"!C
M86X@;&5A9"!T;R!P;W-T+6]P97)A=&EV92!C;VUP;&EC871I;VYS+"!E>'1E
M;F1E9"!H;W-P:71A;&EZ871I;VX@86YD(&%B=7-E+"!R96UA:6YS(&%N(&EM
M<&]R=&%N="!A<F5A(&]F('5N;65T(&UE9&EC86P@;F5E9"P@86YD($A46"TP
M,3$@8V]U;&0@<&]T96YT:6%L;'D@<')O=FED92!A(&1I9F9E<F5N=&EA=&5D
M('1H97)A<&5U=&EC('!R;V9I;&4@=VET:"!A9'9A;G1A9V5S(&-O;7!A<F5D
M('1O(&-U<G)E;G1L>2!A=F%I;&%B;&4@<&%I;B!M86YA9V5M96YT(&]P=&EO
M;G,N($EN(&$@4&AA<V4@,2!C;&EN:6-A;"!T<FEA;"P@8V]M<&QE=&5D(&EN
M($UA<F-H(#(P,34L($A46"TP,3$@86-H:65V960@=&AE(&1E<VER960@<&AA
M<FUA8V]K:6YE=&EC('!R;V9I;&4@9F]R(&)O=&@@8G5P:79A8V%I;F4@86YD
M(&UE;&]X:6-A;2X@5&AE<F%P975T:6-A;&QY(')E;&5V86YT('!L87-M82!B
M=7!I=F%C86EN92!L979E;',@=V5R92!S=7-T86EN960@9F]R(#(M,R!D87ES
M(&EN('1H92!A8G-E;F-E(&]F('1H92!L87)G92!I;FET:6%L('!E86L@;V9T
M96X@;V)S97)V960@=VET:"!C;VUM97)C:6%L;'D@879A:6QA8FQE(&9O<FUU
M;&%T:6]N<R!O9B!L;VYG+6%C=&EN9R!B=7!I=F%C86EN92X@5&AE(&%N97-T
M:&5T:6,@969F96-T<R!O9B!(5%@M,#$Q('!E<G-I<W1E9"!T:')O=6=H(#DV
M(&AO=7)S+"!W:&EC:"!C;&]S96QY(&-O<G)E;&%T960@=VET:"!P;&%S;6$@
M8G5P:79A8V%I;F4@8V]N8V5N=')A=&EO;G,L(&%N9"!(5%@M,#$Q('=A<R!W
M96QL+71O;&5R871E9"!W:71H(&YO('-E<FEO=7,@861V97)S92!E=F5N=',N
M(%=E('!L86X@=&\@;6]V92!(5%@M,#$Q(&EN=&\@4&AA<V4@,B!C;&EN:6-A
M;"!D979E;&]P;65N="!I;B!T:&4@<V5C;VYD('%U87)T97(@;V8@,C`Q-2X@
M/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T
M:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^)FYB<W`[
M/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T
M:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$
M14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68G/DEN($YO=F5M8F5R(#(P,30L('=E(&%N;F]U;F-E9"!O
M=7(@9&5V96QO<&UE;G0@<')O9W)A;2!F;W(@2%18+3`Q.2X@2%18+3`Q.2!I
M<R!A('!R;W!R:65T87)Y(&EN:F5C=&%B;&4@9F]R;75L871I;VX@;V8@87!R
M97!I=&%N="P@82!N975R;VMI;FEN+3$@*"8C>#(P,6,[3DLQ)B-X,C`Q9#LI
M(')E8V5P=&]R(&%N=&%G;VYI<W0@9F]R('1H92!P<F5V96YT:6]N(&]F($-)
M3E8N($Y+,2!R96-E<'1O<B!A;G1A9V]N:7-T<R!A<F4@='EP:6-A;&QY('5S
M960@:6X@8V]M8FEN871I;VX@=VET:"`U+4A4,R!R96-E<'1O<B!A;G1A9V]N
M:7-T<RX@070@<')E<V5N="P@=&AE(&]N;'D@:6YJ96-T86)L92!.2S$@<F5C
M97!T;W(@86YT86=O;FES="!A<'!R;W9E9"!I;B!T:&4@56YI=&5D(%-T871E
M<R!C;VYT86EN<R!P;VQY<V]R8F%T92`X,"P@82!S=7)F86-T86YT+"!W:&EC
M:"!M87D@8V%U<V4@:'EP97)S96YS:71I=FET>2!R96%C=&EO;G,@;W(@;W1H
M97(@861V97)S92!R96%C=&EO;G,@:6X@<V]M92!P871I96YT<RX@3W5R(&9O
M<FUU;&%T:6]N(&9O<B!(5%@M,#$Y(&1O97,@;F]T(&-O;G1A:6X@<&]L>7-O
M<F)A=&4@.#`L(&%N9"!M87D@:&%V92!A(&QO=V5R(&EN8VED96YC92!O9B!I
M;F9U<VEO;BUS:71E(')E86-T:6]N<R!T:&%N(')E<&]R=&5D('=I=&@@=&AE
M(&-O;6UE<F-I86QL>2!A=F%I;&%B;&4@:6YJ96-T86)L92!.2S$@<F5C97!T
M;W(@86YT86=O;FES="X@5V4F;F)S<#MP;&%N('1O(&1I<V-U<W,F;F)S<#MW
M:71H('1H92!&1$$F;F)S<#MO=7(@:6YT96YT('1O(&1E=F5L;W`F;F)S<#M(
M5%@M,#$Y('5T:6QI>FEN9R!T:&4@-3`U*&(I*#(I(')E9VES=')A=&EO;B!P
M871H=V%Y+CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'
M3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G
M/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'
M3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!4
M15A4+4E.1$5.5#H@,S9P="<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF)SY);B!$96-E;6)E<B`R,#$T+"!W92!D:7-C
M;&]S960@82!S96-O;F0@:6YV97-T:6=A=&EO;F%L('!R;V1U8W0@:6X@;W5R
M('!A:6X@;6%N86=E;65N="!P<F]G<F%M+B!(5%@M,#`S+"!W:&EC:"!U=&EL
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M<F5N;W)P:&EN92!F;W(@=7`@=&\@,S`@9&%Y<R!F;VQL;W=I;F<@82!S:6YG
M;&4@<W5B8W5T86YE;W5S(&EN:F5C=&EO;B!W:71H(&$@;&]W('!O=&5N=&EA
M;"!F;W(@<&%T:65N="!A8G5S92X@5V4@87)E('!R97-E;G1L>2!E=F%L=6%T
M:6YG(&]U<B!P;&%N<R!F;W(@9G5R=&AE<B!D979E;&]P;65N="!O9B!(5%@M
M,#`S+B`\+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ
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M:6]N(&%S(&]F($UA<F-H(#,Q+"`R,#$U+B!3:6YC92`R,#$Q+"!W92!H879E
M(&-O;7!L971E9"!A('1O=&%L(&]F(&9I=F4@<F]U;F1S(&]F(&5Q=6ET>2!A
M;F0O;W(@8V]N=F5R=&EB;&4@9&5B="!F:6YA;F-I;F=S+"!W:&EC:"!P<F]V
M:61E9"!U<R!W:71H(&-A<V@@;V8@87!P<F]X:6UA=&5L>2`D,3DT+C,@;6EL
M;&EO;B!I;B!T:&4@86=G<F5G871E+"!N970@;V8@:7-S=6%N8V4@8V]S=',L
M('1O(&9U;F0@;W!E<F%T:6]N<R`H<V5E($YO=&5S(#0@86YD(#4I+B!!<R!O
M9B!-87)C:"`S,2P@,C`Q-2P@=V4@:&%D(&-A<V@@86YD(&-A<V@@97%U:79A
M;&5N=',@;VX@:&%N9"!O9B`D-34N-B!M:6QL:6]N+CPO9&EV/CPO9&EV/B`@
M("`@(#QD:78@<W1Y;&4],T0G($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.
M+51/4#H@,'!X)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXF
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M;W)Y(&%P<')O=F%L)FYB<W`[9F]R(%-54U1/3"PF;F)S<#MC;VUP;&5T:6YG
M(%!H87-E(#$@86YD(%!H87-E(#(@:'5M86X@8VQI;FEC86P@<W1U9&EE<R!E
M>'!E8W1E9"!T;R!C;VUM96YC92!I;B!T:&4@<V5C;VYD)FYB<W`[:&%L9B!O
M9B`R,#$U(')E;&%T:79E('1O(&]U<B!(5%@M,#$Q)FYB<W`[<')O9'5C="!C
M86YD:61A=&4L(&%N9"!E;F=A9VEN9R!I;B!C;&EN:6-A;"!A;F0F;F)S<#MP
M<F5C;&EN:6-A;"!A8W1I=FET:65S(&9O<B!O=7(@2%18+3`Q.2!P<F]D=6-T
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M=&EO;G,N/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=.
M.B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%
M6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S
M='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S='EL
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M=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
M7TYE>'1087)T7V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T
M-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8F5E.#,R8E]F,S9F
M7S0U8F%?83)D-%\S-&,S-68V,C-E-#<O5V]R:W-H965T<R]3:&5E=#`V+FAT
M;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B
M;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I
M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3D4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`R
M("T@0F%S:7,@;V8@4')E<V5N=&%T:6]N/&)R/CPO<W1R;VYG/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N=&AS($5N
M9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T97,@=&\@1FEN86YC:6%L
M(%-T871E;65N=',\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^0F%S:7,@;V8@06-C;W5N=&EN9R!;5&5X="!";&]C:UT\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G9&ES
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M/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@
M34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV
M/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@
M34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@
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M;&5S(&=E;F5R86QL>2!A8V-E<'1E9"!I;B!T:&4@56YI=&5D(%-T871E<R`H
M)B-X,C`Q8SM'04%0)B-X,C`Q9#LI(&9O<B!I;G1E<FEM(&9I;F%N8VEA;"!I
M;F9O<FUA=&EO;B!A;F0@=VET:"!T:&4@:6YS=')U8W1I;VYS('1O($9O<FT@
M,3`M42!A;F0@07)T:6-L92`Q,"!O9B!296=U;&%T:6]N(%,M6"X@06-C;W)D
M:6YG;'DL('1H97D@9&\@;F]T(&EN8VQU9&4@86QL(&]F('1H92!I;F9O<FUA
M=&EO;B!A;F0@9&ES8VQO<W5R97,@<F5Q=6ER960@8GD@1T%!4"!F;W(@8V]M
M<&QE=&4@9FEN86YC:6%L('-T871E;65N=',N($EN('1H92!O<&EN:6]N(&]F
M(&UA;F%G96UE;G0L(&%L;"!A9&IU<W1M96YT<R`H8V]N<VES=&EN9R!O9B!N
M;W)M86P@<F5C=7)R:6YG(&%C8W)U86QS*2!C;VYS:61E<F5D(&YE8V5S<V%R
M>2!F;W(@82!F86ER('!R97-E;G1A=&EO;B!H879E(&)E96X@:6YC;'5D960N
M($]P97)A=&EN9R!R97-U;'1S(&9O<B!T:&4@=&AR964@;6]N=&AS(&5N9&5D
M($UA<F-H(#,Q+"`R,#$U(&%R92!N;W0@;F5C97-S87)I;'D@:6YD:6-A=&EV
M92!O9B!T:&4@<F5S=6QT<R!T:&%T(&UA>2!B92!E>'!E8W1E9"!F;W(@;W1H
M97(@<75A<G1E<G,@;W(@=&AE('EE87(@96YD:6YG($1E8V5M8F5R)FYB<W`[
M,S$L(#(P,34N(%1H92!C;VYD96YS960@8F%L86YC92!S:&5E="!A="!$96-E
M;6)E<B`S,2P@,C`Q-"!H87,@8F5E;B!D97)I=F5D(&9R;VT@=&AE(&%U9&ET
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M9&5D(&EN)FYB<W`[;W5R($%N;G5A;"!297!O<G0@;VX@1F]R;3PO9&EV/CQD
M:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^
M)FYB<W`[,3`M2R!F;W(@=&AE(&9I<V-A;"!Y96%R(&5N9&5D($1E8V5M8F5R
M)FYB<W`[,S$L(#(P,30@9FEL960@=VET:"!T:&4@4V5C=7)I=&EE<R!A;F0@
M17AC:&%N9V4@0V]M;6ES<VEO;B`H=&AE("8C>#(P,6,[4T5#)B-X,C`Q9#LI
M(&]N($UA<F-H)FYB<W`[,3,L)FYB<W`[,C`Q-3PO9&EV/CQD:78@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^+B`\+V1I=CX\
M+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]7TYE
M>'1087)T7V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T-PT*
M0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#.B]E8F5E.#,R8E]F,S9F7S0U
M8F%?83)D-%\S-&,S-68V,C-E-#<O5V]R:W-H965T<R]3:&5E=#`W+FAT;6P-
M"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z('%U;W1E9"UP<FEN=&%B;&4-
M"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C:&%R<V5T/2)U<RUA<V-I:2(-
M"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78],T1#
M;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]=71F
M+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13:&]W
M+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I<'0^
M/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O<G0@
M:60],T1)1#!%3D4^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`S("T@
M06-C;W5N=&EN9R!0;VQI8VEE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&5S('1O($9I;F%N8VEA;"!3=&%T
M96UE;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X
M=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E-I9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@6U1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)R!415A4+4%,
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M=6YT:6YG(%!O;&EC:65S/"]D:78^/"]D:78^/"]D:78^("`\9&EV('-T>6QE
M/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(
M14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9B<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]D:78^/"]D:78^
M("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ
M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^4')I;F-I<&QE<R!O
M9B!#;VYS;VQI9&%T:6]N/"]D:78^/"]D:78^/"]D:78^("`\9&EV('-T>6QE
M/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(
M14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^("`\9&EV('-T>6QE
M/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(
M14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M86YI>F5D(&EN('1H92!.971H97)L86YD<R!I;B!-87)C:"`R,#$U+B!(97)O
M;B!4:&5R87!E=71I8W,@0BY6+B!H87,@;F\@;W!E<F%T:6]N<R!A;F0@;F\@
M;6%T97)I86P@87-S971S(&]R(&QI86)I;&ET:65S(&%N9"!T:&5R92!H879E
M(&)E96X@;F\@<VEG;FEF:6-A;G0@=')A;G-A8W1I;VYS(')E;&%T960@=&\@
M2&5R;VX@5&AE<F%P975T:6-S($(N5BX@<VEN8V4@:71S(&EN8V5P=&EO;BX\
M+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M;F)S<#L\+V1I=CX\+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G(%1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR
M-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG
M:'0Z(&)O;&0[)SY5<V4@;V8@17-T:6UA=&5S/"]D:78^/"]D:78^/"]D:78^
M("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ
M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^
M("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ
M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
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M<FEA;&QY(&9R;VT@=&AO<V4@97-T:6UA=&5S+CPO9&EV/CPO9&EV/B`@("`@
M(#QD:78@<W1Y;&4],T0G($U!4D=)3BU"3U143TTZ(#!P>#L@34%21TE.+51/
M4#H@,'!X)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N)SXF;F)S
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M("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ
M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^
M/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T
M:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$
M14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
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M("@F(W@R,#%C.T-O;G9E<G1I8FQE($YO=&5S)B-X,C`Q9#LI+CPO9&EV/CPO
M9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@;&5F=#L@34%21TE.
M.B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV
M/CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S
M=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/D5A<FYI;F=S(%!E<B!3:&%R93PO9&EV/CPO9&EV/CPO9&EV/B`@/&1I=B!S
M='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)
M3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S
M='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)
M3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SY"87-I8R!E
M87)N:6YG<R!P97(@<VAA<F4@*"8C>#(P,6,[15!3)B-X,C`Q9#LI(&ES(&-A
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M9&EL=71I=F4N/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,
M24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[
M(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I
M=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S
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M9F5C="!W;W5L9"!B92!A;G1I+61I;'5T:79E+B`\+V1I=CX\+V1I=CX@(#QD
M:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T
M.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF)SXF;F)S<#L\+V1I=CX\+V1I=CX@(#QD
M:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T
M.R!,24Y%+4A%24=(5#H@,2XR-3L@5$585"U)3D1%3E0Z(#,V<'0G/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^5&AE
M(&9O;&QO=VEN9R!T86)L92!I;F-L=61E<R!T:&4@;G5M8F5R(&]F(&]U='-T
M86YD:6YG('-T;V-K(&]P=&EO;G,L('=A<G)A;G1S(&%N9"!C;VUM;VX@<W1O
M8VL@=6YD97)L>6EN9R!#;VYV97)T:6)L92!.;W1E<R!N;W0@:6YC;'5D960@
M:6X@=&AE(&-O;7!U=&%T:6]N(&%S(&]F('1H92!D871E<R!S:&]W;B!B96QO
M=R`H:6X@=&AO=7-A;F1S*3H\+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G
M(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(
M5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF)SXF;F)S<#L\+V1I=CX\+V1I=CX@(#QD:78^("`@/'1A8FQE
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3`P)3L@5$585"U)
M3D1%3E0Z(#!P>#L@=VED=&@Z(#<P,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E
M;&QP861D:6YG/3-$,"!B;W)D97(],T0P/B`@("`@("`@(#QT<CX@("`@("`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T
M;W`G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4)/5%1/33H@(S`P
M,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.+4Q%
M1E0Z(#!P="<@8V]L<W!A;CTS1#8^(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)
M1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/D%S(&]F($UA<F-H(#,Q/"]D:78^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^+#PO9&EV/CPO9&EV
M/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M0D]45$]-.B!M961I=6T@
M;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^
M/"]T9#X@("`@(#PO='(^("`@("`\='(^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S
M<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5D525$E#04PM04Q)1TXZ('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T
M9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,
M+4%,24=..B!T;W`[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!415A4+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P
M86X],T0R/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXR,#$U/"]D
M:78^/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`[(%!!1$1)3D<M0D]45$]-
M.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/C(P,30\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O
M<#L@4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T
M9#X@("`@(#PO='(^("`@("`\='(^("`@("`@/'1D/B9N8G-P.SPO=&0^("`@
M("`@/'1D/B9N8G-P.SPO=&0^("`@("`@/'1D/B9N8G-P.SPO=&0^("`@("`@
M/'1D/B9N8G-P.SPO=&0^("`@("`@/'1D/B9N8G-P.SPO=&0^("`@("`@/'1D
M/B9N8G-P.SPO=&0^("`@("`@/'1D/B9N8G-P.SPO=&0^("`@("`@/'1D/B9N
M8G-P.SPO=&0^("`@("`@/'1D/B9N8G-P.SPO=&0^("`@("`\+W1R/B`@("`@
M/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B`@("`@
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M:6YG/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@("`@("`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^
M)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,S@N-W!T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)SXW+#(Y,SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\
M+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z
M(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`S."XW<'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C<L,C<S/"]T9#X@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^("`@
M("`\+W1R/B`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F
M9F9F9F8G/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
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M9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P
M.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!72414
M2#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!R
M:6=H=#L@34%21TE.+4Q%1E0Z(#,X+C=P=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9B<^,RPX-#,\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-
M05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!N
M;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@
M("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,S@N-W!T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F)SXS+#@R-3PO=&0^("`@("`@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`@("`@/"]T
M<CX@("`@(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M)SX@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3BU,1494
M.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B`\9&EV('-T>6QE
M/3-$)R!415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P=#L@3$E.12U(14E'
M2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9B<^0V]M;6]N('-T;V-K('5N9&5R;'EI;F<@8V]N=F5R=&EB
M;&4@;F]T97,@;W5T<W1A;F1I;F<\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF
M;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`S-RXY
M<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C8L-S<W/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V-C965F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO
M=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@
M,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO=&0^("`@("`@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!R:6=H=#L@34%21TE.
M+4Q%1E0Z(#,W+CEP=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^-BPS
M.#4\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@
M,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@("`@(#PO='(^("`@("`@(#PO=&%B;&4^("`\+V1I
M=CX@(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3CH@
M,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\
M+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&IU<W1I
M9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SY#
M;VUP<F5H96YS:79E($EN8V]M92`H3&]S<RD\+V1I=CX\+V1I=CX\+V1I=CX@
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M<B!C:&%N9V5S(&EN(&5Q=6ET>2!F<F]M(&YO;BUO=VYE<B!S;W5R8V5S+B`\
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M9&EV/CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@
M:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N
M8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@
M:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4
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M(W@R,#%C.T%3528C>#(P,60[*2!.;RX@,C`Q-2T\+V1I=CX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/C`Q/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M<W1Y;&4Z(&ET86QI8SLG
M/BP@26YC;VUE(%-T871E;65N="8C>#(P,30[17AT<F%O<F1I;F%R>2!A;F0@
M56YU<W5A;"!)=&5M<R`H4W5B=&]P:6,@,C(U+3(P*3PO9&EV/B`H)B-X,C`Q
M8SM!4U4@,C`Q-2TP,28C>#(P,60[*2X@05-5(#(P,34M,#$@96QI;6EN871E
M<R!T:&4@8V]N8V5P="!O9B!E>'1R86]R9&EN87)Y(&ET96US(&9R;VT@1T%!
M4"X@1D%30B!C;VYC;'5D960@=&AA="!!4U4@,C`Q-2TP,2!W:6QL(&YO="!R
M97-U;'0@:6X@82!L;W-S(&]F(&EN9F]R;6%T:6]N(&)E8V%U<V4@86QT:&]U
M9V@@05-5(#(P,34M,#$@=VEL;"!E;&EM:6YA=&4@=&AE(')E<75I<F5M96YT
M<R!I;B!3=6)T;W!I8R`R,C4M,C`@9F]R(')E<&]R=&EN9R!E;G1I=&EE<R!T
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M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SY!4U4@,C`Q-2TP,2!A
M<F4@969F96-T:79E(&9O<B!F:7-C86P@>65A<G,L(&%N9"!I;G1E<FEM('!E
M<FEO9',@=VET:&EN('1H;W-E(&9I<V-A;"!Y96%R<RP@8F5G:6YN:6YG(&%F
M=&5R($1E8V5M8F5R(#$U+"`R,#$U+B!!(')E<&]R=&EN9R!E;G1I='D@;6%Y
M(&%P<&QY('1H92!A;65N9&UE;G1S('!R;W-P96-T:79E;'DN($$@<F5P;W)T
M:6YG(&5N=&ET>2!A;'-O(&UA>2!A<'!L>2!T:&4@86UE;F1M96YT<R!R971R
M;W-P96-T:79E;'D@=&\@86QL('!R:6]R('!E<FEO9',@<')E<V5N=&5D(&EN
M('1H92!F:6YA;F-I86P@<W1A=&5M96YT<RX@16%R;'D@861O<'1I;VX@:7,@
M<&5R;6ET=&5D('!R;W9I9&5D('1H870@=&AE(&=U:61A;F-E(&ES(&%P<&QI
M960@9G)O;2!T:&4@8F5G:6YN:6YG(&]F('1H92!F:7-C86P@>65A<B!O9B!A
M9&]P=&EO;BX@5V4@861O<'1E9"!T:&4@<')O=FES:6]N<R!O9B!!4U4@,C`Q
M-2TP,2!I;B!T:&4@9FER<W0@<75A<G1E<B!O9B`R,#$U+B!4:&4@861O<'1I
M;VX@;V8@=&AI<R!!4U4@9&ED(&YO="!H879E(&$@;6%T97)I86P@:6UP86-T
M(&]N(&]U<B!R97-U;'1S(&]F(&]P97)A=&EO;G,@;W(@9FEN86YC:6%L(&-O
M;F1I=&EO;BX\+V1I=CX\+V1I=CX@("`@("`\9&EV('-T>6QE/3-$)R!-05)'
M24XM0D]45$]-.B`P<'@[($U!4D=)3BU43U`Z(#!P>"<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;B<^)FYB<W`[/"]D:78^/"]D:78^("`\9&EV
M('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@
M3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/DEN($%U
M9W5S="`R,#$T+"!&05-"(&ES<W5E9"!!4U4@3F\N(#(P,30M,34L(#QD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7-T>6QE.B!I=&%L:6,[
M)SY0<F5S96YT871I;VX@;V8@1FEN86YC:6%L(%-T871E;65N=',@)B-X,C`Q
M,SL@1V]I;F<@0V]N8V5R;B`H4W5B=&]P:6,@,C`U+30P*3PO9&EV/B`H)B-X
M,C`Q8SM!4U4@,C`Q-"TQ-28C>#(P,60[*2X@05-5(#(P,30M,34@<F5Q=6ER
M97,@;6%N86=E;65N="!T;R!A<W-E<W,@86X@96YT:71Y)B-X,C`Q.3MS(&%B
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M(&1O=6)T+"`H,BD@<F5Q=6ER92!A;B!E=F%L=6%T:6]N(&5V97)Y(')E<&]R
M=&EN9R!P97)I;V0\+V1I=CX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68G/BP@:6YC;'5D:6YG(&EN=&5R:6T@<&5R:6]D
M<RP@*#,I)FYB<W`[<')O=FED92!P<FEN8VEP;&5S(&9O<B!C;VYS:61E<FEN
M9R!T:&4@;6ET:6=A=&EN9R!E9F9E8W0@;V8@;6%N86=E;65N="8C>#(P,3D[
M<R!P;&%N<RP@*#0I(')E<75I<F4@8V5R=&%I;B!D:7-C;&]S=7)E<R!W:&5N
M('-U8G-T86YT:6%L(&1O=6)T(&ES(&%L;&5V:6%T960@87,@82!R97-U;'0@
M;V8@8V]N<VED97)A=&EO;B!O9B!M86YA9V5M96YT)B-X,C`Q.3MS('!L86YS
M+"`H-2DF;F)S<#MR97%U:7)E(&%N(&5X<')E<W,@<W1A=&5M96YT(&%N9"!O
M=&AE<B!D:7-C;&]S=7)E<R!W:&5N('-U8G-T86YT:6%L(&1O=6)T(&ES(&YO
M="!A;&QE=FEA=&5D+"!A;F0@*#8I)FYB<W`[<F5Q=6ER92!A;B!A<W-E<W-M
M96YT(&9O<B!A('!E<FEO9"!O9B!O;F4@>65A<B!A9G1E<B!T:&4@9&%T92!T
M:&%T('1H92!F:6YA;F-I86P@<V%T96UE;G1S(&%R92!I<W-U960@*&]R(&%V
M86EL86)L92!T;R!B92!I<W-U960I+B!4:&4@86UE;F1M96YT<R!I;B!!4U4@
M,C`Q-"TQ-2!A<F4@969F96-T:79E(&9O<B!T:&4@86YN=6%L('!E<FEO9"!E
M;F1I;F<@869T97(@1&5C96UB97(F;F)S<#LQ-2P@,C`Q-BP@86YD(&9O<B!A
M;FYU86P@<&5R:6]D<R!A;F0@:6YT97)I;2!P97)I;V1S('1H97)E869T97(N
M($5A<FQY(&%D;W!T:6]N(&ES('!E<FUI='1E9"X@5V4@<&QA;B!T;R!A9&]P
M="!T:&4@<')O=FES:6]N<R!O9B!!4U4@,C`Q-"TQ-2!I;B`R,#$V+B!792!D
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M92`R,#$T+"!&05-"(&ES<W5E9"!!4U4@3F\N(#(P,30M,3(L(#QD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7-T>6QE.B!I=&%L:6,[)SY#
M;VUP96YS871I;VX@)B-X,C`Q,SL@4W1O8VL@0V]M<&5N<V%T:6]N("A4;W!I
M8R`W,3@I/"]D:78^("@F(W@R,#%C.T%352`R,#$T+3$R)B-X,C`Q9#LI+B!!
M4U4@,C`Q-"TQ,B!R97%U:7)E<R!T:&%T(&$@<&5R9F]R;6%N8V4@=&%R9V5T
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M<&5R;6ET=&5D+B!4:&4@86UE;F1M96YT<R!I;B!!4U4@,C`Q-"TQ,B!M87D@
M96ET:&5R(&)E(&%P<&QI960@*&$I)FYB<W`[<')O<W!E8W1I=F5L>2!T;R!A
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M,3(@:6X@=&AE(&9I<G-T('%U87)T97(@;V8@,C`Q-BX@5V4@9&\@;F]T(&5X
M<&5C="!T:&4@861O<'1I;VX@;V8@=&AI<R!!4U4@=&\@:&%V92!A(&UA=&5R
M:6%L(&EM<&%C="!O;B!O=7(@<F5S=6QT<R!O9B!O<&5R871I;VYS(&]R(&9I
M;F%N8VEA;"!C;VYD:71I;VXN/"]D:78^/"]D:78^/"]D:78^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D
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M:'1M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-
M"B`@("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0]
M,T0G=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T
M97AT+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E
M(%1H:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@
M("`@/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14Y%/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYO=&4@-"`M($-O;G9E<G1I8FQE($YO=&5S('1O
M(%)E;&%T960@4&%R=&EE<SQB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,]
M,T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#X\<W1R;VYG/DYO=&5S('1O($9I;F%N8VEA;"!3=&%T96UE
M;G1S/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/D1E8G0@1&ES8VQO<W5R92!;5&5X="!";&]C:UT\+W1D/@T*("`@("`@("`\
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M(%)E;&%T960@4&%R=&EE<SPO9&EV/CPO9&EV/CPO9&EV/CPO9&EV/B`@/&1I
M=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[
M($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I
M=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[
M($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SY);B!!
M<')I;"`R,#$Q+"!W92!E;G1E<F5D(&EN=&\@82!396-U<FET:65S(%!U<F-H
M87-E($%G<F5E;65N="!F;W(@82!P<FEV871E('!L86-E;65N="!O9B!U<"!T
M;R`D-"XU)FYB<W`[;6EL;&EO;B!I;B!#;VYV97)T:6)L92!.;W1E<RX@5V4@
M<F5C96EV960@82!T;W1A;"!O9B`D-"XS(&UI;&QI;VXL(&YE="!O9B!I<W-U
M86YC92!C;W-T<RP@9G)O;2!T:&4@:7-S=6%N8V4@;V8@=&AE<V4@0V]N=F5R
M=&EB;&4@3F]T97,N(#PO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$58
M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$58
M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
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M($UA>2`R+"`R,#(Q+"!H;W=E=F5R+"!T:&4@:&]L9&5R<R!O9B!T:&4@0V]N
M=F5R=&EB;&4@3F]T97,@;6%Y(')E<75I<F4@<')E<&%Y;65N="!O9B!T:&4@
M0V]N=F5R=&EB;&4@3F]T97,@870@86YY('1I;64L(&%T(&5A8V@@:&]L9&5R
M)B-X,C`Q.3MS(&]P=&EO;BX\+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G
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M;6]N('-T;V-K(&%T(&$@<F%T92!O9B`Q+#(U,"!S:&%R97,@9F]R(&5V97)Y
M("0Q+#`P,"!O9B!P<FEN8VEP86P@86YD(&%C8W)U960@:6YT97)E<W0@9'5E
M('5N9&5R('1H92!#;VYV97)T:6)L92!.;W1E<RX@5&AE<F4@:7,@;F\@<FEG
M:'0@=&\@8V]N=F5R="!T:&4@0V]N=F5R=&EB;&4@3F]T97,@=&\@=&AE(&5X
M=&5N="!T:&%T+"!A9G1E<B!G:79I;F<@969F96-T('1O('-U8V@@8V]N=F5R
M<VEO;BP@=&AE(&AO;&1E<B!W;W5L9"!B96YE9FEC:6%L;'D@;W=N(&EN(&5X
M8V5S<R!O9B`Y+CDY)2!O9B!O=7(@;W5T<W1A;F1I;F<@8V]M;6]N('-T;V-K
M+B!%86-H(&AO;&1E<B!O9B!T:&4@0V]N=F5R=&EB;&4@3F]T97,@8V%N(&EN
M8W)E87-E(&]R(&1E8W)E87-E('1H:7,@8F5N969I8VEA;"!O=VYE<G-H:7`@
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M(&5F9F5C=&EV92!O;B!*=6QY)FYB<W`[,CDL)FYB<W`[,C`Q,2X@5&AE($YO
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M/"]D:78^/"]D:78^("`@("`@/&1I=B!S='EL93TS1"<@34%21TE.+4)/5%1/
M33H@,'!X.R!-05)'24XM5$]0.B`P<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XG/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS
M1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S='EL93TS1"=D
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M92!O9B`Q+#(U,"!S:&%R97,@9F]R(&5V97)Y("0Q+#`P,"!O9B!P<FEN8VEP
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M($1U<FEN9R!T:&4@=&AR964@;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$U
M+"!A8V-R=65D(&EN=&5R97-T(&]F(&%P<')O>&EM871E;'D@)#@P+#`P,"!W
M87,@<&%I9"UI;BUK:6YD(&%N9"!R;VQL960@:6YT;R!T:&4@0V]N=F5R=&EB
M;&4@3F]T92!P<FEN8VEP86P@8F%L86YC92P@=VAI8V@@<F5S=6QT960@:6X@
M86X@861D:71I;VYA;"!D96)T(&1I<V-O=6YT(&]F(&%P<')O>&EM871E;'D@
M)#@P+#`P,"X@1F]R('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@@,S$L
M(#(P,34@86YD(#(P,30L(&EN=&5R97-T(&5X<&5N<V4@<F5L871I;F<@=&\@
M=&AE('-T871E9"!R871E('=A<R!A<'!R;WAI;6%T96QY("0X,2PP,#`@86YD
M("0W-RPP,#`L(')E<W!E8W1I=F5L>2P@86YD(&EN=&5R97-T(&5X<&5N<V4@
M<F5L871I;F<@=&\@=&AE(&%M;W)T:7IA=&EO;B!O9B!T:&4@9&5B="!D:7-C
M;W5N="!W87,@87!P<F]X:6UA=&5L>2`D,34Q+#`P,"!A;F0@)#$S.2PP,#`L
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M97,@=V%S(&%P<')O>&EM871E;'D@)#$L-S0Y+#`P,"P@=VAI8V@@:7,@8V]M
M<')I<V5D(&]F('1H92`D-2PT,C$L,#`P('!R:6YC:7!A;"!A;6]U;G0@;V8@
M=&AE($-O;G9E<G1I8FQE($YO=&5S(&]U='-T86YD:6YG+"!L97-S(&1E8G0@
M9&ES8V]U;G0@;V8@)#,L-C<R+#`P,"X@268@=&AE("0U+#0R,2PP,#`@<')I
M;F-I<&%L(&%M;W5N="!O9B!#;VYV97)T:6)L92!.;W1E<R!I<R!C;VYV97)T
M960L('=E('=O=6QD(&ES<W5E(#8L-S<V+#DY."!S:&%R97,@;V8@;W5R(&-O
M;6UO;B!S=&]C:RX\+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5B964X,S)B7V8S-F9?-#5B85]A
M,F0T7S,T8S,U9C8R,V4T-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E8F5E.#,R8E]F,S9F7S0U8F%?83)D-%\S-&,S-68V,C-E-#<O5V]R:W-H
M965T<R]3:&5E=#`Y+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%3D4^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R
M/CQS=')O;F<^3F]T92`U("T@4W1O8VMH;VQD97)S)R!%<75I='D\8G(^/"]S
M=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS
M1#$^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\
M+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E
M<R!T;R!&:6YA;F-I86P@4W1A=&5M96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@
M("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3=&]C:VAO;&1E<G,G($5Q=6ET>2!.
M;W1E($1I<V-L;W-U<F4@6U1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T
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M9&EV/CPO9&EV/CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!
M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!
M3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7-T>6QE
M.B!I=&%L:6,[)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXR,#$Q(%!R:79A=&4@4&QA8V5M96YT/"]D:78^
M/"]D:78^/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=.
M.B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD
M:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^
M/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)FYB<W`[/"]D:78^/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$
M)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'
M2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/DEN($IU;F4@,C`Q,2P@
M=V4@<V]L9"`X+C`@;6EL;&EO;B!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C
M:R!F;W(@;F5T('!R;V-E961S(&]F("0R,BXX(&UI;&QI;VX@*&YE="!O9B!A
M<'!R;WAI;6%T96QY("0Q+C(@;6EL;&EO;B!I;B!I<W-U86YC92!C;W-T<RDN
M($9O<B!E86-H('-H87)E('!U<F-H87-E9"P@=&AE(&EN=F5S=&]R<R!R96-E
M:79E9"!O;F4@=V%R<F%N="!T;R!P=7)C:&%S92`P+C4@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!A="!A;B!E>&5R8VES92!P<FEC92!O9B`D,RXV,"!P97(@
M<VAA<F4N(%1H92!W87)R86YT<R!W97)E(&EM;65D:6%T96QY(&5X97)C:7-A
M8FQE(&%N9"!E>'!I<F4@;VX@2G5L>29N8G-P.S$L)FYB<W`[,C`Q-BX@5&AE
M('=A<G)A;G1S(&UA>2!B92!E>&5R8VES960@9F]R(&-A<V@@;VYL>2P@;W(L
M(&EF(&$@<F5G:7-T<F%T:6]N('-T871E;65N="!I<R!N;W0@=&AE;B!E9F9E
M8W1I=F4@86YD(&%V86EL86)L92!F;W(@=&AE(')E<V%L92!O9B!T:&4@<VAA
M<F5S(&]F(&-O;6UO;B!S=&]C:R!I<W-U86)L92!U<&]N(&5X97)C:7-E(&]F
M('1H92!W87)R86YT<RP@8GD@<W5R<F5N9&5R(&]F('-U8V@@=V%R<F%N="P@
M;W(@82!P;W)T:6]N(&]F('-U8V@@=V%R<F%N="P@8GD@=V%Y(&]F(&-A<VAL
M97-S(&5X97)C:7-E+B!4:&5R92!I<R!N;R!R:6=H="!T;R!E>&5R8VES92!T
M:&4@=V%R<F%N=',@=&\@=&AE(&5X=&5N="!T:&%T+"!A9G1E<B!G:79I;F<@
M969F96-T('1O('-U8V@@97AE<F-I<V4@=&AE(&AO;&1E<B!W;W5L9"!B96YE
M9FEC:6%L;'D@;W=N(&EN(&5X8V5S<R!O9B`Y+CDY)2!O9B!O=7(@;W5T<W1A
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M="!O;FQY('5P;VX@=&AE(&5X<&ER871I;VX@;V8@82`V,2UD87D@;F]T:6-E
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M4F]M86XL(%1I;65S+"!S97)I9B<^3VX@2G5L>2`R.2P@,C`Q,2P@=V4@9FEL
M960@82!R96=I<W1R871I;VX@<W1A=&5M96YT('=I=&@@=&AE(%-%0R!T;R!R
M96=I<W1E<B!F;W(@<F5S86QE('1H92!S:&%R97,@86YD('1H92!S:&%R97,@
M;V8@8V]M;6]N('-T;V-K(&ES<W5A8FQE('5P;VX@=&AE(&5X97)C:7-E(&]F
M('1H92!W87)R86YT<RX@5&AE(')E9VES=')A=&EO;B!S=&%T96UE;G0@=V%S
M(&1E8VQA<F5D(&5F9F5C=&EV92!O;B!!=6=U<W0@-"P@,C`Q,2X@5V4@87)E
M(&]B;&EG871E9"!T;R!M86EN=&%I;B!T:&4@969F96-T:79E;F5S<R!O9B!T
M:&4@<F5G:7-T<F%T:6]N('-T871E;65N="!U;G1I;"!T:&4@:6YV97-T;W)S
M(&%R92!A8FQE('1O('-E;&P@<VAA<F5S(&%N9"!T:&4@<VAA<F5S(&]F(&-O
M;6UO;B!S=&]C:R!U;F1E<FQY:6YG('1H92!W87)R86YT<R!W:71H;W5T(&QI
M;6ET871I;VX@;W(@<F5S=')I8W1I;VX@=6YD97(@4G5L92`Q-#0@;V8@=&AE
M(%-E8W5R:71I97,@06-T(&]F(#$Y,S,L(&%S(&%M96YD960@*"8C>#(P,6,[
M4G5L92`Q-#0F(W@R,#%D.RDN(%1H97)E(&ES(&-U<G)E;G1L>2!O;FQY(&]N
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M;65N="!U;G1I;"!I="!P<F]V:61E<R!N;W1I8V4@;W1H97)W:7-E+B`\+V1I
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M;F<@=&AE('1H<F5E(&UO;G1H<R!E;F1E9"!-87)C:"`S,2P@,C`Q-"P@=V%R
M<F%N="!H;VQD97)S(&5X97)C:7-E9"`Q-#0L,#0P('=A<G)A;G1S('5N9&5R
M('1H92!C87-H;&5S<R!E>&5R8VES92!P<F]V:7-I;VX@:6X@=&AE('=A<G)A
M;G0@86=R965M96YT+"!W:&EC:"!R97-U;'1E9"!I;B!T:&4@;F5T(&ES<W5A
M;F-E(&]F(#$P."PT,#D@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A;F0@;F\@
M;F5T(&-A<V@@<')O8V5E9',@=&\@=7,N/"]D:78^/"]D:78^("`\9&EV('-T
M>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.
M12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^("`\9&EV('-T
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M26X@2G5L>2`R,#$R+"!W92!S;VQD(&%P<')O>&EM871E;'D@-2XQ(&UI;&QI
M;VX@<VAA<F5S(&]F(&]U<B!C;VUM;VX@<W1O8VL@870@82!P=7)C:&%S92!P
M<FEC92!O9B`D,3`N-3`@<&5R('-H87)E+"!R97-U;'1I;F<@:6X@;F5T('!R
M;V-E961S(&]F(&%P<')O>&EM871E;'D@)#4P+C4@;6EL;&EO;B`H;F5T(&]F
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M,3(N(#PO9&EV/CPO9&EV/B`@("`@(#QD:78@<W1Y;&4],T0G($U!4D=)3BU"
M3U143TTZ(#!P>#L@34%21TE.+51/4#H@,'!X)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N)SXF;F)S<#L\+V1I=CX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M;G0M=V5I9VAT.B!B;VQD.R<^,C`Q,R!#;VUM;VX@4W1O8VL@3V9F97)I;F<\
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M97<@4F]M86XL(%1I;65S+"!S97)I9B<^26X@3F]V96UB97(@,C`Q,RP@=V4@
M<V]L9"!A<'!R;WAI;6%T96QY(#<N-R!M:6QL:6]N('-H87)E<R!O9B!O=7(@
M8V]M;6]N('-T;V-K(&%T(&$@<'5B;&EC(&]F9F5R:6YG('!R:6-E(&]F("0X
M+C`P('!E<B!S:&%R92X@5V4@<F5C96EV960@=&]T86P@;F5T('!R;V-E961S
M(&]F(&%P<')O>&EM871E;'D@)#4W+C@@;6EL;&EO;B`H;F5T(&]F(&%P<')O
M>&EM871E;'D@)#,N.29N8G-P.VUI;&QI;VX@:6X@:7-S=6%N8V4@8V]S=',I
M+B!4:&4@;V9F97)I;F<@=V%S(&UA9&4@<'5R<W5A;G0@=&\@86X@969F96-T
M:79E(')E9VES=')A=&EO;B!S=&%T96UE;G0L('=H:6-H('=A<R!P<F5V:6]U
M<VQY(&9I;&5D('=I=&@@=&AE(%-%0RX@/"]D:78^/"]D:78^("`\9&EV('-T
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M/CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S
M=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7-T>6QE.B!I=&%L:6,[
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXR,#$T($-O;6UO;B!3=&]C:R!/9F9E<FEN9SPO9&EV/CPO9&EV
M/CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S
M=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P
M.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S
M=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.
M1$5.5#H@,S9P="<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF)SY);B!*=6YE(#(P,30L('=E('-O;&0@87!P<F]X:6UA
M=&5L>2`T+C@@;6EL;&EO;B!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A
M="!A('!U8FQI8R!O9F9E<FEN9R!P<FEC92!O9B`D,3$N-S4@<&5R('-H87)E
M+B!);B!A9&1I=&EO;BP@87,@82!C;VUP;VYE;G0@;V8@=&AE(&]F9F5R:6YG
M+"!W92!S;VQD(#8P,"PP,#`@<')E+69U;F1E9"!W87)R86YT<R!T;R!P=7)C
M:&%S92!S:&%R97,@;V8@;W5R(&-O;6UO;B!S=&]C:R!A="!A('!U8FQI8R!O
M9F9E<FEN9R!P<FEC92!O9B`D,3$N-S0@<&5R('-H87)E+B!4:&4@<')E+69U
M;F1E9"!W87)R86YT<R!H879E(&%N(&5X97)C:7-E('!R:6-E(&]F("0P+C`Q
M('!E<B!S:&%R92!A;F0@97AP:7)E(&]N($IU;F4@,S`L(#(P,C$N(%=E(')E
M8V5I=F5D('1O=&%L(&YE="!P<F]C965D<R!O9B!A<'!R;WAI;6%T96QY("0U
M."XY(&UI;&QI;VX@*&YE="!O9B!A<'!R;WAI;6%T96QY("0T+C`@;6EL;&EO
M;B!I;B!I<W-U86YC92!C;W-T<RD@9G)O;2!T:&4@<V%L92!O9B!T:&4@8V]M
M;6]N('-T;V-K(&%N9"!T:&4@<')E+69U;F1E9"!W87)R86YT<RX@5&AE(&]F
M9F5R:6YG('=A<R!M861E('!U<G-U86YT('1O(&%N(&5F9F5C=&EV92!R96=I
M<W1R871I;VX@<W1A=&5M96YT+"!W:&EC:"!W87,@<')E=FEO=7-L>2!F:6QE
M9"!W:71H('1H92!314,N(#PO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@
M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4
M.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@
M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4
M.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+7-T>6QE.B!I=&%L:6,[)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UW96EG:'0Z(&)O;&0[)SY3=&]C:R!/<'1I;VX@17AE<F-I<V5S
M/"]D:78^/"]D:78^/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4
M+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N
M,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9B<^)FYB<W`[/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4
M+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N
M,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/D9O<B!T:&4@=&AR964@;6]N=&AS
M(&5N9&5D($UA<F-H(#,Q+"`R,#$U+"`S-3$L-CDX('-H87)E<R!O9B!C;VUM
M;VX@<W1O8VL@=V5R92!I<W-U960@<'5R<W5A;G0@=&\@=&AE(&5X97)C:7-E
M(&]F('-T;V-K(&]P=&EO;G,L(')E<W5L=&EN9R!I;B!P<F]C965D<R!T;R!U
M<R!O9B!A<'!R;WAI;6%T96QY("0R+#@W."PP,#`N($9O<B!T:&4@=&AR964@
M;6]N=&AS(&5N9&5D($UA<F-H(#,Q+"`R,#$T+"!O<'1I;VX@:&]L9&5R<R!E
M>&5R8VES960@,C<U+#,U,B!S=&]C:R!O<'1I;VYS+"!A('!O<G1I;VX@;V8@
M=VAI8V@@=V5R92!E>&5R8VES960@=6YD97(@=&AE(&-A<VAL97-S(&5X97)C
M:7-E('!R;W9I<VEO;B!O9B!O=7(@,C`P-R!!;65N9&5D(&%N9"!297-T871E
M9"!%<75I='D@26YC96YT:79E(%!L86XL(')E<W5L=&EN9R!I;B!T:&4@;F5T
M(&ES<W5A;F-E(&]F(#(Q-2PS-3`@<VAA<F5S(&]F(&-O;6UO;B!S=&]C:R!A
M;F0@8V%S:"!P<F]C965D<R!T;R!U<R!O9B!A<'!R;WAI;6%T96QY("0Y-3@L
M,#`P+CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@
M;&5F=#L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/B9N8G-P.SPO9&EV/CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$58
M5"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/E-T;V-K+4)A<V5D($-O;7!E;G-A=&EO;CPO9&EV/CPO9&EV
M/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@;&5F=#L@34%2
M1TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO
M9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%2
M1TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P
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M9"`R,#$T("AI;B!T:&]U<V%N9',I.CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL
M93TS1"<@5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0[($Q)3D4M2$5)
M1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68G/B9N8G-P.SPO9&EV/CPO9&EV/B`@/&1I=CX@("`\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,#`E.R!415A4
M+4E.1$5.5#H@,'!X.R!W:61T:#H@-S`P<'@[)R!C96QL<W!A8VEN9STS1#`@
M8V5L;'!A9&1I;F<],T0P(&)O<F1E<CTS1#`^("`@("`@("`@/'1R/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`G/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XM
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M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/E1H<F5E($UO;G1H<R!%;F1E9#PO9&EV/CPO9&EV/CPO
M9&EV/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SY-87)C:"`S,3PO
M9&EV/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/BP\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q
M<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`\+W1R/B`@("`@/'1R
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!-
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M=V5I9VAT.B!B;VQD.R<^,C`Q-3PO9&EV/CPO9&EV/CPO9&EV/CPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@=&]P.R!0041$24Y'+4)/5%1/33H@,7!X)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I
M=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D52
M5$E#04PM04Q)1TXZ('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=.
M.B!T;W`[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X],T0R
M/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
M,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXR,#$T/"]D:78^/"]D
M:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%9%4E1)0T%,+4%,24=..B!T;W`[(%!!1$1)3D<M0D]45$]-.B`Q<'@G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`\+W1R/B`@("`@/'1R/B`@
M("`@(#QT9#XF;F)S<#L\+W1D/B`@("`@(#QT9#XF;F)S<#L\+W1D/B`@("`@
M(#QT9#XF;F)S<#L\+W1D/B`@("`@(#QT9#XF;F)S<#L\+W1D/B`@("`@(#QT
M9#XF;F)S<#L\+W1D/B`@("`@(#QT9#XF;F)S<#L\+W1D/B`@("`@(#QT9#XF
M;F)S<#L\+W1D/B`@("`@(#QT9#XF;F)S<#L\+W1D/B`@("`@(#QT9#XF;F)S
M<#L\+W1D/B`@("`@/"]T<CX@("`@(#QT<B!S='EL93TS1"="04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F)SX@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`W,"4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%
M6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8G/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=.
M.B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD
M:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^
M4F5S96%R8V@@86YD(&1E=F5L;W!M96YT/"]D:78^/"]D:78^/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.
M+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)#PO=&0^
M("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!R:6=H=#L@
M34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^
M.#`V/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)
M1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z
M(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@;F]W<F%P/3-$;F]W
M<F%P/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8G/B0\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8G/C$L,C8R/"]T9#X@("`@("`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^("`@("`\+W1R
M/B`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
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M9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q
M<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,S@N
M-W!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXQ+#<T-3PO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[(%!!1$1)3D<M0D]45$]-.B`Q<'@[($U!
M4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G(&YO
M=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
M(#%P>"!S;VQI9#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[
M/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(
M.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H=#L@34%21TE.
M+4Q%1E0Z(#,X+C=P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^,2PW
M,#<\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!0041$24Y'+4)/5%1/
M33H@,7!X.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@("`@(#PO='(^
M("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^
M("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!L969T.R!-05)'24XM3$5&5#H@
M,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SX@/&1I=B!S='EL93TS
M1"<@5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4
M.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68G/E-T;V-K+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E(&EN
M8VQU9&5D(&EN(&]P97)A=&EN9R!E>'!E;G-E<SPO9&EV/CPO9&EV/CPO=&0^
M("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@34%21TE.+4Q%1E0Z
M(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)#PO=&0^("`@("`@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXR+#4U,3PO=&0^("`@("`@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[(%!!1$1)3D<M0D]45$]-.B`S<'@[($U!4D=)
M3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A
M<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P
M>"!D;W5B;&4[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8G/B0\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R
M:6=H=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<^,BPY-CD\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!0041$
M24Y'+4)/5%1/33H@,W!X.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@
M("`@(#PO='(^("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9B<^("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T)!0TM'
M4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^
M("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G
M/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T)!
M0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO
M=&0^("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`\+W1R/B`@("`@/'1R
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B`@("`@(#QT
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M/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@9&]U
M8FQE.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)SXD/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G
M/C`N,#D\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!0041$24Y'+4)/
M5%1/33H@,W!X.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@("`@("`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^
M)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/
M5%1/33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!-05)'24XM3$5&5#H@,'!T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXD/"]T9#X@("`@("`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L
M93L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8G/C`N,3,\+W1D/B`@("`@(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!0041$24Y'+4)/5%1/33H@,W!X.R!-05)'24XM3$5&5#H@
M,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@("`@(#PO='(^("`@("`@(#PO=&%B;&4^("`\+V1I
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M07,@;V8@36%R8V@@,S$L(#(P,34L('1H97)E('=A<R`D,CDL.30W+#`P,"!O
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M="!O=F5R(&$@=V5I9VAT960M879E<F%G92!P97)I;V0@;V8@,BXT)FYB<W`[
M>65A<G,N/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=.
M.B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD
M:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^
M)FYB<W`[/"]D:78^/"]D:78^("`\9&EV('-T>6QE/3-$)R!415A4+4%,24=.
M.B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%
M6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M)FYB<W`[/"]D:78^/"]D:78^/"]D:78^("`\9&EV/B`@(#QT86)L92!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$P,"4[(%1%6%0M24Y$14Y4
M.B`P<'@[('=I9'1H.B`W,#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@8F]R9&5R/3-$,#X@("`@("`@("`\='(^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ
M(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($U!4D=)
M3BU,1494.B`P<'0G(&-O;'-P86X],T0V/B`\9&EV('-T>6QE/3-$)R!415A4
M+4%,24=..B!C96YT97([($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR
M-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG
M:'0Z(&)O;&0[)SY-87)C:"`S,2P\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`\
M+W1R/B`@("`@/'1R/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^
M/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@
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M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`\+V1I=CX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O
M;&0[)SXQ-3PO9&EV/CPO9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!0
M041$24Y'+4)/5%1/33H@,7!X)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X],T0R/B`\
M9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!4D=)3CH@,'!T
M.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXR,#PO9&EV/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/C$T
M/"]D:78^/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%!!1$1)3D<M
M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F
M;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`\+W1R
M/B`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
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M<W0@<F%T93PO9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4
M+4%,24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<^,2XV/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9B<@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@5$58
M5"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M
M0T],3U(Z("-C8V5E9F8G/C(N,#PO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G(&YO=W)A<#TS1&YO=W)A<#XE/"]T9#X@("`@(#PO='(^("`@("`\='(@
M<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^("`@("`@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XM3$5&5#H@,'!T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SX@/&1I=B!S='EL93TS1"<@5$58
M5"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68G/D1I=FED96YD('EI96QD/"]D:78^/"]D:78^/"]T9#X@("`@("`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^
M)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,3DN
M-35P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^,"XP/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494
M.B`Q.2XU-7!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXP+C`\+W1D
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E
M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!N;W=R87`],T1N;W=R87`^)3PO
M=&0^("`@("`\+W1R/B`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8G/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
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M/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T
M9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
M,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT
M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M)SXY,2XW/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%
M1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@;F]W<F%P/3-$
M;F]W<F%P/B4\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\
M+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z
M(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@<FEG
M:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G/C$P-"XQ/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.
M+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@;F]W<F%P
M/3-$;F]W<F%P/B4\+W1D/B`@("`@/"]T<CX@("`@(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SX@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M
M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J
M=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^17AP
M96-T960@;&EF92`H>65A<G,I/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB
M<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)
M1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXV+C$\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@
M-31P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^-BXP/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO
M=&0^("`@("`\+W1R/B`@("`@("`\+W1A8FQE/B`@/"]D:78^("`@("`@/&1I
M=B!S='EL93TS1"<@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM5$]0.B`P
M<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XG/B9N8G-P.SPO
M9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF
M>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U.R!415A4+4E.1$5.
M5#H@,S9P="<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF)SY792!E<W1I;6%T960@=&AE(&9A:7(@=F%L=64@;V8@96%C
M:"!P=7)C:&%S92!R:6=H="!G<F%N=&5D('5N9&5R(&]U<B`Q.3DW($5M<&QO
M>65E(%-T;V-K(%!U<F-H87-E(%!L86X@870@=&AE(&)E9VEN;FEN9R!O9B!E
M86-H(&YE=R!O9F9E<FEN9R!P97)I;V0@=7-I;F<@=&AE($)L86-K+5-C:&]L
M97,@;W!T:6]N('!R:6-I;F<@;6]D96PN(%1H97)E('=E<F4@;F\@;F5W(&]F
M9F5R:6YG('!E<FEO9',@9F]R('1H92!Q=6%R=&5R<R!E;F1E9"!-87)C:"`S
M,2P@,C`Q-2!A;F0@,C`Q-"X\+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G
M(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(
M5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF)SXF;F)S<#L\+V1I=CX\+V1I=CX@(#QD:78@<W1Y;&4],T0G
M(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(
M5#H@,2XR-3L@5$585"U)3D1%3E0Z(#,V<'0G/CQD:78@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^5&AE(&9O;&QO=VEN9R!T
M86)L92!S=6UM87)I>F5S('1H92!S=&]C:R!O<'1I;VX@86-T:79I='D@9F]R
M('1H92!T:')E92!M;VYT:',@96YD960@36%R8V@F;F)S<#LS,2PF;F)S<#LR
M,#$U.CPO9&EV/CPO9&EV/B`@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@
M:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/B9N
M8G-P.SPO9&EV/CPO9&EV/B`@/&1I=CX@("`\=&%B;&4@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%=)1%1(.B`Q,#`E.R!415A4+4E.1$5.5#H@,'!X.R!W
M:61T:#H@-S`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P
M(&)O<F1E<CTS1#`^("`@("`@("`@/'1R/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO
M9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@8V5N=&5R)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S
M<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^
M/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@5$585"U!3$E'3CH@8V5N=&5R)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VTG/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!4
M15A4+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X]
M,T0R/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!4D=)
M3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SY796EG:'1E9"T\
M+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB
M<W`[/"]D:78^/"]T9#X@("`@(#PO='(^("`@("`\='(^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO
M9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!C96YT97(G/CQD
M:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L
M9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S
M<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^
M/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!415A4+4%,24=..B!C96YT97(G/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO
M9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.+4Q%1E0Z(#!P="<@
M8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D%V
M97)A9V4\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I
M=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD
M.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@(#PO='(^("`@("`\='(^("`@("`@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW
M96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N
M8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!C96YT
M97(G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[
M/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@
M34%21TE.+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4
M.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/E=E:6=H=&5D+3PO9&EV/CPO9&EV/CPO9&EV/CPO
M=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.+4Q%1E0Z(#!P="<@8V]L<W!A
M;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/E)E;6%I;FEN
M9SPO9&EV/CPO9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M;F)S<#L\+V1I=CX\+W1D/B`@("`@/"]T<CX@("`@(#QT<CX@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VTG/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[
M/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&-E;G1E<B<^
M/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N
M8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I
M=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
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M9VAT.B!B;VQD.R<^079E<F%G93PO9&EV/CPO9&EV/CPO9&EV/CPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O
M;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE.+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^
M(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P
M<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/D-O;G1R86-T=6%L/"]D
M:78^/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P
M.SPO9&EV/CPO=&0^("`@("`\+W1R/B`@("`@/'1R/B`@("`@(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N
M8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!C96YT
M97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X],T0R/B`\9&EV('-T>6QE
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M+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#
M04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT
M+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!415A4+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P
M86X],T0R/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!
M4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SX\9&EV('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SY%>&5R8VES
M93PO9&EV/CPO9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D
M:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D
M:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE.+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/E1E<FT\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@(#PO='(^("`@
M("`\='(^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,
M24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X],T0R/B`\
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M9&EV/CPO9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]4
M5$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)FYB<W`[/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO
M9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
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M.R<^4')I8V4\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q
M<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE.+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/BA996%R<RD\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)
M3D<M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE
M.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^("`@("`\
M+W1R/B`@("`@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
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M,2P@,C`Q-3PO9&EV/CPO9&EV/CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO=&0^("`@
M("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4
M+4%,24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<^-RPY,3@\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[
M/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(
M.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)#PO=&0^("`@("`@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!R:6=H=#L@34%21TE.+4Q%
M1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^."XV.3PO=&0^
M("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@
M("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C<N
M.3(\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@
M,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R
M87`^)FYB<W`[/"]T9#X@("`@(#PO='(^("`@("`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^("`@("`@/'1D('-T>6QE/3-$)T9/
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M('-E<FEF)SY'<F%N=&5D/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[
M/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(
M.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXU-#PO=&0^("`@("`@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`@("`@(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF
M;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&
M5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXD/"]T9#X@("`@
M("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXQ,2XU
M,CPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!72414
M2#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P
M<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G(&YO=W)A<#TS1&YO=W)A
M<#XF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4
M+4%,24=..B!L969T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S
M<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9B<^)FYB<W`[/"]T9#X@("`@(#PO='(^("`@("`\='(@<W1Y;&4],T0G0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^("`@("`@/'1D('-T>6QE/3-$)T9/
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M('-E<FEF)SY%>&5R8VES960\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S
M<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B@S-3(\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^(#QD:78@<W1Y;&4],T0G
M(%1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@
M,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF)SXI/"]D:78^/"]D:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@
M("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)#PO=&0^("`@("`@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!415A4+4%,24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#!P
M=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^."XQ.#PO=&0^("`@("`@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D
M/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB
M<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!L969T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T
M9#X@("`@(#PO='(^("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9B<^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
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M<F5D(&%N9"!F;W)F96ET960\+V1I=CX\+V1I=CX\+W1D/B`@("`@(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S
M<#L\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R:6=H
M=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9B<^*#,R-SPO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,'!X.R!-05)'
M24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!N;W=R
M87`],T1N;W=R87`^(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&QE9G0[
M($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SXI/"]D:78^/"]D
M:78^/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)
M1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<^)#PO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,
M24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9B<^,3`N-C<\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ
M(#!P>#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^("`@("`@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`@("`@
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T
M9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&QE9G0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$
M15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!P>#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@("`@(#PO
M='(^("`@("`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9B<^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!L969T.R!-05)'24XM3$5&
M5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SX@/&1I=B!S='EL
M93TS1"<@5$585"U!3$E'3CH@;&5F=#L@34%21TE..B`P<'0[($Q)3D4M2$5)
M1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68G/D)A;&%N8V4@870@36%R8V@@,S$L(#(P,34\+V1I=CX\
M+V1I=CX\+W1D/B`@("`@(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`@("`@(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO=&0^("`@("`@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXW+#(Y,SPO=&0^("`@("`@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0
M041$24Y'+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T
M9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
M)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^
M)#PO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!72414
M2#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!R
M:6=H=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<^."XV-3PO=&0^("`@("`@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,'!X.R!-
M05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N
M;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@
M("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<^)FYB<W`[/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%
M6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$
M+4-/3$]2.B`C8V-E969F)SXX+C,Q/"]T9#X@("`@("`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]4
M5$]-.B`P<'@[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`@("`@/"]T
M<CX@("`@("`@/"]T86)L93X@(#PO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\
M+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96)E93@S,F)?9C,V9E\T-6)A
M7V$R9#1?,S1C,S5F-C(S930W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O
M+T,Z+V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T-R]7;W)K
M<VAE971S+U-H965T,3`N:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN
M9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[
M(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@
M/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E
M>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J
M879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES
M($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT
M86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5.13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY.;W1E(#8@+2!);F-O;64@5&%X97,\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E<R!T;R!&
M:6YA;F-I86P@4W1A=&5M96YT<SPO<W1R;VYG/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y);F-O;64@5&%X($1I<V-L;W-U<F4@6U1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)R!415A4
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M>"!A<W-E=',@87,@;V8@36%R8V@@,S$L(#(P,34N/"]D:78^/"]D:78^("`\
M9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P
M=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^("`\
M9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P
M=#L@3$E.12U(14E'2%0Z(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&
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M:&%N(&$@-3`E(&QI:V5L:6AO;V0@;V8@8F5I;F<@<W5S=&%I;F5D+B!4:&5R
M92!H879E(&)E96X@;F\@;6%T97)I86P@8VAA;F=E<R!I;B!O=7(@=6YR96-O
M9VYI>F5D('1A>"!B96YE9FET<R!S:6YC92!-87)C:"`S,2P@,C`Q-2!A;F0L
M(&%S('-U8V@L(&1I<V-L;W-U<F5S(&EN8VQU9&5D(&EN(&]U<B`R,#$T($%N
M;G5A;"!297!O<G0@;VX@1F]R;29N8G-P.S$P+4L@9F]R('1H92!Y96%R(&5N
M9&5D($1E8V5M8F5R)FYB<W`[,S$L(#(P,30@8V]N=&EN=64@=&\@8F4@<F5L
M979A;G0@9F]R('1H92!P97)I;V0@96YD960@36%R8V@@,S$L(#(P,34N(#PO
M9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM
M+3U?3F5X=%!A<G1?96)E93@S,F)?9C,V9E\T-6)A7V$R9#1?,S1C,S5F-C(S
M930W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5B964X,S)B7V8S
M-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T-R]7;W)K<VAE971S+U-H965T,3$N
M:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT
M86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S
M8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I
M=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E
M=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS
M1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C
M<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E
M<&]R="!I9#TS1$E$,$5:1$%#/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/E-I
M9VYI9FEC86YT($%C8V]U;G1I;F<@4&]L:6-I97,@*%!O;&EC:65S*3QB<CX\
M+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N
M/3-$,3XS($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R
M/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#X\<W1R;VYG/D%C
M8V]U;G1I;F<@4&]L:6-I97,@6T%B<W1R86-T73PO<W1R;VYG/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYS;VQI9&%T:6]N+"!0;VQI
M8WD@6U!O;&EC>2!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P="<^/&1I
M=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P="<^/&1I=B!S='EL93TS1"<@
M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4
M.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
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M86YD<R!I;B!-87)C:"`R,#$U+B!(97)O;B!4:&5R87!E=71I8W,@0BY6+B!H
M87,@;F\@;W!E<F%T:6]N<R!A;F0@;F\@;6%T97)I86P@87-S971S(&]R(&QI
M86)I;&ET:65S(&%N9"!T:&5R92!H879E(&)E96X@;F\@<VEG;FEF:6-A;G0@
M=')A;G-A8W1I;VYS(')E;&%T960@=&\@2&5R;VX@5&AE<F%P975T:6-S($(N
M5BX@<VEN8V4@:71S(&EN8V5P=&EO;BX\+V1I=CX\+V1I=CX\+V1I=CX\+V1I
M=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/E5S92!O9B!%<W1I;6%T97,L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US
M:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y
M.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4]
M,T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^57-E
M(&]F($5S=&EM871E<SPO9&EV/CPO9&EV/CPO9&EV/CQD:78@<W1Y;&4],T0G
M(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(
M5#H@,2XR-2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF)SXF;F)S<#L\+V1I=CX\+V1I=CX\9&EV('-T>6QE/3-$)R!4
M15A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z
M(#$N,C4[(%1%6%0M24Y$14Y4.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V%S:"!A;F0@
M0V%S:"!%<75I=F%L96YT<RP@4&]L:6-Y(%M0;VQI8WD@5&5X="!";&]C:UT\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQD:78@<W1Y;&4],T0G
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M93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M
M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M:78^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R
M(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS
M1'1O<#Y%87)N:6YG<R!097(@4VAA<F4L(%!O;&EC>2!;4&]L:6-Y(%1E>'0@
M0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE
M=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N
M="US:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T
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M93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M
M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
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M(%1I;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^/&1I=B!S='EL93TS
M1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)
M1TA4.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S='EL93TS1"=D
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M9"!B92!A;G1I+61I;'5T:79E+B`\+V1I=CX\+V1I=CX\9&EV('-T>6QE/3-$
M)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'
M2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9B<^)FYB<W`[/"]D:78^/"]D:78^/&1I=B!S='EL93TS1"<@
M5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4
M.B`Q+C(U.R!415A4+4E.1$5.5#H@,S9P="<^/&1I=B!S='EL93TS1"=D:7-P
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M<#L\+V1I=CX\+V1I=CX\9&EV/B`\=&%B;&4@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q,#`E.R!415A4+4E.1$5.5#H@,'!X.R!W:61T:#H@
M-S`P<'@[)R!C96QL<W!A8VEN9STS1#`@8V5L;'!A9&1I;F<],T0P(&)O<F1E
M<CTS1#`^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@=&]P)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#8^(#QD:78@<W1Y;&4],T0G(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q
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M;F4[(%!!1$1)3D<M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO
M=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!6
M15)424-!3"U!3$E'3CH@=&]P)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN
M;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T
M;W`G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%2
M1TE.+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%
M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E
M:6=H=#H@8F]L9#LG/C(P,34\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`[
M(%!!1$1)3D<M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!-
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M=V5I9VAT.B!B;VQD.R<^,C`Q-#PO9&EV/CPO9&EV/CPO9&EV/CPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O
M<#L@4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T
M9#X@/"]T<CX@/'1R/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P
M.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#
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M3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[
M(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,S@N-W!T.R!"04-+
M1U)/54Y$+4-/3$]2.B`C8V-E969F)SXW+#(Y,SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,S@N-W!T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C8V-E969F)SXW+#(W,SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-
M05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N
M;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$
M)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)
M1TXZ(&IU<W1I9GD[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8G/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T
M:69Y.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^5V%R<F%N
M=',@;W5T<W1A;F1I;F<\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@
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M<FEG:'0[($U!4D=)3BU,1494.B`S."XW<'0[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8G/C,L.#0S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)
M3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G(&YO=W)A
M<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
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M4D=)3BU,1494.B`S."XW<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G
M/C,L.#(U/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!72414
M2#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P
M<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G(&YO=W)A<#TS1&YO=W)A
M<#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#
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M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)
M1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!415A4+4%,24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#,W+CEP=#L@0D%#
M2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^-BPW-S<\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,
M24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#,W+CEP=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<^-BPS.#4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@
M34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@
M;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#PO='(^(#PO=&%B;&4^(#PO
M9&EV/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^0V]M<')E:&5N<VEV92!);F-O;64L(%!O;&EC
M>2!;4&]L:6-Y(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S
M(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\9&EV('-T>6QE/3-$)R!4
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M=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4
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M<B!S;W5R8V5S+B`\+V1I=CX\+V1I=CX\+V1I=CX\+V1I=CX\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYE=R!!8V-O
M=6YT:6YG(%!R;VYO=6YC96UE;G1S+"!0;VQI8WD@6U!O;&EC>2!497AT($)L
M;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@
M<F]M86X[(&9O;G0M<VEZ93H@,3!P="<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE<R!N97<@<F]M86X[(&9O;G0M
M<VEZ93H@,3!P="<^/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF
M>3L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/E)E
M8V5N="!!8V-O=6YT:6YG(%!R;VYO=6YC96UE;G1S/"]D:78^/"]D:78^/"]D
M:78^/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE.
M.B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L
M87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
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M26X@2F%N=6%R>2`R,#$U+"!T:&4@1FEN86YC:6%L($%C8V]U;G1I;F<@4W1A
M;F1A<F1S($)O87)D("@F(W@R,#%C.T9!4T(F(W@R,#%D.RD@:7-S=65D($%C
M8V]U;G1I;F<@4W1A;F1A<F1S(%5P9&%T92`H)B-X,C`Q8SM!4U4F(W@R,#%D
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M,#%D.RDN($%352`R,#$U+3`Q(&5L:6UI;F%T97,@=&AE(&-O;F-E<'0@;V8@
M97AT<F%O<F1I;F%R>2!I=&5M<R!F<F]M($=!05`N($9!4T(@8V]N8VQU9&5D
M('1H870@05-5(#(P,34M,#$@=VEL;"!N;W0@<F5S=6QT(&EN(&$@;&]S<R!O
M9B!I;F9O<FUA=&EO;B!B96-A=7-E(&%L=&AO=6=H($%352`R,#$U+3`Q('=I
M;&P@96QI;6EN871E('1H92!R97%U:7)E;65N=',@:6X@4W5B=&]P:6,@,C(U
M+3(P(&9O<B!R97!O<G1I;F<@96YT:71I97,@=&\@8V]N<VED97(@=VAE=&AE
M<B!A;B!U;F1E<FQY:6YG(&5V96YT(&]R('1R86YS86-T:6]N(&ES(&5X=')A
M;W)D:6YA<GDL('1H92!P<F5S96YT871I;VX@86YD(&1I<V-L;W-U<F4@9W5I
M9&%N8V4@9F]R(&ET96US('1H870@87)E('5N=7-U86P@:6X@;F%T=7)E(&]R
M(&]C8W5R(&EN9G)E<75E;G1L>2!W:6QL(&)E(')E=&%I;F5D(&%N9"!W:6QL
M(&)E(&5X<&%N9&5D('1O(&EN8VQU9&4@:71E;7,@=&AA="!A<F4@8F]T:"!U
M;G5S=6%L(&EN(&YA='5R92!A;F0@:6YF<F5Q=65N=&QY(&]C8W5R<FEN9RX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="US='EL93H@:71A
M;&EC.R<^(#PO9&EV/CPO9&EV/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9B<^5&AE(&%M96YD;65N=',@:6X\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="US='EL93H@:71A;&EC.R<^
M(#PO9&EV/CPO9&EV/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9B<^05-5(#(P,34M,#$@87)E(&5F9F5C=&EV92!F;W(@
M9FES8V%L('EE87)S+"!A;F0@:6YT97)I;2!P97)I;V1S('=I=&AI;B!T:&]S
M92!F:7-C86P@>65A<G,L(&)E9VEN;FEN9R!A9G1E<B!$96-E;6)E<B`Q-2P@
M,C`Q-2X@02!R97!O<G1I;F<@96YT:71Y(&UA>2!A<'!L>2!T:&4@86UE;F1M
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M('%U87)T97(@;V8@,C`Q-2X@5&AE(&%D;W!T:6]N(&]F('1H:7,@05-5(&1I
M9"!N;W0@:&%V92!A(&UA=&5R:6%L(&EM<&%C="!O;B!O=7(@<F5S=6QT<R!O
M9B!O<&5R871I;VYS(&]R(&9I;F%N8VEA;"!C;VYD:71I;VXN/"]D:78^/"]D
M:78^/&1I=B!S='EL93TS1"<@34%21TE.+4)/5%1/33H@,'!X.R!-05)'24XM
M5$]0.B`P<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4
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M52!.;RX@,C`Q-"TQ-2P@/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M<W1Y;&4Z(&ET86QI8SLG/E!R97-E;G1A=&EO;B!O9B!&:6YA;F-I
M86P@4W1A=&5M96YT<R`F(W@R,#$S.R!';VEN9R!#;VYC97)N("A3=6)T;W!I
M8R`R,#4M-#`I/"]D:78^("@F(W@R,#%C.T%352`R,#$T+3$U)B-X,C`Q9#LI
M+B!!4U4@,C`Q-"TQ-2!R97%U:7)E<R!M86YA9V5M96YT('1O(&%S<V5S<R!A
M;B!E;G1I='DF(W@R,#$Y.W,@86)I;&ET>2!T;R!C;VYT:6YU92!A<R!A(&=O
M:6YG(&-O;F-E<FX@8GD@:6YC;W)P;W)A=&EN9R!A;F0@97AP86YD:6YG('5P
M;VX@8V5R=&%I;B!P<FEN8VEP;&5S('1H870@87)E(&-U<G)E;G1L>2!I;B!5
M;FET960@4W1A=&5S(&%U9&ET:6YG('-T86YD87)D<RX@4W!E8VEF:6-A;&QY
M+"!T:&4@86UE;F1M96YT<R`H,2D@<')O=FED92!A(&1E9FEN:71I;VX@;V8@
M=&AE('1E<FT@<W5B<W1A;G1I86P@9&]U8G0L("@R*2!R97%U:7)E(&%N(&5V
M86QU871I;VX@979E<GD@<F5P;W)T:6YG('!E<FEO9#PO9&EV/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^+"!I;F-L
M=61I;F<@:6YT97)I;2!P97)I;V1S+"`H,RDF;F)S<#MP<F]V:61E('!R:6YC
M:7!L97,@9F]R(&-O;G-I9&5R:6YG('1H92!M:71I9V%T:6YG(&5F9F5C="!O
M9B!M86YA9V5M96YT)B-X,C`Q.3MS('!L86YS+"`H-"D@<F5Q=6ER92!C97)T
M86EN(&1I<V-L;W-U<F5S('=H96X@<W5B<W1A;G1I86P@9&]U8G0@:7,@86QL
M979I871E9"!A<R!A(')E<W5L="!O9B!C;VYS:61E<F%T:6]N(&]F(&UA;F%G
M96UE;G0F(W@R,#$Y.W,@<&QA;G,L("@U*29N8G-P.W)E<75I<F4@86X@97AP
M<F5S<R!S=&%T96UE;G0@86YD(&]T:&5R(&1I<V-L;W-U<F5S('=H96X@<W5B
M<W1A;G1I86P@9&]U8G0@:7,@;F]T(&%L;&5V:6%T960L(&%N9"`H-BDF;F)S
M<#MR97%U:7)E(&%N(&%S<V5S<VUE;G0@9F]R(&$@<&5R:6]D(&]F(&]N92!Y
M96%R(&%F=&5R('1H92!D871E('1H870@=&AE(&9I;F%N8VEA;"!S871E;65N
M=',@87)E(&ES<W5E9"`H;W(@879A:6QA8FQE('1O(&)E(&ES<W5E9"DN(%1H
M92!A;65N9&UE;G1S(&EN($%352`R,#$T+3$U(&%R92!E9F9E8W1I=F4@9F]R
M('1H92!A;FYU86P@<&5R:6]D(&5N9&EN9R!A9G1E<B!$96-E;6)E<B9N8G-P
M.S$U+"`R,#$V+"!A;F0@9F]R(&%N;G5A;"!P97)I;V1S(&%N9"!I;G1E<FEM
M('!E<FEO9',@=&AE<F5A9G1E<BX@16%R;'D@861O<'1I;VX@:7,@<&5R;6ET
M=&5D+B!792!P;&%N('1O(&%D;W!T('1H92!P<F]V:7-I;VYS(&]F($%352`R
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M.B`S-G!T)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68G/DEN($IU;F4@,C`Q-"P@1D%30B!I<W-U960@05-5($YO+B`R
M,#$T+3$R+"`\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="US
M='EL93H@:71A;&EC.R<^0V]M<&5N<V%T:6]N("8C>#(P,3,[(%-T;V-K($-O
M;7!E;G-A=&EO;B`H5&]P:6,@-S$X*3PO9&EV/B`H)B-X,C`Q8SM!4U4@,C`Q
M-"TQ,B8C>#(P,60[*2X@05-5(#(P,30M,3(@<F5Q=6ER97,@=&AA="!A('!E
M<F9O<FUA;F-E('1A<F=E="!T:&%T(&%F9F5C=',@=F5S=&EN9R!A;F0@=&AA
M="!C;W5L9"!B92!A8VAI979E9"!A9G1E<B!T:&4@<F5Q=6ES:71E('-E<G9I
M8V4@<&5R:6]D(&)E('1R96%T960@87,@82!P97)F;W)M86YC92!C;VYD:71I
M;VXN($%352`R,#$T+3$R(&ES(&5F9F5C=&EV92!F;W(@86YN=6%L('!E<FEO
M9',@86YD(&EN=&5R:6T@<&5R:6]D<R!W:71H:6X@=&AO<V4@86YN=6%L('!E
M<FEO9',@8F5G:6YN:6YG(&%F=&5R($1E8V5M8F5R(#$U+"`R,#$U+B!%87)L
M:65R(&%D;W!T:6]N(&ES('!E<FUI='1E9"X@5&AE(&%M96YD;65N=',@:6X@
M05-5(#(P,30M,3(@;6%Y(&5I=&AE<B!B92!A<'!L:65D("AA*29N8G-P.W!R
M;W-P96-T:79E;'D@=&\@86QL(&%W87)D<R!G<F%N=&5D(&]R(&UO9&EF:65D
M(&%F=&5R('1H92!E9F9E8W1I=F4@9&%T92!O<B`H8BD@<F5T<F]S<&5C=&EV
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M;VYS(&]F($%352`R,#$T+3$R(&EN('1H92!F:7)S="!Q=6%R=&5R(&]F(#(P
M,38N(%=E(&1O(&YO="!E>'!E8W0@=&AE(&%D;W!T:6]N(&]F('1H:7,@05-5
M('1O(&AA=F4@82!M871E<FEA;"!I;7!A8W0@;VX@;W5R(')E<W5L=',@;V8@
M;W!E<F%T:6]N<R!O<B!F:6YA;F-I86P@8V]N9&ET:6]N+CPO9&EV/CPO9&EV
M/CPO9&EV/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-
M"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?
M3F5X=%!A<G1?96)E93@S,F)?9C,V9E\T-6)A7V$R9#1?,S1C,S5F-C(S930W
M#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5B964X,S)B7V8S-F9?
M-#5B85]A,F0T7S,T8S,U9C8R,V4T-R]7;W)K<VAE971S+U-H965T,3(N:'1M
M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L
M90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI
M(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS
M1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU
M=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H
M;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP
M=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R
M="!I9#TS1$E$,$5.13X-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S
M/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS1#(^/'-T<F]N9SY.;W1E(#,@
M+2!!8V-O=6YT:6YG(%!O;&EC:65S("A486)L97,I/&)R/CPO<W1R;VYG/CPO
M=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@36]N
M=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/CQS=')O;F<^3F]T97,@5&%B;&5S
M/"]S=')O;F<^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-C
M:&5D=6QE(&]F($%N=&ED:6QU=&EV92!396-U<FET:65S($5X8VQU9&5D(&9R
M;VT@0V]M<'5T871I;VX@;V8@16%R;FEN9W,@4&5R(%-H87)E(%M486)L92!4
M97AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/&1I
M=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T:6UE
M<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P="<^/'1A8FQE('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!724142#H@,3`P)3L@5$585"U)3D1%3E0Z(#!P
M>#L[('=I9'1H.B`W,#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D9&EN
M9STS1#`@8F]R9&5R/3-$,#X@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`G/CQD:78@<W1Y;&4],T0G9&ES
M<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV
M/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O
M;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$
M15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N
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M<W`[/"]D:78^/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`G/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO
M9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#
M04PM04Q)1TXZ('1O<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P.R!"
M3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@
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M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`Q-3PO9&EV/CPO9&EV/CPO9&EV
M/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ('1O<#L@4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[
M/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@=&]P)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`[
M($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=.
M.B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X],T0R/B`\9&EV
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M<#L\+V1I=CX\+W1D/B`\+W1R/B`\='(^(#QT9#XF;F)S<#L\+W1D/B`\=&0^
M)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D/B`\
M=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT9#XF;F)S<#L\+W1D
M/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SX@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@-S`E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XM3$5&5#H@
M,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SX@/&1I=B!S='EL93TS
M1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)3D4M2$5)
M1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68G/E-T;V-K(&]P=&EO;G,@;W5T<W1A;F1I;F<\+V1I=CX\
M+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(
M.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
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M1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`S
M."XW<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C<L,CDS/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
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M;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`S."XW<'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C<L,C<S/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z
M("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R/B`\
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M3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(
M.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!4
M15A4+4%,24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#,X+C=P=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<^,RPX-#,\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!7
M24142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=.
M.B!R:6=H=#L@34%21TE.+4Q%1E0Z(#,X+C=P=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V9F9F9F9B<^,RPX,C4\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%2
M1TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S='EL93TS1"="
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SX@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=.
M.B!L969T.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F)SX@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@;&5F=#L@34%2
M1TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I
M<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
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M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@
M,S<N.7!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXV+#<W-SPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T
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M+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T
M;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,S<N.7!T.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXV+#,X-3PO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T<CX@
M/"]T86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^
M#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H=&UL/@T*#0HM+2TM+2T]
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M:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-151!(&AT='`M97%U:78]
M,T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT+VAT;6P[(&-H87)S970]
M=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V87-C<FEP="!S<F,],T13
M:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#;VUM96YT("HO/"]S8W)I
M<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B;&4@8VQA<W,],T1R97!O
M<G0@:60],T1)1#!%3$@^#0H@("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S
M<STS1'1L(&-O;'-P86X],T0Q(')O=W-P86X],T0R/CQS=')O;F<^3F]T92`U
M("T@4W1O8VMH;VQD97)S)R!%<75I='D@*%1A8FQE<RD\8G(^/"]S=')O;F<^
M/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,R!-
M;VYT:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^/'-T<F]N9SY.;W1E<R!486)L
M97,\+W-T<F]N9SX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4V-H961U;&4@;V8@16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP
M96YS871I;VXL($%L;&]C871I;VX@;V8@4F5C;V=N:7IE9"!097)I;V0@0V]S
M=',@6U1A8FQE(%1E>'0@0FQO8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF
M86UI;'DZ('1I;65S(&YE=R!R;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\=&%B
M;&4@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,#`E.R!415A4
M+4E.1$5.5#H@,'!X.SL@=VED=&@Z(#<P,'!X.R<@8V5L;'-P86-I;F<],T0P
M(&-E;&QP861D:6YG/3-$,"!B;W)D97(],T0P/B`\='(^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<"<^/&1I=B!S
M='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^
M)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!615)424-!3"U!3$E'3CH@=&]P)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ
M(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=.
M.B!T;W`[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4
M+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P86X],T0V
M/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!4D=)3CH@
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M6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q
M+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M(%!!1$1)3D<M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^
M(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@=&]P)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@
M8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@0D]21$52+4)/5%1/33H@
M(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.
M+4Q%1E0Z(#!P="<@8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%6%0M
M04Q)1TXZ(&-E;G1E<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/C(P,34\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!T;W`[(%!!
M1$1)3D<M0D]45$]-.B`Q<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL
M:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^(#QT
M9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O
M<"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@=&]P.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@8V5N=&5R.R!-05)'
M24XM3$5&5#H@,'!T)R!C;VQS<&%N/3-$,CX@/&1I=B!S='EL93TS1"<@5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N
M,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9B<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I
M9VAT.B!B;VQD.R<^,C`Q-#PO9&EV/CPO9&EV/CPO9&EV/CPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ('1O<#L@
M4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I
M;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@
M/"]T<CX@/'1R/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^(#QT
M9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO=&0^
M(#QT9#XF;F)S<#L\+W1D/B`\=&0^)FYB<W`[/"]T9#X@/'1D/B9N8G-P.SPO
M=&0^(#QT9#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=2
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M97-E87)C:"!A;F0@9&5V96QO<&UE;G0\+V1I=CX\+V1I=CX\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB
M<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@
M,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B0\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXX,#8\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S
M='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!
M3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
M)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@
M0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)#PO=&0^(#QT9"!S='EL93TS
M1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M
M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[
M($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C$L,C8R/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R
M/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^(#QT
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M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52
M+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[($)!0TM'4D]53D0M0T],3U(Z
M("-F9F9F9F8G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]2
M1$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@<V]L:60[(%1%6%0M04Q)1TXZ(')I
M9VAT.R!-05)'24XM3$5&5#H@,S@N-W!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F)SXQ+#<T-3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!0041$24Y'
M+4)/5%1/33H@,7!X.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/'1D
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M(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C
M,#`P,#`P(#%P>"!S;VQI9#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!72414
M2#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-
M.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3BU,1494.B`S."XW<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/C$L
M-S`W/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@
M,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%!!1$1)3D<M0D]45$]-.B`Q
M<'@[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F
M9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y
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M;F<@97AP96YS97,\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,W!X(&1O
M=6)L93L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!415A4+4%,24=..B!R:6=H=#L@34%2
M1TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^,BPU
M-3$\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
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M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!7
M24142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXR
M+#DV.3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z
M(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!0041$24Y'+4)/5%1/33H@
M,W!X.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B`\=&0@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D
M('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF
M;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"="04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T
M>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B9N8G-P.SPO=&0^
M(#QT9"!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S
M<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/4CH@
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M3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#-P>"!D
M;W5B;&4[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C
M8V5E9F8G/B0\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)
M1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U14
M3TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[($U!
M4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/C`N
M,#D\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
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M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`S<'@@
M9&]U8FQE.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F)SXD/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!7
M24142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]4
M5$]-.B`C,#`P,#`P(#-P>"!D;W5B;&4[(%1%6%0M04Q)1TXZ(')I9VAT.R!-
M05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXP
M+C$S/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@
M,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%!!1$1)3D<M0D]45$]-.B`S
M<'@[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D/B`\+W1R/B`\+W1A8FQE
M/CPO9&EV/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@
M(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI
M9VX],T1T;W`^4V-H961U;&4@;V8@4VAA<F4M8F%S960@4&%Y;65N="!!=V%R
M9"P@4W1O8VL@3W!T:6]N<RP@5F%L=6%T:6]N($%S<W5M<'1I;VYS(%M486)L
M92!497AT($)L;V-K73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M9F%M:6QY.B!T
M:6UE<R!N97<@<F]M86X[(&9O;G0M<VEZ93H@,3!P="<^/'1A8FQE('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3`P)3L@5$585"U)3D1%3E0Z
M(#!P>#L[('=I9'1H.B`W,#!P>#LG(&-E;&QS<&%C:6YG/3-$,"!C96QL<&%D
M9&EN9STS1#`@8F]R9&5R/3-$,#X@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@
M8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$58
M5"U!3$E'3CH@8V5N=&5R.R!-05)'24XM3$5&5#H@,'!T)R!C;VQS<&%N/3-$
M-CX@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@8V5N=&5R.R!-05)'24XZ
M(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA
M>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE
M<R!.97<@4F]M86XL(%1I;65S+"!S97)I9B<^/&1I=B!S='EL93TS1"=D:7-P
M;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^36%R8V@@,S$L/"]D
M:78^/"]D:78^/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B!M
M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#%P>"<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[
M/"]D:78^/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
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M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P(#%P>"!S;VQI9#L@5$585"U!
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M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^,C`\+V1I=CX\9&EV('-T
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M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(",P
M,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!C96YT97([($U!4D=)3BU,
M1494.B`P<'0G(&-O;'-P86X],T0R/B`\9&EV('-T>6QE/3-$)R!415A4+4%,
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M+V1I=CX\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9B<^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/
M3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$
M5$@Z(#<P)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@
M:G5S=&EF>3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9B<^(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&IU<W1I9GD[
M($U!4D=)3CH@,'!T.R!,24Y%+4A%24=(5#H@,2XR-2<^/&1I=B!S='EL93TS
M1"=D:7-P;&%Y.B!I;FQI;F4[($9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF)SY2:7-K+69R964@
M:6YT97)E<W0@<F%T93PO9&EV/CPO9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
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M.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO
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M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,
M24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@
M,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXR+C`\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM
M04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#
M3TQ/4CH@(V-C965F9B<@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/B`\+W1R/B`\
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M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F
M9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,
M24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#$Y+C4U<'0[($)!0TM'4D]53D0M
M0T],3U(Z("-F9F9F9F8G/C`N,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-
M05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!N
M;W=R87`],T1N;W=R87`^)3PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z
M(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S
M97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+
M1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,3(E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!R:6=H=#L@34%2
M1TE.+4Q%1E0Z(#$Y+C4U<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G
M/C`N,#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z
M(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!N;W=R87`],T1N;W=R87`^
M)3PO=&0^(#PO='(^(#QT<B!S='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C
M8V-E969F)SX@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&
M04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!
M3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XM
M3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SX@/&1I=B!S
M='EL93TS1"<@5$585"U!3$E'3CH@:G5S=&EF>3L@34%21TE..B`P<'0[($Q)
M3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN
M93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68G/E9O;&%T:6QI='D\+V1I=CX\+V1I=CX\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F
M9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
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M;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8G/CDQ+C<\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O
M='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<@;F]W<F%P/3-$;F]W<F%P/B4\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O
M;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T9#X@/'1D
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M:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E
M9F8G/C$P-"XQ/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!7
M24142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494
M.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO
M=W)A<#XE/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&IU<W1I9GD[($U!
M4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B`\
M9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!J=7-T:69Y.R!-05)'24XZ(#!P
M=#L@3$E.12U(14E'2%0Z(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@
M:6YL:6YE.R!&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.
M97<@4F]M86XL(%1I;65S+"!S97)I9B<^17AP96-T960@;&EF92`H>65A<G,I
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M=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM
M3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXV+C$\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=2
M3U5.1"U#3TQ/4CH@(V9F9F9F9B<@;F]W<F%P/3-$;F]W<F%P/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F
M9F9F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
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M8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T9#X@/"]T<CX@/"]T
M86)L93X\+V1I=CX\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-C:&5D=6QE(&]F(%-H87)E+6)A<V5D($-O;7!E;G-A
M=&EO;BP@4W1O8VL@3W!T:6]N<RP@06-T:79I='D@6U1A8FQE(%1E>'0@0FQO
M8VM=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UF86UI;'DZ('1I;65S(&YE=R!R
M;VUA;CL@9F]N="US:7IE.B`Q,'!T)SX\=&%B;&4@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
M<RP@<V5R:68[(%=)1%1(.B`Q,#`E.R!415A4+4E.1$5.5#H@,'!X.SL@=VED
M=&@Z(#<P,'!X.R<@8V5L;'-P86-I;F<],T0P(&-E;&QP861D:6YG/3-$,"!B
M;W)D97(],T0P/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
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M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG
M:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
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M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\+W1R/B`\='(^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ
M(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M
M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
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M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$
M)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA
M;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&-E;G1E
M<B<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT
M.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S
M<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
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M)FYB<W`[/"]D:78^/"]T9#X@/"]T<CX@/'1R/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N
M8G-P.SPO9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[
M($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@
M5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y
M.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N
M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%
M6%0M04Q)1TXZ(&-E;G1E<B<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI
M;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D
M('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S
M($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T
M=&]M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG
M:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
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M="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
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M93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\+W1R
M/B`\='(^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-
M24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM
M04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[
M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M)SX\9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z
M(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U3
M25I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE
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M)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T
M>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE
M=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M
M.R!415A4+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G(&-O;'-P
M86X],T0R/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT97([($U!
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M+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
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M=')A8W1U86P\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@
M<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG
M/B9N8G-P.SPO9&EV/CPO=&0^(#PO='(^(#QT<CX@/'1D('-T>6QE/3-$)T9/
M3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@
M5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T
M>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF
M;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
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M)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
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M;VQD.R<^17AE<F-I<V4\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
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M1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB<W`[
M/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!C96YT97([($U!4D=)
M3BU,1494.B`P<'0G(&-O;'-P86X],T0R/B`\9&EV('-T>6QE/3-$)R!415A4
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M(&)O;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\+W1R/B`\='(^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^
M/&1I=B!S='EL93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B
M;VQD.R<^)FYB<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:
M13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L
M('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M)SX\9&EV('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[)SXF;F)S<#L\
M+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4
M+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X
M('-O;&ED.R!415A4+4%,24=..B!C96YT97([($U!4D=)3BU,1494.B`P<'0G
M(&-O;'-P86X],T0R/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!C96YT
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M0D]21$52+4)/5%1/33H@;65D:75M(&YO;F4[(%!!1$1)3D<M0D]45$]-.B`Q
M<'@G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H
M=#H@8F]L9#LG/B9N8G-P.SPO9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4
M+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I
M;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;2<^/&1I=B!S='EL
M93TS1"=D:7-P;&%Y.B!I;FQI;F4[(&9O;G0M=V5I9VAT.B!B;VQD.R<^)FYB
M<W`[/"]D:78^/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"3U)$15(M0D]45$]-.B`C,#`P,#`P
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M.R<^4')I8V4\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU"3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,7!X)SX\
M9&EV('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O
M;&0[)SXF;F)S<#L\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VTG/CQD:78@<W1Y;&4],T0G
M9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/B9N8G-P.SPO
M9&EV/CPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M
M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5D525$E#
M04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/33H@(S`P,#`P,"`Q<'@@
M<V]L:60[(%1%6%0M04Q)1TXZ(&-E;G1E<CL@34%21TE.+4Q%1E0Z(#!P="<@
M8V]L<W!A;CTS1#(^(#QD:78@<W1Y;&4],T0G(%1%6%0M04Q)1TXZ(&-E;G1E
M<CL@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/CQD:78@<W1Y
M;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!F;VYT+7=E:6=H=#H@8F]L9#LG/BA9
M96%R<RD\+V1I=CX\+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].
M5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4
M:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"
M3U143TTZ(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,7!X)SX\9&EV
M('-T>6QE/3-$)V1I<W!L87DZ(&EN;&EN93L@9F]N="UW96EG:'0Z(&)O;&0[
M)SXF;F)S<#L\+V1I=CX\+W1D/B`\+W1R/B`\='(@<W1Y;&4],T0G0D%#2T=2
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M(&%T($IA;G5A<GD@,2P@,C`Q-3PO9&EV/CPO9&EV/CPO=&0^(#QT9"!S='EL
M93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@
M4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@
M5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C
M965F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
M=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF
M.R!724142#H@,3(E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,
M24=..B!R:6=H=#L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9B<^-RPY,3@\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%2
M1TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@34%21TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/
M4CH@(V-C965F9B<^)#PO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9CL@5TE$5$@Z(#$R)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@5$585"U!
M3$E'3CH@<FEG:'0[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],
M3U(Z("-C8V5E9F8G/C@N-CD\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%2
M1TE.+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<@;F]W
M<F%P/3-$;F]W<F%P/B9N8G-P.SPO=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9CL@5TE$5$@Z(#$E.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y
M;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W
M(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)
M1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[
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M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N;W=R87`^
M)FYB<W`[/"]T9#X@/"]T<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],
M3U(Z("-F9F9F9F8G/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(&QE9G0[(%!!1$1)
M3D<M3$5&5#H@.7!T.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/
M3$]2.B`C9F9F9F9F)SX@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@;&5F
M=#L@34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE
M/3-$)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/D=R86YT960\
M+V1I=CX\+V1I=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.
M1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/
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M1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/C4T/"]T9#X@
M/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I
M;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)
M0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]5
M3D0M0T],3U(Z("-F9F9F9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S<#L\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F
M9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@
M1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!7
M24142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494
M.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/B0\+W1D/B`\=&0@
M<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@
M3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,
M+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'24XM3$5&
M5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXQ,2XU,CPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C9F9F9F9F)R!N;W=R87`],T1N;W=R87`^)FYB<W`[/"]T
M9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ
M(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'
M3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\
M+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
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M3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M
M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM
M97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$
M+4-/3$]2.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`\+W1R/B`\='(@<W1Y;&4]
M,T0G0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^(#QT9"!S='EL93TS1"=&
M3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL
M(%1I;65S+"!S97)I9CL@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@5$585"U!
M3$E'3CH@;&5F=#L@4$%$1$E.1RU,1494.B`Y<'0[($U!4D=)3BU,1494.B`P
M<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B`\9&EV('-T>6QE/3-$
M)R!415A4+4%,24=..B!L969T.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z
M(#$N,C4G/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)
M6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S
M+"!S97)I9B<^17AE<F-I<V5D/"]D:78^/"]D:78^/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=.
M.B!B;W1T;VT[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO
M=&0^(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9
M.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!6
M15)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)
M1TXZ(')I9VAT.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2
M.B`C8V-E969F)SXH,S4R/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)
M3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A
M<#TS1&YO=W)A<#X@/&1I=B!S='EL93TS1"<@5$585"U!3$E'3CH@;&5F=#L@
M34%21TE..B`P<'0[($Q)3D4M2$5)1TA4.B`Q+C(U)SX\9&EV('-T>6QE/3-$
M)V1I<W!L87DZ(&EN;&EN93L@1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,
M63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68G/BD\+V1I=CX\+V1I
M=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
M)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V-C965F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)
M3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B0\+W1D
M/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@
M5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q,B4[(%9%
M4E1)0T%,+4%,24=..B!B;W1T;VT[(%1%6%0M04Q)1TXZ(')I9VAT.R!-05)'
M24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)SXX+C$X
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($U!4D=)3BU,1494.B`P<'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G(&YO=W)A<#TS1&YO=W)A<#XF;F)S
M<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
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M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!415A4+4%,24=..B!L969T.R!"04-+1U)/
M54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G
M1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N
M+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)!0TM'
M4D]53D0M0T],3U(Z("-C8V5E9F8G/B9N8G-P.SPO=&0^(#PO='(^(#QT<B!S
M='EL93TS1"="04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)SX@/'1D('-T>6QE
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M=CX\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!
M34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q
M)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@
M(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@
M,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E
M<FEF.R!724142#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%
M4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!"04-+1U)/54Y$+4-/3$]2
M.B`C9F9F9F9F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%
M.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@
M<V5R:68[(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/
M4D1%4BU"3U143TTZ(",P,#`P,#`@,7!X('-O;&ED.R!415A4+4%,24=..B!R
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M/3-$;F]W<F%P/B`\9&EV('-T>6QE/3-$)R!415A4+4%,24=..B!L969T.R!-
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M.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C
M9F9F9F9F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q
M,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R
M:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@34%21TE.
M+4Q%1E0Z(#!P=#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)#PO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$R)3L@5D52
M5$E#04PM04Q)1TXZ(&)O='1O;3L@5$585"U!3$E'3CH@<FEG:'0[($U!4D=)
M3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-F9F9F9F8G/C$P+C8W
M/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)
M3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!724142#H@,24[
M(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ(&UE9&EU
M;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,'!X.R!-05)'24XM3$5&5#H@,'!T
M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F)R!N;W=R87`],T1N;W=R87`^
M)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C9F9F9F9F
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
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M2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/'1D('-T>6QE
M/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].5"U&04U)3%DZ(%1I;65S($YE=R!2
M;VUA;BP@5&EM97,L('-E<FEF.R!615)424-!3"U!3$E'3CH@8F]T=&]M.R!"
M3U)$15(M0D]45$]-.B!M961I=6T@;F]N93L@4$%$1$E.1RU"3U143TTZ(#!P
M>#L@0D%#2T=23U5.1"U#3TQ/4CH@(V9F9F9F9B<^)FYB<W`[/"]T9#X@/"]T
M<CX@/'1R('-T>6QE/3-$)T)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B`\
M=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM
M97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%9%4E1)0T%,+4%,24=..B!B
M;W1T;VT[(%1%6%0M04Q)1TXZ(&QE9G0[($U!4D=)3BU,1494.B`P<'0[($)!
M0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G/B`\9&EV('-T>6QE/3-$)R!415A4
M+4%,24=..B!L969T.R!-05)'24XZ(#!P=#L@3$E.12U(14E'2%0Z(#$N,C4G
M/CQD:78@<W1Y;&4],T0G9&ES<&QA>3H@:6YL:6YE.R!&3TY4+5-)6D4Z(#$P
M<'0[($9/3E0M1D%-24Q9.B!4:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I
M9B<^0F%L86YC92!A="!-87)C:"`S,2P@,C`Q-3PO9&EV/CPO9&EV/CPO=&0^
M(#QT9"!S='EL93TS1"=&3TY4+5-)6D4Z(#$P<'0[($9/3E0M1D%-24Q9.B!4
M:6UE<R!.97<@4F]M86XL(%1I;65S+"!S97)I9CL@5TE$5$@Z(#$E.R!615)4
M24-!3"U!3$E'3CH@8F]T=&]M.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F
M)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T.R!&
M3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[(%=)
M1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ(&)O='1O;3L@0D]21$52+4)/5%1/
M33H@(S`P,#`P,"`S<'@@9&]U8FQE.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
M969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4],T0G1D].5"U325I%.B`Q,'!T
M.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O;6%N+"!4:6UE<RP@<V5R:68[
M(%=)1%1(.B`Q,B4[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"
M3U143TTZ(",P,#`P,#`@,W!X(&1O=6)L93L@5$585"U!3$E'3CH@<FEG:'0[
M($U!4D=)3BU,1494.B`P<'0[($)!0TM'4D]53D0M0T],3U(Z("-C8V5E9F8G
M/C<L,CDS/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P=#L@1D].
M5"U&04U)3%DZ(%1I;65S($YE=R!2;VUA;BP@5&EM97,L('-E<FEF.R!72414
M2#H@,24[(%9%4E1)0T%,+4%,24=..B!B;W1T;VT[($)/4D1%4BU"3U143TTZ
M(&UE9&EU;2!N;VYE.R!0041$24Y'+4)/5%1/33H@,'!X.R!-05)'24XM3$5&
M5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E969F)R!N;W=R87`],T1N
M;W=R87`^)FYB<W`[/"]T9#X@/'1D('-T>6QE/3-$)T9/3E0M4TE:13H@,3!P
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M=&]M.R!-05)'24XM3$5&5#H@,'!T.R!"04-+1U)/54Y$+4-/3$]2.B`C8V-E
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M1U)/54Y$+4-/3$]2.B`C8V-E969F)SXF;F)S<#L\+W1D/B`\=&0@<W1Y;&4]
M,T0G1D].5"U325I%.B`Q,'!T.R!&3TY4+49!34E,63H@5&EM97,@3F5W(%)O
M;6%N+"!4:6UE<RP@<V5R:68[(%=)1%1(.B`Q)3L@5D525$E#04PM04Q)1TXZ
M(&)O='1O;3L@0D%#2T=23U5.1"U#3TQ/4CH@(V-C965F9B<^)FYB<W`[/"]T
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M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@(#PO=&%B;&4^#0H@(#PO8F]D>3X-
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M;#L@8VAA<G-E=#TB=7,M87-C:6DB#0H-"CQH=&UL/@T*("`\:&5A9#X-"B`@
M("`\345402!H='1P+65Q=6EV/3-$0V]N=&5N="U4>7!E(&-O;G1E;G0],T0G
M=&5X="]H=&UL.R!C:&%R<V5T/75T9BTX)SX\<V-R:7!T('1Y<&4],T1T97AT
M+VIA=F%S8W)I<'0@<W)C/3-$4VAO=RYJ<SXO*B!$;R!.;W0@4F5M;W9E(%1H
M:7,@0V]M;65N="`J+SPO<V-R:7!T/CPO:&5A9#X-"B`@/&)O9'D^#0H@("`@
M/'1A8FQE(&-L87-S/3-$<F5P;W)T(&ED/3-$240P14%(04,^#0H@("`@("`\
M='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1L(&-O;'-P86X],T0Q(')O=W-P
M86X],T0R/CQS=')O;F<^3F]T92`Q("T@0G5S:6YE<W,@*$1E=&%I;',@5&5X
M='5A;"D@*%531"`D*3QB<CX\+W-T<F]N9SX\+W1H/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:"!C;VQS<&%N/3-$,3XU,2!-;VYT:',@16YD960\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,3X\+W1H/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S
M,2P@,C`Q-3QB<CX\+W1H/@T*("`@("`@("`\=&@@8VQA<W,],T1T:#Y$96,N
M(#,Q+"`R,#$T/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA
M<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^
M1&5C+B`S,2P@,C`Q,SQB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^4F5T86EN960@16%R;FEN9W,@*$%C8W5M=6QA=&5D($1E9FEC:70I
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M/B0@*#,S-2PX,#<L,#`P
M*3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6T^
M)"`H,S$U+#(S-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y0<F]C965D<R!F<F]M($ES<W5A;F-E(&]F($QO
M;F<M=&5R;2!$96)T(&%N9"!#87!I=&%L(%-E8W5R:71I97,L($YE=#PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,3DT+#,P,"PP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-A<V@@
M86YD($-A<V@@17%U:79A;&5N=',L(&%T($-A<G)Y:6YG(%9A;'5E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#4U+#4U-BPP,#`\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#<R+#8W
M-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XD(#4W+#0W-2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XD(#<R+#(X-RPP,#`\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*/"]H
M=&UL/@T*#0HM+2TM+2T]7TYE>'1087)T7V5B964X,S)B7V8S-F9?-#5B85]A
M,F0T7S,T8S,U9C8R,V4T-PT*0V]N=&5N="U,;V-A=&EO;CH@9FEL93HO+R]#
M.B]E8F5E.#,R8E]F,S9F7S0U8F%?83)D-%\S-&,S-68V,C-E-#<O5V]R:W-H
M965T<R]3:&5E=#$U+FAT;6P-"D-O;G1E;G0M5')A;G-F97(M16YC;V1I;F<Z
M('%U;W1E9"UP<FEN=&%B;&4-"D-O;G1E;G0M5'EP93H@=&5X="]H=&UL.R!C
M:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@(#Q-
M151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T97AT
M+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O:F%V
M87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI<R!#
M;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\=&%B
M;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%5$%!13X-"B`@("`@(#QT<CX-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A;CTS
M1#(^/'-T<F]N9SY.;W1E(#,@+2!!8V-O=6YT:6YG(%!O;&EC:65S("T@17%U
M:71Y($5X8VQU9&5D($9R;VT@0V%L8W5L871I;VX@;V8@1&EL=71E9"!%87)N
M:6YG<R!097(@4VAA<F4@*$1E=&%I;',I/&)R/DEN(%1H;W5S86YD<RP@=6YL
M97-S(&]T:&5R=VES92!S<&5C:69I960\+W-T<F]N9SX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H<R!%;F1E9#PO
M=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT:"!C
M;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@(#PO='(^
M#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M<&P@=F%L:6=N/3-$=&]P/D5Q=6ET>2!/<'1I;VX@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F5S(&5X8VQU9&5D("AI
M;B!S:&%R97,I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XW+#(Y
M,SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C<L,C<S/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y787)R86YT(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E-H87)E<R!E>&-L=61E9"`H:6X@<VAA<F5S*3PO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPX-#,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS+#@R-3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H
M/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0V]N=F5R
M=&EB;&4@1&5B="!396-U<FET:65S(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-H87)E<R!E>&-L=61E9"`H:6X@<VAA<F5S
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-BPW-S<\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+#,X-3QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*
M("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96)E93@S
M,F)?9C,V9E\T-6)A7V$R9#1?,S1C,S5F-C(S930W#0I#;VYT96YT+4QO8V%T
M:6]N.B!F:6QE.B\O+T,Z+V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U
M9C8R,V4T-R]7;W)K<VAE971S+U-H965T,38N:'1M;`T*0V]N=&5N="U4<F%N
M<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E
M.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@
M/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C
M;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T
M>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T
M(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB
M;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$503D)'
M/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N
M/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-"`M($-O;G9E<G1I8FQE
M($YO=&5S('1O(%)E;&%T960@4&%R=&EE<R`H1&5T86EL<R!497AT=6%L*2`H
M55-$("0I/&)R/CPO<W1R;VYG/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS
M1'1H(&-O;'-P86X],T0Q/C`@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#$^,2!-;VYT:',@16YD960\+W1H
M/@T*("`@("`@("`\=&@@8VQA<W,],T1T:"!C;VQS<&%N/3-$,CXS($UO;G1H
M<R!%;F1E9#PO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X]
M,T0Q/CPO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\
M=&@@8VQA<W,],T1T:#Y*=6PN(#(Y+"`R,#$Q/&)R/CPO=&@^#0H@("`@("`@
M(#QT:"!C;&%S<STS1'1H/D%P<BX@,S`L(#(P,3$\8G(^/"]T:#X-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/D1E8RX@,S$L(#(P,30\8G(^/"]T:#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($1E8G0@
M27-S=6%B;&4@:6X@0V]N;F5C=&EO;B!W:71H(%!R:79A=&4@4&QA8V5M96YT
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#0L-3`P+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4')O8V5E9',@9G)O;2!#;VYV97)T:6)L92!$96)T/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XT+#,P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3:&%R97,@4F5G
M:7-T97)E9"!F;W(@4F5S86QE(&EN($-O;FYE8W1I;VX@=VET:"!#;VYV97)T
M:6)L92!.;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,RPU
M,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y);G1E<F5S="!%>'!E;G-E+"!$96)T+"!%>&-L=61I;F<@06UO
M<G1I>F%T:6]N/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,2PP
M,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M
M<#XW-RPP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S
M/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@
M("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L
M:6=N/3-$=&]P/D%M;W)T:7IA=&EO;B!O9B!$96)T($1I<V-O=6YT("A0<F5M
M:75M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S
M<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,34Q+#`P,#QS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$S
M.2PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;G9E<G1I8FQE($YO=&5S(%!A>6%B;&4L(%)E;&%T960@4&%R
M=&EE<RP@0W5R<F5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,2PW-#DL,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1&YU;7`^,2PU.3@L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!$96)T(%-E8W5R:71I
M97,@6TUE;6)E<ET@?"!#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT($-O;G9E
M<G-I;VX@4F%T:6\@4VAA<F5S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XQ+#(U,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^0V]N=F5R=&EB;&4@1&5B="!396-U<FET:65S(%M-96UB
M97)=('P@26X@0V%S92!O9B!$96)T($-O;G9E<G-I;VX@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M96YT
M+"!&86-E($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M-2PT,C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@
M("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A
M;&EG;CTS1'1O<#Y$96)T($EN<W1R=6UE;G0L($-O;G9E<G1I8FQE+"!.=6UB
M97(@;V8@17%U:71Y($EN<W1R=6UE;G1S/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XV+#<W-BPY.3@\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;G9E<G1I8FQE($1E8G0@4V5C=7)I
M=&EE<R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y$96)T($EN<W1R=6UE;G0L($UA='5R:71Y($1A=&4\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/DUA>2`R+`T*"0DR,#(Q/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y$96)T($EN<W1R
M=6UE;G0L($EN=&5R97-T(%)A=&4L(%-T871E9"!097)C96YT86=E/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV+C`P)3QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@
M("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!);G-T<G5M
M96YT($-O;G9E<G-I;VX@4F%T:6\@375L=&EP;&4@;V8@4')I;F-I<&%L/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T
M9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F5N969I8VEA
M;"!/=VYE<G-H:7`@869T97(@0V]N=F5R<VEO;CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^.2XY.24\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/DYO=&EC92!097)I;V0@07-S;V-I871E
M9"!W:71H($)E;F5F:6-I86P@3W=N97)S:&EP(%!E<F-E;G1A9V4@3&EM:71A
M=&EO;B!#;VYV97)T:6)L92!.;W1E<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'1E>'0^-C$@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&%I9"UI;BU+:6YD($EN=&5R97-T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XX,"PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1E8G0@26YS=')U
M;65N="P@26YC<F5A<V4@*$1E8W)E87-E*2P@3W1H97(L($YE=#PO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1&YU;7`^.#`L,#`P/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO
M=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@
M("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y#;VYV97)T:6)L92!.
M;W1E<R!087EA8FQE+"!296QA=&5D(%!A<G1I97,L($-U<G)E;G0\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$L-S0Y+#`P,#QS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*
M("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^1&5B="!);G-T
M<G5M96YT+"!&86-E($%M;W5N=#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1&YU;7`^-2PT,C$L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y$96)T($EN<W1R=6UE;G0L(%5N86UO<G1I>F5D
M($1I<V-O=6YT/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#,L
M-C<R+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\
M+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A
M<G1?96)E93@S,F)?9C,V9E\T-6)A7V$R9#1?,S1C,S5F-C(S930W#0I#;VYT
M96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5B964X,S)B7V8S-F9?-#5B85]A
M,F0T7S,T8S,U9C8R,V4T-R]7;W)K<VAE971S+U-H965T,3<N:'1M;`T*0V]N
M=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N
M=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\
M:'1M;#X-"B`@/&AE860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E
M;G0M5'EP92!C;VYT96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^
M/'-C<FEP="!T>7!E/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^
M+RH@1&\@3F]T(%)E;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE
M860^#0H@(#QB;V1Y/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS
M1$E$,$4V4T1)/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T
M;"!C;VQS<&%N/3-$,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T
M;V-K:&]L9&5R<R<@17%U:71Y("A$971A:6QS(%1E>'1U86PI("A54T0@)"D\
M8G(^/"]S=')O;F<^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#(^,R!-;VYT:',@16YD960\+W1H/@T*("`@("`@("`\=&@@8VQA
M<W,],T1T:"!C;VQS<&%N/3-$-#XQ($UO;G1H<R!%;F1E9#PO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C(U($UO;G1H<R!%;F1E
M9#PO=&@^#0H@("`@("`\+W1R/@T*("`@("`@/'1R/@T*("`@("`@("`\=&@@
M8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$U/&)R/CPO=&@^#0H@("`@("`@(#QT
M:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,30\8G(^/"]T:#X-"B`@("`@("`@
M/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q,3QB<CX\+W1H/@T*("`@("`@
M("`\=&@@8VQA<W,],T1T:#Y*=6PN(#,Q+"`R,#$R/&)R/CPO=&@^#0H@("`@
M("`@(#QT:"!C;&%S<STS1'1H/DYO=BX@,S`L(#(P,3,\8G(^/"]T:#X-"B`@
M("`@("`@/'1H(&-L87-S/3-$=&@^2G5N+B`S,"P@,C`Q-#QB<CX\+W1H/@T*
M("`@("`@("`\=&@@8VQA<W,],T1T:#Y*=6XN(#,P+"`R,#$S/&)R/CPO=&@^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92UB87-E9"!#;VUP
M96YS871I;VX@07)R86YG96UE;G0@8GD@4VAA<F4M8F%S960@4&%Y;65N="!!
M=V%R9"P@3W!T:6]N<RP@17AE<F-I<V5S(&EN(%!E<FEO9"P@3F5T/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3$L-CDX/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C$U+#,U,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')O
M8V5E9',@9G)O;2!3=&]C:R!/<'1I;VYS($5X97)C:7-E9#PO=&0^#0H@("`@
M("`@(#QT9"!C;&%S<STS1&YU;7`^)"`R+#@W."PP,#`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#DU."PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E-H
M87)E+6)A<V5D($-O;7!E;G-A=&EO;B!!<G)A;F=E;65N="!B>2!3:&%R92UB
M87-E9"!087EM96YT($%W87)D+"!/<'1I;VYS+"!%>&5R8VES97,@:6X@4&5R
M:6]D/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XS-3(L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,C<U
M+#,U,CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T
M97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT
M<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX]
M,T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP96YS871I
M;VXL($YO;G9E<W1E9"!!=V%R9',L($-O;7!E;G-A=&EO;B!#;W-T($YO="!Y
M970@4F5C;V=N:7IE9#PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M,CDL.30W+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^16UP;&]Y964@4V5R=FEC92!3:&%R92UB87-E9"!#;VUP
M96YS871I;VXL($YO;G9E<W1E9"!!=V%R9',L($-O;7!E;G-A=&EO;B!#;W-T
M($YO="!Y970@4F5C;V=N:7IE9"P@4&5R:6]D(&9O<B!296-O9VYI=&EO;CPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^,B!Y96%R<R`Q-#8@9&%Y
M<SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4')I=F%T92!0;&%C96UE;G0@,C`Q,2!;365M8F5R72!\($-O;6UO;B!3
M=&]C:R!;365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@4VAA<F5S+"!.97<@27-S
M=65S/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XT-RPU.#@\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#@L
M-#`Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU
M;7`^."PP,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C
M;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y3=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@5F%L
M=64L($YE=R!)<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP
M/C(R+#@P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@
M=F%L:6=N/3-$=&]P/E!A>6UE;G1S(&]F(%-T;V-K($ES<W5A;F-E($-O<W1S
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ+#(P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L
M87-S(&]F(%=A<G)A;G0@;W(@4FEG:'0L($YU;6)E<B!O9B!396-U<FET:65S
M($-A;&QE9"!B>2!%86-H(%=A<G)A;G0@;W(@4FEG:'0\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6UP/C`N-3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')I=F%T92!0;&%C96UE;G0@,C`Q
M,2!;365M8F5R72!\(%=A<G)A;G0@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@0V]M<&5N<V%T:6]N($%R
M<F%N9V5M96YT(&)Y(%-H87)E+6)A<V5D(%!A>6UE;G0@07=A<F0L($YO;BU/
M<'1I;VX@17%U:71Y($EN<W1R=6UE;G1S+"!%>&5R8VES960\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C8V+#8V-SQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C$T-"PP-#`\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P
M86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:79A=&4@
M4&QA8V5M96YT(#(P,3$@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@
M("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V
M86QI9VX],T1T;W`^4')O8V5E9',@9G)O;2!787)R86YT($5X97)C:7-E<SPO
M=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@
M("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L87-S(&]F(%=A
M<G)A;G0@;W(@4FEG:'0L($5X97)C:7-E(%!R:6-E(&]F(%=A<G)A;G1S(&]R
M(%)I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`S+C8\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E!R:79A=&4@4&QA8V5M96YT(#(P,3(@6TUE;6)E<ET@?"!#;VUM;VX@4W1O
M8VL@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4W1O8VL@27-S=65D($1U<FEN9R!097)I;V0L(%-H87)E<RP@3F5W($ES<W5E
M<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^-2PQ,#`L,#`P/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3
M=&]C:R!)<W-U960@1'5R:6YG(%!E<FEO9"P@5F%L=64L($YE=R!)<W-U97,\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C4P+#4P,"PP,#`\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A
M;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,]
M,T1R93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A
M>6UE;G1S(&]F(%-T;V-K($ES<W5A;F-E($-O<W1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XS+#$P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R:79A=&4@4&QA8V5M96YT
M(#(P,3(@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V%L92!O9B!3=&]C:RP@4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$P+C4\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R:#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-O;6UO;B!3=&]C:R!;365M
M8F5R72!\($IE9F9E<FEE<RP@3$Q#(%M-96UB97)=/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO
M='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L87-S
M/3-$<&P@=F%L:6=N/3-$=&]P/E-T;V-K($ES<W5E9"!$=7)I;F<@4&5R:6]D
M+"!3:&%R97,L($YE=R!)<W-U97,\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C<L-S`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^4&%Y;65N=',@;V8@4W1O8VL@27-S=6%N8V4@
M0V]S=',\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C,L.3`P+#`P
M,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT
M/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C
M;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T
M;W`^4V%L92!O9B!3=&]C:RP@4')I8V4@4&5R(%-H87)E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#@\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@27-S=6%N
M8V4@;V8@0V]M;6]N(%-T;V-K/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M;G5M<#XU-RPX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y#;VUM;VX@4W1O8VL@6TUE;6)E<ET\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@("`\
M=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4W1O8VL@27-S=65D($1U<FEN
M9R!097)I;V0L(%-H87)E<RP@3F5W($ES<W5E<SPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^-"PX,#`L,#`P/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y386QE(&]F(%-T;V-K+"!0<FEC
M92!097(@4VAA<F4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@
M,3$N-S4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$
M=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\
M='(@8VQA<W,],T1R:#X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N
M/3-$=&]P/D-O;6UO;B!3=&]C:R!A;F0@4')E9G5N9&5D(%=A<G)A;G1S(%M-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M93X-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!A>6UE
M;G1S(&]F(%-T;V-K($ES<W5A;F-E($-O<W1S/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D
M(&-L87-S/3-$;G5M<#XT+#`P,"PP,#`\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@
M("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R;SX-"B`@("`@("`@/'1D
M(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/E!R;V-E961S(&9R;VT@27-S=6%N
M8V4@;W(@4V%L92!O9B!%<75I='D\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/B0@-3@L.3`P+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@
M/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@8VQA
M<W,],T1P;"!V86QI9VX],T1T;W`^4')I=F%T92!0;&%C96UE;G0@,C`Q,2!;
M365M8F5R73PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$
M<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y,:6UI
M=&%T:6]N(&]N($5X97)C:7-A8FQE(%=A<G)A;G1S/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@
M/'1D(&-L87-S/3-$;G5M<#XY+CDY)3QS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')H/@T*("`@("`@("`\=&0@
M8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4')E+69U;F1E9"!787)R86YT<UM-
M96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R
M;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P/D-L87-S
M(&]F(%=A<G)A;G0@;W(@4FEG:'0L($5X97)C:7-E(%!R:6-E(&]F(%=A<G)A
M;G1S(&]R(%)I9VAT<SPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^
M)"`P+C`Q/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@
M/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG
M;CTS1'1O<#Y#;&%S<R!O9B!787)R86YT(&]R(%)I9VAT+"!.=6UB97(@;V8@
M4V5C=7)I=&EE<R!#86QL960@8GD@5V%R<F%N=',@;W(@4FEG:'1S/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\<W!A;CX\+W-P86X^/"]T9#X-
M"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XV,#`L,#`P/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y3:&%R92!0<FEC
M93PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q,2XW-#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\
M+V)O9'D^#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96)E93@S,F)?
M9C,V9E\T-6)A7V$R9#1?,S1C,S5F-C(S930W#0I#;VYT96YT+4QO8V%T:6]N
M.B!F:6QE.B\O+T,Z+V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R
M,V4T-R]7;W)K<VAE971S+U-H965T,3@N:'1M;`T*0V]N=&5N="U4<F%N<V9E
M<BU%;F-O9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T
M97AT+VAT;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE
M860^#0H@("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT
M96YT/3-$)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E
M/3-$=&5X="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E
M;6]V92!4:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y
M/@T*("`@(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5(04%%/@T*
M("`@("`@/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$
M,2!R;W=S<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T;V-K:&]L9&5R<R<@
M17%U:71Y("T@06QL;V-A=&EO;B!O9B!T:&4@4F5C;V=N:7IE9"!#;W-T("A$
M971A:6QS*2`H55-$("0I/&)R/DEN(%1H;W5S86YD<RP@97AC97!T(%!E<B!3
M:&%R92!D871A+"!U;FQE<W,@;W1H97)W:7-E('-P96-I9FEE9#PO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0R/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@("`@("`\='(^#0H@
M("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P,34\8G(^/"]T:#X-
M"B`@("`@("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-#QB<CX\+W1H
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/B0@,BPU-3$\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L
M87-S/3-$;G5M<#XD(#(L.38Y/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\
M+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S
M<STS1'!L('9A;&EG;CTS1'1O<#Y);7!A8W0@;VX@8F%S:6,@86YD(&1I;'5T
M960@;F5T(&QO<W,@<&5R('-H87)E("AI;B!D;VQL87)S('!E<B!S:&%R92D\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XP.3QS<&%N/CPO
M<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/B0@,"XQ,SQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')H/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4F5S96%R8V@@86YD($1E=F5L;W!M96YT($5X<&5N<V4@6TUE;6)E<ET\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS1')O/@T*("`@("`@
M("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^4VAA<F4M8F%S960@8V]M
M<&5N<V%T:6]N(&5X<&5N<V4\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N
M=6UP/C@P-CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6UP/C$L,C8R/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*
M("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L
M('9A;&EG;CTS1'1O<#Y'96YE<F%L(&%N9"!!9&UI;FES=')A=&EV92!%>'!E
M;G-E(%M-96UB97)=/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$=&5X=#X\
M<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@8VQA
M<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$=&]P
M/E-H87)E+6)A<V5D(&-O;7!E;G-A=&EO;B!E>'!E;G-E/"]T9#X-"B`@("`@
M("`@/'1D(&-L87-S/3-$;G5M<#XD(#$L-S0U/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`Q+#<P-SQS<&%N/CPO<W!A
M;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^
M#0H\+VAT;6P^#0H-"BTM+2TM+3U?3F5X=%!A<G1?96)E93@S,F)?9C,V9E\T
M-6)A7V$R9#1?,S1C,S5F-C(S930W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE
M.B\O+T,Z+V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T-R]7
M;W)K<VAE971S+U-H965T,3DN:'1M;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O
M9&EN9SH@<75O=&5D+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT
M;6P[(&-H87)S970](G5S+6%S8VEI(@T*#0H\:'1M;#X-"B`@/&AE860^#0H@
M("`@/$U%5$$@:'1T<"UE<75I=CTS1$-O;G1E;G0M5'EP92!C;VYT96YT/3-$
M)W1E>'0O:'1M;#L@8VAA<G-E=#UU=&8M."<^/'-C<FEP="!T>7!E/3-$=&5X
M="]J879A<V-R:7!T('-R8STS1%-H;W<N:G,^+RH@1&\@3F]T(%)E;6]V92!4
M:&ES($-O;6UE;G0@*B\\+W-C<FEP=#X\+VAE860^#0H@(#QB;V1Y/@T*("`@
M(#QT86)L92!C;&%S<STS1')E<&]R="!I9#TS1$E$,$5+2D%#/@T*("`@("`@
M/'1R/@T*("`@("`@("`\=&@@8VQA<W,],T1T;"!C;VQS<&%N/3-$,2!R;W=S
M<&%N/3-$,CX\<W1R;VYG/DYO=&4@-2`M(%-T;V-K:&]L9&5R<R<@17%U:71Y
M("T@3W!T:6]N(%9A;'5A=&EO;B!!<W-U;7!T:6]N<R`H1&5T86EL<RD@*$5M
M<&QO>65E(%-T;V-K($]P=&EO;B!;365M8F5R72D\8G(^/"]S=')O;F<^/"]T
M:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L<W!A;CTS1#(^,R!-;VYT
M:',@16YD960\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<CX-"B`@("`@
M("`@/'1H(&-L87-S/3-$=&@^36%R+B`S,2P@,C`Q-3QB<CX\+W1H/@T*("`@
M("`@("`\=&@@8VQA<W,],T1T:#Y-87(N(#,Q+"`R,#$T/&)R/CPO=&@^#0H@
M("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F@^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%;7!L;WEE92!3=&]C:R!/<'1I
M;VX@6TUE;6)E<ET\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/CQS
M<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S
M<STS1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^
M4FES:RUF<F5E(&EN=&5R97-T(')A=&4\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C$N-C`E/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^,BXP,"4\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@
M(#PO='(^#0H@("`@("`\='(@8VQA<W,],T1R93X-"B`@("`@("`@/'1D(&-L
M87-S/3-$<&P@=F%L:6=N/3-$=&]P/D1I=FED96YD('EI96QD/"]T9#X-"B`@
M("`@("`@/'1D(&-L87-S/3-$;G5M<#XP+C`P)3QS<&%N/CPO<W!A;CX\+W1D
M/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C`N,#`E/'-P86X^/"]S<&%N
M/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F\^#0H@
M("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y6;VQA=&EL:71Y
M/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XY,2XW,"4\<W!A;CX\
M+W-P86X^/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XQ,#0N,3`E
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y%>'!E8W1E9"!L:69E("AY96%R<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1T97AT/C8@>65A<G,@,S8@9&%Y<SQS<&%N/CPO<W!A;CX\+W1D/@T*
M("`@("`@("`\=&0@8VQA<W,],T1T97AT/C8@>65A<G,\<W!A;CX\+W-P86X^
M/"]T9#X-"B`@("`@(#PO='(^#0H@("`@/"]T86)L93X-"B`@/"]B;V1Y/@T*
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M.R!C:&%R<V5T/2)U<RUA<V-I:2(-"@T*/&AT;6P^#0H@(#QH96%D/@T*("`@
M(#Q-151!(&AT='`M97%U:78],T1#;VYT96YT+51Y<&4@8V]N=&5N=#TS1"=T
M97AT+VAT;6P[(&-H87)S970]=71F+3@G/CQS8W)I<'0@='EP93TS1'1E>'0O
M:F%V87-C<FEP="!S<F,],T13:&]W+FIS/B\J($1O($YO="!296UO=F4@5&AI
M<R!#;VUM96YT("HO/"]S8W)I<'0^/"]H96%D/@T*("`\8F]D>3X-"B`@("`\
M=&%B;&4@8VQA<W,],T1R97!O<G0@:60],T1)1#!%1$)!13X-"B`@("`@(#QT
M<CX-"B`@("`@("`@/'1H(&-L87-S/3-$=&P@8V]L<W!A;CTS1#$@<F]W<W!A
M;CTS1#(^/'-T<F]N9SY.;W1E(#4@+2!3=&]C:VAO;&1E<G,G($5Q=6ET>2`M
M($]P=&EO;B!3=6UM87)Y("A$971A:6QS*2`H55-$("0I/&)R/CPO<W1R;VYG
M/CPO=&@^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H(&-O;'-P86X],T0Q/C,@
M36]N=&AS($5N9&5D/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@@8V]L
M<W!A;CTS1#$^,3(@36]N=&AS($5N9&5D/"]T:#X-"B`@("`@(#PO='(^#0H@
M("`@("`\='(^#0H@("`@("`@(#QT:"!C;&%S<STS1'1H/DUA<BX@,S$L(#(P
M,34\8G(^/"]T:#X-"B`@("`@("`@/'1H(&-L87-S/3-$=&@^1&5C+B`S,2P@
M,C`Q-#QB<CX\+W1H/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')E/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92!A="!*86YU87)Y(#$L(#(P,34@*&EN('-H87)E<RD\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1N=6UP/C<L,CDS+#`P,#QS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1N=6UP/C<L.3$X+#`P,#QS<&%N
M/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T<CX-"B`@("`@(#QT<B!C;&%S<STS
M1')O/@T*("`@("`@("`\=&0@8VQA<W,],T1P;"!V86QI9VX],T1T;W`^0F%L
M86YC92!A="!*86YU87)Y(#$L(#(P,34@*&EN(&1O;&QA<G,@<&5R('-H87)E
M*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C8U/'-P86X^
M/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C8Y
M/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L
M87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O
M<#Y"86QA;F-E(&%T($IA;G5A<GD@,2P@,C`Q-3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^."!Y96%R<R`Q,3,@9&%Y<SQS<&%N/CPO<W!A;CX\
M+W1D/@T*("`@("`@("`\=&0@8VQA<W,],T1T97AT/C<@>65A<G,@,S,U(&1A
M>7,\<W!A;CX\+W-P86X^/"]T9#X-"B`@("`@(#PO='(^#0H@("`@("`\='(@
M8VQA<W,],T1R;SX-"B`@("`@("`@/'1D(&-L87-S/3-$<&P@=F%L:6=N/3-$
M=&]P/D=R86YT960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA
M<W,],T1N=6UP/C4T+#`P,#QS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@("`\
M=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@("`@/"]T
M<CX-"B`@("`@(#QT<B!C;&%S<STS1')E/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1P;"!V86QI9VX],T1T;W`^1W)A;G1E9"`H:6X@9&]L;&%R<R!P97(@<VAA
M<F4I/"]T9#X-"B`@("`@("`@/'1D(&-L87-S/3-$;G5M<#XD(#$Q+C4R/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>&5R8VES960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@("`\=&0@8VQA<W,]
M,T1N=6T^*#,U,BPP,#`I/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R
M/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@(#QT9"!C;&%S<STS
M1'!L('9A;&EG;CTS1'1O<#Y%>&5R8VES960@*&EN(&1O;&QA<G,@<&5R('-H
M87)E*3PO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1&YU;7`^)"`X+C$X/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P
M86X^/"]S<&%N/CPO=&0^#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S
M/3-$<F\^#0H@("`@("`@(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%
M>'!I<F5D(&%N9"!F;W)F96ET960@*&EN('-H87)E<RD\+W1D/@T*("`@("`@
M("`\=&0@8VQA<W,],T1N=6T^*#,R-RPP,#`I/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`@(#QT9"!C;&%S<STS1'1E>'0^/'-P86X^/"]S<&%N/CPO=&0^
M#0H@("`@("`\+W1R/@T*("`@("`@/'1R(&-L87-S/3-$<F4^#0H@("`@("`@
M(#QT9"!C;&%S<STS1'!L('9A;&EG;CTS1'1O<#Y%>'!I<F5D(&%N9"!F;W)F
M96ET960@*&EN(&1O;&QA<G,@<&5R('-H87)E*3PO=&0^#0H@("`@("`@(#QT
M9"!C;&%S<STS1&YU;7`^)"`Q,"XV-SQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@("`\=&0@8VQA<W,],T1T97AT/CQS<&%N/CPO<W!A;CX\+W1D/@T*("`@
M("`@/"]T<CX-"B`@("`\+W1A8FQE/@T*("`\+V)O9'D^#0H\+VAT;6P^#0H-
M"BTM+2TM+3U?3F5X=%!A<G1?96)E93@S,F)?9C,V9E\T-6)A7V$R9#1?,S1C
M,S5F-C(S930W#0I#;VYT96YT+4QO8V%T:6]N.B!F:6QE.B\O+T,Z+V5B964X
M,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T-R]7;W)K<VAE971S+V9I
M;&5L:7-T+GAM;`T*0V]N=&5N="U4<F%N<V9E<BU%;F-O9&EN9SH@<75O=&5D
M+7!R:6YT86)L90T*0V]N=&5N="U4>7!E.B!T97AT+VAT;6P[(&-H87)S970]
M(G5S+6%S8VEI(@T*#0H\>&UL('AM;&YS.F\],T0B=7)N.G-C:&5M87,M;6EC
M<F]S;V9T+6-O;3IO9F9I8V4Z;V9F:6-E(CX-"B`\;SI-86EN1FEL92!(4F5F
M/3-$(BXN+U=O<FMB;V]K+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE
M970P,2YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,#(N:'1M;"(O
M/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`S+FAT;6PB+SX-"B`\;SI&:6QE
M($A2968],T0B4VAE970P-"YH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H
M965T,#4N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#`V+FAT;6PB
M+SX-"B`\;SI&:6QE($A2968],T0B4VAE970P-RYH=&UL(B\^#0H@/&\Z1FEL
M92!(4F5F/3-$(E-H965T,#@N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3
M:&5E=#`Y+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q,"YH=&UL
M(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,3$N:'1M;"(O/@T*(#QO.D9I
M;&4@2%)E9CTS1")3:&5E=#$R+FAT;6PB+SX-"B`\;SI&:6QE($A2968],T0B
M4VAE970Q,RYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$(E-H965T,30N:'1M
M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$U+FAT;6PB+SX-"B`\;SI&
M:6QE($A2968],T0B4VAE970Q-BYH=&UL(B\^#0H@/&\Z1FEL92!(4F5F/3-$
M(E-H965T,3<N:'1M;"(O/@T*(#QO.D9I;&4@2%)E9CTS1")3:&5E=#$X+FAT
M;6PB+SX-"B`\;SI&:6QE($A2968],T0B4VAE970Q.2YH=&UL(B\^#0H@/&\Z
M1FEL92!(4F5F/3-$(E-H965T,C`N:'1M;"(O/@T*/"]X;6P^#0HM+2TM+2T]
M7TYE>'1087)T7V5B964X,S)B7V8S-F9?-#5B85]A,F0T7S,T8S,U9C8R,V4T
%-RTM#0H`
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Convertible Notes to Related Parties<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Debt Disclosure [Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Convertible Notes to Related Parties</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In April 2011, we entered into a Securities Purchase Agreement for a private placement of up to $4.5&nbsp;million in Convertible Notes. We received a total of $4.3 million, net of issuance costs, from the issuance of these Convertible Notes. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Convertible Notes are secured by substantially all of our assets, including placing our bank accounts under a control agreement. The Convertible Notes bear interest at 6% per annum, payable quarterly in cash or in additional principal amount of Convertible Notes, at the election of the purchasers. The Convertible Notes mature on May 2, 2021, however, the holders of the Convertible Notes may require prepayment of the Convertible Notes at any time, at each holder&#x2019;s option.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Convertible Notes are convertible into shares of our common stock at a rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes. There is no right to convert the Convertible Notes to the extent that, after giving effect to such conversion, the holder would beneficially own in excess of 9.99% of our outstanding common stock. Each holder of the Convertible Notes can increase or decrease this beneficial ownership conversion limit by written notice to us, which will not be effective until 61 days after delivery of the notice.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2015, we were in compliance with all covenants under the Convertible Notes. Upon the occurrence of an event of default under the Convertible Notes, the holders of the Convertible Notes have the right to require us to redeem all or a portion of their Convertible Notes.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We filed a registration statement with the SEC to register for resale 3.5 million shares underlying the Convertible Notes. The registration statement was declared effective on July&nbsp;29,&nbsp;2011. The Note holders have agreed to waive their right to require us to maintain the effectiveness of the registration statement and to register the additional shares underlying the Convertible Notes until they provide notice otherwise.</div></div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The Convertible Notes contain an embedded conversion feature that was in-the-money on the issuance dates. Based on an effective fixed conversion rate of 1,250 shares for every $1,000 of principal and accrued interest due under the Convertible Notes, the total conversion benefit at issuance exceeded the loan proceeds. Therefore, a debt discount was recorded in an amount equal to the face value of the Convertible Notes on the issuance dates and we began amortizing the resultant debt discount over the respective 10-year term of the Convertible Notes. During the three months ended March 31, 2015, accrued interest of approximately $80,000 was paid-in-kind and rolled into the Convertible Note principal balance, which resulted in an additional debt discount of approximately $80,000. For the three months ended March 31, 2015 and 2014, interest expense relating to the stated rate was approximately $81,000 and $77,000, respectively, and interest expense relating to the amortization of the debt discount was approximately $151,000 and $139,000, respectively.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">As of March 31, 2015, the carrying value of the Convertible Notes was approximately $1,749,000, which is comprised of the $5,421,000 principal amount of the Convertible Notes outstanding, less debt discount of $3,672,000. If the $5,421,000 principal amount of Convertible Notes is converted, we would issue 6,776,998 shares of our common stock.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 19, 20, 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.19,20,22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPUAE">
      <tr>
        <th class="tl" colspan="1" rowspan="1">
          <div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Current Period Unaudited) (USD $)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 55,556</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 72,675</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">945</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" onclick="toggleNextSibling(this);">1,057</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">56,501</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AssetsCurrent" onclick="toggleNextSibling(this);">73,732</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AssetsCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,996</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
        <td class="nump"><a title="us-gaap_PropertyPlantAndEquipmentNet" onclick="toggleNextSibling(this);">2,820</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PropertyPlantAndEquipmentNet</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other long-term assets</a></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAssetsNoncurrent" onclick="toggleNextSibling(this);">130</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAssetsNoncurrent</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">59,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
        <td class="nump"><a title="us-gaap_Assets" onclick="toggleNextSibling(this);">76,682</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_Assets</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">2,383</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_AccountsPayableCurrent" onclick="toggleNextSibling(this);">2,549</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AccountsPayableCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_AccruedClinicalLiabilities', window );">Accrued clinical liabilities</a></td>
        <td class="nump"><a title="hrtx_AccruedClinicalLiabilities" onclick="toggleNextSibling(this);">3,518</a><span style="display:none;white-space:normal;text-align:left;">hrtx_AccruedClinicalLiabilities</span><span></span></td>
        <td class="nump"><a title="hrtx_AccruedClinicalLiabilities" onclick="toggleNextSibling(this);">3,811</a><span style="display:none;white-space:normal;text-align:left;">hrtx_AccruedClinicalLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued payroll and employee-related liabilities</a></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">1,656</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_EmployeeRelatedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,731</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeRelatedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other accrued expenses</a></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,320</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_OtherAccruedLiabilitiesCurrent" onclick="toggleNextSibling(this);">2,931</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OtherAccruedLiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Convertible notes payable to related parties, net of discount</a></td>
        <td class="nump"><a title="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">1,749</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</span><span></span></td>
        <td class="nump"><a title="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">1,598</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">11,626</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesCurrent" onclick="toggleNextSibling(this);">13,620</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesCurrent</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#x2019; equity:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock</a></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">296</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CommonStockValue" onclick="toggleNextSibling(this);">292</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CommonStockValue</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">383,512</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
        <td class="nump"><a title="us-gaap_AdditionalPaidInCapital" onclick="toggleNextSibling(this);">378,007</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AdditionalPaidInCapital</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(335,807)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">(315,237)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">48,001</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockholdersEquity" onclick="toggleNextSibling(this);">63,062</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockholdersEquity</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders&#x2019; equity</a></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 59,627</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
        <td class="nump"><a title="us-gaap_LiabilitiesAndStockholdersEquity" onclick="toggleNextSibling(this);">$ 76,682</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_LiabilitiesAndStockholdersEquity</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_AccruedClinicalLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of clinical obligations incurred and payable.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_AccruedClinicalLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 19<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.19(a))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.30(a)(1))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.18)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 12<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 18<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_Assets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.9)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 3<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6801-107765<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 9<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Cash Equivalents<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 1<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (a)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 230<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 4<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.32)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 25<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 32<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.21)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 21<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Carrying value as of the balance sheet date of obligations incurred through that date and payable arising from transactions not otherwise specified in the taxonomy. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 20<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Glossary Current Liabilities<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6509677<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 8<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6935-107765<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.20)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 6<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6911-107765<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 9<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e7018-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Aggregate carrying amount, as of the balance sheet date, of noncurrent assets not separately disclosed in the balance sheet. Noncurrent assets are expected to be realized or consumed after one year (or the normal operating cycle, if longer).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.17)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 17<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 45<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 360<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 1<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.13)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 13<br><br><br><br> -Subparagraph a<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 03<br><br><br><br> -Paragraph 8<br><br><br><br> -Article 7<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 310<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (SAB TOPIC 4.E)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Staff Accounting Bulletin (SAB)<br><br><br><br> -Number Topic 4<br><br><br><br> -Section E<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.29-31)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30, 31<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 2 - Basis of Presentation<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccounting', window );">Basis of Accounting [Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2</div><div style="display: inline; font-weight: bold;">.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B</div><div style="display: inline; font-weight: bold;">asis of Presentation</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (&#x201c;GAAP&#x201d;) for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and disclosures required by GAAP for complete financial statements. In the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three months ended March 31, 2015 are not necessarily indicative of the results that may be expected for other quarters or the year ending December&nbsp;31, 2015. The condensed balance sheet at December 31, 2014 has been derived from the audited financial statements as of that date, but does not include all of the information and disclosures required by GAAP. For more complete financial information, these unaudited condensed consolidated financial statements and the notes thereto should be read in conjunction with the audited financial statements included in&nbsp;our Annual Report on Form</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;10-K for the fiscal year ended December&nbsp;31, 2014 filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on March&nbsp;13,&nbsp;2015</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">. </div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccounting">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BasisOfAccounting</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accounting Policies</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Principles of Consolidation</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V., which was organized in the Netherlands in March 2015. Heron Therapeutics B.V. has no operations and no material assets or liabilities and there have been no significant transactions related to Heron Therapeutics B.V. since its inception.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents consist of cash and highly liquid investments with original maturities from purchase date of three months or less. Our bank accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (&#x201c;Convertible Notes&#x201d;).</div></div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Earnings Per Share</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic earnings per share (&#x201c;EPS&#x201d;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying Convertible Notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Because we have incurred a net loss for all periods presented in the condensed consolidated statements of operations, outstanding stock options, warrants and common stock underlying Convertible Notes are not included in the computation of net loss per share because their effect would be anti-dilutive. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table includes the number of outstanding stock options, warrants and common stock underlying Convertible Notes not included in the computation as of the dates shown below (in thousands):</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div>   <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0">         <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As of March 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td>     </tr>     <tr>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>      <td>&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock options outstanding</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff">7,293</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff">7,273</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #ffffff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants outstanding</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">3,843</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">3,825</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td>     </tr>     <tr style="BACKGROUND-COLOR: #cceeff">      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock underlying convertible notes outstanding</div></div></td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff">6,777</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff">6,385</td>      <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td>     </tr>       </table>  </div>  <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Comprehensive Income (Loss)</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of our net loss, and there were no other changes in equity from non-owner sources. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In January 2015, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2015-</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">01<div style="display: inline; font-style: italic;">, Income Statement&#x2014;Extraordinary and Unusual Items (Subtopic 225-20)</div> (&#x201c;ASU 2015-01&#x201d;). ASU 2015-01 eliminates the concept of extraordinary items from GAAP. FASB concluded that ASU 2015-01 will not result in a loss of information because although ASU 2015-01 will eliminate the requirements in Subtopic 225-20 for reporting entities to consider whether an underlying event or transaction is extraordinary, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring.<div style="display: inline; font-style: italic;"> </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The amendments in<div style="display: inline; font-style: italic;"> </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We adopted the provisions of ASU 2015-01 in the first quarter of 2015. The adoption of this ASU did not have a material impact on our results of operations or financial condition.</div></div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, FASB issued ASU No. 2014-15, <div style="display: inline; font-style: italic;">Presentation of Financial Statements &#x2013; Going Concern (Subtopic 205-40)</div> (&#x201c;ASU 2014-15&#x201d;). ASU 2014-15 requires management to assess an entity&#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in United States auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, including interim periods, (3)&nbsp;provide principles for considering the mitigating effect of management&#x2019;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&#x2019;s plans, (5)&nbsp;require an express statement and other disclosures when substantial doubt is not alleviated, and (6)&nbsp;require an assessment for a period of one year after the date that the financial satements are issued (or available to be issued). The amendments in ASU 2014-15 are effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. We plan to adopt the provisions of ASU 2014-15 in 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In June 2014, FASB issued ASU No. 2014-12, <div style="display: inline; font-style: italic;">Compensation &#x2013; Stock Compensation (Topic 718)</div> (&#x201c;ASU 2014-12&#x201d;). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The amendments in ASU 2014-12 may either be applied (a)&nbsp;prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earlier annual period presented in the financial statements and to all new or modified awards thereafter. We plan to adopt the provisions of ASU 2014-12 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for all significant accounting policies of the reporting entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18726-107790<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18861-107790<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18743-107790<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 5<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18854-107790<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E3OAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 14,504</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_ResearchAndDevelopmentExpense" onclick="toggleNextSibling(this);">$ 11,628</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ResearchAndDevelopmentExpense</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">5,856</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_GeneralAndAdministrativeExpense" onclick="toggleNextSibling(this);">5,694</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_GeneralAndAdministrativeExpense</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">20,360</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
        <td class="nump"><a title="us-gaap_OperatingExpenses" onclick="toggleNextSibling(this);">17,322</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingExpenses</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(20,360)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_OperatingIncomeLoss" onclick="toggleNextSibling(this);">(17,322)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_OperatingIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Interest expense, net</a></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(210)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
        <td class="num"><a title="us-gaap_NonoperatingIncomeExpense" onclick="toggleNextSibling(this);">(216)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NonoperatingIncomeExpense</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (20,570)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (17,538)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share (in dollars per share)</a></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.70)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
        <td class="num"><a title="us-gaap_EarningsPerShareBasicAndDiluted" onclick="toggleNextSibling(this);">$ (0.74)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EarningsPerShareBasicAndDiluted</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share (in shares)</a></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">29,392</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
        <td class="nump"><a title="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" onclick="toggleNextSibling(this);">23,686</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.4)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.7)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 7<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The net result for the period of deducting operating expenses from operating revenues.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 985<br><br> -SubTopic 20<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 730<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E6SDI">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="4">1 Months Ended</th>
        <th class="th" colspan="1">25 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2011</div>
        </th>
        <th class="th">
          <div>Jul. 31, 2012</div>
        </th>
        <th class="th">
          <div>Nov. 30, 2013</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2014</div>
        </th>
        <th class="th">
          <div>Jun. 30, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Net</a></td>
        <td class="nump"><a title="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" onclick="toggleNextSibling(this);">351,698</a><span style="display:none;white-space:normal;text-align:left;">hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet</span><span></span></td>
        <td class="nump"><a title="hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet" onclick="toggleNextSibling(this);">215,350</a><span style="display:none;white-space:normal;text-align:left;">hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from Stock Options Exercised</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 2,878,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">$ 958,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">352,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">275,352</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</a></td>
        <td class="nump"><a title="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" onclick="toggleNextSibling(this);">29,947,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</a></td>
        <td class="text">2 years 146 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member', window );">Private Placement 2011 [Member] | Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">47,588</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">108,409</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">8,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">22,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">1,200,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Class of Warrant or Right, Number of Securities Called by Each Warrant or Right</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">0.5</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member', window );">Private Placement 2011 [Member] | Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">66,667</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised[us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">144,040</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_WarrantMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member', window );">Private Placement 2011 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromWarrantExercises[us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromWarrantExercises<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromWarrantExercises[us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">0</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromWarrantExercises<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">$ 3.60</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member', window );">Private Placement 2012 [Member] | Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member]" onclick="toggleNextSibling(this);">5,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Stock Issued During Period, Value, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodValueNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member]" onclick="toggleNextSibling(this);">50,500,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodValueNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember;us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member]" onclick="toggleNextSibling(this);">3,100,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member', window );">Private Placement 2012 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member]" onclick="toggleNextSibling(this);">$ 10.50</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_SubsidiarySaleOfStockAxis<br>= hrtx_PrivatePlacement2012Member</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Jefferies, LLC [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[dei_LegalEntityAxis=hrtx_JefferiesLlcMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">7,700,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ dei_LegalEntityAxis<br>= hrtx_JefferiesLlcMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[dei_LegalEntityAxis=hrtx_JefferiesLlcMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">3,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ dei_LegalEntityAxis<br>= hrtx_JefferiesLlcMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[dei_LegalEntityAxis=hrtx_JefferiesLlcMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 8</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ dei_LegalEntityAxis<br>= hrtx_JefferiesLlcMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfCommonStock[dei_LegalEntityAxis=hrtx_JefferiesLlcMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">57,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfCommonStock<br>/ dei_LegalEntityAxis<br>= hrtx_JefferiesLlcMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_StockIssuedDuringPeriodSharesNewIssues[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">4,800,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesNewIssues<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of Stock, Price Per Share</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SaleOfStockPricePerShare[us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">$ 11.75</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SaleOfStockPricePerShare<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=hrtx_CommonStockAndPrefundedWarrantsMember', window );">Common Stock and Prefunded Warrants [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payments of Stock Issuance Costs</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaymentsOfStockIssuanceCosts[us-gaap_StatementEquityComponentsAxis=hrtx_CommonStockAndPrefundedWarrantsMember]" onclick="toggleNextSibling(this);">4,000,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsOfStockIssuanceCosts<br>/ us-gaap_StatementEquityComponentsAxis<br>= hrtx_CommonStockAndPrefundedWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity', window );">Proceeds from Issuance or Sale of Equity</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOrSaleOfEquity[us-gaap_StatementEquityComponentsAxis=hrtx_CommonStockAndPrefundedWarrantsMember]" onclick="toggleNextSibling(this);">$ 58,900,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity<br>/ us-gaap_StatementEquityComponentsAxis<br>= hrtx_CommonStockAndPrefundedWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=hrtx_PrivatePlacement2011Member', window );">Private Placement 2011 [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_LimitationOnExercisableWarrants', window );">Limitation on Exercisable Warrants</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_LimitationOnExercisableWarrants[us-gaap_StatementClassOfStockAxis=hrtx_PrivatePlacement2011Member]" onclick="toggleNextSibling(this);">9.99%</a><span style="display:none;white-space:normal;text-align:left;">hrtx_LimitationOnExercisableWarrants<br>/ us-gaap_StatementClassOfStockAxis<br>= hrtx_PrivatePlacement2011Member</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=hrtx_PreFundedWarrantsMember', window );">Pre-funded Warrants[Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1[us-gaap_ClassOfWarrantOrRightAxis=hrtx_PreFundedWarrantsMember]" onclick="toggleNextSibling(this);">$ 0.01</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= hrtx_PreFundedWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights[us-gaap_ClassOfWarrantOrRightAxis=hrtx_PreFundedWarrantsMember]" onclick="toggleNextSibling(this);">600,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= hrtx_PreFundedWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share Price</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_SharePrice[us-gaap_ClassOfWarrantOrRightAxis=hrtx_PreFundedWarrantsMember]" onclick="toggleNextSibling(this);">$ 11.74</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_SharePrice<br>/ us-gaap_ClassOfWarrantOrRightAxis<br>= hrtx_PreFundedWarrantsMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_LimitationOnExercisableWarrants">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>There is no right to exercise the Warrants to the extent that the holder would beneficially own in excess of the stated percentage of The Company's outstanding shares of common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_LimitationOnExercisableWarrants</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period, net of shares retained for cashless exercises.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_StockIssuedDuringPeriodSharesStockOptionsExercisedNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Exercise price per share or per unit of warrants or rights outstanding.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(4))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(i)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph i<br><br> -Subparagraph 2<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Unrecognized cost of unvested share-based compensation awards.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow for cost incurred directly with the issuance of an equity security.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3291-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the additional capital contribution to the entity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOrSaleOfEquity">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of common stock, preferred stock, treasury stock, stock options, and other types of equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOrSaleOfEquity</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of non-option equity instruments exercised by participants.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Price of a single share of a number of saleable stocks of a company.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of new stock issued during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.28,29)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)(iv)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.3-04)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 29, 30, 31<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=hrtx_PreFundedWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=hrtx_PreFundedWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=hrtx_PrivatePlacement2011Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=hrtx_PrivatePlacement2011Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=hrtx_CommonStockAndPrefundedWarrantsMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=hrtx_CommonStockAndPrefundedWarrantsMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2011Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=hrtx_PrivatePlacement2012Member</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0E4EAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Document And Entity Information<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Apr. 28, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
        <td class="text">HERON THERAPEUTICS, INC. /DE/<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
        <td class="text">0000818033<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
        <td class="text">--12-31<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
        <td class="text">Accelerated Filer<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
        <td class="text">Yes<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
        <td class="text">No<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding (in shares)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="dei_EntityCommonStockSharesOutstanding" onclick="toggleNextSibling(this);">29,632,533</a><span style="display:none;white-space:normal;text-align:left;">dei_EntityCommonStockSharesOutstanding</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
        <td class="text">10-Q<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
        <td class="text">Mar. 31,  2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
        <td class="text">2015<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
        <td class="text">Q1<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
        <td class="text">false<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_AmendmentFlag</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:booleanItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>End date of current fiscal year in the format --MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gMonthDayItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:fiscalPeriodItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:gYearItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_DocumentType</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:submissionTypeItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:centralIndexKeyItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityFilerCategory</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:filerCategoryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation 12B<br><br> -Number 240<br><br> -Section 12b<br><br> -Subsection 1<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityRegistrantName</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:normalizedStringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>dei_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>dei:yesNoItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EHAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity - Allocation of the Recognized Cost (Details) (USD $)<br>In Thousands, except Per Share data, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 2,551</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense" onclick="toggleNextSibling(this);">$ 2,969</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare', window );">Impact on basic and diluted net loss per share (in dollars per share)</a></td>
        <td class="nump"><a title="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" onclick="toggleNextSibling(this);">$ 0.09</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare</span><span></span></td>
        <td class="nump"><a title="hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare" onclick="toggleNextSibling(this);">$ 0.13</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">806</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember]" onclick="toggleNextSibling(this);">1,262</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_ResearchAndDevelopmentExpenseMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 1,745</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AllocatedShareBasedCompensationExpense[us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember]" onclick="toggleNextSibling(this);">$ 1,707</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AllocatedShareBasedCompensationExpense<br>/ us-gaap_IncomeStatementLocationAxis<br>= us-gaap_GeneralAndAdministrativeExpenseMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Impact on basic and diluted net loss per common share in dollars per shar</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_ImpactOnBasicAndDilutedNetLossPerCommonShareInDollarsPerShare</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EBXAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (20,570,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
        <td class="num"><a title="us-gaap_NetIncomeLoss" onclick="toggleNextSibling(this);">$ (17,538,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetIncomeLoss</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used for operating activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">152,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_DepreciationAndAmortization" onclick="toggleNextSibling(this);">114,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DepreciationAndAmortization</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">2,551,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensation" onclick="toggleNextSibling(this);">2,969,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensation</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">151,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">139,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">112,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" onclick="toggleNextSibling(this);">(1,624,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">(166,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInAccountsPayable" onclick="toggleNextSibling(this);">2,238,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInAccountsPayable</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_IncreaseDecreaseInClinicalLiabilities', window );">Accrued clinical liabilities</a></td>
        <td class="num"><a title="hrtx_IncreaseDecreaseInClinicalLiabilities" onclick="toggleNextSibling(this);">(293,000)</a><span style="display:none;white-space:normal;text-align:left;">hrtx_IncreaseDecreaseInClinicalLiabilities</span><span></span></td>
        <td class="num"><a title="hrtx_IncreaseDecreaseInClinicalLiabilities" onclick="toggleNextSibling(this);">(1,029,000)</a><span style="display:none;white-space:normal;text-align:left;">hrtx_IncreaseDecreaseInClinicalLiabilities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued payroll and employee-related liabilities</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(1,075,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" onclick="toggleNextSibling(this);">(1,254,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities', window );">Other accrued expenses</a></td>
        <td class="num"><a title="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" onclick="toggleNextSibling(this);">(531,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</span><span></span></td>
        <td class="nump"><a title="us-gaap_IncreaseDecreaseInOtherAccruedLiabilities" onclick="toggleNextSibling(this);">272,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used for operating activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(19,669,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInOperatingActivities" onclick="toggleNextSibling(this);">(15,713,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInOperatingActivities</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(328,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
        <td class="num"><a title="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" onclick="toggleNextSibling(this);">(57,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used for investing activities</a></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(328,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
        <td class="num"><a title="us-gaap_NetCashProvidedByUsedInInvestingActivities" onclick="toggleNextSibling(this);">(57,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInInvestingActivities</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing activities:</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from stock option exercises</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">2,878,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromStockOptionsExercised" onclick="toggleNextSibling(this);">958,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromStockOptionsExercised</span><span></span></td>
      </tr>
      <tr class="reu">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">2,878,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
        <td class="nump"><a title="us-gaap_NetCashProvidedByUsedInFinancingActivities" onclick="toggleNextSibling(this);">958,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_NetCashProvidedByUsedInFinancingActivities</span><span></span></td>
      </tr>
      <tr class="rou">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net decrease in cash and cash equivalents</a></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(17,119,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
        <td class="num"><a title="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" onclick="toggleNextSibling(this);">(14,812,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at beginning of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">72,675,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">72,287,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents at end of period</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 55,556,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 57,475,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_IncreaseDecreaseInClinicalLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to clinical liabilities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_IncreaseDecreaseInClinicalLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 830<br><br> -SubTopic 230<br><br> -Section 45<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6450594&amp;loc=d3e33268-110906<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 360<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherAccruedLiabilities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in other expenses incurred but not yet paid.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherAccruedLiabilities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The increase (decrease) during the reporting period in the value of prepaid expenses and other assets not separately disclosed in the statement of cash flows, for example, deferred expenses, intangible assets, or income taxes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 26<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3574-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 24<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3521-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 25<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3536-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Other Comprehensive Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6519514<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Net Income<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6518256<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.19)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.18)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 944<br><br> -SubTopic 225<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.7-04.22)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br><br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 19<br><br> -Article 5<br><br><br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Paragraph 20<br><br> -Article 9<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Investing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6516133<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 13<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3213-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with the amount received from holders exercising their stock options. This item inherently excludes any excess tax benefit, which the entity may have realized and reported separately.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (j)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As of March 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock options outstanding</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff">7,293</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff">7,273</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants outstanding</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">3,843</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">3,825</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock underlying convertible notes outstanding</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff">6,777</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff">6,385</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EZDAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Principles of Consolidation</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The accompanying unaudited condensed consolidated financial statements include the accounts of Heron Therapeutics, Inc. and its wholly owned subsidiary, Heron Therapeutics B.V., which was organized in the Netherlands in March 2015. Heron Therapeutics B.V. has no operations and no material assets or liabilities and there have been no significant transactions related to Heron Therapeutics B.V. since its inception.</div></div></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Use of Estimates</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and disclosures made in the accompanying notes to the financial statements. Our critical accounting policies that involve significant judgment and estimates include accrued clinical liabilities, income taxes and stock-based compensation. Actual results could differ materially from those estimates.</div></div></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Cash and Cash Equivalents</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Cash and cash equivalents consist of cash and highly liquid investments with original maturities from purchase date of three months or less. Our bank accounts have been placed under a control agreement in accordance with our Senior Secured Convertible Notes (&#x201c;Convertible Notes&#x201d;).</div></div></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Earnings Per Share</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Basic earnings per share (&#x201c;EPS&#x201d;) is calculated by dividing the net loss by the weighted-average number of common shares outstanding for the period, without consideration of common share equivalents. Diluted EPS is computed by dividing the net loss by the weighted-average number of common shares and common share equivalents outstanding for the period determined using the treasury stock method. For purposes of this calculation, stock options, warrants and common stock underlying Convertible Notes are considered to be common stock equivalents and are only included in the calculation of diluted EPS when their effect is dilutive.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Because we have incurred a net loss for all periods presented in the condensed consolidated statements of operations, outstanding stock options, warrants and common stock underlying Convertible Notes are not included in the computation of net loss per share because their effect would be anti-dilutive. </div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The following table includes the number of outstanding stock options, warrants and common stock underlying Convertible Notes not included in the computation as of the dates shown below (in thousands):</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div> <table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">As of March 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock options outstanding</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff">7,293</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #cceeff">7,273</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Warrants outstanding</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">3,843</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">3,825</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Common stock underlying convertible notes outstanding</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff">6,777</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 37.9pt; BACKGROUND-COLOR: #cceeff">6,385</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table> </div></div></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Comprehensive Income (Loss)</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Comprehensive income (loss) is defined as the change in equity during a period from transactions and other events and circumstances from non-owner sources. Our comprehensive net loss for both periods presented was comprised solely of our net loss, and there were no other changes in equity from non-owner sources. </div></div></div></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Recent Accounting Pronouncements</div></div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In January 2015, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) No. 2015-</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">01<div style="display: inline; font-style: italic;">, Income Statement&#x2014;Extraordinary and Unusual Items (Subtopic 225-20)</div> (&#x201c;ASU 2015-01&#x201d;). ASU 2015-01 eliminates the concept of extraordinary items from GAAP. FASB concluded that ASU 2015-01 will not result in a loss of information because although ASU 2015-01 will eliminate the requirements in Subtopic 225-20 for reporting entities to consider whether an underlying event or transaction is extraordinary, the presentation and disclosure guidance for items that are unusual in nature or occur infrequently will be retained and will be expanded to include items that are both unusual in nature and infrequently occurring.<div style="display: inline; font-style: italic;"> </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The amendments in<div style="display: inline; font-style: italic;"> </div></div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">ASU 2015-01 are effective for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2015. A reporting entity may apply the amendments prospectively. A reporting entity also may apply the amendments retrospectively to all prior periods presented in the financial statements. Early adoption is permitted provided that the guidance is applied from the beginning of the fiscal year of adoption. We adopted the provisions of ASU 2015-01 in the first quarter of 2015. The adoption of this ASU did not have a material impact on our results of operations or financial condition.</div></div><div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In August 2014, FASB issued ASU No. 2014-15, <div style="display: inline; font-style: italic;">Presentation of Financial Statements &#x2013; Going Concern (Subtopic 205-40)</div> (&#x201c;ASU 2014-15&#x201d;). ASU 2014-15 requires management to assess an entity&#x2019;s ability to continue as a going concern by incorporating and expanding upon certain principles that are currently in United States auditing standards. Specifically, the amendments (1) provide a definition of the term substantial doubt, (2) require an evaluation every reporting period</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">, including interim periods, (3)&nbsp;provide principles for considering the mitigating effect of management&#x2019;s plans, (4) require certain disclosures when substantial doubt is alleviated as a result of consideration of management&#x2019;s plans, (5)&nbsp;require an express statement and other disclosures when substantial doubt is not alleviated, and (6)&nbsp;require an assessment for a period of one year after the date that the financial satements are issued (or available to be issued). The amendments in ASU 2014-15 are effective for the annual period ending after December&nbsp;15, 2016, and for annual periods and interim periods thereafter. Early adoption is permitted. We plan to adopt the provisions of ASU 2014-15 in 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In June 2014, FASB issued ASU No. 2014-12, <div style="display: inline; font-style: italic;">Compensation &#x2013; Stock Compensation (Topic 718)</div> (&#x201c;ASU 2014-12&#x201d;). ASU 2014-12 requires that a performance target that affects vesting and that could be achieved after the requisite service period be treated as a performance condition. ASU 2014-12 is effective for annual periods and interim periods within those annual periods beginning after December 15, 2015. Earlier adoption is permitted. The amendments in ASU 2014-12 may either be applied (a)&nbsp;prospectively to all awards granted or modified after the effective date or (b) retrospectively to all awards with performance targets that are outstanding as of the beginning of the earlier annual period presented in the financial statements and to all new or modified awards thereafter. We plan to adopt the provisions of ASU 2014-12 in the first quarter of 2016. We do not expect the adoption of this ASU to have a material impact on our results of operations or financial condition.</div></div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367179&amp;loc=d3e4273-108586<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 305<br><br> -SubTopic 10<br><br> -Section 05<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Financial Reporting Release (FRR)<br><br> -Number 203<br><br> -Paragraph 02-03<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for comprehensive income.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=18733093&amp;loc=d3e5614-111684<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 810<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.3A-02)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27015204&amp;loc=d3e355033-122828<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph k<br><br> -Article 1<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02, 03<br><br> -Article 3A<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6367646&amp;loc=d3e18780-107790<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6143-108592<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6132-108592<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 275<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6927468&amp;loc=d3e6061-108592<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EKJAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity - Option Valuation Assumptions (Details) (Employee Stock Option [Member])<br></strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top">
          <div class="a">Employee Stock Option [Member]</div>
        </td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">1.60%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">2.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">0.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Volatility</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">91.70%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate[us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember]" onclick="toggleNextSibling(this);">104.10%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate<br>/ us-gaap_AwardTypeAxis<br>= us-gaap_EmployeeStockOptionMember</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life (years)</a></td>
        <td class="text">6 years 36 days<span></span></td>
        <td class="text">6 years<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.D.2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(i)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section D<br><br> -Subsection 2<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(ii)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)(iv)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ETAAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 3 - Accounting Policies - Equity Excluded From Calculation of Diluted Earnings Per Share (Details)<br>In Thousands, unless otherwise specified</strong></div>
        </th>
        <th class="th" colspan="2">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded (in shares)</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">7,293</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember]" onclick="toggleNextSibling(this);">7,273</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_StockOptionMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded (in shares)</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,843</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember]" onclick="toggleNextSibling(this);">3,825</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_WarrantMember</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Shares excluded (in shares)</a></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">6,777</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="nump"><a title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount[us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">6,385</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount<br>/ us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 260<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (c)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Antidilution<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6505113<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Diluted Earnings Per Share<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6510752<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Contingent Stock Agreement<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6508534<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ELH">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity (Tables)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"></div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Three Months Ended</div></div></div> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31</div><div style="display: inline; font-weight: bold;">,</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2015</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">2014</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> <td>&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Research and development</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">806</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1,262</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">General and administrative</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">1,745</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 38.7pt; BACKGROUND-COLOR: #ffffff">1,707</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Stock-based compensation expense included in operating expenses</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,551</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2,969</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: top; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Impact on basic and diluted net loss per share</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0.09</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">0.13</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 3px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="6"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">March 31,</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">15</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">20</div><div style="display: inline; font-weight: bold;">14</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 70%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Risk-free interest rate</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">1.6</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">2.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Dividend yield</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 19.55pt; BACKGROUND-COLOR: #ffffff">0.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Volatility</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">91.7</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">104.1</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">%</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: justify; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expected life (years)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">6.1</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 54pt; BACKGROUND-COLOR: #ffffff">6.0</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity [Table Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><table style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 100%; TEXT-INDENT: 0px;; width: 700px;" cellspacing="0" cellpadding="0" border="0"> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Weighted-</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Remaining</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Average</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Contractual</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Shares</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Exercise</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Term</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(in thousands)</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Price</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: center; MARGIN-LEFT: 0pt" colspan="2"> <div style=" TEXT-ALIGN: center; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">(Years)</div></div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 1px"><div style="display: inline; font-weight: bold;">&nbsp;</div></td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 55%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance at January 1, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7,918</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.69</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7.92</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Granted</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">54</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">11.52</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Exercised</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">(352</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.18</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #ffffff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; PADDING-LEFT: 9pt; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Expired and forfeited</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 1px solid; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">(327</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">)</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff">10.67</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #ffffff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; BACKGROUND-COLOR: #ffffff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; BACKGROUND-COLOR: #ffffff">&nbsp;</td> </tr> <tr style="BACKGROUND-COLOR: #cceeff"> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; VERTICAL-ALIGN: bottom; TEXT-ALIGN: left; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff"> <div style=" TEXT-ALIGN: left; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Balance at March 31, 2015</div></div></td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: #000000 3px double; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">7,293</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">$</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.65</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BACKGROUND-COLOR: #cceeff">&nbsp;</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 12%; VERTICAL-ALIGN: bottom; TEXT-ALIGN: right; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff">8.31</td> <td style="FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif; WIDTH: 1%; VERTICAL-ALIGN: bottom; BORDER-BOTTOM: medium none; PADDING-BOTTOM: 0px; MARGIN-LEFT: 0pt; BACKGROUND-COLOR: #cceeff" nowrap="nowrap">&nbsp;</td> </tr> </table></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 1<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5047-113901<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SAB TOPIC 14.F)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Staff Accounting Bulletin (SAB)<br><br> -Number Topic 14<br><br> -Section F<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (h)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for share options (or share units) that were outstanding at the beginning and end of the year, vested and expected to vest, exercisable or convertible at the end of the year, and the number of share options or share units that were granted, exercised or converted, forfeited, and expired during the year.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (c)(1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 718<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -Subparagraph (f)(2)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EAHAC">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Business (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">51 Months Ended</th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2013</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained Earnings (Accumulated Deficit)</a></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (335,807,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="num"><a title="us-gaap_RetainedEarningsAccumulatedDeficit" onclick="toggleNextSibling(this);">$ (315,237,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_RetainedEarningsAccumulatedDeficit</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet', window );">Proceeds from Issuance of Long-term Debt and Capital Securities, Net</a></td>
        <td class="nump"><a title="us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet" onclick="toggleNextSibling(this);">194,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and Cash Equivalents, at Carrying Value</a></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 55,556,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 72,675,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 57,475,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
        <td class="nump"><a title="us-gaap_CashAndCashEquivalentsAtCarryingValue" onclick="toggleNextSibling(this);">$ 72,287,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_CashAndCashEquivalentsAtCarryingValue</span><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6506951<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Cash Equivalents<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6507016<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 1<br><br> -Article 5<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.1)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 1<br><br> -Subparagraph (a)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=28358313&amp;loc=d3e6676-107765<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 4<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3044-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow associated with security instrument that either represents a creditor or an ownership relationship with the holder of the investment security with a maturity of beyond one year or normal operating cycle, if longer. Includes proceeds from (a) debt, (b) capital lease obligations, (c) mandatory redeemable capital securities, and (d) any combination of (a), (b), or (c).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (a),(b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebtAndCapitalSecuritiesNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 31<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 04<br><br> -Article 3<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.31(a)(3))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EPNBG">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 4 - Convertible Notes to Related Parties (Details Textual) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">0 Months Ended</th>
        <th class="th" colspan="1">1 Months Ended</th>
        <th class="th" colspan="2">3 Months Ended</th>
        <th class="th" colspan="1"></th>
      </tr>
      <tr>
        <th class="th">
          <div>Jul. 29, 2011</div>
        </th>
        <th class="th">
          <div>Apr. 30, 2011</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Mar. 31, 2014</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement', window );">Convertible Debt Issuable in Connection with Private Placement</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement" onclick="toggleNextSibling(this);">$ 4,500,000</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromConvertibleDebt', window );">Proceeds from Convertible Debt</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_ProceedsFromConvertibleDebt" onclick="toggleNextSibling(this);">4,300,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ProceedsFromConvertibleDebt</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes', window );">Common Shares Registered for Resale in Connection with Convertible Notes</a></td>
        <td class="nump"><a title="hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes" onclick="toggleNextSibling(this);">3,500,000</a><span style="display:none;white-space:normal;text-align:left;">hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpenseDebtExcludingAmortization', window );">Interest Expense, Debt, Excluding Amortization</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseDebtExcludingAmortization" onclick="toggleNextSibling(this);">81,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebtExcludingAmortization</span><span></span></td>
        <td class="nump"><a title="us-gaap_InterestExpenseDebtExcludingAmortization" onclick="toggleNextSibling(this);">77,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_InterestExpenseDebtExcludingAmortization</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfDebtDiscountPremium', window );">Amortization of Debt Discount (Premium)</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">151,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
        <td class="nump"><a title="us-gaap_AmortizationOfDebtDiscountPremium" onclick="toggleNextSibling(this);">139,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_AmortizationOfDebtDiscountPremium</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Convertible Notes Payable, Related Parties, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">1,749,000</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent" onclick="toggleNextSibling(this);">1,598,000</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</span><span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member] | Common Stock [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_DebtInstrumentConversionRatioShares', window );">Debt Instrument Conversion Ratio Shares</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_DebtInstrumentConversionRatioShares[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember;us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember]" onclick="toggleNextSibling(this);">1,250</a><span style="display:none;white-space:normal;text-align:left;">hrtx_DebtInstrumentConversionRatioShares<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember<br>/ us-gaap_StatementEquityComponentsAxis<br>= us-gaap_CommonStockMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member] | In Case of Debt Conversion [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_DebtConversionByUniqueDescriptionAxis=hrtx_InCaseOfDebtConversionMember;us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">5,421,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_DebtConversionByUniqueDescriptionAxis<br>= hrtx_InCaseOfDebtConversionMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments', window );">Debt Instrument, Convertible, Number of Equity Instruments</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments[us-gaap_DebtConversionByUniqueDescriptionAxis=hrtx_InCaseOfDebtConversionMember;us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">6,776,998</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments<br>/ us-gaap_DebtConversionByUniqueDescriptionAxis<br>= hrtx_InCaseOfDebtConversionMember<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="rh">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember', window );">Convertible Debt Securities [Member]</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDate', window );">Debt Instrument, Maturity Date</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">May  02,  2021<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt Instrument, Interest Rate, Stated Percentage</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentInterestRateStatedPercentage[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">6.00%</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentInterestRateStatedPercentage<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal', window );">Debt Instrument Conversion Ratio Multiple of Principal</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">1,000</a><span style="display:none;white-space:normal;text-align:left;">hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_BeneficialOwnershipAfterConversion', window );">Beneficial Ownership after Conversion</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_BeneficialOwnershipAfterConversion[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">9.99%</a><span style="display:none;white-space:normal;text-align:left;">hrtx_BeneficialOwnershipAfterConversion<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes', window );">Notice Period Associated with Beneficial Ownership Percentage Limitation Convertible Notes</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">61 days<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaidInKindInterest', window );">Paid-in-Kind Interest</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_PaidInKindInterest[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">80,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_PaidInKindInterest<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentIncreaseDecreaseOtherNet', window );">Debt Instrument, Increase (Decrease), Other, Net</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentIncreaseDecreaseOtherNet[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">80,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentIncreaseDecreaseOtherNet<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent', window );">Convertible Notes Payable, Related Parties, Current</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="hrtx_ConvertibleNotesPayableRelatedPartiesCurrent[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">1,749,000</a><span style="display:none;white-space:normal;text-align:left;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt Instrument, Face Amount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentFaceAmount[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">5,421,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentFaceAmount<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscount', window );">Debt Instrument, Unamortized Discount</a></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="nump"><a title="us-gaap_DebtInstrumentUnamortizedDiscount[us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember]" onclick="toggleNextSibling(this);">$ 3,672,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_DebtInstrumentUnamortizedDiscount<br>/ us-gaap_LongtermDebtTypeAxis<br>= us-gaap_ConvertibleDebtSecuritiesMember</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_BeneficialOwnershipAfterConversion">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Percentage amount the holder would beneficially own of the company's outstanding common stock.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_BeneficialOwnershipAfterConversion</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Common shares registered for resale in connection with convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_CommonSharesRegisteredForResaleInConnectionWithConvertibleNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Convertible debt issuable in connection with private placement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_ConvertibleDebtIssuableInConnectionWithPrivatePlacement</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_ConvertibleNotesPayableRelatedPartiesCurrent">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Including the current and noncurrent portions, carrying value as of the balance sheet date of a written promise to pay a note, initially due after one year or beyond the operating cycle if longer, which can be exchanged for a specified amount of one or more securities (typically common stock), at the option of the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_ConvertibleNotesPayableRelatedPartiesCurrent</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The multiple of principal used in calculating the number of shares converted from the notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_DebtInstrumentConversionRatioMultipleOfPrincipal</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_DebtInstrumentConversionRatioShares">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of shares per $1,000 of principal of note.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_DebtInstrumentConversionRatioShares</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Notice period associated with beneficial ownership percentage limitation, convertible notes.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">hrtx_NoticePeriodAssociatedWithBeneficialOwnershipPercentageLimitationConvertibleNotes</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>hrtx_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfDebtDiscountPremium">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Amount of noncash expense included in interest expense to amortize debt discount and premium associated with the related debt instruments. Excludes amortization of financing costs. Alternate captions include noncash interest expense.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 225<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 2<br><br> -Subparagraph (SX 210.5-03.8)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26872669&amp;loc=d3e20235-122688<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_AmortizationOfDebtDiscountPremium</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The number of equity instruments that the holder of the debt instrument would receive if the debt was converted to equity.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21475-112644<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 7<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21521-112644<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 505<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 6<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21506-112644<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(5))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentConvertibleNumberOfEquityInstruments</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:integerItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Face (par) amount of debt instrument at time of issuance.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28551-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentIncreaseDecreaseOtherNet">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Net increase or decrease in the carrying amount of the debt instrument for the period for reasons other than accrued but unpaid interest, additional borrowings, forgiveness and repayments.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(f))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph f<br><br> -Article 4<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentIncreaseDecreaseOtherNet</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>credit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Contractual interest rate for funds borrowed, under the debt agreement.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(1))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:percentItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDate">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Date when the debt instrument is scheduled to be fully repaid, in CCYY-MM-DD format.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 02<br><br> -Paragraph 22<br><br> -Article 5<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 210<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.5-02.22(a)(2))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDate</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:dateItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscount">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The amount of debt discount that was originally recognized at the issuance of the instrument that has yet to be amortized.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 45<br><br> -Paragraph 1A<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6451184&amp;loc=d3e28541-108399<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 835<br><br> -SubTopic 30<br><br> -Section 55<br><br> -Paragraph 8<br><br> -URI http://asc.fasb.org/extlink&amp;oid=34725769&amp;loc=d3e28878-108400<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscount</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebtExcludingAmortization">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Represents the portion of interest incurred in the period on debt arrangements that was charged against earnings, excluding amortization of debt discount (premium) and financing costs.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 03<br><br> -Paragraph 8<br><br> -Article 5<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_InterestExpenseDebtExcludingAmortization</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaidInKindInterest">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Interest paid other than in cash for example by issuing additional debt securities. As a noncash item, it is added to net income when calculating cash provided by or used in operations using the indirect method.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 28<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3602-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_PaidInKindInterest</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromConvertibleDebt">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The cash inflow from the issuance of a long-term debt instrument which can be exchanged for a specified amount of another security, typically the entity's common stock, at the option of the issuer or the holder.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Glossary Financing Activities<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6513228<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 230<br><br> -SubTopic 10<br><br> -Section 45<br><br> -Paragraph 14<br><br> -Subparagraph (b)<br><br> -URI http://asc.fasb.org/extlink&amp;oid=31042434&amp;loc=d3e3255-108585<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ProceedsFromConvertibleDebt</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:monetaryItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>debit</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_ConvertibleDebtSecuritiesMember</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td></td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td></td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 1 - Business<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Business Description and Basis of Presentation [Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Business</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Heron Therapeutics, Inc. (&#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d;)&nbsp;is a biotechnology company using its proprietary technology and innovative efforts to develop products to address unmet medical needs. Our proprietary Biochronomer drug delivery technology is designed to improve the therapeutic profile of injectable pharmaceuticals.&nbsp;Our product development efforts focus on identifying current therapies with the potential to be reformulated to expand or extend therapeutic effect or duration of action, minimize drawbacks or to apply new delivery methods. In addition, we continually evaluate potential development programs, technologies or product candidates&nbsp;that may be complementary to or synergistic with our existing programs and product development goals.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Our Biochronomer technology, with which our lead investigational product candidate, SUSTOL (granisetron injection, extended release) (or &#x201c;APF530&#x201d;), and certain of our other product candidates are formulated, consists of bioerodible polymers designed to release drugs over a defined period of time, depending on the medical need of a given therapeutic target. We have demonstrated that our Biochronomer technology can deliver drugs over periods varying from days to weeks and that the technology is potentially applicable to a range of therapeutic areas, including the prevention of chemotherapy-induced nausea and vomiting (&#x201c;CINV&#x201d;) and pain management, among others. Furthermore, we have completed comprehensive animal and human toxicology studies that have established that our Biochronomer polymer is well tolerated. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">At present, our clinical and preclinical development programs include SUSTOL, in advanced development for the prevention of CINV following administration of chemotherapeutic agents, as well as HTX-011 for the prevention of post-operative pain, HTX-019 for the prevention of CINV and HTX-003 for the management of chronic pain and opioid addiction. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">APF530, which we intend to market as SUSTOL<div style="display: inline; bottom:.33em; font-size: 82%; position: relative; vertical-align: baseline; vertical-align: baseline; position: relative; bottom:.33em;"> </div>subject to regulatory approval, is being developed for the prevention of both acute- and delayed-onset CINV following the administration of moderately emetogenic chemotherapy (&#x201c;MEC&#x201d;) or highly emetogenic chemotherapy (&#x201c;HEC&#x201d;). Injectable 5-hydroxytryptamine type 3 (&#x201c;5-HT3&#x201d;) receptor antagonists have been shown to be among the most effective and preferred treatments for CINV, however, an unmet need remains for patients suffering from CINV during the delayed-onset phase, which typically occurs 1-5 days following administration of chemotherapy agents. For patients suffering from delayed-onset CINV, only one injectable 5-HT3 receptor antagonist is approved for use following the administration of MEC agents, and none are approved for use following administration of HEC agents. SUSTOL contains the 5-HT3 receptor antagonist granisetron, selected due to its broad use by physicians based on a well-established record of safety and efficacy, and because it is only currently approved for the prevention of CINV during the acute-onset phase. SUSTOL is formulated with our proprietary Biochronomer drug delivery technology, and in clinical studies has been shown to maintain therapeutic drug levels of granisetron for up to five days with a single subcutaneous injection. In 2014, we initiated a Phase 3 clinical study evaluating SUSTOL for the prevention of delayed-onset CINV following the administration of HEC agents (&#x201c;HEC study&#x201d;), which, if successful, would differentiate SUSTOL from the other currently approved 5-HT3 receptor antagonists. We completed enrollment of our HEC study in April 2015. </div></div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In May 2009, we filed a New Drug Application (&#x201c;NDA&#x201d;) for SUSTOL with the U.S Food and Drug Administration (&#x201c;FDA&#x201d;) under Section&nbsp;505(b)(2) of the Federal Food, Drug, and Cosmetic Act. In March 2010, we received our first Complete Response Letter (&#x201c;CRL&#x201d;), which stated that the May 2009 NDA requesting approval for SUSTOL could not be approved as it was initially submitted. The primary points raised in the initial CRL were related to the dosing system, certain identified deficiencies in the chemistry, manufacturing, and control (&#x201c;CMC&#x201d;) review, and a request that we perform additional studies showing bioequivalence and metabolic rates, on human factors, and to perform a QT study. We met with the FDA in 2011 to clarify the comments and requests and subsequently performed additional work and data analyses which we believed addressed the concerns raised in the 2010 CRL. In September 2012, we resubmitted the NDA requesting approval for SUSTOL and, in March 2013, the FDA issued a second CRL. The FDA identified several additional issues precluding the approval of the SUSTOL NDA resubmission, including further issues relating to the CMC review and deficiencies at certain of our contract manufacturers, and requested that we repeat human factors testing using commercially equivalent material, as well to provide data to allow reanalysis of our Phase 3 clinical results under the revised American Society of Clinical Oncology guidelines for the prevention of CINV following the administration of MEC or HEC agents, published in 2011. We believe that we have substantially addressed the issues raised in the March 2013 CRL, which will be reflected in our upcoming SUSTOL NDA resubmission. We intend to include the results of our Phase 3 HEC study in the resubmission of our NDA for SUSTOL, which we anticipate filing mid-year 2015. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The lead product candidate in our pain management program is HTX-011. HTX-011, which utilizes our proprietary Biochronomer drug delivery technology, is a long-acting formulation of the local anesthetic bupivacaine in combination with the anti-inflammatory meloxicam for the prevention of post-operative pain. The effective management of pain with a reduction in the use of opioids, which can lead to post-operative complications, extended hospitalization and abuse, remains an important area of unmet medical need, and HTX-011 could potentially provide a differentiated therapeutic profile with advantages compared to currently available pain management options. In a Phase 1 clinical trial, completed in March 2015, HTX-011 achieved the desired pharmacokinetic profile for both bupivacaine and meloxicam. Therapeutically relevant plasma bupivacaine levels were sustained for 2-3 days in the absence of the large initial peak often observed with commercially available formulations of long-acting bupivacaine. The anesthetic effects of HTX-011 persisted through 96 hours, which closely correlated with plasma bupivacaine concentrations, and HTX-011 was well-tolerated with no serious adverse events. We plan to move HTX-011 into Phase 2 clinical development in the second quarter of 2015. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In November 2014, we announced our development program for HTX-019. HTX-019 is a proprietary injectable formulation of aprepitant, a neurokinin-1 (&#x201c;NK1&#x201d;) receptor antagonist for the prevention of CINV. NK1 receptor antagonists are typically used in combination with 5-HT3 receptor antagonists. At present, the only injectable NK1 receptor antagonist approved in the United States contains polysorbate 80, a surfactant, which may cause hypersensitivity reactions or other adverse reactions in some patients. Our formulation for HTX-019 does not contain polysorbate 80, and may have a lower incidence of infusion-site reactions than reported with the commercially available injectable NK1 receptor antagonist. We&nbsp;plan to discuss&nbsp;with the FDA&nbsp;our intent to develop&nbsp;HTX-019 utilizing the 505(b)(2) registration pathway.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">In December 2014, we disclosed a second investigational product in our pain management program. HTX-003, which utilizes our proprietary Biochronomer drug delivery technology, is a long-acting formulation of buprenorphine for the management of chronic pain and opioid addiction. HTX-003 is designed to maintain therapeutic drug levels of buprenorphine for up to 30 days following a single subcutaneous injection with a low potential for patient abuse. We are presently evaluating our plans for further development of HTX-003. </div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">Liquidity</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We have incurred significant operating losses and negative cash flows from operations, and we had an accumulated deficit of $335.8 million as of March 31, 2015. Since 2011, we have completed a total of five rounds of equity and/or convertible debt financings, which provided us with cash of approximately $194.3 million in the aggregate, net of issuance costs, to fund operations (see Notes 4 and 5). As of March 31, 2015, we had cash and cash equivalents on hand of $55.6 million.</div></div>      <div style=" MARGIN-BOTTOM: 0px; MARGIN-TOP: 0px"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We believe that our current working capital is sufficient to fund operations through 2015, including pursuing regulatory approval&nbsp;for SUSTOL,&nbsp;completing Phase 1 and Phase 2 human clinical studies expected to commence in the second&nbsp;half of 2015 relative to our HTX-011&nbsp;product candidate, and engaging in clinical and&nbsp;preclinical activities for our HTX-019 product candidate. In the event we were to pursue clinical product development in other areas, potentially acquire other strategic assets, or begin to make significant investments in preparing for commercialization of SUSTOL, we would need to raise additional capital. If we are unable to obtain sufficient financing on acceptable terms or otherwise, we may be required to reduce or defer our activities. Our capital requirements going forward will depend on numerous factors, including but not limited to: the scope, rate of progress, results and costs of preclinical testing and clinical trials, including completing our Phase 3 HEC study; an approval decision by the FDA with respect to SUSTOL; the timing of and costs associated with the commercial launch of SUSTOL, if approved; the degree of commercial success of SUSTOL; the number and characteristics of product development programs we pursue and the pace of each program, including the timing of clinical trials; the time, cost and outcome involved in seeking other regulatory approvals; scientific progress in our research and development programs; the magnitude and scope of our research and development programs; our ability to establish and maintain strategic collaborations or partnerships for research, development, clinical testing, manufacturing and marketing of our product candidates; the cost and timing of establishing sales, marketing and distribution capabilities if we commercialize products independently; the cost of establishing clinical and commercial supplies of our product candidates and any products that we may develop; and general market conditions.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">We may not be able to raise sufficient additional capital when we need it on favorable terms, or at all. The sale of additional equity in the future may be dilutive to our stockholders. If we are unable to obtain adequate funds on reasonable terms, we may be required to curtail operations significantly or to obtain funds by entering into financing, supply or collaboration agreements on unattractive terms.</div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for the business description and basis of presentation concepts.  Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity.  Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0ENE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 6 - Income Taxes<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
        <td class="text"><div style="display: inline; font-family: times new roman; font-size: 10pt"><div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;"><div style="display: inline; font-weight: bold;">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Income Taxes</div></div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif"><div style="display: inline; font-weight: bold;">&nbsp;</div></div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">Deferred income tax assets and liabilities are recognized for temporary differences between financial statements and income tax carrying values using tax rates in effect for the years such differences are expected to reverse. Due to uncertainties surrounding our ability to generate future taxable income and consequently realize such deferred income tax assets, a full valuation allowance has been established. We continue to maintain a full valuation allowance against our deferred tax assets as of March 31, 2015.</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">&nbsp;</div></div>  <div style=" TEXT-ALIGN: justify; MARGIN: 0pt; LINE-HEIGHT: 1.25; TEXT-INDENT: 36pt"><div style="display: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman, Times, serif">The impact of an uncertain income tax position on the income tax return must be recognized at the largest amount that is more likely than not to be sustained upon audit by the relevant tax authority. An uncertain income tax position will not be recognized if it has less than a 50% likelihood of being sustained. There have been no material changes in our unrecognized tax benefits since March 31, 2015 and, as such, disclosures included in our 2014 Annual Report on Form&nbsp;10-K for the year ended December&nbsp;31, 2014 continue to be relevant for the period ended March 31, 2015. </div></div></div><span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div>
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:stringItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 15<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32718-109319<br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 235<br><br> -SubTopic 10<br><br> -Section S99<br><br> -Paragraph 1<br><br> -Subparagraph (SX 210.4-08.(h))<br><br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher SEC<br><br> -Name Regulation S-X (SX)<br><br> -Number 210<br><br> -Section 08<br><br> -Paragraph h<br><br> -Article 4<br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 9<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32639-109319<br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 2<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32537-109319<br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br> -Publisher FASB<br><br> -Name Accounting Standards Codification<br><br> -Topic 740<br><br> -SubTopic 10<br><br> -Section 50<br><br> -Paragraph 3<br><br> -URI http://asc.fasb.org/extlink&amp;oid=6907707&amp;loc=d3e32559-109319<br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>nonnum:textBlockItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>38
<FILENAME>0001193125-15-179414-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001193125-15-179414-xbrl.zip
M4$L#!!0````(`/%ZJ$:=HP=K'U\``!I1!``1`!P`:')T>"TR,#$U,#,S,2YX
M;6Q55`D``S4-354U#4U5=7@+``$$)0X```0Y`0``[%Q9<R,WDG[?B/T/6&VL
MHQU!4CQ$G;8FV#JZ%59+LJ0>V_OB`*M`$NXJ@`:J)-&_?C,3J(NLTMUMM]<3
M,],4"T`>R./+!(K?_>LNCMB-,%9J]?U:K]-=8T(%.I1J^OW:QZOVZ.K@Y&3M
M7_O?_5>[_4XH87@B0C9>L.M9JD)A#G4LV,]O+T]9FW7[N]W^Q0?V\?J`];N]
M8;L+_]UNM_>_NQN;2.[B_S.@I^SW:[,DF>^NK]_>WG;PZXXVT_5^MSM8E\HF
M7`5BS8W<#72J$K/(9]!H*X+.5-^L^X<PLS=H=WOM02^?EAH#@C3-\T]QXD9U
M8BAD_1QX4#-<W`6S^O'XI&;"S"1W^829,%HE=YU`QSATV!T4`Z6Z$3:I7]L]
MJQ%;6KW1[VW=IU\W(IL02?7IGM'X>,QMOAN*R\#6\T2/D*5>E26EE4KC>AIA
M8M:3Q5RLPZ`VC!)&!MD\*X-Z0O"@AHQ-YJ9A/#RIF9`X`P[!@"O,71Z^.Y8@
M]]3BMF2C4]N><C[/1TZX'9,(_D'-3J>):=3LSCH\S0;B@W#)ZORXS77WL#Q4
M/L%[[E;V]W9`HWL[.SOK]#0?:NO&P:J]]9\_G%X%,Q'S]LKZ5CYEUOY__@=C
MWR'574N/+L6$$1?@%V("2X%WM#-/Z-S9<,T_1BOY?LW*>!Z)M76W#GCD[B@6
M*H3_)<<1G[(`O$G<)9>X5/BKBT&X[?[C@'9'AM^O!>W>8&U_PB,KOEM?6:=8
M_H`"17(L;<"C7P0W1RH\A!#X%$I`J-WN]>$;1ZIIS8+JH0[2.!]R`5ZAPV/X
MSCY)P/[:_H^>9.."3321K:=3[*WMX[=U-/,%5RDZ=IZAV%[7T7/?5JE6%EVE
M>0WF]!12.VO[O6[[QRH-7*18^D@E,ED<P/>&1R<06NY^$(NGT(#]ZL)_MGO;
M8/R.4NV:*R1U'&MUE>C@T]6,&V'/TP3]#7-XA;[T1#?:_>TU%HI`QN``WZ^=
MG!UG/,#WJ9)N.,6:MJ4E0=$[FX/^<(FQ>RBO<.FL_E+,M4G@^57"DZ>9UW!M
M_Q=A*_1KUURF#-%<F`,P@ZDV3]J0C;7]41"(R(,>6J=,OK+P,M5+,946MDTE
M9SQ^FEFO[;\_NCP_8]?PS^CBZ./UR<%5BYV<'738^N'1>IF%*I5E'OZM(\!'
MW#A.GZ3LS;7],UVFM+36,JF?1!3]H/2MNA+<:B7"$VM389Y"<FN99,.:CC1F
MBEW8'I.*\`!2A(0@<RKY&%)W(H6M-7Q'K3!\",V.=J_?W=KHE8W?PZ1V"BEH
M?S`$G^QVOUM_@.@S.=MPV>$>SG8:.=ON]9[(V5M`\1,92!Z=WP*>MS,Y'TT2
M,&2M?!VPNFD]#!INT^CCH/OKJ593F!4?BC$%PM&=M&VW1B+'D<#OKP0`;:+_
M0<1C8>J##HJXN;VU$GGFJ0'$T.UT`:IX`1_FO22HCTX4F)R?"",@[9E+87DD
M3A3,4B)(8-9/,IF5>#_3B:CQ%A!]"T)G\7'G/H%V&D/I8(AQ/MNT%[)9$;BB
M??06/EY=X<+(&PA:%Q$/!*:Q58/T>WR?=/TFB]Q8$NY9+-4+1?)>\`6N<"DB
M#,H7W*!Y^430Z/2O;*U;W5Z3^+VMC9U:\1]D_K5E;@XG_8V_,/</!L/^L)'[
MX<[VB[DG,X5ZQ1#$*P++)0=C_9!&B80*Y'P"%JL".>?1GQ(L-QM54,C_5$$>
MJP,7J3Z;V+\BB*,@</1[ZC#F''*_2JR?G4/.A]4T;`S!O?[P47IRPI94<Q+/
M>9"<J[?<RF`$Y86,4C"G,Y&<:FLO,!7EX?Q$'>HHX@:_IB\>AX::Y!EVM^JW
MO3T7IEV5#[.FE^]%''\^R3<*R3<>EKP!FM5*WAN\MN0J,(!`P5S=OY"]'H!U
MC]C;:E#;:DPH@#(&A5,_BI67LW[_YBRQW@@%H$#O[SR?]U,9RP2=4)VKHSMA
M`FDQ@/_$#=8[]1%HTW,]P(\0@?)@<A!Q:\\G%#@HD"Q##IR_&E$VREF_M_$8
MC/H`VR4!(2W)0+A.Q<A:#;@6S!/Q4`W.A6$!L,FGHB#P*,CZ.KFH%%6WU_8O
M-GN'7MQ7%Z*D(-HM*OK"0^!'31T9%Y3IX?D<E[!>S^3;+PNR6QN#>W![;W-G
MV\O]+-Y>7[:GA%'PU>;V3F\XR%/B"V3S[7`L1?%L)D-=SP>KO4:LTQ]LN\AX
M/\WG\?5P3=Z0C(&OH0?13^(K#"6JE$<77(80&OD<_"-ZAL(&C:D$]#6$(176
MZLD^D[<'E39HS!6#+8#N6\_@+8IT@!&'C!,RO0@1,0IE*;@<W>''1P&O7R$_
MZ5CD&>,4UX4E*#Y"+2ZX"6:((L2-B/2<$*I;?35M5*0>-E>+V]W-JLB/DN9U
M-+`:.3ZC!AKWO=??[/]I*GBB$;CS[P@T,`IC0"[8>$WDC7BL$@;WE-W#K\4.
M7JJ$>WH/R_[_IUK"/2(T-B#ZPV'O+[2/]XC0G%1W-G=>+D*,YS%_.!`\04!Y
M*"WEP`LC8IG&+\-HFSN-_?#>\@8\Q,F+&7\2`.MV&QD?[+R(<97($,M;\,0"
MO!_=!5$:BO#8Z!@W+?5UR>2(&X4W'+)B%ZBEZE'(^=<74GJ[J%^`8DL)6CX0
M1S9VFGL[6UG%_*K*^2+ZKHG%?Q5];]ZC[ZVO5=]?V+Y]#^!!73>7:8/MC:]5
MUU_8MA^KZ^8;#X/M_O`KU?47MNLGG&0L:;_YD'1S:VOK*]7^%[;TYVI_6$$C
M2]H?;']^V[=6),^ZJ-%830YW-OM+5D-$'D?XX9Y/8P6WM;FYW7\DX>?WPIIA
M^W!SV.W5T*_O-=W/QH-J:#J'`C4,M@9U:JAE`X]E[/G$=\>6+ZLU507[WT3)
M7BAOF$T6D8!QTLXCOMAE4D52B3TV@47:$Q[+"+Y,9"PL4^*6@85RY9]:^8?8
M9;WN/%G[9IKL+:W(KH]^OFZ/3D_>G>VRWU*;R,EBCWT87;X[@2]@TAX[/3D[
M:K\_.GGW_AK6Z?2'=>NL<'9\?G;=OCKYWR-'VW]Q//IP<OK++KLF5L^`U4MD
MM>6^:#$KC)P\:GV2[5;(Z2S996,=A7LTK8_SUF'B"];H?,/C^9X:V_G>8S^]
M?06R:"%,3QC4/!;/#3"X+"];]YFQKV9/"\U]3EGVW*23L\.C,_AJL%EO^J\N
MWO5,,`X.'L^Y6J"+IXJGH<3KE.#L(;8.Z)/5D0SIEN5$*J[PT`AX\OTGRV;\
M1K"Q$(K-C9A#/@F!0UK8A'BQG-W*9$9_^T@R=[<:(F!OZAI6T0*?BWGBYB;`
MV$=%C%"?R[(WM!7_?0>Q)MA[-QI=%'^'>]^"A1J8EX!D<8E'J>#[F.R2<14Z
M/G!M23<*Z(*398EFQS",X15B&C:"=!U$`KY`Z[X4TS1R:URU?^ZP$<D%8D2+
M%BZV8*%F2B>P**5;!M+@/$>GR@#L8!!IF^(5#2-^3Z5QK^N@0"0#[D4D$E&K
MZ`X[<:K1<ZEP2:`"&\NG]+A%A'F(-N?VY0UNG;2D<ABJD)4(Z.+[-?@=QPN)
MD$&^I3V6(=YL@V@<"&NY61`_G$VX-+BON8>7MMM+'';8^1ROX>*B,#*-@#C.
M1EZ3F1&"Q1!!9I8),*J0?<!.-1OT6O0>$L,+"*B_C#*D!E@YE`%U+C-59NLF
M,YZ`U`O@@(F[N0C(+(&8AE&&_9YRD^!M6D]^(;A!LLC:(1!`S%5X=<9#AZ$K
M%#8_YA$9KIT)D3`@F$W-N-X`+5BG!%`;L`D\0`XCDID+U?H*MTX@6!,]JL7&
M*7S2F`9?;D(=-&30-=WH6#&DTDIDN%8\T]^1#61-T:DVJEV`#]F93J,0M\4(
M3EX,*_V6*O*RPO7NU4YF4/"AV"2=&C92"BR5N;OD#-9#CWU*"GN]3`!AXH?<
MNB?T^D1N9<!YHY%MP.!(E()0`=1)HX#69UQ-!<-[+]+25=\W.*X<^:Z.#JJ!
M#P:1.Y7X&[2*/]"XOZ2:.NPQ`*``H"LH<PF$IA;8LO90V,!(:H6-5.@GE6''
M-0#3MY$./OV#4C\+2NT]!V+ZS?L'$GY%D/`]OO.*V=#PN4@!!\'3$Q5TJ@#L
M5K3*8:@2HE);>82AK?P8HGDE@A7ZA&*"L[&$I!+,E([T=,$\-&5H25,F(4/,
MC0;T*/!5%U8:B%2D4OK&808Q@0"=$+0+W7$X3@P!\=%W/`PA=EA(?S&D]U@@
MUHC`PT4(&.L\-14J;Z4.9J`4'4/Z#TTZA24C(%)E`)@/A953!1$>*,@8EK@1
M'@'ERL2%,0M@<I?J-P`O>.6$S6<<$G-`0P"/E7S-,X.<9Y+02P&9@!-Z"Q!V
M#-";0KNB0MWW#AQAS"]YSIF#=F$<2`M,4JI&3)#2I6O\"A`5JA*R&\10X?)\
MSCP0!8[Q89@:ATA`#AXX1(''S3$$1=`1OQWSX)/#8*#M^1P0'<;/7'&@]ID.
M':#E_B))B]VZ<U.)J1YFB!L>I?C28<%T606@EJGA,=AGO@THJBX4%N"[;HAC
M;*'0,GQT&`D7(VO2.-<NH![!USQ`7M(:H@]QYU%T1I/LK6Y?IIKV[Y\H]]>.
M<NA6%;\N/+GEMOUV)@.W^9%#L_A*OYQR=^5IU<1:[.KCU?7Y*7L#!J*D%0G&
M4>?C9-S.G\#+C(CP?NVW[`V86SDRCBZ.AX-N)3BVR-`"81(NR=F0(5?HK!HY
M%5*%.[>8+_^HXH"X"I$]E!1N=+2(L48J1RS/%D4XF`%N"M$X%`#3X?F<;AA2
M20*J;,'W<U]3:5>1EF,H!04V!4]7E?`!7C8528?])%P)&0JH"NF""G*`?JF;
MMP7ES.)'F4?'F64WX,+(#U5A(5]0G+\5XE-6KO#$!>-*R,XC"_8?($R!#*@@
M#%K,$!AW55@N`\>[T2U?IR`]"JH&(H#*XB&^.:_=G$4;ZM@TP*J:IU9P8N5&
MQY*"226C'IR<_;N*["G$X+972GQ0V=19`$3/X]3@)RSX*'J26K/*+Z1/1LR@
MK,.<"%:)Y3\N.TMA39#R3@9.%38!:80OKFD5L'90A80"N&EOO!6A&F]%A`G%
MOXK;7`/\$__^(O%OE&0MG19M;."O^ON\)O*_ZQ)NWJ5P$:]%S;[P!ALF865"
M5B17_0,M'1Y%D;ZE)E3IGMJ*`WFGFV)SH(6]$[(T^/?]]<]0T_4:2,RU3=K:
MM:3`EM&+6G[*SGU<H?0TK#O(AQ7>YW@#\T<<AXY)2&DNM0P)Q%"@_\S&_V<9
MS-_='RCUMGS6OQ742U:4%V-N/F$/T'IS?XB5L4X2'>]V!@,15UH%V_W_V4/+
M)+"[B_F6K'./T?$P.%N;1Y"-H>J&-.S6:GY2MTZ%,HE5L46;CA&,N%Q/+6W\
MP07(>E"H\*B%<7PLT".]"_NVZJJK`!WLYJ>):+N.)'"P$&$;DCDH:LF]J>6W
MXN*Q#BE7(,J'6D"#@X-3E3-G-3M^6&E[&3:3T]ECY[]?FH^%1UY]#=NS16CT
MW2(QBWG"@5=``/@+)(/J(L/V^^M!E0V(E&*>8)\<7YO1BM!6T1^W,WVK?*7E
M,C=%%(A.OI9R>9E"[D08[.0F`#!\^QZUC]IL,5@&-L`@&O0U*^$L(V((0V[@
M''1+LVP**YL<"M%VA/2:"!&O;A84GE9D9@\RH[&!3G4`):1EO?;00:E'1NN%
MC]2N#=W$T:JY0`Y22%6)<E%,ZJ[3,%JJ,UMOH@"M'K0XL*`BCX#&%5)#P'S/
M2JNKO,]7Z61X'RM6V@6DV\QSJ2K`P!.Y<XLP);")C8VQT5!G(`/C!>S+PN*[
M6;`L^GR(,)M3\FN7@1D0TH;PMN43D;@V"%@6;&.P<'*.18#0$TB@VDC/OCT0
M+:JR-^3$DNTXGR]93JX$:4N%1U$W/[F-TO*-G`*09,@T/V[)?0IMG\JB,E2@
MA2,,8%3UE&LQVM\YSIR@VY%ANX-)AMTEL#B(D"`A5T*GMBC=J$F!_?N62PP0
M=TE*SBY0!Q`E*LSF?0O4FE=/O7J?$3<+^UN);X[X4O5(C@VA'0PD#?!T;9)"
MI+^E@YI0HEM2^9.(G-/L$,L5F36FTFCBEBJ[HOH0RH`T&7!"<\BYQ!T>@65$
M_O"M&5/@?Y9QA8,0[;?GU]?G'Q!)W&6PHGU]?D%?O#YH^/^`@D[P+&G!\`?P
MR-;=>16G.8?H6"-7(I,U5NSO['"T>A[O32KO/7[L7$%BT"'YN%NO:N"5)8^7
MEZ3?`\1#,[IFDN_$L#M\,_[V3?_;[,#T6""VB(A4B^BXJ'*@+61.B!&C("&?
M=L?0L'J7I$63IH-<--6)-!"T#[)#U$MAY^BF[%0D"7!1+=TO3^O<SIUKEEH/
MF6X9:(N.;H5K*F80K*RT@%P4CX3'I10%,1#B^"W^0V$(<S4$K5@F5'9?4XB!
M*A]BZEQ+C!*&X_N?V94*/XL!QR"Q$0X\NOX/@0--?7:[L(F(6WG?R?>6)95W
M^,ZP4`'&9+\J(@#<1(C>8%?IA`<)Y0S?O(+\"(%@264?#I:!U(T4MVX&SY3C
M5`=;`Y4<II>\55S*"Y@.D&?L;_V>2E"CP(-[7`=VFX\U&"Q#J&D19?C.![*H
MC4<"('N^/OOQVD4HBF4(M'+K!7M$@?%5;9P21!S<9N$4H./B8-SS[OZ`S;'X
M-X503T6$93ENM?GD4#1/L#_$HX7%AGU6B(PA28H;-P?/+$3H28*41BUO,!HS
M[B[9]Q5>IZ%+"_!UW]MX;BXT_A&6"+Q1A9][RZ!5Z(->0L8$*O#^@*-\G3TL
MK,8B>L7N0B$W3;6NUU!TTG(&O"]['AR;Q#J=BY<;<!/7`\L6=.40+N=,&BS-
M&Y>O54KV"\:UU%HE8P7C*!FRR.S$ZRGS:-+F7&"_K&Q3`&:<+MV1%9F&"9RK
MY@:*Z^-=)2R[>-X^0[AT`UISIH`]2`0#>)N"K,+=M4,N5W!'=C?&A4AW6^:&
M[&)$/]H*[%UI$!D0(L*Z;-JY\NV_:2I#*BSMXWHVS1!;FQ)&:;%YFD%5[SKD
M5]ZF<SU2P82N`M@K:\96K#W;VXJM%P:)=I?7[A)TZ0ZV/,;&W4T1^L%>E##9
MLDT19T79G_6XRE>/EM1?@3/9N&RY;#"2*;RIU&%`4?&7?>B*#OZ@+8MEV*:+
M)`^!HJ^_B?K*L.SO",8PC-+1T\I!3V;12X<#67\6BS'?'NUD'S*[@QHIDG_@
M*>GSJC,ZHH^TFK;QU!>CKZ_ZO,6C%^`+J=A(AC@X([PU3N<0]@(NJ;['D#B6
MBB_="@-O:$LUB7@<N\94+"(\GP!Y'MWC=;FGZ*Q46[>D+E_P&1&ZVY^9ZV*)
MC!Y+W5R;J0L#)^T!!N<J/:IS/!:VI=.]F;;T.PC^Y5`':,8I=EFR=@TL*F.\
MQP9"TX$24EZ]BM`JVM$`.1P@+)]79=F"5RNYZI%]=M_`R8U->OQY%^LN5AB'
M_$I%W@V7D;N1L&1;VOVBB#NP]Q&P5R2@Q.6RHO@K`X9A*Y>"!S.'9EPKRM+E
M17_[07\"`RGSC/M.O<:R`3E@YTVC4[ZH0DK!4TP4DH$SVIA7IOJV``%?"\[/
MZ6@3J?3;`]</\-;``;4ABLPL&@\N<_`,.?\3/(&-8!K&F9NLXU')]84J2RY"
M*:3L/B7VG/&6W,;9,4W)U#?'WS[S$,3H=#IC.YM@<:DI+#;2%KNJ@389MB?>
M:M1!$%+Y_&VKUG;K44D[/]1SRRA-$0K[(V!,P`VXVXUKAT'V!"*N,X,W7[*E
M(*5J;S!]5GNNY)7N,:2_P(MB__WSX-\B4T%(.(,=SRH-UR?C2NF43@0QU=0<
M(Y+C^3.Y3GXX1PFFG)A*#>&E7,/Q90.)011L%R)F:C""2-7N+?4F?N@]V+2_
M!_9V&"Q0W^C']G'1-$\]-EW);_=US,H'L=1V4U%%Y@;:14N@]F6)O">-9_16
MFS&BAO]K[UM[VT:21;]?X/X'(B>+ZP"21M1;DS,!G,29DSFSB1$G.]A/`UIL
MV3Q#D1H^;.O\^EM5W4TV)5*B9,DBI1XL-K9%-:NJZ]75]1BUD4YA'.!)A:C&
M508F0_$8\?T"%0RF"X")<R+4II:HD4CRZZ78IQ\!!"&.&9'Q?IY!IVZ6LM-I
MJKN`<15$5/``$AT*T-EXQ,,='-ALJ9+!38C1Q6X"G"H@<)SP\$P&EE5-LRY0
MRYN)C#HM%5VIW##_/@Z5C#(U0I!-6J?31*0D(:8?2W)PATR>J=)85B`ZAQ/]
M@++WC]9"IY750!,FA2*))A0%&VJ<I"B;;+UCWY*Y"2_ES8.W`(ZA'\SOT5_8
M.2%"9E0LI<B6N;]9A8#?X'3;*Q>3ZR]QI../`94TG52Y..5..KDQJ-:%4G8S
MMSE$9M<2-ZXR\*3:-NFKM;LGX;?L5BNP6<C/BAR_.W_'C@WF],2H<=JJ7":I
M@N<14V(&*BX';];I-"RK'4&QAZ)^RV-W(C1@A??&%#1-R*]3Q=/)(8LBGG@+
MA@68L;PTYY%I4B&ON]U^:V3,'->E$`*IPFS19,NX<=`=ZO#@SDKJ)\:/(QY'
MI]MN."UZ-JW#J&\W`O(3U9LFW2D`@MM(EN5Y=\F14L09,#=!G',1/W+`X:,G
M9\;S>%Z;XUZKFP`M3])W=P'2A36`/H0<QG*IMG+BAQ@BQOOXF.R&I))Q$3)P
MRJBXL$<4Z[\!3SF'"@U)2P*);IOPAS3.3J41]V26@*S]?FL@`5SC3.D[YY>5
ML\QU`-W"B/H5O!NC2Q31T=3AN41T@1/E,8Z,BG#>2.^(YG$0QKPX>27Q+:6O
M$J9/_RA$"K\LHU[(3C*@P>]^5K)5DL)D#*_1[>"$9>,<Z1ON+7<JHQU)-A]5
MH\3RV&0JQY#5P@-*^O'NK#NJD?(RR;SJ%].L7G3W'GCE*55.Q^GY;&7]I.B<
M#L8H<!1`PX@H4I6EK\NKAT&/EI\;>>)\)N%^0M7+X@%>"'"'Z;[4E*2!9\Y;
M^(-(]OF+950P=Z%EU;!H/"!\6.7()\.P0-_D!H:)!!C*H<-L2+Q64N\F!;\!
MYE,*9014*"T*`_Q;<EH51DQ4)F5I41<#_C`+9NG)^=$)>9*^*#Y*:K<I'Q.K
M!*BP"O,`:4/2/>(':BD$XGL<\SM?H/QH!3:_^^*E&0@*36Q$+SBY[DXE`JO.
M\13N8J-O`N)GSIP3$*<&79A3S!Q/'BP,&\D=&+_2%T4E*D_)>T]Z(!,7SKQ8
MD:?<N[2W9!?E-3#VN*';M-M%<NE,-@C`F8MD5KZO;WEUAS,3S0Y2.*VD[7E>
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MD?%![--)$,Z4UTBFVHVE=:V.QT6?CJW*ZY??F:GUR#`T9G>QL!@G?IGE+91:
M6G&#CSI-4)%7_(JV+C)['BV>PV^03M*+.7TG#7=8IJ,)2\CMIF((5TTH'"&8
MAPQ"MM:ASAU3ZP'D,C&09.>!B\`EX%=@*!.DP=/5Q)E%.%#3&--RI!V5;>^D
MQQ1BU]1[.'U3A=P:"V[9L"RE7_"C$<:.<9"A"EJ^N0;_%%9P5<]3<4TPDSU0
MWL.7!P/&J#\1^6B4A"R\A@:7//I61FW!X0G,SDP>8P"!B)*3"%F$KU"6"GIM
M;-U,(]N,XP.<K>`+^,]5>L*ZC#Y8`=5>_LMRXVSGZU)]\P9K^N;!?]D6_*5@
MV`O8&_OLC0OG!@P[@V'_2&!W-X)=V)YQV.F,AD>C]H;FBN/"SO3]8>]0U.:#
M598G(SUOEM2HL#MZTQR:YK@$)OE@[1.A;29,C0N[IC?-WFAIHLG>$<+\WL5V
MW7\D[(/><#A\@5Y`NKO0IA#Y!QF^HQ^4[2UCX$Z<-MO=IM38R?Q0&,,5?2SH
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MO`^*,I0IL73E0]<Z/$V?^]=.,(EG6&PWD5ZQYWM-'\<`&R%XJI/DSC$#'R9P
M(&QI889LOB:RY?"&S>*U)0%5ZH6^BZDAXD)!?K\A[[<"<9?L^;+=`&$8*B@6
M0?<,][>D6EQ6IK(I-M#UN0JTKQ5H!13H=3J$`%/]U0W6"K0F"O3[?@98J,6^
MR8$?<WF+FB%3EQJ,-=S[U"_I$=5TF)PT&CG?--ZW_M5*ZG\QIR^XLSR0N*2&
MXPM#)>A:>%V4J9]K%2U'77%0>Z874;RW45)?+I)I*+#AI!?)J0).PQI8VZ4D
MV&3LB-(GH@B4D/(1'4Y-1K=+SPE2K-&W6<TLAV_RF0B5[@/OLFE4#9VP8RAR
MMZ_U=N@=OQH<`];[)KCPV@J0B[?E+IU;71&M_5GI_L2SE^EJG#0AM=Y5)F-<
MRWCM91)>Y7-IYCQZPZ.QLOB"5X>\[K7Z*0F5C.05KJ)ZCZ3QCY(T_5K)92Y,
M74Z:924?\(+AD.6]2;-EQ=D2G8E5O8.Y(Z$(V=\NEMN4\#D]E)TFLE:5K&/@
M3)GGF+U+*+PZX!DPJT#<8EL0FF^%;9&LR!C\`P]?6&4;SQK&W%I0UHJHG:82
M4I&F'_#NO$DJC1B]A9X!GX_)?=_L^QJ&:%E%?0J5W@[R]@13:_(AI?L6QL?2
M+(P.YNEW3*6#):XBLG/DHGF++&3"#<_L74@!SW\>TX>\A<AUA%\H7Y*_);TU
M&;\-11L#74A97U%4"U;(6O`(<]K`"4.B/`F,V"))938;G7Y;/HTFA%$]Y&NS
MT6ZW>6YN(AF8YHBST;A%XD*'K3K3_DHY^OT[^=,..>0!W6%0\C\]5\"WHD<5
M-0_AW<Z`?:?8_>#.>4#5(29N()HQ=G>@%4(YP$NPN$AGOV4>E1!9XD1"490G
MF:,\;HW'_T@F",01*C&9D)U0K&5<I9)3+&[8%L41R1H\:5W\'-U3$V$)!YV+
M*.-6@9RGG*,J?0RP$1D>/.`409EY<9AIXR3R#=.&+C@BRC4&)B_^Y)1**EL%
MN'PU+>)5%_'">BX*"?(^"G,XLZ;S(X$C)OX#\RPOT^HL1Q1_S,58"FID',C&
M`<"VO(B%FJ].K=B-UJU3TEC1"9K:?TFAEZ8K#D5Q!QAW[BJ0X^H'BDEU@AP$
M-/-6G'G_2)NC9CHU)#$E9<K?U0?1<AT[]P2R]`"3G+NM?E(O*0P3L:.[D,4=
M^6:F\)T6WAE@9TIF*UH3GODM=A?*4,!Q=D*@R5?%%R3LSMMOH%]*49]'R^%<
M#OQ:P.=J/7_Z=D_8GZ@8;-&$,Z$0[RZ8=OHL1QEA'"(<R"I;8PG+DM1?Z:+/
M:HA/OGLG.\*@FI[=,MOFL5OI-TP9/UKPFA/J@=N$C6V"]\(6<@Y1<A*G@I66
M\3[IGNXI$C%UGK)KOY"3R"T*#S(H;^<>$YWK$OC1<V.VZ)3F^A:6./H3/J&.
M/,TI#?VQ>-4V]ABATQS2A7>%%T.8/7G.PV('5WJ<4RPL>Z`$A4*[EDM16<!^
MR^[XTO"5I'T-KQ'$X'$6*!K4)!Z8BRTPV[S7)18R%,+0,CZFW><W#A)NK.['
M:I7ZJ$U;B72:6X[=!";ZR_%X3VKL5RZ#4'GP*+LO!@1+=Y5CGI(\U5Y+E"B`
MAT],*(4E0<J;RR1H8KFQ%[*5YK>B`S5Q-V*\_&[.UKC@Z^$0?VXH6^0FW?@W
MO$5P0:8)Y"I7+G<+Z"LO-[OCU;=K+ZCJ:CS?A:=4!5%IL4G'Y#%&8]@3W,!E
MRU$S"L1*K_N-7H<S4%Y`JT"AI:?>!J7YK@KGZVYC,.QPB?Q<ZE6KKR%XZ8_8
MPS.I-J<>QL:@,1P.&N/Q:$W<8LNRKH(+L-5;LL\T]!Y=+@5HF7/'LRG31\(R
M%VA_XK(?$D/V?O'#<_Z.F5I@AIF$G[T/8(:_3K-/B_S,WWWO#HT`?OA],6<B
MC3,!$/^>W@=LS$%L]U=R$.=`EE?O!D!XH'N6;MN19!U)/X%%O>1<491]N'=4
M"RNY^O!C)E.P"-;G8E3!_2^N$]L'499KE+[BT>(+BTI)RWY1'127Q(W::Q`M
M0F$]VMP'^`9*FA*P[6L68/=8ZRXGQ17P[F%N\9[Q'?4*1+O=:@^*L2V&?!W&
M_^1U(XN/Z#NM;"YAR#?W><BFC#L<O'J'=R7--K!+IP@=%:QUX/_PA%?&[(_2
MOKV87BJHQWCUK@O&=0UGY@"]C"-V''$L4;I\J3J>SRK*'!3F7)O]98@+07@&
MK-O46PX*ZXY-L[<;K%=6X&'++Q"-&W1+L"9\`M_XB+7U_*2\#6U5?C"[W7%!
M;GU.(4JSW1HJ"&R`ZYE(K"=Z%@D@[%9(]/:$Q'-334<ZU;0"B5-R5XUKG&"%
M^ZHS3&MRQB5I-9C<0$RZ(#G/%FM>7=]D>XSC(=!R)Z*WX^T"3ID/3M*S*<FD
M%VVM.,<PNVGAG*2[I(N4Z#B57@^H%[=)RW)*PN=CZ^%S7BUK,V5"I[*$6E?;
M,J1J!/#E,3O>*[RRQ5#>Z]<@`VH8_1$J?N!SE"@TANYJ'"S$[?Z,`;ZVF#4:
M!W,_9.*F02$^797SY\4("R"4*";+0$>/*'<,A=D'1%M^*7++LE]7D:/P<)`T
M=*?\XB335X&.[B*5;:"&.?R>15S^8R&(Z'&S-C)04P$[;>TAIJ\^+G>3M;+5
M-'@YO%I,([DE/Y-=R5^GR35IDUE5L/;'^YB-L<+(I#$21DYP2M6DG#^;86F9
ML,+'_B3<O;:J1UO""ES:*2/@Q!`%XH=0;7U($<U],^`FYK.22V9^3<6G!-\R
M[/=^0<_[<8B5%6]^/ALFH_L%_)GOE8#G&:]_:_SQ^>/W_\(OMO^QQ(9T.?[H
MV-']S\:PC;^],B;,=<,Y)<'^\JK-?Y_CW9CX_1:O*0/\,04U2'^T]P+ROZZ^
M??_\X?)WN961/S]0.Y;(UK"OA?VM\?[KMX]7WY*,BO^@K@!MPYP_&638WF:D
M;D)E`4G.Q>]7GXC1HE?8)P\8R_OEU2!EG2+9S:Y2Q^-C]IYMC<XJNV"C=.G,
M<?@"Q^#%5/<+.%Q??OSX^<NOR8=FR:R;9PG!3ZHBTCKI=&$_@$[JG(-.PGAC
MU;3(432%%BLM5GL5JYX6JW4&.&>)#!W.^_,LV>36O+_\\-^_?OOZX\O'YH>O
MOW_]!N(XF3`VG;[:-P.)`^(0SX?+S'3K1Y$_>[ON8)T*/BB0S4#7X;A^H\8_
MU,C("XNV/+JOV9CU%%_'E&<&8:<D=U.EQ!)O=T>MX6;V'C8ZX^[QZ+R--,(Q
M[3&PYK^\XO]J7JD;A"_"S<.3Y.;2YG9*_^W=W.[?Q"X#6@<3*[N#ULZZ*L2N
MJ#XZ!H0'TD<**MW&J%=U?23`K9%UU=Q\-&[N]$^1FX]]F"VS;6I/MSV=7BO3
M)NY#P?6\VH/%6RZMJH7AU0>!O:NJ86N\F>^Q_&U8<56EC[6G`>%+<'-W5'7#
M^^QC[4^4/93^6KHN=4,IPU+=PVSN^@O&1(O/W]->M1_$,/`=9CH4%_4,EL8*
M;GS]LZ'=./:A4UC6TQEVS7U`>\."!V?"9!$*L[$5.O-"RJ#[XM,()69?XBCI
M\#OVJ%`__^"'T1<_^C<#`"?^'6]<7&9/EHK#^L5HCL>]82Z>>P?\A>C#Q]I]
M\@/Q)WS.W*J$!PG6>?7NNO-OLS?X^`*4R04Y2ZY?^6A?+"BS9XXG.OH\L"O1
M'F+W0CRSVRV>CM@?+<GL!CB>"73IBCPL<"M4-/W!N+<[T'PZP7?KJ2;]K:L4
M$]SU<GJWKPUV:'$M1K;`]IYT*^N])PF<6A>5CVS*`M[\FA@BLIYDUW[,D<^T
M[0^H6[4TOU0TQ69S/[`"K-B:PD*,AKK<LN@1>_KG3CO@37V2=V5[M82RX`H^
M"2B5WI&=LY(B+6S<%/*.I.I+J;[K"?OW,-'0#3L],&SBQ+M[PE,X.-LC7$";
M!7[,:P2H?S)AN<`'^?#X*)GT#;#(:@,$FE<.@+;\.Z99]SBWVP6""(@*R8G=
MLJ:QZQ*BHFP`RQFHNQ5.4J`Q"&`QX65.>,]LZ@Z.>M;Q.`9)B[LU"UEW\`"V
MGHJ#%!9U3W.:YNA61U474BQ^<69S:Q*)1J(),ZM\-O=#A]="B=YIZ4<!`U;V
MC!F@R<?))U(L6FV[5G!'S;UYRQ7J<N>$QLP'`7"=O[`W$OR-NN6*VL,0UK)X
MC23V.Z7!)[)",V`N>Z`Q'LAY<73O8]>(EG&Y"7*U\:X"I#,U8'$4$FJ<1)!8
M1K_]#PZ;<^_[U)SIEE'-CX1,=D7.3!E)9I,HXYY06F)/>2$")?KBA6*VR&H?
MM`9*$TI]@[HX<1<I&>=BRX71AP/,/6R`]XUA_U7<('!R9RG7FNWF?V<4G&B^
M]I%-J-]%^J0`H)?1#+<*R9=J6?.:N)4;8)6ZC>L\P16?,=/=Y;-W*;K.7XLF
M\<]KE+%F>OD@ZY]OA.39@&_3-6-8/%6QTQWM%_#B\_GSB#\L;*S2--O#_@8D
MBJ':)SY;[4EA`Z.FV>GW#H8/=3RZY+TB][<Y_4)D^DOQF](0[0V1K79E4!R(
MZAP&CVN<\>#8TA,6AV$X)//UN./T/+TU+&8U<Q-69<`[#(I;]04:%8<[.YN$
M:1<4>6,M\2AV<KIZ$J-/GM.8:;G)6>'&C9:%JAP\^\*B?/<@Q*)P;X;#/6"A
MB!IL&64<BS[>O(?A#L'S;B'=^^-!)POTIM<_%]C-(Y.+R3L8C#K[`?89%Q&%
M&M4$T1P4@9<;S-_/74/AYIK=0:>]%4!?6/3!"N^O><MU^_WB1\CLS]XG'GD`
MKL5VOGNPKZ-"F#NC8=:!*P_2_E#91E./"MEUW#\H)I_I0F"?FU+8@K39[91"
M)0>D_:&RU:84.]?]X2$Q^<H[M^QO4X9K?)WQ8#`N@TP.4/M#9BMOM%!6FF9_
M:';WA0P_8>/X].==8!7[*\U.FQ@I"V_ZWJU`VNIZ:@T)A_WNBI@6@_0H#L)`
M2J"QYV,HB6+*N1.TMVU6.&KK9H45N'KYQK",UDBWVLCN==F[JEJ0Z)0;-GWV
MC-\L+\:[H;0S_Z?D1DC9X!O,W<0<`>.]#_]D>QM^NKQYO]S<,,0I&[D+_)AC
M`Z;L"I<W/[(+?/%;!%)S#:7W3HZV64H@Z$/X6V2!,A/M4@QQ5WLC+]%2='IO
MKYZBP/(#.*$AI?%RZH<7AQAK_@P/A\;%37P;^7-G8G0Z?3`";S*7(LN$,H2:
MS!"L92B?&`PGZ'ET-R?:P^&\;8R^LPPH#KV>AM3^>GEYW3)P)^EQ'AVG*P9U
MX23VS\>9T#`3WL\-A]]Z4S^8\<.P;.IFN=A7Z^Y^=94$1G$;08.BY+!U8XDB
M8B86#4;#H8?`4^0X\/F)U'`1^R)B)()?O229R&*<6Z!.*\=;DPPA...+MGKB
MN@YV*;TQ,.YBQZ;+.P2$DXV(@S>:L=A,`-L3LTT#/E<.21(DEY"$-ET#B$L9
MFI0C_LB>YA9=`P!*<MC\TGMN_>@^YV7\LE9Y#Q]I!\BW=F7GLFWV#G*)9@$3
MV)(1:H>!RN=TW9V.E`*NF`)'P>;1];@R.\>9);T=L4<K[T87LJ7';]F=XV'"
MI)AK*2^>#-3<_,[H<EE(%C0IUYK/W868Q),0=Q[XRBB=O*^"I^@7?Q_86%T!
M&9>:5`(>07&KRKQ\`QPJBB.)+9L7P:-\SK&[:X1?%*/:A#;"-1)A=&@VC.M@
MIH.<M)U22;3[4XA(-[/B)71U3[^($5KTGI#7X$\S^BH!/0@C.4$9G^$T)YZ5
MD,ONLOAUV[%)5_)!>>FEIKPEYE>/7),N=>@TB%<DI;"]I[-V+/&R#U+EN73U
M]I<NXSN\H.?CM<A<2E\'=EQX+;TF2N2NJNM:-4/`%:D_=I-FZ*3&O_O6^-47
M+3$G+/!4;Z+=;_9*>!,(;[XW@9](VXQ#MSWKCD]D1&$/0[SHQ[%YI"ZR<[25
M9)WD%AQ'.1EWOB@0(F!OJ?6Q'V"&$JD>U(G<%N)OE+8@DQ'$<"67*3:1#V^-
M^#SS'W"$A9T@,H4\VX'W%Q6N9\NX`77E3)T)3D!N+"NT"_--,A<2I^:!`#KJ
MQ#(:1*=,=S=L'RC=,"XZ;Y)!ES1`-LGYX;,!4[W*M>)+FB-UVOR2J0'`NV]2
M<968*U1&BR7=*]EB&Y2R<\>W2N1\`752QL@R`>""'5TO>BF!Y&:JV1C4T7J%
ML*3=79<].-3,F)A'N)W417RIA_DF&/H*KNIN/:&)"HWLL%&:!UH21E3Q*9S<
MJE\,\M_&989>,^6C?GD&""I_3V25<.,N&]6F5D^QG&FB7L"D_KG`]1XLQZ5,
M")YPPC]Z(VR4ZE=E!'S53R')X.DP:8[*JN>A),=P%V3`T2?<U*^'N;X.$IG1
MBFL]`++4N(VD=?")8GM-^`!Z"`M]S_9I@WC6H1@<FV.K8>4CF&D=]#A2T",&
M8=MDPCN[FW"UAB)KJGFOI\SG%]_)6`_-42E+W2FTU)W44G/[B")$1W+TE2/,
M'A19@Q8)>VB(ZP@^7QD_F"1MUR?W#E@O6]%&M'@(%A9IB34E4C7<\L$+B9)6
MWYK*1`90/(!G%$X);9$Y&2T]7^)HA`K&P?!`OHI9IR$[=`AB#AD%)(XX<UQ8
M6?NY>ABRJ*[&N,/F(SB;,C!FO@T.2(:P*25(X<-#%[=OBHY78D4:'KZZO8IG
MI'983WN?KYR.F"1+1MN7.K;)L=P(%@;$,]AQ,%4-OY42[ZP[=%54LZ]/T-SV
M;F3I9@6>EW=4/-2XEV*J<7%*&HU"5*]]BB#8&="M;J@*$R0`T,$N@"97?N+3
MY][J%5<MMKN#+"E77KTU9%N1KO`&WAQV.YV=(-O;76CQE?H:LA5=/Y8";RO2
MK4D_+:9=(7CYJ8_/R!HJW-E.=RE'9_V[GP?GYF2BPEWNC)<27[>'DQ(/0>8G
M.Y/1+*X"[^91<>F-.P&UD69F\0S'[8&ZMAS[L_??CF?+[,&C3*,M9(.E:;2K
MX"ZCLR"[^75*[O1G\-[1!\)JY1R!!ZP&Z236`4YB30)I/*$/W7$X?L.*`D-L
M:D-+BPG$-W#N=VS'"A8WELO$:^G9Z\!Y@+6N78O;<GS)QO&G:QB.Q#9#BF)4
MGT.43K,]%$2A'V&W#TJ4SD:B=`KK1DA%O`11NDU3B@#]B#-[V9WE7E%\DU#[
M#9WU`+C]=W<BZ;`=W=:0H%MH;KKC%R)!+Q66WK;"<NG9UP&;XN6K+1LN;L2Y
M5VC#>NUGX_S=OYS0B1C\;;#.T0)8THL`3D1E/EO6S-LG-Q8*\G)N8WF(]H?)
M5KF-A>9F*;5Q9T1X^4!NV<#N'E#Q+/=Q+UOM5.+]>P!XHUEO%QZXS/8RI;>'
MV)\P9H>?`G^V9*7+S"=?-U>]T'+WNLM"6@Q$,;12E+].%7520?U<2(8^Y9<7
MT2$7O3+40`?LNW#`@`$^6'.,,J8NUQ>6O[/K%%A?W=CB0>SF>.W6;@5C"50#
M[D/DU'<<R2P5Z\/1BBW>B%`Q`0C"K[SU_]43"R9.^+QIZ@A[H5)<J8/8",JS
M(=^F"`K,4-FRAV<`+GA`/EDJ@K'7$X#9,XOC;@4X+@/]'/16MV2_Z`W'[4*G
M;E?T\EV,9?U7TFDHY++.>#Q89K/"-S\'QLU^0N%IJ#/JK*B?DC!^8R'#)@/P
MT$?VP%R?'MM/5Z[B>C%PQ+*UI6O!>!;$V\3VBDNLL.1NM#O$/+E3]C:\G$SB
M&1_R_I%-G8FS`\<"3Q87475!,PZ7H-T$PO-!WEQP61PZ[9K]3O=Y("M:"A34
MA,D.DJN`)M&-/4<K"OB]":+8?+H-7*?)!]RC8]_J*Z@6@;XK@L?QA`L4?`[Z
MH\.AOK4KN!FO+;;5;`W[6^,VN6=VC$]>PD[)L>:IL\PKN9G-3T_)\&KP(Y=:
MI>Y20M4T^X<JGWJI^=%Z@+2&70^0U@.D]0#I,Y/K.L.N)]WNMF\=/4!:BY46
M*SU`6@^0KM+GQYZYI0=(ZP'2IP^A'B"M)VV=#H1Z@+0>(*T'2)_+0-OJ0Z@'
M2.L!TJ<#H1X@K0=(ZP'2%3.\^B"@!TCK8^UI0Z@'2.]Y@+2JS97<JKUG315E
M996:FGOIPA+B#<MS<:D8;;?DK(%.SM*)$"<-NT[.VG'?2MS6GC@)OM\'C!G_
MA`_O0^,*2[DT4=[J=+TJ9`MH37]:L.N\HMWV3:?K:;'28J73]72Z7J4^/_8-
MAT[76U8$LIJ8SYA)ZXGUM<9A`Y0(WNL*1X1+@#]J#^I!:WVUH3FZ%/AFHS/H
MU(/:.F^O?GE[OS*/!99+IM:R9X[GA!%VZ7U@M;"V5<MWVGB"JP@.ZY36=L?0
MW7.FS,:P=\2KVYPSFDX+U&)213%I'S%?YX7%Y-BG\7//-Z12N>:MQ7L5*E-X
MF.@IYLC9MXYG)&,DY*?K)UM711M6[$!3H$BZH$APAIK+ZG7F*8'.'HY%G4:_
M;U9'*W9+:T5]_M?B<@QQ&0_&9R,N>P@M/-\!U2OH%:KGS]+UY+DXLY^3.7;@
MT#H3?I^$V='@OGHL,EP<@`4^K$$]*[7OJHWQBQCC=JM]/K982XN6EF=*BWG$
M.O$C>J[EJW[V7)535/R3OZXZ7>(2A_$ZT>([0KY;E<](5_F\1/XTY^_:YDMJ
M\(\/?EXZ:LU1TN!K\+4\G,R.U!Q\G>^?MS%_T%^8W5P;KSE-=GO9&KN3$"(-
M?M546,U1TN!K\+4\G,R.U!Q\[2/F3FMZ8(%UM_Y&[S2937N(&OQ:@:\MH@9?
M6T0=-:DKN]4<?"TM>1OSC<TLQ]O42?DTV4U[D!K\6H&O/4@-OK:).J923V:K
M.?A:5O(VY@/\.;`F46RY9R@OVH,\-_"U%LC;&,J77E\2KWGMW,#7HI*W,5=/
M+)@XH?8N-?A:6#;.>F#![`P%1;N5YP:^;HF^V]9=.)X1W?MQ:'EV^*9RJJ*"
MPTNT%&HIW+<47@?.I'H.K1:^6H&OA6]'$_AO9@7:]FWO5\MWO/@`C'Z_9"/U
M4^Y8]-YR+6_"#"LR?K.\V`H6AMDP-DZ.TOU6J@SA@2<$#!MC<W0\(NO6056C
M,H)7\ZD7H]8QVU5JECXC"`^MG5MC/;[EJ(W:I5/-B3">E]W$LN-<*N,\_AI8
M<&Q;/_BY*I)>M8D4U8#P$+I(P:/?J[@FTI-57I#*=743U=DH9JM?=>MZ3)ZN
M*"/7#*Q58U]10$^E2?G^?;G:!0)E0E0]O#E]LCS"R?*B6WG;M^9D60\Q7'^!
M=,[,K6.5::Q2A]_WXZR\)!_7#*Q2/F@5`-T5+!U/K)SQNWJ:.P&S:6S.U`^F
MS-'1Q=T@U/-N2PK&1;=SQ%FWVZ3FM/<Q![<>>J`>3G#%9/[<(K'MUN"<)+=*
M_E6=0X]5<)NK`.C6#'SZL=[3#.PJ&9[_M(+)O='5"9[[=JS5"7050>+X<_2&
MC<[XB(/T#F.A=1*>CM5NF5?:US*@9:"*$!Z<];NF9OTE#[C\C-5=AY]N'J9Z
M;2UFS(LN'ZW`5M?[E^7&])++,(QG_&_/&*PZU(-5==^(\P#_`$6S@W,HFDT.
MI&O/HI78T:J5S6JY/'WP=2W^;EO7:2]OV0Z+;`B0'8<?=+N,BH&O1?28(MK3
M(EJ-2Q9QD!JV2X84_B<.(V>ZV/.=R]*J1Y6+;T[X5W,:,`8K@JRR,#("*UK?
MGNF<@U'5A_#`X3*S-:A'5#XO^/6/L^>.ZD-X8/[MM-HGQ+]UR`[>SHB6S0:N
MDA']Z#PX-O-L8^$P5V<"UQ?"Y^@><]SJ]S<S=;OR^F=-=E^U[*?F8<W#>^#A
M8Q]*]4$4U_^7[UJ1XSK1HA;V4_ON1_#=QV;KB+GT^O!Y^A`>.GC2[K6.F&RD
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M0=@TOG-(GNUF2-LM(FUK;`X/3-XLOA4@\'YX-TO@7@&!S5:[9YX*@3%%YE/`
MV&>1(/-B_-L>%_)OVQP<B+QYV!Z=N(?@W78Q<3OUH^T7W^-H7_T=@TA\]L(H
MB/'3,.F86HIG;R*`";_'UT$H?`^7(3+_82$D$2?MGS?Q;>C8CA4L;BSR0)'X
M]-QUX#S`.M>N-:'%X`7FZGY\_O))V9%A9]7%"&E2_*MW`_AO'PJ[!)6.N1\Y
M;'[,_5@UGW(_S%ZOW=N'@_)R&R+.0)]XOS:0]/#2LZF3&ZT0?O:NX>CGEY*2
MPK-#OS,HI%FW,RQQ=M@C)B],N#\H)YC9EP\LL.Z8W#^:]KDM4;.<V.\,\T]D
MS3D+FDN<B?V67I#(Z[#>[P;0%)/DO;\&?A@^DU=7+:"D8K^W5U;-`7V_M/D:
M1V%D>5CA^B5&M9:AC,,5JME92PYS6$B.X=@<[94@*_"^.#DV<\>J\YF0HS/N
MUI0<I954$<\L:29S5%HSX>BV@Y#LY530SH3<K.*[[6T(V:\Z(<,-;Y5KOXCU
M[&U!6G.T!6GWBN6>*9RU.8<DKUG>.<&Q/'ND;WD<<XA;J//:@V:W_><'UPK#
MKU-QPO@:?,/%Q6&"?8H]F]GBLW#C2:([WH9$P]X2B8HPN-TL];?;1)2^LV!F
M[C>RHUB*_JMWUX-_=P<?E[`["!;'H]9S0C4*M09$K1J1:J,Y^<9FEN/!WS\`
MR0)K$L66BP!T-M!0N"`*;<9`F^&_N]W^/EAI=[@K2+C"-C_<QS"!<*-_FV:W
M4H1S[CQGZDQ`DUY.)G[L1?"5:]]U)@X+MVMI=*!&1G7(@=JQ;+G;4J[A2_Z4
M[I(AMZE,?;=1FWRR_9>`GR,YP&OQ)L[<A=7]J0$Z@-HLD'8Y,?ILW/>]X++4
M^:P[R-=0>T?O^STS+!#YV=SR%BCTL6?%-H[\0)UL@\7@/XGMA5^FCF?!UELN
MP"2B]R&`,W%CFQF16"[&/P)C_!<+?,^`EP36G,61,X&7?_8F+9HNXL`SC_>^
MZRX,_]&#I<,DQ-_(^:;QOO6O5@.^X4SNC4<+U@_N+`\4.JSDT9N_,/C_P(6U
M$2+1:1DM2*MH.>,>UO%\PP=?G8<^"3+XRPQP"Q!+."@P1"8P7,>ZQ2M94(GT
M%+Z,P0H/S+AES,-OA:FY,\`J@KV=\%4#YA+U(K\0E-#!#M$.IR8C^]LZ`?G1
MZG8/Y/@1,A2G*T`$&?/43/+IZ]AYP.865S&XD05*%#7MU`]F3K0P'IWHWOCU
M\O(:=,??L1/`2V!YB[OMJ$=FUE_,8)(C2"-9Z2D0M),5&=9T"F=!KI9G7"L#
M('X0I4HS%Q1<#.@P<?TPYF^VF?Q"QEQX/KX;H"E:JF5\C0-C$H#:G*`V3=W+
MN7`O.:2.]^"[H$E5#?H_L7U'V"(X*:;2V,!:08SF";:)%E<4=`.?\F=@D:PG
M09P0C^1-.ND8$^4TU#(NZ?0"E`EC-\)[I]A%](%V06('P$A-X20!P/JA0O8U
M&AK_6^9:D5:;U_/V^]=K^L/^6?(E9:S*2O2#%=X3)]`/>"?_8+G(HR>F36MC
M<8^ED!-&F.`/+&4$\G2=,$(5/9$/W0.E0/I=!YY#K?D`PL^U)*EH/W#N0.^Y
MJ"GB@'N'I"GF,;B?H&T,])MQQ>@>.U'-@/SWW)]DH5"/MY;W5^HWIQ[E'%-:
M;`/CT8%A490D\$&)WL%"I!A!)>/7`INFBW!X8+T;YCD^_C.)<90?',\>6!`Y
MV+'Y"RGL"]KM_W@"YWCR=N7C]$/[[9L=?=#*C%ZICSA4F1Q75H#!OM"X!DZD
MD.&)D>6T7=#W5NA,#"8W$4Z[!MU)917!U?5-1O0-!S2BY4YB?G:]78!3].!@
M,)C</8]%AHN).O`!_OXH(L1-BX>(#8^G9Z`R]6>@]_@[0?>E464<,4I?GM,M
M7X-T&'S.-;'-4I=974+5V2WCH^/&"!^`3Q"#;Q?O%5XR%06O7X.,83/P'6<.
MAC;B4$(1!<P"IWK!_5%CQ@!?NV5\@J^"Q9B#=QER8Z$0'TC0$,_[W+T'0HG[
MR0QT]`B9"Y?<\U7-C^!+VO)XQ"W+?EU%C@X5\`W?`PLH_.[DY*!`AQ#;RC8\
MWC-ZQ@D,QH\@@`T]X#RPPT8UCB5BIZY!V,2*0Q0:[I\`,\0!S0E.Y0K9'TY*
M@OU#//2&V"0WY9C\D*)R\`0^2F-QC8QP[8__X="ZRLRD-1)F3G!*5>6MH$"&
MK1_IK`@B!*`XS83##6T1*\[/&)29^J[K/Y)BIFDF@B=";BT28[!_)MS$@)8P
M`?SL$`(#^H\><!E`:US0\WX<8IC[S<]GQ6@BL$*ET"\T?^:9XV?D?P1RD`T,
M':A-2.3/#]OK6B.P&0$]C&:WS;LDS2='TBQOX`X+;CW5YAC,<=RY-A+AGQ0%
MI?75>2&@1VCLMGD;9S@?:SN/HD6TE&DI.Y"4;3UEYG2EK)RMSEEOE3+ZH0T/
MY=.Z9!OE?;.@'O"SK$]NU'",&J@YAH8X4"/8,P?S.6WVNJ/6<#.W#QN=<??(
M%#_,X.LS9YV:@/DB'#X\70[?VD:K;9`/[2:>9]-F63Q;3Y.\L9OLF8-Y((6E
MX--MC'JU4%A;M\`]<]:I"9@OPN&=_LER>*6.S64V4DU7W=,YN3(9L!\*\A(F
M2EX"K^.HI;76QXL#ZK)A:[Q9#`:-X7!8!UVF#]`G">9+<'AW5`MKO9<#M/R+
M',Y@9-(9==U'+;/L=B,'MHT)V#WS0N>!8>D^UE1>_.Z'&V8PU8\^IYWNFMU'
M41M[@1G.5.5ALRF5*5@\]W5RC_V!,#.54>=BPXX#]!@M6=G`2V'5!@>8`.MC
M1P2#/22E`Q,GF,0S="DGLBK.\[TF=GN`PX`?!_!G42"<@2^340[Z[SXGI1P[
M0-"WJ-MTZ+L,^TA,J?Y-?K^A]&EX9)3Y+8#D&(8*BD70G0!K:TVX!W)\8YA'
M8:C]D0+?@Y]YT_%3*R(^;77XV3-^L[S8"A;4'Z9!6N]3TKY`V>0;/`];`:B>
M]S[\DRV8^W1Y\WZY8B[$E@2Y"_R84R5P9H7+FQ_9!;[X+0*IN4SW0Y*C;982
M"OH0_A99KC,1Z;72)TA:^:?H]-Y>/8&-\`,;"`N41EW\PXM#[+7P&1X.C8N;
M^#;RY\[$Z'3ZS4X[XU.L$,H0?>&RY<F&\HG!7&<&+XM$#<?$ITXZ:!98!A2'
M7D\J'UMLM`S<27J<UV102PIUX4?'=:EL@S>)H,)K;J)@;8>:=O#2#5DE9+E8
MI'%WO[I*`B.!*)I[)!U`EBA"%I"W[$!F@J=XA7GD)U5\6&Q'-LWRU.@.F6$L
M,U?,-)KZ#"$XXPNC*FI/,JT_C+O8X<7E"`@G&^\L`I_%8C,!;`^+WQF^SI],
MP`(#21`S6-5=<+1O$=?(XFX&O$/^D3W-+<_FI8BRL\?2>\@#6'T9]9!2WT.O
M1D>EM2L[%UK[0TL@]>$")K`E(]0.`Y7/J4:6"N30FT/.F0)'P>;1]-:&V#EL
MK#)+/#LL_.6E32%;>OR6W3F>1P[H%+YD?`133,59J+EY?Z_+92%9&#,+5,Y\
M[BY$^YN$N//`#^<<-G>1^U7+#?WB[P,;JRL@XU+58X`]%PIK'_.;XUQ9(*Z&
M9?,4)I3/.98,1_A%@!.'F`EMA&LDP@C/(6@.DZ[X/5.H)&K'%"+BG^1+6L8?
MC/]"2S/^GI!G4$TS^BH!/0@CXV\PEQ&OB.,T)YZ5D,N29?RZ[=BD*ZE0U$I;
MJ3FS.>@A`Y^.@Z3=3J;DTR!>D93">E%G0R,T&:Y0/9&3;[-S1+_I,KX#&)$%
M>@UN-J7/`SLOO)=>$R5S5Q5VK9HCX([4+[M)"X53)Z#[UOC5%W66$Q9XJE?1
M[C=[);P*A#??J\!/BAIP86?`$`^Z0FVD*XS?PI^I%=5"6&K0+C'#X[5EW/GB
M\H6`O:6Z>C\`#621"J)>5V03J1WC'`=^L@`-)VH8V70SL8U4A4W6#Q[XX5'G
M1B(3O`H;.?*B5>&"MHP;4%O47LMUA?%7%-N%^48J'8"38@).*MS@KX!JHB:-
M$58[PW[8/E"Z85QTWD@:$34>Y"A6=$+`VTKU*]>.+VF6&L*IP+<OF1P`O/LF
M%5B)N4)EM%S2S9+]&T`Y.W=\JT0-.%`G98PL$P`N6"9\T4L))#=3;:]&[1)6
M"$M:WG79@T-5\L0\POVD%A5+#3(VP=!7<%5WZPE-59A:)2644PY&5/4IG-RZ
M7PSRW\9EAEY#W0)D0`F-@,>XK>)&7E8_I]9/L:!IH[J`2?US@>L]6(Y+E<&\
ML07_Z(VP5:I_E1'P57^%),/ST.$4$#(ND%D/),51N"(#CC[AIGX]S/5Y*#)%
M*Z[U!,ABXS:2UL$GBNTVX0/H(2ST/=NG#6+4%9[CE6>S8>47,=<Z`%(50_Y;
M#`*WR8QW=C?CF9G5&7/-L_8SGU]\)X,]-$>EK'6GT%IW4FO-;22*$1W/T6^.
MK.".16IOS-#`?F[2\-('DZ2GQ^3>`0MF*QJ)%@_!RB(M'W#&B%`/M[RS3Z*H
MU;>F<I$!%`_C&:530F-D3DE+SY<X)J&2<3!4D*]FUFG)#AV(F$.&`8DCSA\7
M5M:&KAZ,K$<*?]UA1BA\`1"=^38X(1G"II3@[?("X^+V3=%12ZQ(_>Y6MU?Q
MCM36'6E3C963$I-DR6C\4D<XSC8<+)PVD,&.@ZEJ^:T4>6?=`:R"VEW]69E!
M46H$Q-+8"-00GTDA?:2K)SX$B!K/A:#7Z*.<"8$FSO?A8R-,,>IG_8Q1GAM%
MKSO,G-'VJ'#2W(@7?RJ4*H7U?BBU]73<@U.JLSHK7E*J-^R/1L>AT]93:P]/
MI]6YY.E\T%&O/3X.H3K-]E`0BGX\-*$ZFPE5/*ZV;QY1]+I-4[(4_0A*ZG=V
M9[E7%$4@?']#<QB`?OS=G4CB;$?,=0/+BD=1#X='I$LO5=Z]W93W.J2+F:$W
M.C32RC2P[29DKT&HUR]$J#/L=S.C^+:&;?^X;36[MW@V-^!5?JMV1XUFJM7+
MSRB80@C<T"G)WUFD]T*G"AJ%@IFV8!/:_3W1Z=YW;1:$','MIQ/WNOTB&%%5
MF:LP9EZX/4";ID?W,LHS`]"@VQ[D2.16`'WQ(_8QB316>BA<[;-;=_M:?X=!
M<NH^_S^#[W29@Z,.%QX=EQT#?CLR%YHW0^AR(U'F)\PJM4G'K$!PVFQ@Q^D0
MJ&",6FT#U+CK*(WD>;IOIO$N!E(Q_W<>^!/&;'KH=:?3&B5?OL"/,2%B#L\\
MT1P?=V&\!HR31QR/PN$B>AM&X1O>H9U9DWO1#EJ.][#Y-2J?"^('F!XR80Y&
MC?%"2S0(Q@!<,@^DW>HK"&2`Q[`E7LEQ7Q6O(B<T.N1UMS5HI[VH>:0V:3Y,
MJ<W.#+M(<ES$`G01)NZ3'>KB#G1U%\JE52/]F8<4,^MBP)<RM*173_>A.!<%
M^\$W##]H&,Z4;B7OG#`25Y'I1:*X&XSPYC"-[U)/^>2>3EZV`37`O9,!V0+R
MT)[@M^A:/"&3^)*$NX&7ZB'=B]L\7!K&-#*0/D:P,3Z/-](\2IK]%+[[:"WD
M!!B<T9*\B,A#%XZ82$[51+BQ"1PJ$'(F%C@PE"YP;\':/-Q]YSPHM\?P'`&0
M687;S:2[N,>FSH0/H<)&T)BT_C1A//EPW!J/_R$E(=.J.I^&@#V]C]_P8BYB
MA*%QL=<VPP%<<MR#Y2V,N06$PC[_0<+!=%L)2P@HE\@/=//X+0*^Z]'"/:<@
MM@]L0KD/]%*1+@G4#O#V`<<G1LCM0(\XY',@Y,[`"L`DUE_JG3L.)"`NX$0&
M_DXNPBUC8#9MP$>LR,/Y^DZRZFK_*U=/1F?<2%7_U'%IR$"!BB$V01:XN?J`
MK,,?`W;A>;.D4Q2%(LI!RND7SEGY.H9KRB*@+*RHF8#(`.BIXO.3Y*D>1Y!G
MXJ%BOG4QIX0GP>)<;<H0R5R+>4+<H^+7XLV*NV2,<'69#Q$RURU)""6/."/:
M<CJ+(L&<SA%8*OJ5SZKZ%L,KS5Y/0DR3J'CF\B7/F#''W6Z#KDI14["EQ'KY
M_:5KWD3]IEE/I`C0TDJ<<:0L9<YX>,/KN(Z8O@7J45RIBALYU$<\=T6E3PZ&
M690:Z45Q\DJ<(DM#N6@#N<K#0:Z)B9`9,'&XAQUV(IFE%4H51\K\D4R45G,5
M5W,\E,03ZM2)<%P,9.OSABA,D0ZD.$DKSMA@T!@,AJEL<C;E@WF6')?TAEG>
M*,MEDU%R<K`ROPA.[[S15TY<8>#.WK#1'XW2+2IR9/D49?PV.8R)-T[FO65L
M083>.B*@0+9[[9>F@MD>-7KM<:$;OQY[+:*5PN7%PQT='>[0X8ZE<(=+E8B=
M--R1C4[T6V:9X`=/>).!AC1\8+9;?25^T!`*CB=%KX1+E@(C?0Q8;`B>=%MF
MNF/KHBA?TPH"[@5WGN7FP]_"Q(M-??X=W?,;-H]XRMR`P[;.G:I+X<G1A7M_
MNO/,M>1>C5#7$'W!>#;N5THXV=#WJ]XD/NUC!5B1+_X#UUZXO4669-@:;F%)
M;H'3X'/.&XI!&;7:F7CT'RR->T<^,.A&HS+<')'OML;EC`HJ^P3(1XIFVA2A
MQ^=XK98:@<ZW"]+WQ^_/`_;@^'$(4'#+I!J@7<_8];H\WJ/6WLJ5JZER>7']
MW=/Z^]3TMU*1DZ^[>XK.W%UWFV9KV%>5-[P:)UCR,=-4O3*165DR("F722$;
MM-L-'%T$JK(YC2ELH]Y])8>0Y\'96[[TS'L=+VW(O3=MM]JF,L-W^3(4Z-UM
MHZO?,7>Q8:/6>),-ZRFWUJNF*ZW>5V\_5V))43[B=3%\9ZA%3M'H"$/#JXMD
M/FVIOE<U)>]I&YQ/(O.BQ"5$MV\V!N-14;B;YY_P\E%5]RQ?H"X-S\[$H+(A
M\AQ%VFF,AB.T.#P3I^3-@:B%6[TXZ`S[C6Z_LPQ3)C%$J$7$+OUBN0L&8>XZ
M[?;0N!0WG*C)OS%2N[9(B,3N6=@\XH%"P=X23?)N'CHFPMU>=_.0<^600\]Q
MGU/S',XRAPTOUYT6I->;[S&7+5.4?4J4.6U5_IW2JUS7?Z1+54IH"./9S`J<
M_V4A5PW-6XL7YBA5]U@V[(7H%[HR^T1]=FXM>$.0;`%WQKUT7:GKF*PN4%Y`
MCNJ=J)2>;E#;Z29UEQ(3^Z37Z-![P:O?XQ#^$K[Y^7SX4EPZX&]B@SE,>VD[
MWL:1DAG>I:N+1\>.[G'@)/[VRI@P%Z?.3H#)?GG5YK_/\>0H?K_U`["-^&-Z
M0Y(,_\A>FN@AP:>+P`&F'`_2WH9%,EW_*<>E[.UID^`[F89_<M-PA:9!$^6M
M/--L<[%;L%2C]&G]B.H"ZQABZL7.*CUA6QN`4T7@`!:L<PX6#%WU2FJ8HV@1
M+65:R@XD93TM9=O9ZISU5BFC']KP4#ZMY;Z^\%A/$;L8MDM.?]MNZG;9*9]5
MNK#ZQD)&9P6:X<`>F.O/-R:7ZQ&">YR[AS"^?@EXGS/RL`0.H_:@1E37\SPU
ME^_"Y6:C,^C4B.X'GL&M3"<_N+_X?`.M0EL7`_TK\UA@N;P%ACUS/)&-]<#J
M8Z(5NE=&>6T^1U8)D75:;;L3<>Y`XU%KN%EDS,:P=^R!QCG'Q>UDOVYV7XO.
MB8A.^]C3[E]8="IU[B_C2J@)'GLZZ%<F9^1F4S:/(Z=8.IYLYH^-D_BGZ_-U
M*Z4NJWA,*E`R75`R.`_)934\297`:0^'K4ZCWS<KIC:[I=6FCC1H$:J`"(T'
MX_,2H7T',?;DS.IE]#*EEJFTYTR7MN?B-G].YEV!Z^Q,Q)QS-\:,=BRRH6'N
M2:6H]I*UB3^&B6^WVF=FX;4$:0G:KP29W?.2H&4?0_X%JX3X'U4+=GJ5476L
MV+NDDMSE.FOJ2TQ]&%YWQHUQ;T@=-K`K!+6CB+V`3?P[S_G?Y=`?=I-0J_@\
MWVMB;V*<3E"BHH_7-&^HY:,YXOSJ$F>=PAMHDJFHL+Z3'2G*0/KHP`HX0];&
M;1*#!:9Q%.-\]'NL&*3ALSB8=V:)SZ?,P<]#ZM,AYYUB)T#Q'C[L=/5=/C:/
MMPR>7LCLI@6_6W=,&3S>:?52;L,)Y+I#:^7E!WD@X0Z:+F`Y@?&`D[EP2VE.
MA\J9ANCGSG^A$<-Q*#L0OW<MD)";R;WO8DD]_QKVD,$'9K[-W+0-2EIFN\)1
M5AC&,]Y(8,>ZU$HQT(;U"YN+[%99+ZP7&6I=WKKVJJO>B?^G@X.N<]UM_Q*O
MIXR"J,"VGG4]XNF(ZRG@H$NF=MN_3GMYWW98I'JUC6O2@4Z!VT\!!RVQQY38
MRM5)'E5B*W49J<OW5LKWG/"OYA0;H#@HO0Q#>E:DKR)/!LQ#ES.UZEZT]P_-
M+'4#\\`\W6FU3XVGM[;"NB[OT);WHX/3-#W;6#C,7=]RK%)27\F"H@J!^1SE
M9(Y;_?YF'F_70T&M*?NIH-'5?*WY>O]\7:GCKS[RXOK_\ETK<EPG6M3'Z.H3
MP5%/!&.S=>SJ6WW,/3LP#QVZ:?=:QRZ.U`?=TS_H7E'>)+,-UYDRXX*2'=_4
MQ_3J<\'+:RD%F4$]=)3N#G.28#Z'N?N],MQ=]Q/O_DI$Y!.J3:OB;/NSR65/
MQJD2=R\5;F#%ACD>#XVKV=SU%XR)F<#7\DLX6PZGK>+BM^S.\3Q,8)=K>P!;
M.GZ5ET5LDQQ/8TBQ;@7_S_/SUDN'/_T=6T%$H_AR)@TF8YYT`4;5F7;#R#$:
M::N,5C0LG$"+-47/F`)V"E45>N"73A34.%08A[QTS%/`2^.@<=`R<OI[<PHX
MZ)3XO-WY0Q8<KPW8GC#CY5\HG!2*&H=SP4';4(V#QD'+B,:A6ORE_<Q+WL]&
M>YG:R]0XU!P';4$U#MJ"ZDC-R3'>*>"@A2=O=[ZQF>5@@LJY"H]V0#4.)X.#
M=D`U#MJ&ZA#.B;'=*>"@12=O=S[`GP-K$L66>Z[BHQU0C8/6$(6[<X,#PM;/
MT=5<=^8X:,G)VYVK)Q9,G%#[I1H'+3M;[LYW%LS.56ZT0ZIQT-W4G[%_%PZ.
MO_+CT/+L#0T_JK.WQY^[HH52"^7AA/(Z<"85=86U+-84!RV+.QK(?V]NA56=
M33V^-.9[Y/)=QQDETN^7[!"D#CG>4U/5RLQ-?F^YEC=AV.WE-\N+K6!AB.8J
MQ^#GFG5YK`F8!VY&.6R,S=&1R7VX:>EGS#=[HC?"^/H$^'S4&HQK1';-YJ<%
MYJ&U>&O<.5GNWMK]/'9K8>X?2E>=4V0\+[NM95L-5\8+_97W)ZR/RZF;KQZU
MLW"_5P=5I1L+'X7>M?8W%1Q,L]6OA4D^.I]7F;GK"-NJCU!E:'>%K5(QR<,[
MA;4+3<KLKQJYA?H,>]0S[$6W'@9SS1FV'J)9HQDP513)\XR>ZDN"?;LY+\[;
M=82ME#-;&6AWA4U'.*MM,:^>YD[`;)I8,O6#*7-TO/.Y8&[,7*H2(NO,ZW8Y
M6#N&DRZZG6,/0MTF+4F=%[5S^*D>NJ%&WG05]<!9QH;;K<'927/E/+/:AT`K
MXW]7!MJMF?K,HL^G&6I6LF"S$P;K8YFK&.<J\&N[X-?:?GSKLFIALH.+KJ*R
MEU3:SKA;K4W;DUD_>ECM=*3J/*/'@_ZQN4/+1;7EHDI@'EP<NN:QJ5T=<5AV
MI>5?\J>5JS__YT]QV+RSK/G/-`'[WG=M%H17?\=.M/CB1^RC$TY</XP#]IT]
M1>]=>.;=__T_AO&?\FL_0O9U>B6F<8?&Q/<B>/`;FX*3^B<ZD,VV"?\3/W:;
M7?.5X=B_O)J8G4%O.!R\>K?)M:6RNZDU<USX8T3;YL&V!;AMXM/0^5_&=[E\
M(=]S5JSNM.0RF*^6,,(FXG#S9!O7.OW*S[4@R<8!TGO`Y)A#Q><!FUN!14/#
M81.GC@<G.<=RX:6PES/F12&\#R5SZ@<SG"C^Z$3WQJ^7E]=&P$#2`W@)+&_=
MT<-&Y,-O?S&#)4*-5S96&,8SFDR.L\KAF&A-IVP2T61R:^;'^!8`Q`\B9AO4
M/(/E@X*+V8E6P3?;3'[!FDS\V=SR%C@BW?/QW0!-T5(MXVL<&)/`B9P)?(!?
M!C#PJW/?=28.$Y`ZWH/O/C`C=.X\9PK/`I+_$]MWA"V"DV+J>!,WM@F0(`9$
M)K!-M+CK6+>."V]"^L-3_HP9D?4DB$.#VYNW5HA?`0R8%])^M(Q+ZHL)E`EC
M-T+U&+N(/M`N,/"5`:#D+HPIZ![L-Q(J9&^5E<)579Y5REF%+4<MB(ZW7^+9
M+0N^3JE'W]<X`O)Z.*[\O14ZDTO/_NBX<41HE5#L-IO`*]WPEU?-;J+FS6ZO
M#9_%GL.__70;N$XSI)Z`K][!<6_<@8-D"OQN`!X&R5Z*9&\CDIUB)+N#T6!O
M2`)/_O7SU/<CE)#?X1?CB?X4^*AC[J-H_O-//ST^/K80B)8?W/T$!.[^A!__
MA`^^$L]'BSD\#_@RSV;VJY_XZ@3YSX@(X>:$?J]C#IMQ:+^B!Y)'9LQ""7XG
MGOCYQ\W'__PI^Q$M^%.Z8NX;.*GF\'S!"_AO^,`SUI=;L>8-_)&=WJ%0J3EG
M07/-.T%8'9N)OV56`B8`9HC\(/EP6UK3-WY:MZ+RNH_,\V>@5M>^<!-EEM^X
MNJC\5,&[B)Q"_(BB)'[FJH[)$A,T.!BT9>S@/?#WJ0,Z-IS<@['(2$7()JT[
M_^&G#Y__^]4[C&&-S%&[VY5`I5]>0B#S+O$FV&O'MY??#](;1!]!];Y+<9"K
MI)\M?0F$4'Y%X)J^V%:^(/^JO%K^2=!O$TE[@J3T8[==2Y+VMB2IP/6%2/KG
M[[YW!\9]]I'=1M]!S5X^.6'S@^^!MH\<.)3AWV_8)`[(H_@G0^U_A'U(R<O(
M&UK6`S:`\31'7RKB,(+K`L^%X-K\\DJ:LCQ<7[V3GVY`FH.V\IX5W9(%4/-/
M#BG_O)&>,3^^?P!'U/?041;?GLU\CT[YFM\*^6T;0-;26X5HB?":YVGM0<KS
M`^3Y+=GWSYOX-G1LQPH6-Y8+YQWZC)Z]#IP'6.O:M2:T(+ZDWCQ_*%;;"H8B
M>K]Z=Q]$3S\74_U8##_8GN$'+\#PW66&_^!:87@F#+R,Z\DP3_>PS#-L=D;I
MC^-:.NV(PY;RB+@>A*0=7)O+(_W8-0]K@#HG(K_U,D"=(^H0P6';,+S@Q(,P
M?+=IFHD!@A_QE,'N+/>*L".V_8UA7!I\Y=_=R7F<*6SF_+Q$!<%,J[0XVZ.#
MX)SMC"%QV$$8.2<F7SMCV-L^*-@[8%!PE:1_7@)B-MXZ.`\L/41?/=']F/TI
M\&?(M'%$]UQ?IU=6@!.(PVL6T!W&^T7^`J<<"#L@R:H=3SMO;B;U_)6NQC7_
M;N3?%6IICGUQCOW#"K#=H.;6C=R:H93FU'Q.?;0".[FDN)K-77_!V.EH116]
ME#,*\=1<DLLEGREG*CGW_.Y/2#")9WYE'@LL]]*S+^V9XSEAA.EL#^SJ"3.I
M6+WY9PWB*3>5HH#FK*TYZQL+&9:S80H5>V"N/Z=#]]GP50G\-5?E<I6^C3RY
M8/`Q+Y3JSO`91U@S^RJS;W52T(Q^3$8_)^;5S+,OYC$[YW/30+@>BJ2#5!ZW
MR_L")_8Z8-,8JQ6$NJWYC<$&VT(B6HH`QY+6;9-D>@=,DGD.:YTT&U7K-KEB
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M3JA"H1#1Q%#EHGL$Y=`[H(NBZPFJ:A(.N^NU-`F]`YJ$.I5(*"3I']`DZ)2T
MG72,3DFK!UN?$T_J_<_L?Z_9&=50T_>4+N,[D$3^!?\??OW_4$L#!!0````(
M`/%ZJ$9JH-($"@8``$-#```5`!P`:')T>"TR,#$U,#,S,5]C86PN>&UL550)
M``,U#4U5-0U-575X"P`!!"4.```$.0$``.U<46_;.`Q^/^#^@R][5ITTV]U6
MM!NRI#L$Z-J@70][&Q2;:83)4DZ2V^1^_5&.TV5K;,O.&NN``XJD<4B)'TF1
M%%GT]-TRX<$]*,VD..OTCKJ=`$0D8R;NSCJW-V1P,QR/.^_>GOY&R)\@0%$#
M<3!=!9_FJ8A!C60"P>?WUQ<!";K')]W^Y&-P^VD8''=[KT@7?UX3\O:4,_'U
MQ+Y,J88`MQ0Z^WC6F1NS.`G#AX>'H^54\2.I[L+C;K<?;J@[.;G]-C:/#-O$
MK\+UEX^D3Y9^Z&>TO3=OWH39MX^DFNTBQ$5[X>>/%S?1'!)*F-"&BLC*HMF)
MSAY>R(B:3&F5$()""ON);,B(?41ZQZ3?.UKJN//VUU^"8*TZ)3E<PRRP[[?7
MX\<]YZ"D,,NC2":AU7BWW^^%EBA$@0TD(`R))-I):(CM;UIR%EL3DD<"3>2,
MR(6U+,+1)!4TC1F2(-IL\[F"&>ZHS))L]K#RO?B)6YC5`LXZFB4+#IUP"WA$
M>93RC.T"/^?D%N%A=;`6$)8&<*'<-!L9N8R^U]26A\ZHGF;F3C6YHW1A)7P9
M`C=Z\\3J]"7I]G*KO\@??UD?-CX0\2!.F&#:6.'NX7RYL$@V@G$Z!7[6J<FU
MAL.M"TN5*_QYX5R"&6-<2>!":ET@_$Z:%D25(G<%<;>6IUSGE?2'AW"UD2>7
MI$CCA70MBESI)B64AQ?[&C10%<WQQ(W@'KA<V'A2[C!./&50MJ+B0$6!5)B(
MSSJ8NA^`W<U-GL?7Z^!&WX7+ITDHIPAUFB39F@0C7[+AGRF9N#B,;(0/R9RP
M]7S!5BO`NJ+;LAQY?G@[CHUT#@D-(#T;HMWY0M:.S#XY826FRNCW#<UIN*N&
M.F19&5$])S,N'YZOK"S;PHNRLEI`Q[+RB:;LDR_H!@KP]C""]?M8#)&)(<(+
M1J>,,\.>I/_ZC(=/K(-$*L/^R6QT-1O!U(R8CF0JS$1!PM*D(+DZ\QT>TA`]
M`1.'?3O_.V7WE%L?F8!B,O[1&@7HFBQQ>*`C6"B(V#I^8J;<,DD!+@>.P\-X
M>D(&4>9)>D)7=,J+C.3,YP.D<PR.<@68![@-7L5!8Y\E?`!Z93"DHR%4V@QE
M!;\/$#'"+2C#HGL&2D&<%SMXGM:R:PW&'6^=Q5KI)]@@.%'RGF'J?+^ZQ30\
M%A^8H"+"ZF@0855>9N#Z"W@#<BSN09L]0)8LX`W(QSJW*<B2!?YO?Y6(BCDJ
MJUT_R4&$)88"5"RJTJPFG`J#Y]\6'MF-O@!'_05:`*ED!!#K#WCYNC$R^GJU
MR#J_YTM0$=/?*O0?L;GR'1[2S9PJ>(^A.Q[*Q,;JLGJKG-C/WE.#<RX;5)B>
M=0/V@.QB9%>TQ]ZC;5Z7NNJ@[[T.2E*(*\B7WH-L6)J[*N#5?U`!I?=+5^"_
M>PN\:;_*%?D?WB)OV-5R!?[Z$(.'G^WL]2^F7LUA&MS)Y/[%M6=SF[I7;]FX
M!/<)>*/NK=S_INM32?M,.JCLV_A4Z#Z3#BK;.NV.!J>4VS^B(WH.&*%)E&+T
M1NI%!OLGS@=K[M/2D+"1E'M-"O,"V7$\6$U=J\6Q6Z2A1)?%P@9KUDMI8%._
MYA>V"55VO^%:-;N$;,+?PBCS^^I\-QXWXA:$C]$/\0A0/L&B"XMNNF"&\B+I
MRZE;$+]LZ-'V$&.]?X4_[*+Q978]P#RDU`I3SE^4I_6&U@6\+4"322)%5DJ6
MHB@@.[S`Q7VM<E=RYCL\I"U9T%,R)<\EQX),6X\QJP)$KFRM`BHWBD]6*.BC
ME0-P8VH+3!8]+Z6('#`4T+8QG<HZ'#L[&^7&J,'9RM!M=ZL"[S/%\[9*EC;^
MZ-M0)B`^ITI@_M+H_6F29D%U!#,6L2(X[HPMS`]=@VZS,-M>UV6W]\N]ZA.?
M.BJ5^&H'!9]Z9C_4Z-*I,O;//`6=3,?@YE/SJAB/0Q;UR;-*BA59[S[ND[N5
MHZK5VO')Z]R,5?.&X]/@W\%NS;M=/@W_W2Q9YU;A4U`I*8ZV@XI+F\RGJ.(&
MJ[Q%XE,X<<-3MUSWR1&=6R/2O1?ADT<VP5=U<W&8C^5?V!?[/QOPR;]02P,$
M%`````@`\7JH1K0>6$S;&@``G$0"`!4`'`!H<G1X+3(P,34P,S,Q7V1E9BYX
M;6Q55`D``S4-354U#4U5=7@+``$$)0X```0Y`0``[5U;<]PVEG[?JOT/6LTS
M+<O.S:DX4ZV+4]HXEDJ2DYFG%$2B6]BP@1Z`E*7\^@5(]D4M7@[8)'C81M74
M6)$`\'P'MW/'3_]\G,<'#U0J)OC[P^-7KP\/*`]%Q/CL_>'GFV!R<WIQ<?C/
MGW_ZGR#XA7(J24*C@[NG@]O[E$=4GHDY/?C7R?7'@^#@]9L?7[^Y^NW@\^WI
MP9O7Q]\&K_7_?@B"GW^*&?_K1_-_=T31`_U)KK+_?']XGR2+'X^.OGSY\NKQ
M3L:OA)P=O7G]^NW1LO5AT=S\-4I6'38;?WN4_W'5],707]YF;8_?O7MWE/UU
MU52QLH9ZT..C?_WV\2:\IW,2,*X2PD-#BV(_JNR7'T5(DHQIC1`.*EN8_PJ6
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M+XZ>Y<=C$99-2C8A4Z+NLEE)53`C9&&^_<T1C1.U_(UAPS?!Z^/B5/M'\>L_
MSY@*8Z%226_U9T_T1_Z:W*E$DG`U=S&YH_'[0XL>.8S8',U"%ASL%\9%QLQ;
M\EA"704.2!?W0&Y"RHEDXC-7"QJR*:/1V;/S:@M%8_L10R@_1)Q"66Y:O=_I
MA?Y156&H;#@@T4O&3AY9(]UE;0<D_9;<Q;2)YF>-ZHA=G]L3&1X(J07F]X=:
MQ,ZOKQ_-[J?1^\-$IJOABIMQI_M^*L6\D6QA-1GZJPZQ55[G%<A*Z1:M=SH0
M[''G8)^=5EUC[79"BU]JH4/?7>=Q1IJ67>C,_&#-@PU]HP+VR_.M;`&7[$S'
MDUFFF;2!!)9V'._,9GP0RD4;<6B-]*>C$K&X2^'^3:`U<J8",0T6DBK]^TS9
MMY3R&T9Q(>Z#2'`I]Y\8<BZGDS`4*4\8GU5<MI7MW`L'>Z*J>`G?2_A>PO<2
MOI?PO83O)7POX3N3\!M$.3=B?23"-/N!\"C0_[+D*6!\*N3<4K('#M2S<&]%
MA;U\KVCX:B8>CB+*\BM6_[!]L^I?_3G1-$2&C@\QV9;D*__>]O*'$G6:2FD^
MJ5<IB?]-B3SGT9EF7`E]34W[)O6LF,:<@"NJ3_7H@_[=ME`%:NN66,,M&*DO
M6KHB-.=1]>S7MG-%Y*W^3@UMFW_NFZ3S[!PYU5^5)+[0)\;CK_2IA+;:=HZ(
M%/.YX#>)OGIN[HFDZC)-3)!&]-*B8-?)$?GYN7--%T*:&]%(#*4["=+<#<D?
M6$SEJ=X@,R&K%T5I*S<$7M,9,T((3SZ1>=F6JFOFAL3?1:PE(")S-E7/=T4[
M-T3^0>/X5RZ^\!M*E.`TNE`J78N"+XAM:#]B*]$>0/"&+F_H\H8N;^CRABYO
MZ')MZ(+)7$!0;]"!JM5_@*C>(D(%LX4`@7V#"%BC9@+$]"TZ3!"]$`CN.W3@
M:I4@(*KOT:$":4M`=#^@0P>WL``AOD,$L=HD![V8W;EHX&AJC)]06)@$#I#I
M&0H,D]`!-/]#H6&2/&J\1`YC_HZ#NU1I$I5M,L_+CBXB^ZJ^ZC28KZ#@C*I0
MLD6VQGA4^'NO-N(-FW)BV@_DPP&'-C'N`01O)?564F\E]592;R7U5E+7`O#7
M%PZXHZSG4"7X)M#K_8'*A.E5EOU*!8D()(U-&91@0?1?K'/_[09UH4JTH0BH
M9KQ@AOG-GQ?\E"AZ.3VC=\EI]FES'/[V;(T5=S&XO7L98L/854IZ8[LA2%[-
ML^'E#0U3R<SD-@``]1I`%7NV'DZ>/G/VGY1N'BS5`JE5WZ&A&;=9K6K3U'RT
M`(97S0QE\.H>#:V]N:(EC//_I+E_82&XOKAJUU)MVQ&2/OP>^"CX+*%R;E:W
M<7_4G*MU38<GO);Y]8U'2?SP2\?;&5':&;<.&@4QW=7U\293;S+=9Y-I\[6&
MSB[3<)V)E@H>2LMP[?343",>JW`?YOWF`QO=HJV7W078JH)RE<(F1K12!]S&
MT7:X6EL88M"MVD;SB["V9*)<P'9S53G)3>8=M]'3WK'J':O].U:'P;C318,?
M9^?G$7[(NTFZW9Y%/B;`QP14;$R[F`"0U\2-XU^Q&==G?4A,<9U5R:)@(6(6
M:HUX]<.2MF:OO^V(/;O\VY'C,JQX72GJJJ"EP6/5W&$`5SM1]Q,>F7_,Y?I`
M8G/_9O0]-3D1K?H.$OBPD/3>7%8/-*_?F],&1&?9?9`P":5IB;(P)"BHYBX#
MN!Z)Y'I7J"LJLWPL&!9@+_=P/M$O&UM='W7ZQS`[U93-`FP[C'O`6X0T'(,-
MK4?L.-L#"(A\?R]D3N\P&Y'#K!]B/QNKY+E*V%S34\7@\D9[X-WS=CO\A@^?
M$/%U&3]`T@PZPT<3U<)>:T6'$4"X:*,9H5NH=D#K;D>WWMGNY]#>(.'6A]<Y
M8BL=&(C575$DVQW:QB`#!.VN:I(=Z-V,``Z3T-Z66FD3<\_;IIY!AG*1<`:G
MPZ79V5LK4%DKPGL:I;&^4B=ZG40L3A-].JU#$\\?PSC5*^.#/@/,`9;F2:/Z
M!MXZN9NL@?U]R)MXO(D'D8DG^WS3;BAOY$T\WL3C33S>Q-.QB:?NL$%G]:@@
M5KB3)!PJ'=\&RD36WXM8<UD%-`L/;*=T0(9RH73`Z?!*AU<ZSO52%$]4[U[Y
MP$*:;<L3H@\8LW'U59;MW$F<$9?MX6L:BAEG?],HK\UY*E2BX+I'3]\;DH7E
M&+*,G<LL.%=-0GU`ZET(DDR[&Q@'4Z[(DSF<)E^(C#9I_YW$:3[;2J7S_'>M
M&;3[1[P2ZY58K\1Z)=8KL5Z)]4KLUZ3$]BJ2HIML&\YT+U^ABP]HQXY=Y'&'
MUHUU[7Q]K22$Q2HPAV-*5F>;=>G_JH'</@503X5+NT9YQ,@D.252/C$^,QND
M2M:TZCM`4+X4(:61,F8\\WH/X:'>!";?\K;(M\R(7["$Q&OCWR=:&;:_ZWCN
M67!MEAFGT=)P.0G#=)YFY6+/]+H.6156>,<1V['V``("4YRW`NR#%<`KUEZQ
M]HJU5ZQ;0+*5%=#I4,`\AV[$/W3QUC#T+61]AXHB[&6$'97(W3[B0L'L@L*=
M'HPXH3S;\22^_,*I5/=L,9DF5*Y+^&P)+):]K,2M<A*+>H39JZ?Y>]=4TNB#
MD-=4Z45]P?57.0W-?/S!DON-DIN?Q,N,RRZ'[`3<LP*AV3%U]Y*"*ZDW<$*O
M8I)'TI>#VFFH;L%D?+HB3X:"ZWPU7^6+N7A:N0$!N'\'9&?<XDH?UX8?ZS5\
M;:QMOVD)CBV,,4XSCH=LL=Y^FZ2W':-O\O,U;DWQ\VX=$#GXPS3E9.EEQD*:
M&]4G2@E]I.F59K9)R1&GFVGY-R$S^I'-61YB!CEM>ON(>UUV,C?OH?]=N"66
MQ:5,PLF5I'.6SBO46W"_06KN^,>&_&-#+J#YQX:&!;)]W>4G:FI6_^4T+]2Y
M;E*WXMH--#3H#UKBTP=Q^D+X@C8?&L`%#R758L$9S?^]3+2B5>W^L>L\/#BC
MA*A$RU\TT_"CM2@`!-@\P-`@?R.)N72>SC1Y(%!E'88&\9F37)RAT5**`6&I
MZ3=``3O_[->`W%_NU?-'$]61R6-Y#@OCLTU9N0*5;7?W`/V[9B,E?OB]<458
M=,%_93Q:+O.J\([*AL.&KFPI6H#@E(H>(PYSV`,(P^\$_Z:<#SKQ02?<ORGG
MWY3S;\IA7+3^33G_IIQ_4P[K`O9OROG05!^:.B*,_DTY_Z:<?U-NK%'54,?5
MR**INXLM'&D@-=A0"\3GKEAUFW4+]R(#X;HK4PU8Q]9!CT"0WXT&9&,L*A#Q
M]Y@0V\:C`S'^@`ECSU&D0):\P\223L/XH5*'.SL%\'IJ\()"<>$6IV#16U"L
M6&2KW>(YH&BQ"526P>!0F%CDJAU36:!PL<A5=L&C4'18!*J6D7Q0F%BDJ'*8
M]L'-:]S#%%)>4K-+!>7GB`8HG?R<`/O:0HJ&KV;BX2BB+`\8T#]LQPGH7_UY
MSA-CH"@+CJGZ<]M`AAY(ZBH\!TK:1SHC<4Y`21A(38ON4F#-4IGP2-^2T]0L
MB3^(E$3OP>HT.JN.'1#ZOW0ZU1H*51_CL)JJZE8=D*!!?@!RIZ%I)\0\-XCI
M%L=U]#2U[H>D-U8DO=F!I&[2WV*BU.4T6]6UH7W5#4=%]/"!B`5-Q3:YE-=L
M=I_4!,,UMD<"`3(1=3U&#@/!PAI?\JT1^+6LGFX\)K+]&N)V%E!SCQ$FT8R8
M].'7_0W)RKN:]6S<V9?36[TY%<E,E?71ZN".>P4*P8SYS`B,F1&;TA(D.K^J
MO4_N\,D=7WMR1U_$K@U<^;(U!O$2F:@2AV7_`2"F=XI%C,BGC9NL;CDUM7</
MH5`/:H7PTC9[D"T$G`YT<>P6LJ"PM##AC'MNG">QNTSI-OC0YQ$!%$R?1[1_
M>41`@1S=2JTQ*>_'&=LX+Z*.&1C.U"[/FQJ1!QVH;L2!4N^.V\CM#HZ91G<L
MFH.ETM.^G*,F9RFJ8Z2.[P+JPW<;1]_AI09T>Z%9>S:>KO61`?"9HUJ3\-EI
MFDH\DE@7=US;`!&W>1\^W]?G^UIA'1'&=C+VB`#N>4)S5S<*?J0=F][P`K84
M8+N]/7R&=L_1[=!`''02.H3R9W/7RF<V=/3^CL\]68TY6'1_UR\)^VA_'^W_
M]4;[K].;+_GYH]84F3+7U1)R&3W`+CX58;]3$<I)RC:/*6^BU<E4,C[+$^[S
M'//LCY=9J2)5K!P:O7Q_8O>!1I6>,$JBAP]A]#D5/J?"'9SE*:,/4?,([O*6
M*?ZJCFV`0L="`GV9NKPNE'RJ56,:G3R=D_#^>5L;-K09%SU+MB>S&X94C>H3
MCB#I+EI%%4^4WE#YH#=<)D&<$"TP&'LIY2H393^95'V5T&CRA<A(W8J$Q)M_
M/Q4J^222?]/DFH9BQDWI@@KHO7]OCUB8"W59Q:'L5Z9=U5DZ#!$C3,\:,>G#
MW_Y7Y"FKRU%(N\MW[\VZJ3K,(5T&`+)1=G%)TN5TXURN0@/MAP22S-TEY\]*
M?T`PE78<%E2I7@O`5-MO6$B%Z+*DJG(/`;KL54;F7H(:_OC>H#%3K_3=G@D*
MS9!*FX\XR70/("!83J5"YL2<3[/,B'KRM&Y2R`&9Y*GET/P\?E'PJ^E<=_')
M@1B9;;$ZV,\:^*QHGQ7MLZ)]5G1U5G25>^@3_9+]J9KQ-IV1@;/1$=H/A`;T
M[R1.:<L)+>_K\]M]?KO/;]_'W$N?W^[SVWU^>PO`/K_=Y[?[_':?WPY8JCZ_
MW>>W^_SV=I>:SV_'N";AL^/SVWU^.\*%Z_/;;;"."*//;X>'N6'$Z?/;?7Y[
ME[>'SV]W]U)U?1`:.FD..F?VCD^WNGW?4.M<@F[URNY6+3C\V*UDWAG`CK.'
M@%S`]H)F!ZED0.18'M6TSS8'`L3R+KG[D#\@@["\4FX7I@N5.M"]0&Z7<0&%
MB4VZZC3G$<H$=!)819@K%`\V,<LVLP:*$XN0U54M"BAN;+*79981%"8VX6K7
M0$DH;BRBU<JPYB97&<H>;(+9D"G':Y[U64PN%#S2A-+(_*1$S"+]ERA8-5"!
MF`9B064&104I)VG$DO4$-]>6V_D3/9>:ZX@^^\IS.^19$\GU(:66<K!>DRR<
M\.B,Q6E279@`ULM]</$OE&ONQIJ42337,VH*,R;L@9X_FDU4E8H`[.4>CK[\
M+[A><?2C4%4AWJ5M!B!5\&)E\UE.3SW/&]N[AW"YI*>@I(KCE>T0D-SP`')C
M^P$A-*[TFI;NR;ZFBNJ+]=Z<>O2!QF*1N2%KUSRHSXBS;/<``H)$89^LZ),5
M*Y.GJ+%@:07A01^%,[JR>1DA[#)-M*3)(WU`PJ2XW0;;AW0L'Z8UI+,=<YB6
MCYP8R%`"E%`=[\MF=,UTBU:"(+IIM`)JI5FC"X6Q@MJ@%:(+?FD'KDKU0A?Q
M8@4/:(Q`%_5B![+:4(0ND,4*F)4U$EWDBA74+D1V1.Z`D*C[8!J++_VY`^H^
M@<$=T$P?T!U0_HJ"WO&2$D7/:/[O!3_5G5A(XH^,W+$X"Y38T@_M.[I7A"?1
M_Z4JR;AX*XSKBX<LIL^.N%MQJGE[)<4#BTP8R&<]$Q=\M=TFH19$,A0--M,^
M/S4`X^9")NSO/`YN>D;O$O,8E4AY<B7IG*7S*BY`^PU025SS7A]VYA\3*/)`
MXBP#)#DE4CYI]F>1NA6PK/IB@9;[?+=WJ!7"^B'<`SVC"ZFU]CQ<46L+&ZNM
M`A>@AWL8+T_-29AM$G5%GFKLB^!^&"`M8QFN:6PNM.J+9)<A,`!='>"G9,$2
MK<;67Q3V`Z``F6A91J\V+=ZVFLJ&_A@@ZAMJ05AT1J=42AH5@K8^-'+:E:*5
M%=EW&VR0B($R4>0#XT2++9NB2'4X@>4`F$$V[-CV`Z$!?9&%C.TPLS4#8`;9
M;F8!`Z$!7:(^V(&M&0`SR'8SBU+9&E'\UC+W[U9,0JTFF-0"8Q)-GJYBPA-]
MO1GE8;'IY*IXNP0^@'\A`U/DRQY`0!"\4QK7786CMK&///*11ZTBCWSPC0^^
M\<$W/OBF!:1=96MT43D[`.K4<XXM>;A_GQ:ZI=`KY`W6@OT2Z,X(5QR"R+WH
M]I4KYECZ6=&%E<'.G[:N$G2G2@L@M6RP]RZ@.T:Z9DFM)Q3=.=$.?=N0&W3;
MO^O)ASJ*T<6?=LT(D)L578#J;EQHZ]=`MQAVTK[`/BMTE^,.@$JJ$MHZ%M!=
MC-VPHZT;%]W9L-.F`+OHQ[(I((#ZKZ8T,BZT#59!)S5VPX[VH9[HY,@^&5(;
MW>LF.X*+A`;?!LKLW'L1:^:J@&9%[@*1;>1`TYIF1H"`*)7.\]T=1#0A+%ZM
MYN8<B8X^U'.F1*=4NBR?E!7JNM6?K?$ZEK9Q[VU<52!;WQ:U;[`VMA]QH,`>
M0,`:ZP"H-?R!,)F=O)/U5C:&KE`K^&?,G/<\NM9'0Q5+7'UW3UCZNXCU,+$^
M3%TSM?S+(V?K-5-_?9"47O"$2JURN6)JW7<1LE1585M?ASPR&KQYN*7^".SQ
M4YYQEI]"<NW<-6^J.YN3ZI;*^7$=&WO]H`_U\Z%^^QSJ5Z,!H3//]7K;E!6$
MKE>O4(9`EL^GS3,DG=T\;@V;/OS5A[]:8<6/<9"]W.TZ]U'!2!^5:J?&HG/.
M#,"E9K,4.H_-@%RJLS.--!;$E=+IQMU540GKCL3FE:=`W5.:J"!,I32M%YG#
MLL.*8);?&:8L6"LB=ZH-5D23`0N"-;>V4JO+23HU+^#(A.FK\Y-(Z#+FLXC^
MNR(R>]<M9TT9D6WZ#U"#ZWE$:SD>6.,A*J]%V18@\15AT04OXOBJJ*]O/0#Y
M==5>AJ[>DG^_83V4M1F8U*8*>G5ML115VX]Z<>NG/FM15#0;+BKA97QW_2X`
M]W,/:8,6O5)N-F):GC]CN84(VFU00/63@G068(=4<X<!WD8J#_JOGP58IZ'`
M9%?!)\%#`(:*MD/4C<FRLDJSL>HGPZ+G(.5PR@/I-QZ=?5D)I[&+>R#7)@Z0
MTVA9"5RO_G2>9C?#F=;90E8%!]YQQ*%B>P`!0=B!]YCO@\>\+V*!0AXFL>XE
M+0T24G.'/8A5\'Y9_#Y+7Y;HZW)``NQ'Z.*(ZFGN*D<)R32"P5JK0^B<P6"H
MNX-RY[NUF#^H^H?.[PK&"+`]H,NEMER5R/<8[%:`&NS070T`PC=G#.#_0W<A
MP"!:^971K5*[:;1T6*"[(NS0VMB@T=T4%HNW?;P!NBO$;H)'MWZARA/,Q('N
M3@$0OJESU/I_T=TF=N!`(2?H;A,[C+9^"X3;T09ND]D4W15B!\_.]>\F9#,K
MR?$V(+GTJ==8L!"Q7EAT59F#/H9Q&M$H,-`#+;J%9@$:VYV8!E'^\FQ`BP5J
MXA@#92)66]8P<4&*BRHG[G`XK8.B\63TL0=Z0[7.G"WF\P*.*5)EPIC3I"AK
MN_UB\V1N.%+A=NAT[`$"Y78C_^2I?("Z@C/]?Q$+&QMSX*'=]@;0\)[R#9W(
ME*]>$UE;;@C8:\0Q#'L`8?C%Y<,P?!A&?40#H+09HI)F?Q"3TI74DEO:9@]"
M+9S)*>BL-6"I9%L''ENA"`<SW+B@<)60Z&EUU)P1Z$Q=;?!9B8=N9]0'G_G@
M,RNL^#$B.[>[W0$^6J_G:+WN[74.3=[E5:CU+!M)N[#$)O<TD#04,\[^SM+X
M5=)I96[KKPU7GKLEJ3O5+;B8+TB87/(3HE@XX=%9;AC_1!/S"IM>1X5[TZRF
M"WXFXIC(U?+:TK&Z&W``"V+.>QJ5%U4I@BRK[(A6G=V#^X5R*DEL7E",YGH-
M&^^9.5$*PFH59JN^[J'E+P:N#]-B`]48A0`]T,"HM2R"^NP!E.$-I==447UM
MFM#R,_I`8Y&%Z4)VCT7/$9NR]P#"\(O,6^/WPAH_$GLQ^!9$9^^%77MBAS,8
MI5D(,F'-\XO(0-3#3+>05;UYTYLWO7ES!XQ=GDO>-HGCX`7:)EM8/=#YS^JA
M=FW1&MSV6KP`J-+YG,BG/IY`K!AZ.*LJA"Z7X;U>ZT:E=;>MH5V\$?Q!R"EE
M22JS=`-]YC&9C:`N>/Y6;!5+7'UW#UGZ!V6S>WT"3QZTM#^CRV>:KR0+.W\]
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M<""4B]VNXF9]H/B]^3]C;]._^7]02P,$%`````@`\7JH1M69*RU[*0``:#@"
M`!4`'`!H<G1X+3(P,34P,S,Q7VQA8BYX;6Q55`D``S4-354U#4U5=7@+``$$
M)0X```0Y`0``W5U[;QPY<O\_0+X#XPUR7D"S?FPVR&[N$LB2?="=UQ)L^3:!
M$2Q:W1R)V9[F7+/'TMRG#XOLUXSZP:[FHW7`X5:6V*P?BU5DD:S'[__K89.2
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M9J+R@1?TFK]CF;0'6)3*U;F@0/B<%A%+Q;64PUV4=@G-M"\QXF-&P;4@`0IR
MS4F-@]1`2(F$E%#\"]7$2>`S.#M3T$1%8]7ZB=UF;,WB2/X<Q3'?25'/;E=;
MGK*845'_T"5^-OK#".4<NJY%M4;4`M3@J5!4__4OK5;FC%N?"`>2G4D%6WW?
MB:&(;E)SD3;NR)8LCQ+T)L2`Y/O'XJM1+$-XS6=G2&HGLMR5N/X@?\'CW^YX
MFLBSPXK^=2?M#HRXFG1D55R'"'H5UQ_:.#2,Q8FKT>R,BJLYR_VNKB40^A"G
M.WE\6@%'5G&4QKM4&\]\O4I8NH-C*(WR3'XLMP6:K\1=E--5H@T@"ZNS72`>
M5G<[@$/O#GH4U2!@#*TA\'4Y@`J_A*_0E^`7I*5>A`JY*;F0%+^;6I2FY74W
M8"WNZ"JG,9>VX]\DY)B+`K406*+E86LTQA1Z]VR`\K6$V:`$D,O36EL2@-Q^
MD=/J5_?X5@'\&J4[#3428K=1OQ06U6X*&0\:9P(GM+)IC#7$%L*GHFF3)AVI
M9--G,HA^24R;*-_;UZB>COWIT!&`96A-">J)*4K?7,Y3C<$),E:&EE^$H/%W
MM_SKBX0RR957_PH_@*+\Z^KEJ]*[X!OYJU]/)<`$0+Y+H]LCB>_]^T3!?=2/
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M,&GI?XI2>KG^!">"TP=V;*$9MT>*86^_KD4/R!&^)HJ@W%XER3`R-LY9/IE=
MGF6IVMS/TD@(`UD::X^5I;Y^7<N2HK<,81IE+9_,+\_"U,CUAV@C?[S.HTQ(
M@Y'Q[)QO(G;L!#O]0ZQXC1+PO&9IHH$$S9S;',]"OZ+75H-!4>MOB!2MQQWZ
M7K)"RM(`.[DYCUS>358>W>^8B*/T?^2)XYW\S?'^9M`2<5_9TZ,W%WQ-EP!A
MHBA[O\4<XRF?P"A_4J(CILSDI*/M;$EI]>E;5C3I14A+%V<[Y:6779[W()X)
MGK)$O4Y>@=/.'ASZWTAJO_7M1@:?8/>E@:Z=[U!MVB=$4R=?RO\"#*)P!-JS
M3)C.,9ST;&Z#5]>;2-#DC&_@;J(KSLRL,=:L[NS4N2D-9L0*(IT3$K?H$JIO
M:,(8U</\Y=.8YF.KJX.:S^51<F";ZVPW8XL[Z,_;]E;N:Y(L`;K!MK9N;G)C
M%KF4C+-=GA\88?W",=84(1]]73K?K#3=`V,YF)B,\I5/8=;,Q]Z+S5:>[R\S
MN5BQ&%YIM&\QQ(MS(:20R@5LPS.UH%UDYSQ-HQQ^K7[1]0YLI4/,$_$LPJX%
M4(,C<@.[`7CZ,4\#)!DM2"HADBW-B7+C)L]91A*-L/GMM\.2&IXE2;FT=9@=
M-E@3*[`EASH8Y/_EW8ZL<_NSY==(!<#B<GU:AS/TV*>][9"FZ:/^7&NQ(@BW
M<@U)\B7T4:>?J]R857[EY2KG,:6)>"?'(0]>7VE>L)N4GM.;8\^B"5\@96B@
M9]?29`!ARHKO9$1%3Z:;@6%5]`F(*6DA(.,C<J0B)N+#$1STJS:G0M!"E%9A
MCZ)TMD&JQD%?OI3A@"A&_&>B+GK240U`5QFL2%P>,2)%/XB8=T\^-^*-RS/G
M6Y5EIR3[D6YY#CL0/&]WWKV;-$></8>Z=2W=FC:ICJ$U=:+)>S^"&K&83^5;
M."OB0H@=)%V\7+_GV>TUS3>P6$L;^BS:,JF=GZA43U8P*J0U;6!CH/JS8(%,
MHAO"/ID$<*[UXI@;LVV;"A^<"`#A2O:X45:..L26*$D#\X2,<L6#!803[A[[
M:,8<N=]R_L)3>=J)\OT[ELK)[MUK>MJA-YFC_CSM+C55HLD&VE7ZF,F-.>1>
M,!35LZB@MSS?]XI%9RNT4!STYDDD%$U2$0TD$-ULY(:\\?%,=BUI#+R.M?\\
MXU$,NO'V%@;$@CV`'3",CW'!MS=T$UO[5H760C#4.1-QRL4NIV/N')._1WM+
M&]+Q\A1?`OD=T5"(2MS9@`E_"SI]6OAL7OL5W(LLSFDDZ#G5_[W(KG*ZC5AR
M3M=4'LZ2,GA%VEZ7D,Y%'_9[I'A>9TB1QA'U=<S!H<.<<9SS82"UO\$11T&I
M'&V$.LIP@!'R:FNFO'*[S/>K^'"P*LJ#%>R>`Z$[0TV12MO5I6N5/#Q,GRAC
M)F38SB!;^11>!8F8^"7*\R@K+O./[/:N>/M`\Y@)>I4S.+:7?Q3E7\6K'M&:
MU=>\N(MI-'WM%RAPF.W"$Q<0UV%UE$I)GO"<*/HGI,)'%,!6&U$W"K.3S)/C
MQP$O<Z8E4!SHY?HL$G?O4G[?E]%CRB=SHT$[NG9_I*F*#$BY!.I$D0^5Q6,2
MM[L"1$=9&-9@&0S6&VYLR6CQ$[37;;:$#-T;8>Z`Z1(^W!/JJ24[%9#:Z4VO
M#NV7.D'<:5RPK_+8?@TYLD=O<*QUC%WZ9@-POD"6"%4$JG(OU*$8;90G96QJ
M"?2$5%#)%P4V>`R0Q7GF[B8O]"72Y18J-;+LMGRP&[$(IG=@[;*HCY#SX($[
M^2\JP.685Q#*NQ!U.9*RZ(:EZHWSIX5<CHS.R>"%B!FCP^\&5]$>K)_3^RA/
MVFKWERI][&F3/1:],\PG8G&7P(,)M6.4B(F"_&C+J'&3%O`E[Q\6I&%D+[$U
MQ0NX:1JXJ!QM;_/&R&N.H>.KD)#WEN-<'KO/"'V#>97#EEOLKR2S5<'&O^Z8
M2B$XZ,<W^@G>5:^W:]<"5M%6)@>M")]`B%0HC[)Q-G,,[Q:P<GW800)`N2S7
MWFMG49K2Y,W^;13?';:=LL)A^K6Y$DZA'_0>?0I0:W?J;KEC]WY=8U765HV6
M:+CD9D\`\*.OEK,'H?1@;*_"3Y][A\-?:)K^.>/WV2=YQ.(93<!O]E&"6>/V
M:"?$GGX]N2,"]=5O0)Y4](D&$,@U<8S-?#+O@F5C5"]./8'YILWG9UX\Z-;7
M#M)''[,QV!L+8KT_2"!Y4CZ=2@3$8#CN$TEVBTQW^L@!WBW`O#/)'CGTA4V3
MS',^R<?'TP6DEASD]=BV'_ZEZBIBR47V9Y;)_Y=:3T7OT;2W(?9`^JA#;T%A
MCRBCHKTLX,>$<4FR*RDS0)B8X7=UBNZ7"&[.)K_BWG*+_"!'.!B//M@6*?2=
M?;J6>T64I/4+?T!?V&&>\DF,"N:!5)>>N>*"J6MM8T^DT4_G>R3UDO#JF=14
M&JI@+,A#:7P6NCV5#%GKV6.I><(=SJ_1WQ#KJ?2H0U\[^&/*F!W<!O[9.3=:
M+_!AW*SZI8*;L\IS-IGD_W:B4#6_KOE'"J-D*?U`BXLLYAL**<>N.;@57N7\
M*TO@&NVSH$G+.Z#T;I'#&5F[79+"YK9Q`,FUXK8PDX*3O$+=9,F3OX6?8_!H
MW<'K^UH>\UH^*S7D,'XJ3N6`^YQ<OZH*/ID7F<2A`FB/_764E=?_'#KM8Z0Z
MF1'QM;.9H<'L=J[&B3C#JC0C#9834J$ASRL\WYX0!2E<VI&)PL?G<=KS,;A:
M+,J`P;%=<+0]]CC<UZ_S(W&]L52QHF&VE7'&\LG<\BM*;S?;E.\I_43SKRRF
MW8[%'R`3H2AHHES#A+*`VW\_XZ+XP(O_H05L>;<9^QM->D31.3VD*#O#Y6OG
M<38`S&:U(&XB]K<*/2GA#\0AU&/07J;BY.#O!(8`"2O(GD+J/3.6.EJKW&L>
M]RX`GL^M`',D#+ZS#?:DV.[+^1$/B`4/=^]F'S?BR=_)QEF5F\K+7T&[OLCX
M,""6ML5V@GWR^V[GJ!:U&5OB^Q)WZ).JH@]<8[6&]_>U<P]KN8_MW$"$_%]X
MZ<3K`H84;89#R,>:S[C4ZNK6>0X_N-EI"$OMD:3#^NF,<IA/95M(@7JS_YRQ
MO^[H.15QSE0HU8`Q.>E;*Z+60\.SW)$6^9#6Z#3^]PJB$5-#WNO_'!7@MK[O
MJ,9F_H&5^_MVQV'N[-L(YM_3SQN/C;OY"H'_@G,31*?W]KV??W[UY0,M#%_M
M>O1G>@=(?3(GY$N_S!%A],WE>!'>(1^,'L&#Z"%"!/E\/B]"3R_4R62*XPB^
M([MZ.T#0M?[6I(-[;\R8C'$)-N9PJ*PC1H?OTU1)G/SI<GU\O(:#MS!/0.*(
MWNQ<))9Q^4Q+,N&^JAD`?-@,H;J04H-87IX25T+3F;+$J22$/(BU2OY5(<4Z
M*7S39.BN`->1E8.;"<$P!SH39/,/>F[&;^,`V$+6CMTOJRD8,\'+X7"2V/8>
M&J?/A>=WY`T4LOM;N38!=JCW`-5QKW*Z8;M-W]NRZ7?8]^:Q_GTI\"@05'5.
M^Z-#J&<;!:BA4M<*"'E>0AFIM^[J\=U8OCB:K7XU[2,55-*Z@Y+F]"M-N4K[
M4_K?_4QA;>C1M0E?(K7-@()K?:L@J,1.+1"D1$&^:!QAC,LI4\!G\-5SQ#9/
M6;RO;<^1:XB1UMC8[>Y>O05P=Y-'17';&@EF*:\KVA,%(]2]WIB,\(GL\IX6
MF&]H':7YOCRS#;ZZ&WV#3_[;W[?[*S<@3II0W(I\V#=X,WYS%!,7(6T#;_`&
M7]B5-!_O[0-R%NZUW833XS(6^F7]S4ZPC`K1?NS/DC>18.)R+4UB(;$JH&,7
MLOB.D/(XG:!K,:T0'?B#@*VJ0,'QJ0TK?"7(&5/&[<V#7WDWRFYN-3NYW^SB
MW50QMNI<W`@3%6J)"J((A[%-QQ.16TDDGA</()\_O/R^E$[XS:]7.?LJ=X>K
M-(K5%B%;O.H\]!NVGBBO([VZS]JL*).:-`':AD=ZQR-)RHK,:AF;/*+MT8@V
M"H57^3:5&#Z1>9[?F+L?SB#%W:V"^6;?71V@+`SP1U5A[B+3CVI_S+GHLZ(=
M4L*^*]M'Y%JC%4F:D.<L(P*PB3#WQ"XGDWN<H=#UC\H+)"&QPR;8?P`U^\Y:
MM:.C_GU96*-`[!2\GCTZ_%6A(%N3D;@[7QL*TF")ID'^>7Y(S0J6L'17L*^T
M2;W^]B%.=PE-WLG1P\JQ*\K'J;=1GK'L5E3)@=_LNSL8"N]U3Q'[>.L.F?/0
MXQ;E=DV!D''('N:9!YB\8+D-3S-=4NJ.IXE</[4_1H^2F7XV/^]A9_<!LB!V
MXIB9$]'2V-`9$EN9$=6=G6B!^9=O'J3(_/@?JIK0V$C=9TX<EK+N/(H&[%W"
M9C@:P6KZF=5MR5]$:\_>LH3(5F/.CVX4RXAT'3VOB;X#6Y/4(TN@2->HT+HD
MY>H^`0')>6T<[0.J4[\$U06G$SKE3F'V+'FN,=*XNH+K7;,D##JW&7Z%K34R
MW+OS>B,->>U=V3Y1A/1G,^4Z1[+2=T+]ND#LH*SUMD.GRC_JS],B>5EF(P@I
M0?V\Y,8,\A_>`O[`*1>[?/29>*3UC$"5CEZ]Y+1HZ(;W3ACC+I_(L@#KC2I[
MEYS+13"[U=?Z:K,6'^B]^E/O\].DC^>L3*-$O%6F,T*#JE/G:)R8JG6JIKO&
M0C28,D[R1(=8PD&/WA.3P;I<L\U%[W@AG\CG1>@DU(NG2)7L_M:N1A[2"*R0
MAV`LZN/<45I61P5GJ=K8(W7CRCC$9+^Z6%8F'+3%.]L@=>N@+]<Z5)6.#&I]
M=W./&['$<XQ1SF-*$P$/1ZWC@'C[0/.8B=[D[,;?8>..QOIW[Q.G`1"86?TB
M0;@^V-$2`VH)=C`P3&W)@]'IQ;@$0FHD84*4C`6+HYD:VING2DKQD:9109/6
M4Y&Q8\]X%]9\?/I)A7/WZ<=DQ_/'YIAQ3D`Y&$;;:"^[2-6C*"TAK7*-*7@]
M.910#OH+F7(]M/[JDJ5ZCC#*._*]-<WMH1-.;7L`V=%9:Z-%**PNO!N5:EM5
M&EJ(6HZ)VZ!.&G'5=ZJ&(F(932K?)HENM]FI)>.<KEG,^D+DS3]$)VH8(^#<
MB:&A2!)-$J-=+@:"4*L*!JEPD.?M`990PKBV3Q`FCF=LJ$R",]T,S5,(VB8T
M.W>@+4`^DP;VN<56J/4QKX5;I?6J=$I"UU?@R\L5:%TZ.I,$NIGR<!<Y<,48
M22Y?KB7N#<_4D=C@(F?P.PL7.9W]>TLE,P9D[FV.I='-OLVI<(".:R3$8'P>
MKG.&Q:OG.L>`JR'3<+Z+8GJZ@2B7`4>%H>964FHVW89)G-G0GY\><\Y8;"3!
M!/K$9#!>TEQV"$QO,LL^SMF/C7\]*3;^M9/8^-<!8^-?6XV-1X_$8FS\ZT7%
MQA]+S$!L?"?S%N;-/A)]_([G:\J*7:Y"1=X^;%FN>J@#DG^A[/8.JJ5]I7ET
M2ZM7#<F-N"\4>!&8`L7;S\+NS<<CY"!1OB-/:U8PI2(!DSPLPVO+6J,M4R@D
M/$VC7)"M/"FK=`I/,YN"':6VF'?!HDPL;,GO#0[IS#CA8H&WC\![N--DI(M9
MO.T-R<E2'9+CB(6YG<WFJ2S%#M3/2G#:S!GV?*FI@8O+=>U4"7=!JB9+WWVF
MP2?8J\R!KKW=8@Y@0%U@6AT3YNZR!`"WE8U3L+J_-!B4JUM+$R'B&"XNHL9=
M1R4^7(T[@X[LUK@;(.A:`VO22ZUQ9S(9J"J-2\C]/GO#J_:TH#8W"D0HLWL2
MV"=C>4\:51#CVS'?41<CI1OUWY4%CE-&FT;XC)GV;D?H'/KO^_.V=K;![_Y-
M7[Z6E@.BR/K2<U`C2TBG@=`B4HP;H75G-'6()S?BQ\P'U/=LPTK?H:Q4:7"S
M*F/`CO5IRB>8I]21KEUKFPF&R8^JUL>$D.X&`Y'_:Z$@RQD6[L'X^H[FE#!!
M,DYRV*!(P>L@.%+<-2.$/\"_Z4,![\K%752H?^O,=^2>[]*$W-!,>;I&:;HG
M_#XC#$+J8BC>P=>JN2B4>Z\T,&(`>ZM<F20*Y<$89?O?R9:[0K;*$CB/Z037
MT";6[DXJ6N\[_R_9IEK+,?.[L//6B&ESV<Q/@-?KB=0#O5,;HES,T<K.<$*\
M/3OC]%:9[6^S9-I>\29*U0VG7![_%&6[*-^35R?@AO/#DSIA6=9"BP_+J`E_
MLBNL+EWM?BT]I!-^U=1XGN#ZJ($'7@FQW'.SYCWE*B7]*N)F2>N:.;^+UQ^E
M#9]'Z6F6G"8;EC%X((#HF;)V<L]29/@5<F$9Z=UYR1U-7GF/10<`@LBT*:\Y
MDH%/9+/\(,]62G]T;L[&67XTPXT/DKZW4`-HB]]-#<;@=6-UPE-,1C5`M[H!
M>*0]!-(:`[G9DW:[<APZK?<)D4-9E<EKRU2VK=&<!$X,Y$4?;>S7DP7BB2RE
MICZ[H2(2EAYUL/B5U70@BXP>F,#='S5W,WJKL@Q-?`KOBQ%XR@<8<]WRZ?P?
M-IR>;B.6E*:OQ*?SX`A!"W&VRW/:&_`[X4MT2/TH!?=1D0I"G>E(Z0-729!B
MC8!$"D^@H'/S*>`S^#KS7?A/=+V6@D[%^S3N#ZCM;X5Y_7W<FVM1J2F>D/?O
MS_"!LS:0X]X_CT<0*E!V0!*X(9-\)_V6&RSP^SW+Z(7\L3_#=U]#=#KOXPZ=
MI^.I*)(O0),HHJ%J?_1RDYNSR*^HU&['HWYF`RV1PM+1HR];O8,TQKJV,@*$
M_QD0TDEGN$8@K;<@(C\D%'P"G\+E;"J=/FJ7T%[K<OP3"YF:CKL.D:3I&,/<
M_$SSQS0[-5.5G-YP3!YR,O7*4$\ZIF$F^JYH5R>$4L45>E2FKQFZ9MUA=^Z+
MU#4^;8&*T?7PCYLRQ;,IT9VQ=OC4;O81UL`8[-QYX-IR<A,;<IGC6#?S.'Z1
MG46"7JXAJ9:NIBA83\5"X_:8(_I0OZYEY2(C0!Q\:55BM(8^_N!N=SRX(_PO
M=S13KL4)C&J;LRQFVR@%I^98%\Z4JL&RTGUYER4T3_?*M[A.!QK`G]A(POAD
M-B^B\I>N33:EY`R^(Q=5^H(4I<$CLUZ];^[XYSW"M.,1C1Y>PLUPF*?\$G?S
M:"\@S,+D_2Y$<4/C0C]S)RS0I5;YI#!ZI77<;NZ%5M6?]^NLMT96IC/TB*NL
M:_BDNL:2&W]8.[E7(+HNL[KYM(#TX_FG"-*K:S\8@PNMX0]M)B`_(!`T`_D!
M$FLIR&>.SV(.\IP`%%5OP&"(/K.0=PO96!KR`<[ZU;C^8EG#-QW&WR'U;;1_
M#R5PEE\\S7P6.)JUGN7QJ"K&%4]9O!\K!&/X%586AWMW+8F/*ZR<$`V!?"G_
M&[K4BBG_.9*IGE\$(G%WFB7P'UB@O\JE.BO$:7$6Y3E<YPP^$TSY%OMV8$+#
M^8."I*X6Q1A^H`T.C/7A:$0ZQNQ3$>7%-#.D=W`0=W9#;UD&L@OFR!;MR^IT
MS)/CZ@9'3,$M;X%C11B8]3C5#RTP)S#0"H\N'A_FG6S2`L)G\=COLGK@`CF2
M*7*P+7+9[.S3^3)YX,<:)M/C,#/Y)`YY+YK+-[3V,1L1FI'6^(*X7;VZ?T,#
MLJ3E$%A1#F/BC3&73^38[')"]!T\L"55FINA6D*#37&%A#J[].`OOUHKNG6N
MI!D5A"P-`5L^J![*?97VB8/7,43%2*,#DC!M>0:"7Z9S@B7BH!*=;B]WM@!O
MJF,RQ:=PV?,V',=0W$M<17M($S5\S3/<&+L1=W;JX4)'484;'2`;9BL>YB>?
MQJ0E'(OUT]EQQ>])I^/A+JP>DKM)^;JZGX+)WC'+UIB1F463DB"\',>X2P.O
M1ZT1:1P]<9FP>[:/V6'G%]F9_(C%<GJ:R]QN9[,)'^*\S@P(>$D.:H0$X87F
M9'R(BXSJ?2(NZ9N_1?@;%CI1J%PKRD7C>;5\?$L2Y:JA;,&<;GFN'MCUG12L
M+?#[Z/8V5ZY`)%(53,%VY#<IN]5!):1ZMREX)]^"..=-T4B.GZ^92TXI;H;K
MS'AKS.+2WZNOQT`KRF9S&#@-JZ\YO\*=()RWRC/639E=3=Q1V+E!D2`?;C7J
MMBI)#0635.<P*$WJ`/IC(&E\(M]G:DHKB$$:!_(`N#:\IYCT(49_C`AX"D31
M)WB0G1I'D_\9?:GA:(0X+;O(UCS?:)=+M?&HW4O[AF\/_%S@-ZSV=3E,0*WU
MZ_%M20!=FR:@'#\G,S5PNGNG/*=T:>2LCC`:BB+HQ9Q&(9NLOY[&OSQGZA.R
M8';AEC^=7A26,^5:3[B&0I[S,ATUV66L$-_6-0"2MH5?Y7_9ENS):%%W!79\
M$;&,JN1)ZBXAA;S_54<AUL9Y2P6W-Z&SK1<5Q\2D-?>!%[2Z?BQ]Q:ZBO-\U
M$/T]SI8QI^/>I*FQD`S`5/8P[/;5D7.K(=62G#"A+G@1-H[+D6-<*EK#5XA(
M">F$E*#(537X$M?"!HVU[^)TEQPO6&"N93RKUR^XIU"K?CSMT!61^YP5!<W`
M5MRH$BD<Y$K^`63L1.X=\NRBJI\DT-VZ@,4VHV1/HQP<IF_HGDLL0*&)1XCW
ML9PEMB8IEYM6?D+N[UA\)[%ELCW43[F#S4ROJQ$16QJS-8-#7G.=DBEW[`V7
M"W@3UDB>2W;!J4K":5NOWRJW&HU!%[59MTJY!+%A$>L3GRV%?E]J('BS21AZ
MD4G1H*+X*$&J1_GDJBZ)T_-.,[T#Y"N-.2%?;S3FB#`O-"['BUBZ571V@^>$
M5(@(0#K1WB<),1VSHW<:A#3R^2SW7!N19_4JK?UGAI/@C[;'UDSLZ]>]OU,I
M>67(G#*4PM3X&V4MG\POS\+4793Y'<NDH6&A8+=!1UCQFTS0M5S6I)=:L-MD
M,L8+=AMS.%#NQVLPM'JDM+O1W)R/JC./^1X5O<"I'@\9V)7FL8,KGMW74C6E
M-.E.'#V\:T[[&.O>9D3$N62U+B+C]H5EN;^&<7^;QG\^CZF+V'0OY)%1%`<+
MZ[3-=J`#NYML!R%?ARYS1,@:U<[&BW2*4_YO.U'>M+`*2<O&6)*),22"XZ;%
M*)\]FQ3RM!?EC'_.ZNNM<[Z)6-9G78RUQQH:??TZWQE*PB>D19I\T<0#&2"C
M/.:3&1<B4NDZ>CAG(DZYV.5T+&C=Y)-9,4O=77L*7)+$24-=FK>!0]2-N/TH
MB,F$A8%.1)4:G#ZPT83X76WGGH_:??I:LL@7H!;XD-3)S*ZS4C^'%F&9=ASY
M9U\#>;O^"6R9=B"R:)E:&>\<RW1;`@*/EG7'!=B2C-,A*43=>\U754'C[V[Y
MUQ<)95I+Y0_'RBE_]>M[>ANE;[."%?N.57R@Q43UZNC)M?XH<D33"[%J#S&/
M&W#$\Z8.EQHWXT70;HZ+H+V+6*X2.YP*L=M4OD'2+"YH<DWSS:L^R\`Y0:QY
MX0R8\S1-)3&2LC4ES\$-(V0=/[>3>US`S\.,!=!(3%G"H5']A8,7>"H7''A^
M'E)-/Y3GZ*A;A*Z5M:'VM"IM(N;81JU-[,2Y-)[TSOV1WJH*\UGQ(=H<J]18
M,X09U=6=\YU%6U$-40)4O9M3@YSDINQQ+Q)G4FKS*+W($OKP9WJ<,7BT'5HH
MCOKS)!4E5:+($DDWD%ST<9,;LRA`00GMABH&4TOW-YQ3$.*@0Z\%'PXHH\L=
MS,2/3JTN6L3_Y9L'.;D__H=*)!%J)^^7CN."`P,L<[\H=CYQ]?T9O03Z><"J
M;A5"O%CULHR/\<&W"_@VIS'3!EZ6G&X@#N%O!P$.1VIM\`7:R;NW9W]>W;T0
M<&[<%D>$\MMNZ*N(D\AX0,Y\M,>EAR,8Z-DH8+<96[-86JYE_BV(P8/,U(R*
ML??<:1]CC0<C(L[?XQH4I(%!*ASA7WLGS@6?QV#/'I!)PD!1HO0J8@D4;-LR
M:1KU2.5(:ZR/8W>OSO.PU&3)5M)=J91BBG(8=\81WO*)#'O"5YP?F?CM74YI
M.[[&QP7G$-TE7&]VX7.M)4!SM99$H1:E#JK))=FG?],Y.-FN[CG'9]!SC2R-
M5USSTU@>)7-ZE4,$4K&_2F'/RA(X8&XW_3E=IW>`K9EE3,A;[2QC1*@:6B[&
M.Z?"Y97\_5T$B4:@>D,)1E<R,ANGHT4!(8%\/IL7D2W7J)S1I&_MYL?U6]IH
MH!K'PBH<39N2\22QRZEVY.11\)R!EU66^'[G[J*[!#.P"Y]KY:IHD3VC::!R
MO=[FV/4K=__$!<G>W[J3&*ND,_K!O"S^'1U[RN1_>.,4MCJ*`9<?Y_8?99V'
MM_(F.:-.,G:Y*T0A=V2)K?_AW.`C_"OZ0.>^GM1;*4I/=$8_05HPS.O%NWMM
M-YD"CN-KH'@6_2YZ5I5]$29Q+4/?S(UOZ>K;N0`JFJ0ANHB`ET$N=P6^C+/.
M7I9"E=X'<N?*GR\R^8=,[M=RY_Z%%7=7N;2W"RK/A3'MN!"QT=7,W(532'K)
M\XK$-B>AGUL>S$QHJ#-DE>@@7VN#C]Q+@*1$2)X`*Y#)XEO<2(`;K,6-^(@;
MVY(;VPIEV!1_*(WNR/:'GQ?/ET[-)M^99WZT'?8RZ;@_KUGDS=+%N[H8ZF4E
M-^:/7R$YVIT'DQ\,MD4*2V>?OBVKL/D.AMG*)_'*\PJ31D)<KLOL_9?Y1W9[
M5^A4WY?K3W4^V+,H32'(LLKR7S;L,^@M]8I=O>91]_5X-1,FJJ"<;\Y@K#7`
M"`]<)77(3JS(GY`F!7V#E6BP$-E<UQNIO@A4ALZ2\'-'\^;=A-GF](YF@GVE
M.@F'?BPQ?#J;^#G>X#$BX\$.:G`0#61Y;V=3YX3/9;3OW#_:,Z1,0@>'A;</
M96YX`\?KJ9^C<P*9D?&UG9GBP>Q;[L:*V*#JS,9OJ\S&@`?*P%3U`\R'ZRPY
MTD01Y'-Y[?G(L]FF?$]IJX3*X/EXM#WVZ-/7K_/C3TFX/#%KTF$/SN,\YI,9
MYUFJHCR30@X5?ZL'91:?9LDY2W<%3?IDR^PKK(0-]^Y:SA0YY=&3:(*JW$W*
MI86^I57=)W@^2WB:1GGKMV%299A.!D=RV+-S0%8PQ7=I*S56OEZ-:?).CAS,
MJ9V^`+Y<'X_D5!5YZ?,CL-DWUN7`!@8OB9>A&)E&%>RQV,W$<:>S$<#S[2IG
M\:"+VD&#.;YDJB-OH=XU152(]PR\V.**Q`"M2S>UPWD^]B?K8,;,-^S#NC3Z
ML4E(3?D(^O+S+BW8-J67:TDXB]GV47S7K#XPK]93:7EYKIX*:O+CK/M1SR_;
M1!I81.$B%3"X^ESRV'$OTM=WE&Q:(]Q6`'1&=144F,:[JN*R;)T=UB(5\&X-
M;[N0?[TJP*PJ-P9XKD;K,+<R33-7L3<THVL6LRB]O,\DW3NV/852A`V,KG7+
M_"O,2C7>NY>U:1S&9(UT,3+$^M/`(#6.L@+EP@:'6V":DG!5X<NF9B6YY[LT
M(3<UV'1/^'U=V!)*K439_G>"\);#:+LD9H`E9H*Z<>1DN#2&](EJLOUS^)EU
MDT=W'][*T3CL;N[8L;FP998T/BN5T/6EUS^_.GGY\N6A^2+_`5;(THR0(T4R
MLCNZ.#QSC?C`"WD&TQ713X7@D#Z&)N""U[%8-4OX>[9A>L*.R_=VK2C.B&#6
M'^M@O*Q6UE%/UOT%\`VQ$FK41,,F#6[M6=MI<[4,E08\>520_2DR$+G4:AYN
M-0^C(QXV1AN8;"4/MPT/TQK_275"5$P,=31TMQAQ/Q/M]S[W%PK>2S0YE8@D
MR-K?";:B5K23V3/=O,Z0]\0XHIY>-.K+%76K#\>:&]/7OI#O'S,GDMN=G=F!
M3\J17+%39UFF.4W>\?PC%='CV`03B\=2E[A`J%FD/05$S<*(B`;RS!-4@)2.
MOM#K0H-2%;/4.+M"I>;;)=Z9@PV9TM<]FC_Y(7_RFC_'P5-+,#ELK0;<Q8R%
MSA`^DFIA_`-K&<-]I5KXU)]N^Z>%Y-L>2K1@RCC?N9G;%R>?LS)Y+R09$?&`
M"X[Q=^@\S2/]^\O6/`($E[/9^NCF7W="#=X:"#$;GK,,SJ;2Q=%,]:MG[UET
M`X5I(-)EE^>0YF=X`1__`*E9_1T[#Q#1Y$C:(`BS<!OPED]GV!,ITZ<]EMLI
M5X[.DA\I!';*WTL#2`US%Z50`^WUD&=:&"2^"_OA$7OUM?,[-+13W])G0'9X
MPR?[(T3RGS$E44'^%&6[*-^35R<$;D^>5OU%"\IIHS"CK?GV[/PN!.T-,#_\
M(];]7'7B:U71U#"*CL6)+LH4&4!UY=U^.+%\F`N>SWG2!DZYV.6T#E,=,4`-
MOL">[?I[]G:JZX>`.L_9'!'NN98*4G!2EA"7>E`G0`NC"R;2PQ$,]*LU'^A]
M*S]FSC/YH\ZL)*8D`L!V@]2OJ>1<*YW$<U"9YP#1XC($H">+VYH!OS+^6=#+
M]5M1L$WT^%5NN!%2/@\[<RU]DAHXL]7T%B=P/;SE9@P[%I;V$-[+G^0OJU_)
M_P/[6O[F_P%02P,$%`````@`\7JH1H(+G&.U&P``:F<"`!4`'`!H<G1X+3(P
M,34P,S,Q7W!R92YX;6Q55`D``S4-354U#4U5=7@+``$$)0X```0Y`0``[5U9
M<^0VDG[?B/T/VIYGMEIJM]OM<'NB=#FTEJ4*26W//#DH$E7"F@74$*0.__I-
MD'5*))%@D00)(6)B6I9P9'Y,`'D"/_WS:1;M/9!84,Z^OCMX_^'='F$!#RF;
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M?#7G/8DY2Y[>!WRV+Q'_\/'CP;YLM`\$)V1&6.(QGA#O>^`!&A$O\9^(`#ZR
M8>]C,H&QXN3)6_:6,_\#U3EYGI.O[P2=S2/R;G^#V'E,!/3-T+F`7RS:2[*:
M(CR?FSPE!&1P@=1R^H@'"O;D;_Z\A-'%+3^C#+XL]:.;Y;QB=">2V`^2Y621
M?T>B?!R-7CF)D902'B_P*25Q0Z8GOKC+!"05WM3WYQ*>[_9)E(CE;R0SWWD?
M#A9R\H_%K_\\H2*(N$AC<@O(',$D?Y6PHM%CX&QXA^88.<\$]]9_*J"OA!-,
ME^X9N0D(\V/*OS$Q)P&=4!+"MN]35L*%LKT!%I;K%#8D<@X_BC+:2QL:)'H)
MZ.B)*NDN:FN0]%O_+B(JFK<:51&[>;2,XF"/QZ""?'T'2@O\94+BF(07B]VZ
M[,C-#IF,$)@P4QM^E"N-A%_?)7&ZHL*/@ZT#Z_5`BQ;[<S^6IU5P3Z-PV7L2
M\YG^B<%QT,#$@X9%P6,1"N5";1T8A:QR[<T5C<O!0'!1"TG)CMV>A"1@-I$+
M,W"\9I;74HAL63\859;74;36`/VT7VC>-&FF'7I@"%+A\8FW.8VFO:88I1O#
M#46$L^"VM*8CB=C59!0$/&4)9=,2Q:FTW<"M-4O8,&ET.EO-V6K.5G.VFK/5
MG*W68R%QMIJSU;"VFD+;[<I`"WF09C_X+/3@7YH\>Y1->#S3M-&0`[5NIFG1
M@;34-A0208+W4_ZP'Q*:ZR+PPTL5!'[UYPAH""4=9Y'_TN`I_7M=+0E+U'$:
M2RD^`TGUHW\3/SYEX0D`5T"?JFG;I)XL/F-.P)C`>1.>P>]>:I^HMMT2*]'"
MD?JJ95>$YAB5?_W*=ET1>0OS5-"V^>>V23K-]I%CF#7VHW/8,9Y^)<\%M%6V
MZXA(/IMQ=I/`\7-S#X>6N$H3F><1OG:\Z'7JB/Q\W[DF<Q[+4U&J&X4K"=.\
M&Y+/:$3B8U@@4QZ7"T5AJVX(O"93*A41EESZLZ(E5=6L&Q)_YQ%H07Z<PU3^
MO4O:=4/D'R2*?F7\D=T07W!&PG,A4A*7$JMHKT5TL;-XN1>.6)A/>?Y:T]ET
M$V/:.^^>\^XY[]X0+$_\DG9^/>?7<WZ]X?CU#"%1Z-+#*8C6284"BTH;#PW&
MX=#!P+F)T'A\'#H>2EL/#<5W=D"!,=#1F'RR`Y-*(Q8-QO=V@($RDM&@?+8#
M%+P_#HW,#T-'IMSOB\;@BRT85/CE\8K8X+525#`%C\?@-5-D'`R/R.#5TXHH
M:Z<9T`?>72J`2*%;I/JZ8S=YSF7SNM3F[=3F!4@G1`0QG6?KAX6+U([QQ@=1
ME4C6'VC@6<66L.&2HUWXQ(5/AN7^=,G1+HCB@BCV!E%<<G1_Y$0W.7I'=;A3
MX^X[+^#L@<0)A260_4IX"?=B$LE;I3P`)Z':MQ/I#=J-45B'IIT,QG-V[`MR
M-3DA=\EQ-K6\T.LW,KM[E76%;M]`UI5]=NR&O[D0764[$R2O1%%^[AL2I#&5
M\J=@`-7+@#6Z);)'S]\8_4]*-O>_<N-"JZ]IUF3J0*5YJFINA@'\;5>*U@-W
M=%C"ADE_S>E_TCS$-^<,MO_*Q5#9MGO2+SB;@EH]DS(NXW`5FU)54_.$5X)>
MW=@Y^'9Q.+T0:('QF57U<;Y*YZMTODKGJU2YH=3'D2U85'+*:YI";]!?J3YU
M;)$8',L<[0:P+OVY5%AJ6-ZV"(T>ZUS;0V==SK@+H[DP6F,[,,(O8`LVVAN-
MGB/1%IBP:A_&N6%=D8J+3KOH='/1:92'OZL0M*!3!N=CX,LKKU:7B7ES'M$`
MC+G5#_CXL^Z(K0>?ZQ&T4^1Y8_+:9&P&?YL8KWO7V_IRNO&"%D7$1=W!0*#8
M%_<C%LI_I-;TX$=2L<KH>U;%\K3Z&@G;PQJ[)TS0!Y)?_I[3AN1.L[N1(+\`
M6L)L"\$RI>YB(.;GQPQ6A1B3."OHP_&"[-4].Y?D<6.IPPX./P:Y*UI'`.L.
MTSW#+PA1;(.*U@,EW]4XN+BABQNV0^PWZ10]%0F=`3UE`!<WLBS(V8BF[,*?
MSL?L?,S.&;:S,PRI"MFR=E2**]<W]6V!!L$OKV.%VK*]Z.%3I<K8DCZ@*3'Z
MKB9;0N1Z0&DY16R)9.GN/G4<>VBL>GX-FQY6N_F@.BTT_%AH_"12G=,M+\0,
MU4U1(9Z2Q@,ZZ/E5D1Q-1ISC3).%>Q*F$2@,(P`WI%&:P+:VSE<]?0JB%.3B
M#'8!N?.EN62"?O'BI%"YH]N;R'D;G;>Q1][&;'K5:BAN-`AB<9&*8=FA#1P^
MSBOJO*+.*^J\HCM[1:MW6UN63,D!R+M3&#NU+C_!F0(4W/,(/H[P2)9A7L^Z
MQ`S5C76)IZ0=ZQ(S/\JZQ#/BK,N:UN4IB")_)K!^XP<:D&QA'OFPQ<BE2YC(
MMZ\H(RY;Q=<DX%-&_R9A?M?R,1>)P!N9+<UG$L)B'K)"P:NL5D.,`M@B0711
M6GUS`_<#E+'_G#W5]>C'X2;MO_M1FG]M(=)9_KO:`.T^B?-6.&^%\U8X;T5K
MW@J4,N.\%<Y;X;P5SEOAO!6->RM:M3QL66LZ@#:O?=N2!%4/Q5V,O$Z=9NMW
M<KR0)#Z-A)<`6:D?:;K,U`-U_?!/-1T[/P14=(_923[C[?:$F_XQO9Y]*38=
M)<=^'#]3-I7;0)F]A>IKL@AK'/.`D%!(=[9\I1&^`:Q:>:'$[>)"B8S\.4W@
MRZR<X)>DM,ZL[G@F0;B6DL9(N'3ACX(@G:79#>@G9$(#6L:MNJ/'7(6=\R*]
M>2_2L/3O.L>2<VTXUX9S;3C7QLZNC1HZ17ORTEN4&M,SVS/*>XM=+:.D4Q,<
M]RK1CN;Y;I/TZ7FF%LWZ(\*R3<>/KAX9"/0]G8\F(-GK2QB+3'IUKYKF7C&1
MB[N+I:M)7),I%3`5"<]X?$T$"/<Y@WD9">07^8,F]QNW9&?7KQ=QL..0#;.W
M=:MWMMW=O:9A',-23L@X\O-:IV*V:@W5%CL95F/_6=)PG<OT.!?IXS2.U3PH
M^S=*>(88$[!Y2TS6LGPMU_IO:930N71Y`GA@,<R+G5VZ8W3'0"[KVC3GW1HE
ML\=/Q/7.PUE**@U('M<9"<%A5E@:<F47[,S0+)`'UI1<T!G-#R[,%MGX)"9=
M@*,9!TK^7L3&EK>!RNJ+<4QF-)V5N$*4_4PRY9X`-,V.>P(0V]P,`R^/M7PS
M2J707$WR"]G73:H^E-Y`)C>%;6K/0,.#/2Q]I6JIFO>'A7,6Q`04@!.2_WN5
M@'E5'J'"=>X3>]+T$`EH6R33',+U68IDL7R`_K#YFY_(/?OY!`A$L;79H3]L
M?&-^KA&0<*D(H+@IZ.?>LZQ%^E+<3Y]DNDFF#^0U6Y1--[6U$FZPW4U^'?=D
MIY%4"9^&Y^Q7RL*EC)3E0+QJV)<,CQ=Z,B*'XT4/=U]P,]%U]V2J6:)=8L8@
M`^XN,<,]F^J>3>T\.<,]F^J>354)BWLVU3V;ZG(&7<Y@YSNP>S;5/9OJGDUU
MJ;AM/)N*#CB\H0S<)O/(WF#RK89SM3V]K[?HU(]<MK=1]PZLNDEY:(BT'P,8
M($2(7$LT7M_;@9=^UC8:H<]V(-1ZRB,:T!_L`+3A-'LT?%\&#Q\^V(S736W5
MW+%)7GBDAJ_&[YKO@L?*'MU=.]D;#]+P5?B=:W/P8`U?A=?-KL5C,WS=O7:"
M)!ZDX2OLS>6>=UK86WA+Z)*>76ZBW^;)R!7TVR0@JVXW<H,$"=Y/^<-^2&B>
M%@0_O,P&@E_]><H2Z84L2GTK^W/=="4L21=DZD?YQ`49514MFBO^E=]CQ$(X
MB">IQ/T//XY]$/?RLD&MC@T0^K]D`CL.G'\745!.57FKADH815'NU*OG%%^6
M+^)Z-4`B?(<SY`=4-&V$F&W_-;0XJ*)'U;H=D@ZU2#HT71-W'/E"7$VRA5>9
MP%O>T!C1"TF[BJ_I]#ZIR!Y5MN\)"Y@/4-7#%;5B2H1`805M,=UX%*ADO]7H
M,7`V7'53O31P/[M55TJU3..XFMS"TA1^YB&MKH9`=W25';NDYV\>6ICJ@K+V
MKCC%%:>\]>*4MHA=F^ZYV$H#I^"H*N5#L[\!%M,[04/JQ\\;VWZ5.*G:=\_"
M0NFL5/$*VUA8[80TOEVETTL4<&)M#2!*=KFFI\*6C&!7ZU0%BJMUJBLLU<J[
M=8)2RNZ;WU>P2ZA"8[$&DUU.H4+GM/WU;\H(V="WDBH&E^*@BGR]G5(<9/!@
MZ$*!9W>]8R`B?M;I(:K#I6XTN[UZ@+XM*%=77(#)&ZTKKE)BL9%GZS025VQ=
M[U32CI1;<SAAM/RZL<>ABY!"VZW.TFNOZJRWI_*%JSC73YBP16'!I+IL"4VM
MZ)OY+.<=7RO2&M-@%G0C;Q&YK&B7%=U=5O2Z//>*G3Z1.*!"'EE+EHOH471I
M]#F<`;T[XY*W>YR\74Q2MM+E_2U@_J<Q9=.\NCTOR<[^>)5=+2468D["UT\K
MU!_(Z.LX+@^]/RP,,`^]B*BE;,/2E>^1+O>VQ5_%@0Z#JK%ZL':V"5Z6'*[O
MSSWVHXB$1\^G?G"_W58'")UQ!P3*RP_:#"0O1W7OC^F5!H#)Q)\)N2'Q`RR[
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M#>_P'X'6379&0V/1`\^Z]2%X1=4>1;[A(DD\A!8I^Z7)VG@T[-'H]>N7\"@-
M7Y]O[L('/&KVJ/G:561XD.S1XW=/<<:C-GPM?A4PZ*J<'`^N/3:`V8KR->+M
MWF`7<!8"L?#)X2?!(QK"7T)OU4!X?.+Q.8FSB867,C\-:;*N55!?:+?S%*W?
M;]<0A?K7W>UP"X`?,]@FQ=)T`LFDP8B%)S1*D_+[)W"]NB]*^(4P0#<"4D;A
MC#(J;X1,Z`,Y?9)+J:R0"=FK>W;.&8@;6>TSBG=3%:V[)Q\TMYRF"R[**ENV
MVG@?#1++V6)ILFE.4;70*-MWS\+5DIX%)668OVIG$O=7Q"BD7-G>(`M*:2]H
M:1+[:SCW0$.XEULW>2`1GV=Y)I5RC^KC+AEP1<X5=+LB9_UR2R)]CF`@/,`.
M,B4K+Z54OZ[2!'1,%L*^@M/?=AO,G@).K.;DBC;+4'"YNF\^5[>'J6.&D*CT
M`R'U5EM`4;/+:^F4MBP?+7RT'!0M9M))MV2W/E8MF)1V;8O)<T.!IMSP;"]U
MKL<K"^G%:3$EKN>"4^F?LR4-7@L1+>=W>TEO/4:H"?.R5X&KP!?WWB3BC^T%
MKJJFZ$?@2DTA,G!5_*0([#(Q\04Y(?F_Y^P8.M$`=D?JW]$H2\5ZX<_`=S1Y
MV=<H_+]4)!F.MUP&:UE`([*UL=[R8T!W'/,'&LI4LV_P+<[9:M&-`M#V,CX4
MSO$VIS(`W(S'"?T[3S&>G)"[1+[8QE.6C&,RH^FL#`55/Z//&P#ZL.G)?V1*
MV(,?R:\U2H[].'Z&#Y"5?Y0PANKK?6<S<Y_ZQER>AO%R$]+BL7@(DX&A$P)'
M2T!S)06LSHT%5<)910^3J^WUX3`*LIU`C/WG"K>_LE^_F%HF&5V32)[<Y2=F
MG2'ZQ>KJI#KVYQ1L)W52A.8`O6`R`;4-)`ZT^5H?LZ1_O[XD',9SGX8G"ZMG
M85G`YI%3+P0I?<ZCWF`>^VPT&:9(\5I<'+JI>)5GRB`',)I&@Z92L7#K#]0;
MIL^SI,X=OFW!`#W\M@54UONVB(%ZPW2!P:3';,$`/?RV^B9H_8&&D*!H\J6>
M11G\+1\%8#O(LBOINDZ>QY'/$CCII$61!<Y*.,$/8/2@;.V9)9><UO@+.&7T
M5S9VF75Z1%]-Y(9Z)CVOBKT7T\6E")I/$1QF2@=*NERJ7!D*+E7.I<JY5#E,
MJMRN)D1[:!FH,MT!C-(TCLXNJ>NC=+4?([5*_EJ%:^.S:`20;)'7KJ#%F&,M
M9HW:*[/:B0;MH=S'G;9N[*V%_?-+CA(CTRRXV75UD2X,E2#6"G6UMV<:6-]-
M(ZJ([5NU-];#KGZF78LY]T,!KXFDB_:R\RV`$9GN8%46_VX8U@]*MK>>^ZC"
M[!JIMDR5V0&.@@N]:P0B6U1CNE_"S:!9/W?$EHJOG98R.J'(%A_L#CCH7$?Y
M]M:M)H+U\_FLJO!M!LQ=$NO;TVCF^>VCB1\G]H"J*#=I[U#)T3QE_=!Y6L'R
M4QF6[19!,I[`W)Z0^_@]C^#S"(_D]U7S;%OW@-XT]\7[0J2S?*_W0I+X-%J=
MMNI2R(8F:KT@LE$Z=RJ+7-/4.'6;190M3F.@;E!>HGL+TU8D&A6VZ9[4U>W`
M:Q5J^Q78ES>OJMJ[Y,;&DAL1[[2<^33.=N[16OZE/SX`R_R$RO."A=>PGLJ@
MZ&I>2R#]G4<P3`0[4->@%L\\<%BOJ?CK+";DG"4$#LZD*U"KYNTAI**,M_49
MPD+INI+OIE9O?2U.90BX.[5,W.DLM%L2SPZJX&MU0I>:[C*ZWT!&=^LJO\L"
M?X%"A;EA"PC%+!:]A%)MN]B2W>=*`UQIP.Z+IGV5T;J<1%=E@7LKK5N3SI85
M:P!<M6?'NC7</;A5'IZWE?/4E9G=572KY';+.S^2[[-ZXI[(A.D@C3/X\BAC
M@_=\:LYCZK+/6F3N%-I:)&PBK_E4M]9R)A23="S?88P3"@K$)9C"RX3P17KN
MV(^S]Z!S:(J(K-/?0'QL.]V]F!]<8Q.WJ8;94Y=^-/9I>,X6R:YEU%>W-D!^
MU;5FB]H-@]<`Y10H)&*S36^(5=V,6]6V+W>)-GA1JD'6^&S&6>;DJ>2BI)FY
M&/SK(HSJ=8#NUSU+&[2`I-QLN'/S9^A+.%)U,[G8T9_E=<-^D:W8J-0=##QP
M65Q?4_T=<)U,,9,=!Y><!0@>2MJ:N!HMJ_PLK/BL_A@:/8W<^%9<_G%)ROE1
M=S'QGFKB@V4=+I\(`>E/9VEV.IR0"0UH&3OXCBZ_Z\T%V:\FBUQC,&*XR,P9
M_#UPRJXN>\!\]D!;Q"+5OGXI>J^I44J[JH,]F1NU5KC+QBA#P07>WVK@W46+
M]8)""/^9+8!4LZI;TV7G\D%CI&UX6E7<BH:ITJ=N2_A90VBPUKTM5QB@H4%X
MI*RZYD9S!=5>.CW?;W&'--9W;,M)C>!W4T(0D6Q;Y`6'C%9BA2TY9GI"HQGD
ML^6HU@-))]1CRXFML<+J9P59=93KR90ZC&O+AH3,RD1Z.6TYVQ'\;IKBE=DD
MMISJ>IB@<M_L640ZT.C&6]L[U@WLPWI0J8-#[9WHO0='-V&JJY3WK([WH^?G
M%@](N#?G$8@U697SDJ<@2D,2>I)]#_3^0(J_K.OE$R^D42ISPLEB><@L<$_(
MG/^:5SYU04HWET)UQTD[UT9U03_J8JGN@.PT)1GXR>BC#^2&!&F<[0VG"W;D
M99FRIB9-%D]&+,^?,8FSDIK13")2$N=N=.S!07/T7#Q`U1U?[<_8%QB55\]@
MNYG(%U]9Q_(%E35QE1>A(7NY=+DWER[GLLK:3\]"W%38HQL*__!E[6I226YA
M&WORQGJ@B[DLM)?^F:[4$UL@[0*PEYX/^^\IZAC5BHW6%E]DQXAJJ<*V2*U+
M\NU#DF_/H]@=+T0]&]N6W<YE4FMF4C?OQNLTK%!\/:@?96;2PBQ([HD7DX!/
M&?T[NVA&)(T^%J$]F\D7(VH2NY/__WPV]X/DBAWY@@8C%I[D=MHE2>3CQR!+
MBX"YE*AS=L*CR(]7(E;DQV]DP`9NZ-&\M58;>U3LHM'OW*GS.">1A,57J"VR
M],M<R%J=NV?N%\)([$?R\?AP1AF585NYR2X(JW3_:/7MGK7\W?+U^;*0LPH7
M)Z)';]BH](^C^I@H]1<$CEU9_W-"'DC$L_H$C*AI]'31"Q>]>*O1BV&9`-WH
M"\Z%_@(%]"EG"R08AOD.9XTM[D%-G&JH?[8@Y1RI?7"D]MS'I[F<-'1V6Q!R
M7E!-+V@-9X)U6VXA0DV[VWK@'%Z\'272V<R/G]MX-KAD:)-N7PQE!IX&+J%G
M![\GAE'GP]!CH>X+%WFZBCCC\830)(VSNA383&F<C2#.V3B[T+\,BK;G]=AG
MBU']@]#I/6S3HP>P)J9@/9`XH(*,8QHT_K!J$S1YA\/]&+_(+*(5E[_$<"RV
M!''%3,.#[2I-8%-G(673R[0J?;?I>;Q/5H!F8(DC9^\UP*6OU%TMGPG*.6EU
M*VV4B%[OG2I.M[<T$UCC*3`.=)VGL)1+]YI(#1-^?PPVABPO3OU(OI%U6`5X
MMY1X[EEL%\3K;0G2N1`I&&II#)*;;R*9_(N-K/W5AEYJ[F@/A+1?AN6Y:\'H
M=Y%*%T1Q5TX/)T20/_-XRL*N;UMI];U7K"W:GH2]%5QU#-/V0GXP^1T`VUNL
MS>KOME3U="/<2J]?B]=>@9[57R$V8_6CT<;?A/DE1YN1:7:S:Q_QWMT^0>/V
MO9/21OR`:,`_VR2HG<<-T3#_\';DNLM08:=9)87WDVBFCU2.8?#NP`830K++
MI6_YZD&PE5B)DA?4-'MU[^D[H4*N/1#96T#F"";Y2_$8'*+'P-DP&@^Q(+6&
M3AD0$LB795:K<;Q8C"NPR_C1ZNS")BYL\E9JGS1.$1<;<+$!%QL83FR@MP:1
MAI)DR_K!J+=\-WT%8]DM_B+_3SJLX3?_#U!+`P04````"`#Q>JA&B#27W:$)
M```R5@``$0`<`&AR='@M,C`Q-3`S,S$N>'-D550)``,U#4U5-0U-575X"P`!
M!"4.```$.0$``.U<W5/C.!)_OZK['[1Y.>Y!).%C=J"`+3Z&K5PQ0PJ8W7W;
M4FPE4:TM9249POWUUY)L)W$<Q['-`!>JI@K'4G?_6MWJ#UN>DU^F88`>J51,
M\--6=[?30I1[PF=\=-KZ?H_/[R][O=8O9R<_8?PKY50237TT>$8/XXC[5%Z)
MD*(_+NYN$$:=O>/.7O\K^OYPB?8ZW4/<@7^?,3X[F2K_6'EC&A($\K@Z]D3$
MM7P^;8VUGARWV].!#'85]79'XK$=#[:!QS[N=/%^MY6015("O%5T\:@A/%@D
M]"G+IX&!G.ETZHWSYYN1'(*QU-.48$REX'JZZXG03#WL[,\F,OY(E<[G[<9R
MU`X8_RLE>7IZVK5D0HY@;F>_;88'1-%D.B?,4_DB[)"1T%V4P`7G49@OP]>R
MK9\GM`V3,,RBDGDIW7JB10+%O'QD,)"#2^F)7#$?1G(((H5'A$Q2FB%1`PLH
M'LBQ'8Q($5"52V-'\HF,>OE$=B2'R"C@9XP?6_&P[0;GI[("FS.N-.%>:O/I
MDH\\[=O9W:.CH[8=3:<J/V\BL.VV__AZ<V_W:0L1K24;1)I>"QE>T2&)`H`>
M\;\C$K`AHSY$BH"&E.N%"7/#FL@1U=](2-6$>+1X?YS]\Q\(V4#!PHF0&O$E
MND);NO!R(SRB;2B;7^-<PC8-M$KNX!FK7<#0:I>`L\;?5P`JI`(8G2/<W</=
M3Z5A%#M>]66QO*JL2W&\+`*T1&2O:F/(S0ME<"P0IK]JX\F&NC)0$AIS@6?$
MU9S5>%G;1+8VIR.3T,MY:R#E`E45;RV163;;.()_J[YWUI8=I;QDCB[Y@6=,
M*IMH/LB761-+8G[AA,XLR;Y9DJJ>FE.1E%F1.;+XNLIZ%-9I96`D-.:B_J;-
MUANE=FU"9*^J[-LUU5L9$#,J=UD9QE*I4M(K$P+CCH>5\MIR%58]KUE>!>Y`
M.!?:<K7WDKN3">-#$=^"FZ:B.DXJ[SLZ1+;&.B;2,P***['V1(H)E9J!4G/%
MNV4PEG0(U-!/X*0V^C,@@UVHW9(I2P(60X`-T4!"@YL9O(36!,W3EH)5#VBL
M]0]7QR/!INH`B1<%UBIO5"F?#C=5"D@89V]8IXFDF^H$)`I:@DJ6,@P>8`)B
MT*!`!M.VN\"^\")[0;B/X2_3S]CL11E:*2UDZ+[?]0K["X>N/-,46@)N9BS7
M1I7IQ\\ZG0["Z"J6-7]YSGWTQ8I%O9G8DW9&UA*,2%'_EI_9Z\RFB(GC&46$
MBXY7GBYKW'S*^&YBS7)&]@3W*0=&YDJ)@/FVPAR0P!8R:DRI5MB5X!J#$S/A
MXXB3R&>V?JWB`S5E-N4B7?"+^P047%\FL,Q5"@M=.%CHWL)".Y<.%^I;7.A[
M@NO?'TZ4,6@Z06$QQ"8"6N'JA?RGA+BF7&>OG.ND4Q020W2;(D(['UY3THP>
M46,\#,33C_&:7'%-><U^%:^Y!$3HVB#Z\!IC1F@2*.[B0:08ITI5\X4LDZ8L
M?&!*#::\0*A(4OCQ#00ADV@N8E%;;K@]R/**V:TV+ZJ&%5=Q;,JDA[DF-0G@
MPL@U6[0_)W?+[;N/B6<?Q3$^PA,(:1[T/#6LF\^O*=M^RK6M"=/GJ534CZ5N
MN64/3-I\-$WL(*#VEL):8$D#FT8GQ+:W-4Q=4D!3MO\YU_8'+BTG,.Q-A;1`
M=PX&ZCL86^X,AU`V">^OL0A\*A6F?T?04->P?3Z_IDS].=?4A[8:FTG]%_IB
MQ6ZY:3]AQL%>%&LRK;6?,XR:,N;1XH,=:TH3QWM6&'HPPK;7A(J-.!LRCY@G
M;,N9LV9*+LV](6-W.]F=>S]#D)>CT4YRM>T=4F[A!%L1DEKC]5C"MBFK=S<I
MR]#.@Y6^[0;/3:'U#5[(MBF#[VV4H#\LGGU^@7VJ"0M@(]*ICDC0R$.1):9-
M67M_[4,2M'/E9*,')WO;39T?=N/-2*=>$/G0(@VE"/&<[N:9B,^"R+1/E$@.
MQ,J\3L%J3"1-[-MX-F@(5E/N=I!YZEJ83'`28[[$Z-$UH$>7,_3F@<^50X^^
MQ.C-NR!T;]"GGKOM'ENNFV\P<%44V)27Y3\F+/LXX2/@E2H[FO.6<OR;<H[\
MYXRKZYL/9RAA+!($\2DTDU#TF,)>]P2TA_^UK_B4;B#!U97<E`/]G)?#5OH/
MI+84H4E7@!`"3H(0`I+2'WFJT,)B8JW[2(+(V9DH%843=YS@I=RJE-"F/.KS
MAAYU:W&@WQ)PZ'P&[L.9RM@5EBLD\OFEW2<KIBF'.:KF,/<.SE:XR$D[>V(Y
MOK-XLMF>:XX_X;)>9`Y__@G=B(RH?PF,&6A]P\B`!<R]4S.'M$];A3-8$)B'
M(J<M#7-:2$4#I9F.C-!?I8@FIRW[9=LQ`P.VD#L.ZNZ$@H-IY',/1HPR+>3N
MQ\?Q3EN>I#[3R6UW'._!,G#?.^CY4]Q+>EU0#J;P&`ENGSBXR)A-SH>:2E<6
M*_ORW^E7:F85/7D4&M@>X,HJ.:^-'[GC687J7(H0%LSV>NJ.CI@"@-2_%O*.
M*A+0'@>TG'J&S^],C^>*?UO[)[K69U/=X+;-5E57@H`<23R=",ZNC(D&Y]SO
M2SHT'RK[OQ,IP4?45QH.J,SHOW9R)7/;;VJ/?1$2QALP>+KT5W2@>Y#V#**L
MA?J2/4)P[`?$LPQFBE8E?[,[.NN,??)L@,8M;=S1QJ=D<Y:A#,V;U=W:$.9)
M^_YQ%IGNC"-]C0+-)@&]'8(YN<<FID5U^E>@>Y4U*+4E"I5Q,:V4WNG4-Q?+
MDA?,$)O<QP*]^>\>8M6*Y]3028,7C&H'KEXX`=5NN3FFY@'(^*'E-ZIOA%)]
MDU?3'-3C5P+P2G/;WDB4K,ND1KIV/)NV+`1>*&AOA\8Q9^ZXF)S6S'G]G-3C
ML(,!XA5U?P'PZK*Q[.07C#<^'6P>;E::\#]T.`0>5-T$WJ+A<D=>WUPW+&2N
M_K_E7Z90B#)E$"7%3H)^_;17*GY76L*D\@=QS3B8&<KVM#V,>[V'Y#&MTZ_T
M[-<*G85ZJCSH:EZWE3/>D3[G,<EZO>9FOGJJ`Y3,H^Z#K'.E!""%)&7JZIR>
MLN\V`QG1V89;U::]!./JJY6L1>/^`/W7=4&SMGKXU6)K@2J+C93YYCZK3<&,
M=Z'0WEJ%]EY?H50!V^2;OI?Z5Y'9[FX[N>+?#KI'A2K.>;:Z3'2K2OSF.HJY
M0Y0_\FB'6\77$O[F$M^&"Y&<GJNTBBGQ^UF%VB]:URQ4??[O?2U7O0NJM'`K
MF?V?K-*:UZ]UUFP=Z_>^@B4CUQKB=[$*Y3]Y6+T8&_#X86OBWAVZ_V\)?OX/
M4$L!`AX#%`````@`\7JH1IVC!VL?7P``&E$$`!$`&````````0```*2!````
M`&AR='@M,C`Q-3`S,S$N>&UL550%``,U#4U5=7@+``$$)0X```0Y`0``4$L!
M`AX#%`````@`\7JH1FJ@T@0*!@``0T,``!4`&````````0```*2!:E\``&AR
M='@M,C`Q-3`S,S%?8V%L+GAM;%54!0`#-0U-575X"P`!!"4.```$.0$``%!+
M`0(>`Q0````(`/%ZJ$:T'EA,VQH``)Q$`@`5`!@```````$```"D@<-E``!H
M<G1X+3(P,34P,S,Q7V1E9BYX;6Q55`4``S4-355U>`L``00E#@``!#D!``!0
M2P$"'@,4````"`#Q>JA&U9DK+7LI``!H.`(`%0`8```````!````I('M@```
M:')T>"TR,#$U,#,S,5]L86(N>&UL550%``,U#4U5=7@+``$$)0X```0Y`0``
M4$L!`AX#%`````@`\7JH1H(+G&.U&P``:F<"`!4`&````````0```*2!MZH`
M`&AR='@M,C`Q-3`S,S%?<')E+GAM;%54!0`#-0U-575X"P`!!"4.```$.0$`
M`%!+`0(>`Q0````(`/%ZJ$:(-)?=H0D``#)6```1`!@```````$```"D@;O&
M``!H<G1X+3(P,34P,S,Q+GAS9%54!0`#-0U-575X"P`!!"4.```$.0$``%!+
4!08`````!@`&`!H"``"GT```````
`
end

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<FilingSummary xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <Version>2.4.1.9</Version>
  <ProcessingTime />
  <ReportFormat>Html</ReportFormat>
  <ContextCount>49</ContextCount>
  <ElementCount>116</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>16</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>4</UnitCount>
  <MyReports>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
    </Report>
    <Report>
      <IsDefault>true</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Current Period Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-operations-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Disclosure - Note 1 - Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-1-business</Role>
      <ShortName>Note 1 - Business</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Disclosure - Note 2 - Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-2-basis-of-presentation</Role>
      <ShortName>Note 2 - Basis of Presentation</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 3 - Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-3-accounting-policies</Role>
      <ShortName>Note 3 - Accounting Policies</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 4 - Convertible Notes to Related Parties</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties</Role>
      <ShortName>Note 4 - Convertible Notes to Related Parties</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 5 - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-5-stockholders-equity</Role>
      <ShortName>Note 5 - Stockholders' Equity</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Document - Note 6 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-6-income-taxes</Role>
      <ShortName>Note 6 - Income Taxes</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 3 - Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-3-accounting-policies-tables</Role>
      <ShortName>Note 3 - Accounting Policies (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 5 - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-5-stockholders-equity-tables</Role>
      <ShortName>Note 5 - Stockholders' Equity (Tables)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 1 - Business (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-1-business-details-textual</Role>
      <ShortName>Note 1 - Business (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Statement - Note 3 - Accounting Policies - Equity Excluded From Calculation of Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-3-accounting-policies-equity-excluded-from-calculation-of-diluted-earnings-per-share-details</Role>
      <ShortName>Note 3 - Accounting Policies - Equity Excluded From Calculation of Diluted Earnings Per Share (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 4 - Convertible Notes to Related Parties (Details Textual)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-4-convertible-notes-to-related-parties-details-textual</Role>
      <ShortName>Note 4 - Convertible Notes to Related Parties (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 5 - Stockholders' Equity (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-5-stockholders-equity-details-textual</Role>
      <ShortName>Note 5 - Stockholders' Equity (Details Textual)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Statement - Note 5 - Stockholders' Equity - Allocation of the Recognized Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-5-stockholders-equity-allocation-of-the-recognized-cost-details</Role>
      <ShortName>Note 5 - Stockholders' Equity - Allocation of the Recognized Cost (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Statement - Note 5 - Stockholders' Equity - Option Valuation Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-valuation-assumptions-details</Role>
      <ShortName>Note 5 - Stockholders' Equity - Option Valuation Assumptions (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Statement - Note 5 - Stockholders' Equity - Option Summary (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://herontx.com/20150331/role/statement-note-5-stockholders-equity-option-summary-details</Role>
      <ShortName>Note 5 - Stockholders' Equity - Option Summary (Details)</ShortName>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Info">Element hrtx_ConvertibleNotesPayableRelatedPartiesCurrent had a mix of decimals attribute values: -3 0.</Log>
    <Log type="Info">'Monetary' elements on report '003 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">'Monetary' elements on report '013 - Disclosure - Note 1 - Business (Details Textual)' had a mix of different decimal attribute values.</Log>
    <Log type="Warning">Warning: The equity rendering routine was not applied to 014 - Statement - Note 3 - Accounting Policies - Equity Excluded From Calculation of Diluted Earnings Per Share (Details).
None of the elements feature the 'periodStartLabel' preferred label role.</Log>
    <Log type="Warning">Warning: The equity rendering routine was not applied to 017 - Statement - Note 5 - Stockholders' Equity - Allocation of the Recognized Cost (Details).
None of the elements feature the 'periodStartLabel' preferred label role.</Log>
    <Log type="Warning">Warning: The equity rendering routine was not applied to 018 - Statement - Note 5 - Stockholders' Equity - Option Valuation Assumptions (Details).
None of the elements feature the 'periodStartLabel' preferred label role.</Log>
    <Log type="Info">'Shares' elements on report '019 - Statement - Note 5 - Stockholders' Equity - Option Summary (Details)' had a mix of different decimal attribute values.</Log>
    <Log type="Info">Process Flow-Through: 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Mar. 31, 2014'</Log>
    <Log type="Info">	Process Flow-Through: Removing column 'Dec. 31, 2013'</Log>
    <Log type="Info">Process Flow-Through: 002 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 003 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</Log>
    <Log type="Info">Process Flow-Through: 014 - Statement - Note 3 - Accounting Policies - Equity Excluded From Calculation of Diluted Earnings Per Share (Details)</Log>
    <Log type="Info">Process Flow-Through: 017 - Statement - Note 5 - Stockholders' Equity - Allocation of the Recognized Cost (Details)</Log>
    <Log type="Info">Process Flow-Through: 018 - Statement - Note 5 - Stockholders' Equity - Option Valuation Assumptions (Details)</Log>
    <Log type="Info">Process Flow-Through: 019 - Statement - Note 5 - Stockholders' Equity - Option Summary (Details)</Log>
    <Log type="Info">	Process Flow-Through: Removing column '3 Months Ended
Mar. 31, 2014'</Log>
  </Logs>
  <InputFiles>
    <File>hrtx-20150331.xml</File>
    <File>hrtx-20150331.xsd</File>
    <File>hrtx-20150331_cal.xml</File>
    <File>hrtx-20150331_def.xml</File>
    <File>hrtx-20150331_lab.xml</File>
    <File>hrtx-20150331_pre.xml</File>
  </InputFiles>
  <SupplementalFiles />
  <BaseTaxonomies />
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
  <head>
    <META http-equiv="Content-Type" content="text/html; charset=us-ascii">
    <title></title>
    <link rel="stylesheet" type="text/css" href="report.css"><script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else {
							e.nextSibling.style.display='none';
							}
							}</script></head>
  <body><span style="display: none;">v2.4.1.9</span><table class="report" border="0" cellspacing="2" id="ID0EDBAE">
      <tr>
        <th class="tl" colspan="1" rowspan="2">
          <div style="width: 200px;"><strong>Note 5 - Stockholders' Equity - Option Summary (Details) (USD $)<br></strong></div>
        </th>
        <th class="th" colspan="1">3 Months Ended</th>
        <th class="th" colspan="1">12 Months Ended</th>
      </tr>
      <tr>
        <th class="th">
          <div>Mar. 31, 2015</div>
        </th>
        <th class="th">
          <div>Dec. 31, 2014</div>
        </th>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Balance at January 1, 2015 (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">7,293,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" onclick="toggleNextSibling(this);">7,918,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</span><span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Balance at January 1, 2015 (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 8.65</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 8.69</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</span><span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Balance at January 1, 2015</a></td>
        <td class="text">8 years 113 days<span></span></td>
        <td class="text">7 years 335 days<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" onclick="toggleNextSibling(this);">54,000</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 11.52</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
        <td class="num"><a title="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" onclick="toggleNextSibling(this);">(352,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 8.18</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="ro">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod', window );">Expired and forfeited (in shares)</a></td>
        <td class="num"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod" onclick="toggleNextSibling(this);">(327,000)</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
      <tr class="re">
        <td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired and forfeited (in dollars per share)</a></td>
        <td class="nump"><a title="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice" onclick="toggleNextSibling(this);">$ 10.67</a><span style="display:none;white-space:normal;text-align:left;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</span><span></span></td>
        <td class="text">&#xA0;<span></span></td>
      </tr>
    </table>
    <div style="display: none;">
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>For presentations that combine terminations, the number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price of options that were either forfeited or expired.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(3)-(4)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Gross number of share options (or share units) granted during the period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of options outstanding, including both vested and non-vested options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)-(ii)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(i)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>instant</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (e)(1)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:durationItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>No definition available.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>num:perShareItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
      <table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
        <tr>
          <td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td>
        </tr>
        <tr>
          <td>
            <div class="body" style="padding: 2px;"><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div>
                <p>Number of share options (or share units) exercised during the current period.</p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;">
                <p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 04<br><br><br><br> -Article 3<br><br><br><br><br><br><br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6928386&amp;loc=d3e21463-112644<br><br><br><br><br><br><br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 505<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.3-04)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br><br><br><br><br><br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 210<br><br><br><br> -SubTopic 10<br><br><br><br> -Section S99<br><br><br><br> -Paragraph 1<br><br><br><br> -Subparagraph (SX 210.5-02.28,29)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br><br><br><br><br><br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher FASB<br><br><br><br> -Name Accounting Standards Codification<br><br><br><br> -Topic 718<br><br><br><br> -SubTopic 10<br><br><br><br> -Section 50<br><br><br><br> -Paragraph 2<br><br><br><br> -Subparagraph (c)(1)(iv)(2)<br><br><br><br> -URI http://asc.fasb.org/extlink&amp;oid=6415400&amp;loc=d3e5070-113901<br><br><br><br><br><br><br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br><br><br><br> -Publisher SEC<br><br><br><br> -Name Regulation S-X (SX)<br><br><br><br> -Number 210<br><br><br><br> -Section 02<br><br><br><br> -Paragraph 29, 30<br><br><br><br> -Article 5<br><br><br><br><br><br><br><br></p>
              </div><a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;">
                <table border="0" cellpadding="0" cellspacing="0">
                  <tr>
                    <td><strong> Name:</strong></td>
                    <td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
                  </tr>
                  <tr>
                    <td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
                    <td>us-gaap_</td>
                  </tr>
                  <tr>
                    <td><strong> Data Type:</strong></td>
                    <td>xbrli:sharesItemType</td>
                  </tr>
                  <tr>
                    <td><strong> Balance Type:</strong></td>
                    <td>na</td>
                  </tr>
                  <tr>
                    <td><strong> Period Type:</strong></td>
                    <td>duration</td>
                  </tr>
                </table>
              </div>
            </div>
          </td>
        </tr>
      </table>
    </div>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
